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Abstract 
Oct4 is a member of the Class V POU domain family of transcription 
factors, and a master regulator of embryonic stem cell pluripotency and lineage 
commitment in embryos. A number of studies have attempted to define Oct4 targets 
and have suggested that Oct4 might have a direct role in the suppression of lineage 
specific gene expression. However, despite a wealth of genomic data, it is unclear 
whether direct repression of developmental gene expression by Oct4 is relevant to its 
capacity to suppress differentiation or maintain the pluripotent state. In this thesis I 
have established correlations between PouV proteins molecular function and their 
capacity to support ES cell growth, both based on an analysis of structure function 
and the global activity of these proteins in transcription. 
In the first part of this thesis, I have directly tested the capacity of 
repression by PouV proteins to regulate ES cell self-renewal and embryonic 
differentiation by asking whether activator or repressor fusion PouV proteins are 
capable of suppressing differentiation and maintaining ES cells self-renewal. I 
employed a series of reiterated modular activation and repression domains fused to 
either Oct4 or a functional Xenopus homologue of Oct4, Xlpou9 1, to generate global 
activators or repressors of Oct4 target gene expression. Expression of Oct4 or 
Xlpou91 activator forms (Oct4XVP2, X1pou91XVP2) in both Xenopus embryos and 
ES cells appears to suppress differentiation, while expression of their repressor forms 
(Oct4?EnR, Xlpou9 1 ?EnR) induces it. Moreover, activator fusions to either Oct4, or 
11 
Xlpou9 1 maintain murine ES cells in the absence of endogenous Oct4. Oct4XVP2 
cells express pluripotency genes and are resistant to differentiation in the presence of 
high levels of Oct4 expression or upon LIF withdrawal, a phenotype that seems 
correlates with Nanog levels. More importantly, profiling of Oct4?VP2 expressing 
cells indicates that the same set of genes that are downregulated in response to Oct4 
depletion are upregulated in response to Oct4XVP2, indicating that positive 
regulation of the pluripotency network appears to be the essential activity of Oct4. 
Although, activation of transcription by PouV proteins seams to be 
sufficient for maintaining self-renewal and blocking differentiation in both ES cells 
and Xenopus embryo, previous study carried out in our laboratory revealed that 
while PouV proteins appear to have equivalent activity in transient reporters assays, 
they vary greatly in their ability to maintain ES cell self-renewal in place of the 
murine Oct4. These findings suggest that the difference in their activities might 
depend on the presence or the absence of specific protein-protein interaction motifs 
required for Oct4 to recognize complex promoters in vivo. 
In the second part of this thesis, I identified PouV protein domains 
responsible for maintaining the Oct4-dependent undifferentiated phenotype in ES 
cells by exploiting the sequence similarities and the functional differences between 
these PouV proteins. I constructed a series of chimeric proteins by replacing domains 
from the two proteins (Xenopus Xlpou25, and Zebrafish DrPou2) that have only low 
levels of Oct4-like activity, with those derived from the Xenopus Xlpou9 1 protein, a 
highly related protein with an equivalent activity to mouse Oct4, and tested their 
ability to rescue Oct4 knockdown in ES cells. These chimeric proteins generally 
activated transcription equally in transient reporter assays, and differed in their 
ability to maintain ES cell self-renewal in place of Oct4. Differences in the 
phenotypes supported by these chimeras suggest that two separable activities have 
been lost by these non-functional PouV proteins in evolution. A quantitative capacity 
to support clonal alkaline phosphatase positive growth that is dependent on an 
Xlpou9l/Oct4-like Carboxyl tenninal region of the protein, and a capacity to 
maintain a normal ES cell colony morphology, which seems to depend on an 
Xlpou9l/Oct4-like POU domain. In addition, through the analysis of new Zebrafish 
PouV sequences, I have identified a single point mutation, that does not effect the 
protein ability to activate transcription from reporter genes, but can completely 
eliminate its ES cell colony forming potential. 
Taken together my data suggests that the correct recognition of endogenous 
targets by certain PouV family members requires interactions within both the POU 
domain and Carboxyl terminus. While there maybe examples of targets that are 
repressed by PouV containing protein complexes, repression by Oct4 is not required 
for the maintenance of the undifferentiated state. Rather the predominant role of the 
PouV proteins is to activate a network of gene expression that blocks differentiation 
in multiple lineages, in both ES cells and embryos. 
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1.1. Early mouse development 
Following fertilization, the zygote undergoes multiple cell divisions, a process 
known as cleavage. These divisions lead to the formation of a solid mass of cells 
called the morula (16 cell stage) and culminate in forming the blastula at embryonic 
day 3.5 (E3.5) of mouse development. At E4.5, the three primary lineages (tissues) 
of the pre-implantation mouse embryo: trophectoderm (TE), epiblast and primitive 
endoderm (PE) are established. TE will give rise to the trophobalst and 
extraembryonic ectoderm (ExE), the epiblast is a pluripotent tissue, which will 
differentiate to form all the germ layers of the embryo proper, and the PE is the 
tissue that parietal and visceral endoderm originate from (Figure 1.1 a). 
The molecular cascade regulating these early lineage specification and segregation is 
not well understood. However, recent study started to unveil some key factors 
involved in these processes. Caudal-type homeobox protein 2 (Cdx2) and octamer 
binding transcription factor 4 (Oct4 also called Oct3/4 and Pou5fl) direct the first 
cell fate choice to form TE and inner cell mass (1CM), respectively (Niwa et al., 
2005). Cdx2 expression starts around the 8-cell stage in all blastomeres, which 
overlaps with Oct4 expression (Figure 1.1 b). Interestingly, Cdx2 expression becomes 
restricted and upregulated in the outer cells of the morula (16 cell stage). At 
embryonic day 3.5, the TE and the 1CM, the first two lineages of the embryo are 
generated (Figure 1.1 a). The TE is the outer layer of the blastocyst, and is composed 
of larger cells exclusively expressing Cdx2, whereas the 1CM is composed of the 
smaller inner cells expressing Oct4 (Figure 1.1 b). The reciprocal inhibition between 
Cdx2 and Oct4 coupled with their autoregulatory properties maintain their exclusive 
expression to their respective lineages. The initial localization of Cdx2 to the outer 
cells is regulated by TEA-domain family member 4 (TEAD4) through the sub-
cellular localisation of its co-activator Yap (Yes-associated protein) (Nishioka et al., 
2009). Yap is localised in the nuclei of outer cells of the morula, where it binds to 
TEAD4 and induces Cdx2 expression, while in inner cells Yap is cytoplamsic 
2 
resulting in TEAD4 inactivity (Nishioka et al., 2009). It has been reported that the 
sub-cellular localization of Yap is regulated by large tumour suppressor, homolog 1-
(Latsi-) mediated phosphorylation downstream of Hippo-induced cell signalling, 
which in turn might be influenced by the degree of cell contact, cell polarization or 
the presence of an exposed apical surface (Nishioka et al., 2009). 
The second cell fate decision segragates the PE and the epiblast lineages from the 
1CM at the blastocyst stage (E3.5) (Figure 1 .lb). At the early blastosyst stage, the 
1CM cells show a mosaic expression pattern of the transcription factors, Nanog and 
GATA-binding factor 6 (GATA6). Cells expressing GATA6 are organised to the 
distal surface of the 1CM to give rise to the primitive endoderm, while, Nanog-
expressing cells generate the pluripotent epiblast (Figure 1.1b). It has been reported 
that active signalling through growth-factor-receptor-bound protein 2 (Grb2), a 
mediator of receptor tyrosine kinase—Ras—mitogen-activated protein kinase (MAPK) 
signalling pathway (Chazaud et al., 2006), is necessary for the initiation of the 
primitive endoderm gene expression (Chazaud et al., 2006; Cheng et al., 1998; 
Fujikura et al., 2002). Moreover, FGF signalling might also be implicated in the 
primitive endoderm development (Chazaud et al., 2006). 
After implantation into the uterine wall, a cavity forms within the epiblast causing it 
to acquire a cup-like shape along the proximo-distal (P-D) axis (Figure 1.1 c). This P-
D axis of the pre-gastrulation embryo is induced by a proximal-to-distal gradient of 
Nodal signalling emanating from reciprocal signalling between VE, ExE and the 
epiblast. Up to this point the conceptus is bilaterally symmetrical, but at E6.0 the 
first morphological indication of asymmetry becomes apparent on the future 
posterior side with the emergence of the primitive streak, marking the initiation of 
gastrulation (Figure 1.1 c) (Beddington and Robertson, 1999). 
Gastrulation is a complex and co-ordinated series of cellular movements that leads to 
the formation of the three embryonic germ layers: ectoderm, mesoderm and 
definitive endoderm. This complex process is controlled by graded signals 
differentially converging on transcriptional regulators to confer spatio-temporal 
information essential for cell fate commitment. At the start of gastrulation (E6.5), 
cells of the epiblast migrate towards the posterior pole of the embryo and ingress at 
the primitive streak and undergo an epithelial mesenchymal transition to form the 
nascent embryonic mesoderm and extraembryonic mesoderm. As the primitive streak 
extends to the distal end of the embryo, the cells in the anterior primitive streak go to 
form the definitive endoderm. The definitive endoderm appears on the surface of the 
embryo and gradually replaces the visceral endoderm. The cells that are left in the 
epiblast by the end of gastrulation form the neurectoderm (Beddington and 
Robertson, 1999). Figure 1.1 c illustrates the development of the early mouse embryo 
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Figure 1.1- Early mouse embryogenesis 
The stages of pre-implantation development from fertilization to blatsocyst 
formation showing the early lineages of the mouse embryo. 
The molecular cascades governing the first and second lineage specification in the 
pre-implantation embryo. 
The initiation of gastrulation in the post-implantation embryo. 
Adopted from ((Beddington and Robertson, 1999); (Arnold and Robertson, 2009) 
1.2. Derivation of mouse embryonic stem (ES) cells 
Embryonic stem cells are karyotypically normal self-renewing pluripotent cell lines 
derived originally from the mammalian blastocyst 1CM (Brook and Gardner, 1997; 
Evans and Kaufman, 1981; Martin, 1981). In addition to ES cells a number of other 
multipotent cell lines have been derived from the murine pre-implantation embryo 
including trophoblast stem cells (TS), and extraembryonic endoderm stem cells 
(Xen) (Kunath et al., 2005; Tanaka et al., 1998) (Figure 1.2). All three of these cell 
lines are generated by culturing blastocysts under different conditions, but only ES 
cells are pluripotent. Moreover, the conditions for human ES cell derivation are 
different, and despite having been derived from blastocysts, they have different 
morphology and growth requirements (Thomson et al., 1998). 
The basis for these differences became clearer with the isolation of two other types 
of embryo-derived stem cells; the FAB-S (fibroblast growth factor/activin/BlO-stem) 
and the Epi-S (epiblast-derived stem) cells (Figure 1.2). FAB-S cells are blastocyst-
derived stem cells that have been shown to be "partially" pluripotent (Chou et al., 
2008), whereas, Epi-S are epiblast-derived multipotent cells (Brons et al., 2007; Do 
and Scholer, 2009; Tesar et al., 2007). Analysis of the Epi-S and FAB-S cells 
showed that they have a restricted developmental potential and lack some of the 
pluripotency markers maintained in ES cells (Brons et al., 2007; Chou et al., 2008; 
Tesar et al., 2007). Interestingly, the expression profile of human ES cells is closer to 
these cell lines than they are to mouse ES cells, suggesting that human ES cells may 
represent a later stage of development (Do and Scholer, 2009). 
As the definition of pluripotency is based on the ability of cells to colonize the germ 
line in chimaeric embryos, it is difficult to assess pluripotency in Epi-S and FAB-S 
cells, as their potency can only be assayed by teratoma formation and their capacity 
to differentiate towards specific lineages in vitro. However, in addition to ES cells 
there are other pluripotent cell lines that can be derived either from germ cells or 
through reprogramming of adult somatic cells. Embryonic germ cells (EG) are 
derived from primordial germ cells, are pluripotent cells that can be cultured 
indefinitely in vitro (Matsui et al., 1992; Resnick et al., 1992) (Figure 1.2) and have 
the potential to differentiate into all the cell types of the body (Labosky et al., 1994; 
Stewart et al., 1994). Induced pluripotent stem cells (iPS) are pluripotent cells that 
were artificially derived from non-pluripotent adult somatic cells by ectopically 
expressing certaiii combination of ES cell specific transcription factors (Takahashi 
and Yamanaka, 2006) (Figure 1.2). 
The pluripotency of ES, EG and iPS cells coupled with their indefinite self-renewal 
capacity make them an invaluable source for tissue engineering and regenerative 
medicine. Consequently it is crucial to understand the molecular mechanisms 
responsible for pluripotency, self-renewal and differentiation for reliable 
manipulation of these cells in vitro. 
One of the central factors common to all of these cell types is the transcription factor 
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Figure. 1.2- Embryo-derived cells and their potency. 
The zygote is totipotent, while cells derived from the 1CM (ES cells) or the germ cells 
(EG, EC and mGS cells) are pluripotent. iPS cells are also pluripotent. Epiblast-
derived progenitor cells are multipotent can be reprogrammed to pluripotency by 
addition of external factors or forced expression of iPS factors. 
Adopted from (Do and Scholer. 2009) 
1.3. Molecular basis of pluripotency 
A number of intrinsic (transcription factors) and extrinsic (cytokines, small 
molecules) contribute to maintaining ES cells in a pluripotent state and blocking 
differentiation. 
1.3.1. Extrinsic factors 
Originally, propagation of ES cells in culture required the presence of serum and 
fibroblast feeder layer (Smith and Hooper, 1983). The requirement for fibroblasts-
conditioned medium was replaced by Buffalo rat liver-conditioned medium (Smith 
and Hooper, 1987), and subsequent fractionation of the medium revealed leukaemia 
inhibitory factor (LIF) as the active component (Smith et al., 1988; Williams et al., 
1988). LIF was the first extrinsic factor shown to be required for the maintenance of 
ES cell pluripotent state and allowed their propagation without feeders in the 
presence of serum. The component in serum required for ES cell maintenance was 
later discovered to be Bmp4 (Ying et al., 2003). 
1.3.1.1. LIF/Stat3 pathway 
LIF is a member of the 1L6 (Interleukin 6) family of cytokines. It is a secreted 
chemokine that acts through binding to transmembrane tyrosine receptor kinases 
(TRKs). The receptor for LIF is a heterodimer composed of glycoprotein 130 
(gpl30) and LIF receptor (LIFR) (Ernst and Jenkins, 2004). The intracellular 
fraction of the receptor interacts constitutively with the inactive form of the tyrosine 
kinase, janus kinase (JAK) (Figure 1 .3a). Upon LIF binding, JAK phosphorylates 
both gpl30 and LIFR, which in turn recruit the signal transducers and activators of 
transcription (Stats). Stats are recruited by the Src Homology 2 (SH2) domains of 
gp130 and LIFR to the cytoplasmic membrane (Stahl et al., 1995), and then get 
phosphorylated by JAK. This phosphorylation of Stats causes them to dimerise and 
then translocate into the nucleus to activate transcription (Figure 1 .3a) 
(Auernhammer et al., 2000) 
It was reported that the ability of LIF to maintain mouse ES cell self-renewal is 
dependant on Stat3 activation (Niwa et al., 1998), and that its activation is sufficient 
for maintaining mouse ES cell self-renewal in the presence of foetal calf serum 
(Matsuda et al., 1999). Interestingly, the LIF receptor is not specifically required as 
alternative pathways that activate Stat3 are also able to maintain ES cells 
undifferentiated. Provision of 1L6 together with soluble 1L6 receptor can support ES 
cell derivation and maintenance in the absence of LIF (Nichols et al., 1994; Yoshida 
etal., 1994). 
Despite its central role in maintaining ES cell self-renewal, the identity of the crucial 
LIF targets remains largely obscure. The identification of these downstream targets is 
a crucial component of understanding how pluripotency and ES cell self-renewal is 
maintained. To identif' targets, Sekkai et al (2005) compared ES cell global gene 
expression in response to LIF withdrawal over time with and without expression of 
the dominant negative Stat3 mutant (Sekkai et al., 2005). Expression of Leftyl, Id], 
1d2, Esg-1 and Aes] were all shown to correlate with Stat3 gene expression. Aesi, a 
groucho-like protein, and Esg-I were also identified as potential direct targets of 
Stat3 (Sekkai et al., 2005; Tanaka et al., 2002). Cartwright et al (2005) found that c-
Myc expression in ES cells was also dependent on LIF/Stat3 signalling. c-Myc 
expressing ES cells are able to self-renew in a LIF independent manner and a 
dominant negative form of c-Myc induces differentiation (Cartwright et al., 2005). c-
Myc is an oncogene that is overexpressed in different cancers, is a potent inducer of 
proliferation, and was identified as one of the key factors responsible for the 
generation of iPS cells (see below). 
In addition to the Stat3 pathway, LIF interacts with other signalling pathways in ES 
cells. Paradoxically Stat3 stimulates differentiation through Ras-MAPK signalling 
pathway (Burdon et al., 1999), while normally acting through P13K 
(phosphoinositide-3 kinase) signalling pathway to suppress the differentiation-
promoting activity of ERK (Paling et al., 2004). 
Although LIF signalling is required for the derivation and maintenance of ES cells, it 
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is not essential for mouse blastocyst development. Despite the fact that Lf, Lfr, 
gpl30 are co-expressed in the early mouse embryo (Nichols et al., 1996), ablation of 
any of them, does not affect normal blastocyst development (Stewart et al., 1992; 
Ware et al., 1995). The LIF signalling pathway was only required for blastocyst 
development during diapause where development becomes slower (Nichols et al., 
2001). This suggested that LIF-gpl3O signalling is essential for the prolonged 
maintenance of the epiblast in vivo, and that this adaptive physiological mechanism 
provides the basis for ES cell requirement of LIF-gpl3O signalling (Nichols et al., 
2001). 
Interestingly, human and monkey ES cells maintain their pluripotency in a LIF/Stat3-
independent manner despite the presence of the required components of the 
LIF/Stat3 pathway in these cells (Daheron et al., 2004; Humphrey et al., 2004). 
1.3.1.2. Bmp/SMAD pathway 
Bone morphogenetic 4 (Bmp4), a member of the transforming growth factor (TGF3) 
superfamily, was shown to substitute for the requirement of serum during ES cell 
propagation and derivation (Ying et al., 2003). While the TGF-13 family is large, only 
Bmp4, Bmp2 and GDF6 have this capacity (Ying et al., 2003). These ligands bind to 
hetrodimeric complexes of type I and the ligand-specific type II receptors (Figure 
1 .3b). The type II receptor is a senile threonine kinase that recruits and 
phosphorylates the type I receptor upon ligand binding. The type I receptor then 
phosphorylates a receptor-regulated SMAD (RSmad,). For Bmp signalling the 
RSMADs are SMAD 1, 5 and 8 (as opposed to 2 and 3 for Noda1ITGF-beta 
signalling), which in turn heterodimerise with SMAD4, a cooperating SMAD (C-
SMADs) (See Figure 1 .3b). These SMAD heterodimers translocate to the nucleus, 
interact with specific transcription factors and stimulate transcription (Hill, 2009). 
Ying et al (2003) reported that Bmp signalling maintains ES cell self-renewal by 
blocking neural differentiation through the activation of inhibitors of the pro-neural 
transcription factors, dominant negative bHLH proteins that inhibit the DNA by 
forming inhibitory heterodimers. Stimulation of Smadi, 5, and 8 in ES cells 
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maintains the expression of a number of these inhibitory (Id) genes and exogenous 
expression of Id proteins (Id], 1d2, or 1d3) bypasses the requirement for Bmp 
signalling in the maintenance of ES cell self- renewal (Ying et al., 2003). 
Although the downstream targets of the Id proteins in ES cells are not yet identified, 
the Id proteins may be repressing neural-specific (bHLH) transcription factors such 
as Mash 1 and Neurogenin 2 (Ying et al., 2003), or non bHLH proteins such as Pax 
factors (Norton, 2000). It was also proposed that Bmp signalling maintains ES cell 
self-renewal by inhibiting the ERK and p38 MAPK pathways (Qi et al., 2004). 
The Bmp4 and LIF pathways co-ordinate their functions to block both neuronal and 
non-neuronal differentiation. Thus, in the presence of LIF alone, ES cells 
differentiate towards the neuronal lineage, however, addition of Bmp4 or activation 
of Id proteins blocks this neuronal differentiation. Similarly, presence of Bmp4 
alone is not sufficient to block mesodermal and endodermal differentiation that is 
inhibited by LIF. Moreover, Stat3 and SMAD1 are known to form a complex in 
neuropithelial cells, and cooperatively regulate transcription (Nakashima et al., 
1999). This complex was also detected in mouse ES cells (Ying et al., 2003). The 
formation of the complex is likely to be dose-dependent. The precise balance 
between activated Stat3 and Smadi is important for the maintenance of self-renewal 
as the overexpression of SMAD 1/4 can induce non-neural differentiation even in the 
presence of LIF (Ying et al., 2003). The interaction between the LIF and Bmp 
pathways is supported by genetic studies in the mouse. The ablation of Bmp2 renders 
the uterine environment incapable of supporting embryonic development after 
implantation (Lee et al., 2007b), which is reminiscent of the L[ knockout mouse 
phenotype (Stewart et al., 1992). 
As with LIF, Bmp signalling has a very different role in human ES cells. Bmp4 
induces differentiation towards mesoderm and ectoderm, whereas Bmp2 addition 
directs ES cells towards the extraembryonic endodermal lineage (Schuldiner et al., 
2000). Moreover, the antagonism of Bmp signalling by Noggin in the presence of 
basic FGF (bFGF) maintains human ES cell self-renewal in the absence of both 
serum and feeder cells (Xu et al., 2005). 
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1.3.1.3. Wnt/-catenin pathway 
wingless-related MMTV iegration site proteins (Wnts) are secreted glycoproteins 
that are involved in tissue differentiation and organogenesis (Cadigan and Nusse, 
1997). Wnts bind their membrane receptors, Frizzled and low density lipoprotein-
related receptor (LRP) and signal through several pathways. The best characterized 
or so called "canonical pathway" signals through -catenin-mediated transcriptional 
program regulating cell fates (Logan and Nusse, 2004), while there are also 13-catenin 
independent pathways that signal through calcium flux, JNK, and G proteins 
(Veeman et al., 2003). 
The canonical pathway employs 3-catenin as a mediator of cytoplamsic signalling 
and transcriptional activation of gene expression (Fig 1 .3c). In the absence of Wnt 
signalling, 13-catenin is phosphoiylated by a protein complex consisting of glycogen 
synthase kinase (GSK3f3), adenomatous polyposis coli gene (APC) and Axin (Figure 
1 .3c). The phosphorylated 13-catenin then undergoes ubiquitin-mediated proteolysis. 
However, Wnt binding to its receptor leads to activation of Disheveld (Dsh), which 
then inhibits GSK3I3 resulting in the stability of 13-catenin and its accumulation in the 
cytoplasm (Figure 1 .3c). The accumulated f3-catenin enters the nucleus and binds the 
T cell factors (TCF5) transcription factors converting them from repressors to 
activators of gene transcription (Figure 1 .3c). 
Wnt signalling has been shown to play a role both in suppressing differentiation and 
promoting germ layer induction (Grigoryan et al., 2008). The canonical Wnt pathway 
plays a vital role in the formation of the anterior-posterior (A-P) axis, and germ layer 
differentiation, especially mesoderm induction (Huelsken and Bircbmeier, 2001; 
Niehrs, 1999). Canonical Wnt signalling also suppresses neural differentiation as 
Wnt3a (-I-) embryos have no primitive streak and exhibit ectopic neural tube 
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Figure 1.3-The external pathways governing pluripotency and self-renewal 
The LIF-Stat3 pathway. 
The Bmp-SMAD pathway. 
The WntJf3-catenin pathway. 
The FGF pathway. 




pathway in ES cell pluripotency. Sato et al (2004) reported that Frzd5 is highly 
enriched in self-renewing ES cells, and that Wnt signalling is endogenously activated 
in ES cells and only down-regulated upon differentiation (Sato et al., 2004). In 
contrast to LIF and Bmp signalling pathways, WntJ3-catethn signalling appears to 
have a similar role in regulating differentiation in both mouse and human ES cells 
(Kielman et al., 2002; Sato et al., 2004). The inhibition of GSK-3b activity with 
either 6-bromoindirubin-3'-oxime (BIO) (Sato et al., 2004) or Chiron (Ying et al., 
2008) enhanced the self-renewal of ES cells in undifferentiated state. Furthermore, 
Wnt3a was implicated in the maintenance of mES and hES cells in undifferentiated 
state, and required to sustain the expression of pluripotency markers Oct4 and Nanog 
(Ogawa et al., 2006; Singla et al., 2006). Additionally, the recent discovery of Tcf3; 
a transcriptional co-binder of 13-catenin, as a key factor of the core regulatory 
circuitry of ES cells, confirms the involvement of this pathway in maintaining ES 
cell self-renewal (Cole et al., 2008). 
1.3.1.4. P13K pathway 
Phosphojnositide kinase (P13K) is a kinase that catalyses the phosphorylation of 
lipids at the cell membrane. These lipids are a type of phosphojnositide (PIs) known 
as phosphotadylinositol phosphates (PIPs) (Figure 1 .3d). PI3Ks are divided into three 
classes depending on substrate specificity and sequence homology (Takahashi et al., 
2005). Class 1A of P13K consist of two subunits: a regulatory, and a catalytic 
subunit. These subunits come in several isoforms. 
Class 1A of PI3Ks is activated by various growth factor receptors such asFGF, EGF, 
and PDGF (see Figure 1 .3d). Activation of P13K can be achieved via a number of 
distinct mechanism(s) however, the principle activation occurs via Grb2 (growth 
factor receptor binding protein 2). Upon binding of growth factors to their receptors, 
the receptors and their associated proteins are auto-phosphorylated. The adaptor 
protein Grb2 binds to the phosphorylated receptor and activates the Ras/ERK 
pathway that in turn activates P13K (Figure 1 .3d). Active Grb2 also binds and 
phosphorylates Gab 1, which can directly activate the P13K pathway. P13K can also 
be activated via direct binding of the P13K regulatory subunit to the phosphorylated 
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tyrosine residue of the RTK or GTP-bound Ras (i.e. active Ras) (Takahashi et al., 
2005). 
The active P13K localizes at the plasma membrane, and catalyses the 
phosphorylation of inositol phospholipids (PIP2) generating 
phosphatidylinositol3,4,5-tris-phosphate (PIP3). These PIP3s are the ligands for the 
pleckstrin homology (PH) domains of several signal transducers including 
phosphoinositide-dependent kinasel (PDK1) and protein kinase B (PKB/Akt). PDK1 
and Akt binding to PIP3s leads to their co-localisation to the membrane and their 
phosphorylation. Active Akt phosphorylates many substrates including mammalian 
target of rapomycin (mTOR), BAD, mdm2, IKK and the FOXO transcription factors 
(Takahashi et al., 2005). 
This pathway has multiple auto-regulatory loops. Akt and mTOR regulate each other 
activity through phosphorylation. The pathway is negatively regulated by the p53 
target, PTEN (phosphatase and tensin homologue deleted on chromosome ten). 
PTEN can remove phosphates from PIP3s thereby inhibiting Akt activation. Akt in 
turn regulates PTEN via p53 degradation. Moreover, Akt-dependent phosphorylation 
MDM2 induces p53 degradation. As p53 normally activates PTEN, its degradation 
results in reduced PTEN expression (Stambolic et al., 2001). 
The P13K signalling pathway is involved in proliferation and inhibition of apoptosis 
during embryogenesis. Genetic ablation of multiple components of the pathway 
supports a role in the early embryo development, and self-renewal. Expression of 
catalytic and regulatory subunits of P13K class Ta starts at the one cell stage of 
embryo development (Lu et al., 2004; Riley et al., 2005), and the signalling 
emanating from P13K is required for pre-implantation development as the inhibition 
of the P13K pathway leads to the induction of apoptosis in both murine blastocysts 
and the trophoblast stem cells (Lu et al., 2004; Riley et al., 2006; Riley et al., 2005). 
Moreover, the deletion of the gene encoding the P13K catalytic subunit p1 10f3 leads 
to embryonic lethality at the blastocyst stage (Bi et al., 2002), whereas deleting the 
pllOa catalytic subunit causes mouse embryos to die between E9.5 to E10.5 as a 
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result of a proliferative defect during gastrulation (Bi et al., 1999). Disruption of 
other components of the P13K such as the regulatory subunit genes p85a and p853 
also results in lethality at E12.5 (Brachmann et al., 2005). 
In mouse ES cells, inhibition of P13K activity suppressed their transition from the Gi 
to the S phase, and lowered their proliferation rate (Jirmanova et al., 2002). 
Similarly, Pten null ES cells show an increased rate of cell proliferation and viability 
(Sun et al., 1999). Moreover, suppression of the P13K activity appears to reduce the 
ability of LIF to maintain mouse ES cell self-renewal by increasing the LIF induced 
phosphorylation of the pro-differentiation signalling kinase extracellular signal-
regulated kinase (ERK) (Paling et al., 2004). 
1.3.1.5. RasIRafJERK pathway 
Ras protein belongs to the low-molecular weight G-proteins super-family. Ras 
signalling can be activated by binding to many receptor tyrosine kinases such as 
FGF, EGF, PDFG growth factor receptors (Figure 1 .3d). Upon binding of growth 
factors to their receptors, the receptors and their associated proteins are auto-
phosphorylated. The SH2 domain-containing tyrosine phosphatase 2 (SHP2), and 
Grb2 bind to the phosphorylated receptor (see Figure 1 .3d). The binding of these 
adaptor proteins to the phosphorylated receptor leads to the recruitment of the 
guanine-nucleotide-exchange factor: son of sevenless (SOS), which in turn catalyses 
the transformation of the Ras from its inactive GDP-bound state to a GTP-bound 
active state (Okita and Yamanaka, 2006). Active Ras leads to the phosphorylation 
and activation of the Raf kinases, which activate ERK (Figure 1 .3d). The ERK 
pathway phosphorylates multiple proteins essential for cell cycle progression, 
survival and differentiation (Okita and Yamanaka, 2006). 
Several studies reported that the Ras/ERK pathway promote differentiation and 
antagonizes ES cell self-renewal. Burdon and colleagues (1999) showed that 
inhibiting the ERK signalling with the pharmacological inhibitor PD98059 leads to 
increased efficiency of ES cell derivation from blastocysts (Burdon Ct al., 1999). 
This was later confirmed by Batle-morera and colleagues (Batlle-Morera et al., 
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2008). The authors showed that ERK inhibition within the epiblast is important to 
maintain pluripotency, and demonstrated that ERK inhibition is required for the 
derivation of ES ôells from recalcitrant strains (such as C57BL/6) (Batile-Morera et 
al., 2008). 
A role for the Ras/ERK pathway in promoting ES cell differentiation was also 
reinforced by the fact that Grb2-deficient ES cells are unable to differentiate towards 
the endodermal lineage (Cheng et al., 1998). Similarly, ectopic expression of the 
active form of hRas in human ES cells directs ES cells towards the primitive 
endodermal lineages (Yoshida-Koide et al., 2004). Furthermore, the activation of 
ERK promotes ES cell differentiation and exit from self-renewal (Kunath et al., 
2007; Stavridis et al., 2007). 
1.3.1.6. 	Crosstalk between extrinsic factors and the ground state of 
pluripotency 
From the above discussion it is clear that multiple signalling pathways are necessary 
for the maintenance of ES cells in an undifferentiated state. Regulation of these 
pathways in different combinations improves the efficiency of ES cell derivation 
(Ying et al., 2008). For example, inhibition of ERK at the same time as stimulating 
Wnt signalling enables the derivation ES cells from rat blastocysts (Buebr et al., 
2008; Li et al., 2008). However, crosstalk between the different pathways can be 
instigated by external cues. Several cytokines can activate the same pathways. For 
example, in addition to the Stat pathway, LIF binding also induces gpl30 binding to 
the SHP2, which results in SHP2 phosphorylation by JAK (Schiemann et al., 1997; 
Stahl et al., 1995). The phosphorylated SHP2 binds Grb2 and activates the Ras/ERK 
pathway as well as Gabi leading to P13K pathway activation (Takahashi et al., 
2005). Moreover, Wu et al (2009) have recently linked LIF and Bmp signalling to 
SHP2 in ES cells. The authors reported a role for SHP2 in suppressing the Bmp4-
SMAD pathway and transcriptional repression of Id] and 1d2 (Wu et al., 2009). 
Another level at which these pathways interact is at the effector molecules. ERK is 
directly regulated by Bmps, P13K, LIF, and Ras signalling pathways (Okita and 
Yamanaka, 2006; Paling et al., 2004; Qi et al., 2004). 
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In addition to direct cross talk, different signalling pathways can converge on the 
same transcription factor network. For example, c-Myc, a key regulator of 
proliferation and potent inhibitor of ES cell differentiation, is not only activated by 
LIF through Stat3, but also indirectly by P13K (Paling et al., 2004) and Bmp 
signalling via a Ras-ERK activated transcription factors (Qi et al., 2004). Wnt 
signalling can also directly regulate c-Myc as GSK3-P phosphorylates c-Myc 
targeting it for proteosome-dependent degradation (Sears et al., 2000). 
This cross-talk between signalling pathways can be exploited to derive and maintain 
ES cells in an undifferentiated state independently of growth factors addition (Ying 
et al., 2008). LIF and Bmp signals are important to maintain ES cells self-renewing, 
while FGF-activated ERK induces differentiation. However, ERK remains active in 
ES cells supplemented by LIF and Bmp. Ying et al (2008) therefore reasoned that 
LIF and Bmp act downstream of activated ERK to block ES-cell differentiation. 
Using inhibitors of FGF receptor and ERK (the two inhibitirors are reffered to as 2i), 
they showed that ES cells remain undifferentiated in the absence of serum or Bmp, 
but still required LIF for their self-renewal. Without LIF, ES cells degenerated with 
compromised growth, a phenotype that can be reversed in ES cells by GSK3-
inhibition (3rd inhibitor) (Sato et al., 2004; Ying et al., 2008). The combination of the 
three inhibitors (the three inhibitors are reffered to as 3i) resulted in a dominant block 
of commitment and extremely efficient expansion of self-renewing colonies (Ying et 
al., 2008). Thus, ES cells can be maintained in culture conditions in which pro-
differentiation signals have been inhibited and this state has been referred to as the 
"ground state of pluripotency", implying that the undifferentiated state is the stable 
default in the absence of developmental inductive signals. 
1.3.2. Intrinsic factors 
Genetic dissection of factors involved in pluripotency yielded three main 
transcription factors that maintain pluripotency in the pre-implantation embryo as 
well as ES cells: Oct4, Nanog and Sox2. However a number of recent studies used 
these factors as starting point to dissect the pluripotency network. I will introduce 
briefly these factors. 
1.3.2.1. Oct4 
Oct4 was the first pro-pluripotency factor to be identified. It is both conserved in 
evolution and is common to all pluripotent populations. In chapter three of this thesis 
I focus on the means by which Oct4 regulates transcription and in chapter 4 on 
aspects of its coding sequence that are conserved. I briefly review the biology of 
Oct4 here, but will return to it in greater detail later. 
Oct4 is a homeodomain protein encoded by the Pou5fl gene. It belongs to the POU 
class V family of transcription factors. It is expressed in the unlertilised egg and the 
early embryo before the separation of 1CM from trophectoderm in the early 
blastocyst. Its expression becomes restricted to the 1CM and down-regulated in the 
TE and the primitive endoderm (Pesce and Scholer, 2001). Oct4 expession persists in 
the pluripotent epiblast of the pre- and post-implementation embryo, and is down-
regulated in. an anterior to posterior gradient such that it remains expressed in the 
region around the primitive streak. Following gastrulation, Oct4 is expressed in the 
primordial germ cells during their migration and within genital ridges in both sexes 
(Palmieri et al., 1994). Oct4 is expressed in pluripotent cell lines such as mouse and 
human embryonic stem cell lines, embryonal carcinoma cell lines (Okamoto et al., 
1990; Rosner et al., 1990; Scholer et al., 1989), embryonic germ cell lines, epiblast 
stem cells, and iPS cells (Do and Scholer, 2009). 
Oct4 null embryos develop only to a blastocyst-like stage and the 1CM is unable to 
expand leading to trophectoderm differentiation of 1CM cells in blastocyst growth 
assays (Nichols et al., 1998). However, while blocking trophoblast differentiation is 
fundamental to pre-implantation development, Oct4 appears to have a multi-faceted 
role in blocking differentiation during embryogenesis. In vitro analysis of ES cells 
with tetracycline responsive Oct4 allele established that Oct4 controls the 
pluripotency of stem cells in a quantitative fashion (Niwa et al., 2000). An increase 
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of 50% of wild type levels lead to differentiation to endodennal and mesodermal 
lineages, whereas low levels lead to trophectoderm differentiation (Niwa et al., 
2000). Similarly, knock down of Oct4 in both human and mouse ES cells produced 
both primitive endoderm and trophoblast differentiation (Hay et al., 2004). 
Moreover, knock down of Oct4 homologues in Xenopus result in precocious 
differentiation of both the prospective neural and marginal cells (Morrison and 
Brickman, 2006). Oct4, therefore, exhibits an evolutionary role in maintaining 
pluripotency in the early embryo. 
Oct4 is transcription factor that regulates the expression of multiple genes in ES cells 
that are physiologically relevant for maintaining pluripotency in the 1CM such as 
fibroblast growth factor 4 (Fg11) and zinc finger protein 42 (Zfp42 or Rex]). Oct4 
binds the octamer binding sequences within the promoters of target genes, and in 
cooperation with co-factors such as Sox2 and FoxD3 modulate gene expression 
either positively or negatively (Pan et al., 2002). 
One of the first factors to be shown to bind Oct4 was E1A (Scholer et al., 1991). 
El A interacts directly with the basal transcriptional machinery as well as chromatin 
modifiers such as p300 to modulate the expression of core factors downstream of 
Oct4 (Zhong and Jin, 2009). Oct4 binds Sox2 to modulate the expression of multiple 
genes involved in the maintenance of pluripotency such as Nanog, Utfi and Fgf4. 
Sox2 interacts with Oct4-specific regions outside the POU'domain (Ambrosetti et al., 
2000). The Oct4/Sox2 protein dimer recruits large multi-protein complexes to 
control gene expression in ES cells and the early embryo (Rodda et al., 2005). The 
two proteins interact differentially onto DNA of different target promoter/enhancers 
(Remenyi et al., 2003). Fgf4 enhancer contain the POU binding site adjacent to the 
Sox2 response element, while in the Utf] enhancer, the two binding sites are 
separated by 3bps. This slight difference affects the binding of the two proteins to 
DNA leading to a varied expression of Utf] and Fgf4 in the early embryo (Remenyi 
et al., 2003). 
Similarly, Oct4 directly binds FoxD3 to block the activation of endodermal specific 
gene expression of FoxA] and FoxA2 (Guo et al., 2002). FoxD3 activates the 
22 
expression of FoxAl and FoxA2, but Oct4 binds and inhibits FoxD3 transactivation 
of the two genes. 
1.3.2.2. Nanog 
Nanog was identified as a new regulator of self-renewal in ES cells by both 
functional cDNA expression cloning (Chambers et al., 2003) and digital differential 
display of expressed sequence tags (ESTs) (Mitsui et al., 2003). Chambers et a! 
(2003) identified Nanog in a screen for LIF-independent ES cell growth, whereas, 
Mitsui et al (2003) identified Nanog by comparing cDNAs from differentiated and 
undifferentiated ES cells. Both studies reported that Nanog over-expression 
compensate for both LIF and Bmp4 signalling. Nanog had been identified previously 
by Wang et al (2003) as a homeodomain-containing transcript that is predominantly 
expressed in 1CM and they called it ENK (early embryo specific NK) (Wang et al., 
2003). Nanog expression is initiated in the interior cells of the compacted morula but 
later confined and highly enriched in 1CM although in a more restricted fashion than 
Oct4 and its expression becomes down-regulated prior to implantation (Chambers et 
al., 2003; Wang et al., 2003). Nanog is later expressed in the epiblast and becomes 
restricted to the proximal posterior epiblast (Hart et al., 2004). Nanog expression is 
still detectable in PGCs during migration to and in the genital ridges between E9 and 
E13 (Chambers et al., 2003; Mitsui et al., 2003). Nanog null embryos die at the late 
blastocyst stage due the absence of the epiblast supporting a pivotal role for Nanog in 
the maintenance of the epiblast (Chambers et al., 2003; Mitsui et al., 2003). Nanog is 
enriched in human ES and mouse EpiS cells, both of which display epiblast-specific 
transcriptional signature (Do and Scholer, 2009). Outgrowths of Nanog-/- blastocysts 
give rise to high levels of primitive endoderm differentiation (Chambers et al., 2003; 
Mitsui et al., 2003). 
Nanog role in the maintenance of ES cells remains to be fully appreciated. Its 
importance in maintaining self-renewal stems from the fact that Nanog 
overexpression supports LIF-independent self-renewal (Chambers et al., 2003) and 
its essential role for reprogramming (Silva et al., 2008; Silva et al., 2009). However, 
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surprisingly, Nanog null ES cells are able to self-renew in vitro and express all the 
conmion pluripotency markers, as well as contribute to chimera formation (Yates and 
Chambers, 2005). These cells are identical to wild type ES cells except that they are 
unable to differentiate into mature PGCs (Yates and Chambers, 2005). Thus, while 
Nanog is not required for the maintenance of the pluripotent state, it maybe required 
for its establishment both during development (PGC formation) and in 
reprogramming. 
Nanog is a 305 amino acid phospho-protein that binds DNA as a dimer and deletion 
of a tryptophan rich interaction motif disrupts dimerisation and sufficient to block 
LIF-independent self-renewal (Mullin et al., 2008; Wang et al., 2008). 
1.3.2.3. Sox2 
ry-related HMG bp2 (Sox2) is a transcription factor belonging to the sequence-
specific high mobility group box (HMG) domain-containing protein family related to 
SRY (Sex-determining Region Y). Sox2 is a 317-amino acid protein containing 3 
domains: the N-terminal domain with unknown function, a 79-amino acid DNA 
HMG binding domain, and a C-terminal transcriptional activation domain 
(Episkopou, 2005). Like Oct4 and Nanog, mouse Sox2 expression is first detected at 
the morula stage and becomes restricted to 1CM (Avilion et al., 2003). Sox2 
expression continues in the epiblast until gastrulation when Sox2 becomes restricted 
to the presumptive anterior neurectoderm (Avilion et al., 2003). By mid-gestation, 
Sox2 becomes expressed in the developing CNS, sensory placodes, in the bronchial 
arches, and in the gut endoderm (Wood and Episkopou, 1999). Sox2 null embryos 
fail to survive after implantation (Avilion et al., 2003). Chimaera analysis 
demonstrated that there is a cell autonomous requirement for Sox2 in the epiblast and 
further in the extra-embryonic ectoderm (Avilion et al., 2003). 
Sox2 is expressed in both ES cells and in neural stem cells as well as other cells with 
restricted developmental potential (Fauquier et al., 2008). In stem cells, Sox2 is 
essential for self-renewal. Knock down of Sox2 by siRNA in ES cells promotes 
differentiation towards trophectoderm as well as other lineages such as mesoderm 
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and neural lineage (Ivanova et al., 2006). 
Sox2 binds DNA cooperatively with Oct4 to mediate the transcriptional regulation of 
Nanog as well as reciprocally regulate each other's expression (Rodda et al., 2005). 
The interplay between these three factors as well as other key regulators of 
pluripotency will be discussed in the next section. 
The transcriptional networks underlying pluripotency in ES cells mediated by Oct4, 
Sox2 and Nanog have recently been exploited to reprogram somatic cells back to 
pluripotent state. Forced expression of Oct4 and Sox2 alongside c-Myc and K1f4 
(called OSKM) in mouse and human embryonic fibroblasts was sufficient to 
generate iPS that are indistinguishable from ES cells (Takahashi et al., 2007a; 
Takahashi et al., 2007b; Takahashi and Yamanaka, 2006). Nanog appears to be 
required for this process, but was not part of the reprogramming quartet OSKM 
(Silva et al., 2008). Nanog also enhances nuclear transfer (Silva et al., 2006). 
1.3.3. The core transcriptional network regulating pluripotency 
Extrinsic and intrinsic factors maintain ES cell pluripotency by converging on a 
transcriptional network underpinned by a number of core transcription factors, 
prominently featuring Oct4, Nanog and Sox2. To begin to understand the 
mechanisms underlying pluripotency downstream of these three factors, several 
groups have mapped their target genes in mouse and human ES cells and begun to 
establish a core network for the regulation of pluripotency. 
Boyer et al (2005) used chromatin immuno-precipitation (ChIP) coupled with 
microarray analysis (ChIP-on-chip) to identify the targets of Oct4, Nanog and Sox2 
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in human ES cells. Their analysis was limited as the promoters present on the 
microarray used were pre-selected, and therefore, they were not representative of the 
whole non-transcribed genome (e.g. long range enhancers were excluded). Also, the 
authors did not include any functional analysis to verify gene up- or down-
regulation. The crucial finding of this study was that Oct4, Nanog and Sox2 co-
occupied a significant proportion of target promoters including their own promoters 
(Boyer et al., 2005). This strongly suggested a feed forward regulatory network as 
well as a feedback autoregulation loop between the three transcription factors. 
Most of the promoters co-bound by three factors control the expression of key 
developmental regulators encoding transcription factors many, of which are 
homeodomain proteins (Boyer et al., 2005). Some of these co-occupied targets were 
activated while others were repressed. Activated genes bound by the three factors 
such as Zic3 and Stat3 are mainly involved in proliferation and self-renewal, whereas 
inactive or repressed genes such as Pax6 and Myf5 are involved in differentiation and 
lineage commitment. This dataset suggested that the feed forward circuitry of 
pluripotency also involved the repression of lineage specific determinants. 
The core circuitry uncovered by Boyer et al (2005) in human ES cells was shown to 
be conserved in mouse ES cells (Loh et al., 2006; Zhou et al., 2007). Loh et al (2006) 
mapped Oct4 and Nanog targets only while Zhou et al (2007) extended the 
bioinformatics analysis to include Sox2. Loh et al used ChIP coupled to paired-end 
tag sequencing (ChIP-PET) as opposed to promoter arrays. CMPPET involves direct 
sequencing of all immuno-precipitated DNA fragments and is thetefore not biased by 
the selection of tags used to construct the array. This approach is both unbiased and 
has the advantage of generating targets throughout the genome, rather than just in the 
immediate upstream of the curated genes (Loh et al., 2006). 
In the Loh dataset, a considerable number of genes are co-occupied by Nanog and 
Oct4. Nanog and Oct4 co-localised to 345 target gene promoters, which represent 
44.5% of the total targets compared to 433 genes representing 70% in human ES 
cells. Using siRNA to knockdown Oct4 and Nanog, Loh et al 2006 reinforced the 
existence of an auto-regulatory circuitry and a feed forward network governing 
mouse ES cell pluripotency. Loss of Oct4 or Nanog reduced the level of their 
reciprocal expression as well as that of Sox2. Expression levels of most genes bound 
by the two factors changed upon siRNA knockdown of Oct4 or Nanog. Downstream 
targets involved in self-renewal maintenance such as Esrrb, RtIJ, TcJ3, Jarid2, Sail] 
and Rest were down-regulated, whereas genes involved in lineage commitment such 
as Pax6 were upregulated. However, not all bound genes were affected by Oct4 or 
Nanog loss. This could be explained by functional redundancy in transcriptional 
regulation or by the possibility of the binding sites being simply non-functional (Loh 
et al., 2006). 
Further analysis of the binding sites of Oct4 and Nanog on DNA revealed that the 
binding sequences were separated by an average of 25bps on some promoters in the 
mouse ES cells (Loh et al., 2006). Similar distances are also observed when the 
binding sites for all three factors were considered in mouse or human ES cells (Boyer 
et al., 2005; Marson et al., 2008). The binding of these factors close to one another 
supports the presence of large cooperative protein complexes mediating transcription 
throughout the network. Such complexes could contribute to the stability of self-
renewal, while allowing for a rapid exit from the pluripotent state based on a loss or 
change in the levels of any one of the three proteins (Chen et al., 2008a). 
1.3.3.1. Hierarchical regulatory network of pluripotency 
As discussed above, these global ChIP studies uncovered a hierarchical regulatory 
network whereby the key three regulators co-occupy the promoters of key 
developmental transcription factors in mouse and human ES cells. Pax6, Tcll, Stat3, 
TcJ3, Esrrb, Rfl,  Sa114 and Rest are targets of all three factors in mouse (Loh et al., 
2006; Zhou et al., 2007) and human ES cells (Boyer et al., 2005). These 
developmental factors regulate multiple secondary targets to induce differentiation 
(e.g. Pax6) or promote self-renewal (e.g. Stat3). The prediction implicit in these 
datasets is that the core pluripotency factors activate regulators involved in self- 
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renewal while repressing those involved in lineage commitment. Interestingly a 
number of these "repressed targets are co-occupied by Polycomb group genes (Boyer 
et al., 2005; Loh et al., 2006). The implication of these studies is that the repression 
of lineage determinants by the core pluripotency complex is an essential component 
of how these proteins maintain ES cell self-renewal. In chapter 3 of this thesis I 
show that this is most likely not the case and lineage specific repression by Oct4 and 
associated factors may at best be a secondary failsafe mechanism present in case the 
stable feed forward pluripotency network collapses. 
While the combination of the three core factors appears associated with repressed 
promoters, these proteins are all representative of generic DNA binding domains, 
homeodomain, HMG domain and octamer proteins. For this reason, a number of 
these global ChIP studies may be plagued by artificial binding sites. Moreover, while 
a number of candidate Oct4 targets came out of the original ChIP studies, direct 
targets identified in numerous previous studies such as Fgf4, Utfi and Pdgfa were 
not on the lists of Boyer et al (2005) or Loh et al (2006). A number of functional and 
in silico approaches to address this problem have been taken. This has focused 
particularly on Oct4 as it is the best characterized of the three. As mentioned above, 
genes co-occupied by the core transcription factors are not necessarily real functional 
targets of these factors. Moreover, even if they are targets, it is not clear what the 
individual role of components in this large network would be. 
Recent studies suggested that a number of regulators to come out of these target 
screens are essential determinants of pluripotency. An early factor to come out of this 
analysis is Sal14. Sa114 has been shown to regulate Oct4 expression in ES cells 
(Zhang et al., 2006), to bind Nanog promoter (Wu et al., 2006), and has recently 
been shown to regulate distinct circuitries in the two other blastocyst-derived stem 
cell lines: extraembryonic endoderm (XEN) versus ES cell lines (Lim et al., 2008). 
In ES cells Sal14 form an extended auto-regulatory network with Oct4, Nanog and 
Sox2, and its deletion induced differentiation (Lim et al., 2008). While in Xen cells 
Sal14 regulate Sox and Gata factors to maintain Xen cells self-renewing (Lim et al., 
2008). Other targets that were also shown to be required for pluripotency include 
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Esrrb and Rifi. Knock down of both of these proteins resulted in ES cell 
differentiation to a flattened fibroblast morphology (Loh et al., 2006). 
The chromatin modifiers Rest and Jarid2 are also targets of all three factors that were 
functionally tested and validated as real functional targets (Loh et al., 2006). Rest 
was recently shown to control pluripotency in ES and NS cells (Johnson et al., 2008; 
Singh et al., 2008), while Jaridl/2c was shown to modulate H3K9me2 at both Tcll 
and Nanog promoters leading to their activation (Loh et al., 2007)(See Figure 1.4). 
Other studies tried to identify new genes involved in the maintenance of ES cell self-
renewal using functional analysis. Campbell et al (2007) used statistical analysis 
combined with expression profiling to identify the genes that are activated or 
repressed by Oct4 as an alternative approach (Campbell et al., 2007). They identified 
392 genes that correlated with Oct4 expression and possessed at least one putative 
composite binding site for Oct4 and Sox2. After validation of 28 of these genes by 
ChiP and quantitative real time PCR, they confirmed the identification of 26 Oct4 
direct transcriptional targets (Campbell et al., 2007). While only 5 genes out of these 
26 genes were identified by ChIP-PET and ChIP-chip based studies, 25 genes were 
also identified by Matoba and colleagues (Matoba et al., 2006). Matoba et al (2006) 
and Sharov et al (2008) also used a combination of these approaches, to address the 
issue. By looking at immediate early response to Oct4 depletion using a tetracycline 
(Tc)-suppressible system, they reached the conclusion that the majority of Oct4 
targets were activated by it (Matoba et al., 2006; Sharov et al., 2008). 
While all of these studies have examined specific regulators individually, there have 
also been a number of large scale screens aimed at defining functional determinants 
for ES cell self-renewal. Ivanova et al (2006) defined a set of 70 genes expressed in 
ES cells and are rapidly down regulated during differentiation. They stably knocked 
down all 70 genes by small hairpin RNA (shRNA) and characterized the phenotypes 
(Ivanova et al., 2006). They identified eight genes that perturb self-renewal upon 
knockdown. These genes were Oct4, Nanog, Sox2, Esrrb, Tbx3, Tcll and Dppa4 as 
well as the unassigned EST Mm.343880. Knock down of Oct4, Nanog or Sox2 
resulted in differentiation to multiple lineages. The study showed that Esrrb and 
Tbx3 inhibit mesodermal, ectodermal and neural crest differentiation, whereas Tcll 
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loss promotes differentiation towards the neural crest (Ivanova et aL, 2006). 
Interestingly, the down-regulation of Nanog, Sox2, Esrrb, Thx3 or Tcl] all led to the 
induction of 01x2 and PiIx2 (Ivanova et al., 2006). Otx2 and Pitx2 are key 
transcriptional regulators of mesodermal and neurectodermal gene expression and 
are regulated by Oct4 and a Nanog-Sox2 complex respectively (Boyer et al., 2005; 
Loh et al., 2006; Matoba et al., 2006). Knockdown of any of the eight genes (Oct4, 
Nanog, Sox2, Esrrb, Tbx3, Tcll, 01x2 and Pitx2) affected the expression of other 
pluripotency genes including the core three factors (Ivanova et al., 2006). 
1.3.3.2. An extended core transcriptional circuitry 
The expansion of the core group of pluripotency regulators as a result of 
transcriptional profiling, ChIP studies, functional and molecular studies of ES cells 
has lead to a revision of the target data sets. 
Non-biased ChIP-Sequencing has been 'performed by two different groups: Chen et 
al (2008) and Kim et al (2008). Chen et al (2008) used ChIP-sequencing to identify 
targets of 13 transcription factors (TFs) and 2 chromatin modifiers. The aim of their 
study was to locate the binding sites of the core factors (Nanog, Oct4 and Sox2), the 
downstream transcription factors of the external signalling pathways (Stat3 and 
Smadi), the targets of reprogramming factors (c-Myc, n-Myc and K1f4), the 
- downstream targets of other factors implicated in ES cell self-renewal (Zfx, Esrrb 
and Tcfcp2I1), the cell cycle regulator (E2f1), chromatin insulator TF (CTCF), 
enhancer-specific acetylatransferase (p300), and PcG methyltransferase (Suzl2). The 
sensitivity of this study appears greater than the previous ChIP studies as they 
identified new bindings sites for the original core factors. 
They also reported that the binding sites formed two major clusters, one constellation 
of sites that bound Oct4 and the other Myc (Chen et al., 2008b). Sox2, Nanog, 
Smadi, Stat3, Esrrb, Klf4 and Tcfcp2I1 binding was associated with the Oct4 
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binding sites, whereas E2f1, Zfx and CTCF were all associated with Myc binding 
(Chen et al., 2008b). In total, 3583 multiple transcription factor binding loci (MTLs) 
bound by at least 4 factors were identified. To test the activity of these MTLs, 25 
Oct4-MTLs and 8 Myc-MTLs were tested for the capacity to drive heterologous 
reporter genes. Only the Oct4-MTLs harboured a strong ES cell-specific activity. 
Interestingly, 87.4% of Smadl and 56.8% of Stat3 binding sites are within Oct4 
centric MTLs (Chen et al., 2008b) supporting the notion that these core MTL 
sequences integrate signalling with the network. Thus, these Oct4 clusters may 
represent ES cell specific enhancesomes, which may act as connecting points 
between the external signalling pathways and the core transcriptional network (Chen 
et al., 2008b). Further analysis also unveiled an extended feedback loop between the 
core factors and Stat3 as well as an extended interconnectivity between 11 TFs out of 
the 13 analysed. The connections between the nodes in the network were categorised 
into feed forward ioop, biparallel motif, fully connected triads and multiple input 
motifs (Chen et al., 2008a; Chen et al., 2008b). 
The Orkin laboratory took a similar approach to mapping the occupancy of nine 
transcriptional regulators in murine ES cells (Kim et al., 2008). They used in vivo 
biotynilation instead of native antibodies followed by ChIP-seq to analyse the core 
factors (Oct4, Nanog, Sox2), the remaining reprogramming factors (K1f4 and c-
Myc), and Nanog binding proteins identified by Wang et al (2006) (Daxi, Rex 1, 
Zpf281, and Naci) (Wang et al., 2006). They found that target genes in pluripotent 
cells fall into two categories: repressed and active genes. Interestingly, the repressed 
genes tend to be bound by fewer factors, while activated genes were bound by four 
or more factors (Kim et al., 2008). Also, as shown by Chen et al (2008) and Kidder 
et al (2008), this study confirmed that Oct4 and c-Myc bound distinct gene promoters 
and showed similar wiring patterns of gene expression underlying transcriptional 
network in ES cells (Kidder et al., 2008). 
Recently, global ChIP analysis of Tcf3, a downstream component of the Wnt 
pathway, was performed and compared to the datasets available for the core 
pluripotency facts (Cole et al., 2008). Tcf3 was found to bind the same genes as the 
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core factors, and form an autoregulatory circuitry with the core pluripotency factors 
Oct4, Nanog, and Sox2 (Cole et al., 2008). Tcf3 was shown to be important for 
maintaining pluripotency and self-renewal both in vivo and in vitro. It's expression 
pattern and ablation in pre-implantation embryos support a role in maintaining 
pluripotency in vivo and its loss in ES cells leads to differentiation (Cole et al., 
2008). 
Moreover, a recent unbiased screen of the entire genome employing gridded shRNA 
libraries identified 148 genes that were required for the maintenance of ES cells in an 
undifferentiated state (Hu et al., 2009; Kidder et al., 2008). This extended list 
included the core factors and some of their direct and indirect targets. However, it 
also unearthed a novel regulatory network, not evident in the OctlSoxlNanog targets. 
Transcription regulators Cnot3, Trim28, c-Myc and Zfx appear to co-occupy the 
same targets and are all required for ES cell self-renewal (Hu et al., 2009; Kidder et 
al., 2008). The targets of this complex are associated with cell cycle, apoptosis and 
cancer (Hu et al., 2009; Kidder et al., 2008). A similar screen using an Oct4-GFP 
reporter (Ding et al., 2009) uncovered the core factors and some of their targets, in 
addition to a new factor, PafiC (Figure 1.5.). PafiC regulates the Oct4 promoter 
directly and its over-expression blocks ES cell differentiation while its down-
regulation leads to differentiation (Ding et al., 2009). 
1.3.3.3. MicroRNAs are a part of the hierarchical network 
In addition to key signalling pathways, the Oct4, Sox2 and Nanog network contains a 
number of micro-RNAs (miRNAs) (Loh et al., 2006; Marson et al., 2008). Some of 
the miRNAs identified were donw-regulated upon differentiation, and their ablation 
mediated differentiation towards multiple lineages (Marson et al., 2008) while others 
were upregulated during differentiation (Tay et al., 2008). Interestingly, miRNAs 
also target Sox2, Nanog and Oct4 and down regulate their expression (Tay et al., 
2008). miR-134, miR-296 and miR-470 are induced upon RA differentiation, and 
they target the 3' UTRS of all three genes (Tay et al., 2008). 
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Similar results have been obtained in human ES cells (Xu et al., 2009). In human ES 
cells, miRNA-145 was shown to directly bind the 3'UTRs of Oct4, K1f4 and Sox2 
and down-regulate their expression during differentiation. m1RNA -145 ablation 
elevates the expression levels of the three factors, and induced differentiation (Xu et 
al., 2009). Moreover, its expression appears to be regulated by Oct4 (Xu et al., 
2009). Together, the miRNAs involved in self-renewal behave with the same 
dynamics as other factors of the core transcriptional network of pluripotency and 
exhibit similar feed-back loops. 
1.3.3.4. Protein complexes interacting with the core transcription factors 
The network so far has been focused on the trinity of Oct4, Nanog and Sox2. 
However, the notion of co-occupied promoters came out of the ChIP analysis, rather 
than an unbiased approach to the different complexes containing Oct4, Sox2 and 
Nanog. To address this, a number of different affinity purification approaches have 
been used. Using Nanog as a bait to pull down binding proteins, Wang et al (2006) 
identified a protein interaction network (Wang et al., 2006). Nanog binds directly to 
ES cell specific transcription factors, Oct4, Daxi, Naci and Zfp281 (Wang et al., 
2006). All of which were shown later to interact with Nanog but also Oct4 and Sox2 
on promoters of target genes (Kim et al., 2008). Nanog also appears to bind a number 
of global chromatin modifiers such as REST, HDAC2, PcG proteins and components 
of the SWI/SNF complex (Wang et al., 2006). Members of these complexes are both 
partners and targets for transcriptional regulation by Oct4, Nanog and Sox2 (Orkin et 
al., 2008; Wang et al., 2006). Moreover, the components of this network are 
interdependent, as siRNA knockdown of a single component results in loss of 
pluripotency. These results suggest the presence of multi-protein complexes that 
serve as a functional module to maintain ES self-renewal. Using antibodies to the 
native proteins Liang et al (2008) identified a smaller set of proteins by immuno-
precipitation and mass spectroscopy (Liang et al., 2008). This list overlapped 
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considerably with those derived from BirA tagging (Orkin et al., 2008; Wang et al., 
2006) and contained a number of global repressor complexes associated with both 
Oct4 and Nanog including NurD, Sin3 and Pm! complexes. Interestingly, the 
composition of the newly identified NuRD complex was distinct from known NuRD-
associated complexes. The NuRD complex associated with Oct4 and Nanog called 
NODE (for Nanog and Oct4 associated deacetylase) contains preferentially Mtal 
while Mbd3 and Rbbp7 are either lacking or present at low levels (Liang et al., 
2008). Knockdown of Mtal, Mta2 or Hdac2 lead to impairment of ES self-renewal. 
In particular, Mta] loss upregulated the expression of endoderm lineage-specific 
genes Gata6 and FoxA2 recapitulating Nanog knockdown (Liang et al., 2008). 
1.3.4. Epigenetic regulation of pluripotency 
The central role of transcription factors in pluripotency brings an intriguing 
possibility that chromatin and DNA modifications (i.e. epigenetics), the major 
substrates of transcription, are important for pluripotency. Epigenetic modifications 
modulate transcriptional regulation in specific genomic regions and underpin the 
cross talk between transcription factors and basal transcriptional machinery (e.g. 
TATA binding and RNA II [i.e P0111]). For example, DNA methylation is indicative 
of silenced loci, trimethylation of lysine 9 and lysine 27 of histone 3 (H3K9me3 and 
H3K27me3, respectively) indicates repressed genes, whereas trimethylation of lysine 
4 of histone 3 (H3K4me3) and acetylation of histone 3 or 4 tails represent active 
genes. Epigenetics is known to be important for oocyte to zygote transition, and 
determines the totipotentiality of the zygote (Surani et al., 2007). Pluripotent cells are 
epigenetically different from either the zygote or more differentiated cells even 
though they have the same genetic makeup. Therefore, epigenetics is one of the 
major determinants of lineage commitment and differentiation. 
1.3.4.1. Chromatin and chromatin modifications of ES cells 
Studying chromatin structure of ES cells and mapping different chromatin 
modifications across the ES cell genome suggested that chromatin is more 
permissive in self-renewing ES cells and becomes restrictive upon differentiation 
(Surani et al., 2007). 
Meshorer and colleagues assessed the global chromatin status of ES cells by 
measuring the exchange rate of chromatin associated protein, they used fluorescent 
recovery after photo-bleaching (FRAP) to analyse the mobility of chromatin proteins 
in ES cells versus differentiated cells. They reported that major chromatin 
architectural proteins such as the linker histone Hi, histones H2B, H3, and 
heterochromatin-associated protein (HPlct) bind loosely and briefly to the chromatin 
of self-renewing mouse ES cells making it more accessible to transcription factors 
and chromatin modifiers (Meshorer and Misteli, 2006). However, upon 
differentiation, the dynamic nature of these architectural proteins decreases. 
Moreover, they also showed that heterochromatic markers are dispersed in mouse ES 
cells and become more concentrated in distinct foci in differentiated cells (Meshorer 
and Misteli, 2006). 
Other studies also investigated the global chromatin state of ES cells using different 
assays. Azuara and colleagues used replication time as an indicator of chromatin 
state (Azuara et al., 2006). Early replication during S phase is a characteristic of 
transcriptionally active regions of the genome, and therefore is an indicator of open 
chromatin. However, late replication is an indicator of heterocbromatin, and gene 
repression (Azuara et al., 2006). They reported that lineage specific genes that are 
not active in ES cells replicted earlier in pluripotent cells than differentiated cells, 
and had both actiye and repressive chromatin marks, suggesting that these lineage 
specific genes are poised for expression in ES cells and held in check until their 
appropriate time of expression (Azuara et al., 2006). This in turn suggests that the 
chromatin of pluripotent cells is more permissive than that of differentiated cells. 
Global analysis of histone modifications also suggests that there is an overall loss of 
the open chromatin state with differentiation. ES cells are characterised by high 
levels of activating H3K4me3, that is lost and replaced by repressing H3K27me3 and 
H3K9me3 upon differentiation (Bernstein et al., 2006; Meshorer and Misteli, 2006; 
Mikkelsen et al., 2007; Reik, 2007). Similarly ES cells exhibit high levels of histone 
acetylation which decrease with lineage commitment (Meshorer and Misteli, 2006). 
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1.3.4.2. Bivalent domains and poised expression in ES cells 
As discussed in earlier sections, the core pluripotency factors were found to activate 
genes involved in self-renewal while repress the ones implicated in lineage 
commitment (Boyer et al., 2005; Loh et al., 2006). In fact, it was reported that most 
of the co-occupied targets are repressed rather than activated (Boyer et al., 2005; Loh 
et al., 2006). While this has yet to be formally proven, a number of groups have 
looked at the chromatin states at some of these genes. ChIP mapping of H3K4me3 
and H3K27me3 revealed that a number of these genes contain both active and 
repressed chromatin marks (Azuara et al., 2006; Bernstein et al., 2006). While this 
was initially puzzling, the presence of these marks or "bivalent domains," was 
thought to represent a class of genes repressed, but poised to be activated. 
Interestingly genome-wide ChIP-seq (or chip-chip) for these modifications suggest 
they are mostly associated with differentiation-specific genes that are inactive or 
expressed at very low levels in self-renewing ES cells (Azuara et al., 2006; Bernstein 
et al., 2006). It was suggested that bivalent domains offer a model for transcriptional 
regulation of tissue-specific genes (Bernstein et al., 2007). They are silenced in ES 
cells but are activated upon differentiation (Mikkelsen et al., 2007). However, this 
model is challenged by findings that OCT4, NANOG, and SOX2 are marked by only 
active chromatin mark (H3K4me3) in undifferentiated human ES cells, but acquire a 
bivalent domain configuration upon differentiation (Pan et al., 2007). 
Many studies question the functional relevance of these bivalent domains in ES cells. 
They report that bivalent domains are not unique to pluripotent cells, but were also 
observed in progenitor cells such as neural progenitor cells, committed cells such as 
MEFs and terminally differentiated cells such as lung fibroblasts and T cells (Barski 
et al., 2007; Mikkelsen et al., 2007; Pan et al., 2007). 
1.3.4.3. Polycomb group proteins 
The H3K27 trimethylation in the "bivalent domain," is catalysed by the polycomb 
repressor complex 2 (PRC2) and this modification is generally associated with PRC2 
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targets. PRC2 consists of three proteins including proteins: embryonic ectoderm 
development (Eed), suppressor of zest 12 (Suzl2) and the H3K27 methyltransferase: 
enhancer of zest homologue 2 (Ezh2) (Pietersen and van Lohuizen, 2008). 
Interestingly about half of the genes that exhibited H3K27me3 were also bound by at 
least one of the pluripotency transcription factors Oct4, Nanog, or Sox2 (Boyer et al., 
2005; Boyer et al., 2006b). However, ES cells mutant for specific PRC components 
do not display a defect in pluripotent gene expression, but rather have strong 
phenotypes of differentiation (Boyer et al., 2006a). Null embryos for PRC 
components are embryonic lethal and exhibit gastrulation defects, suggesting a 
failure in lineage specification (Faust et al., 1998; O'Carroll et al., 2001; Pasini et al., 
2007; Pasini et al., 2004; Pasini et al., 2008b). Specific defects in individual PRC 
components appear to have similar phenotypes in ES cells. Eed null cells exhibit 
global reduction of H3K27me3 and propensity to differentiate but retain the 
expression of pluripotent factors (Boyer et al., 2006b). Similarly, Suzl2-1- ES cells 
self-renew but are differentiation-defective (Pasini Ct al., 2007; Pasini Ct al., 2004). 
Moreover, Chamberlain et al (2008) have shown that PRC2 is dispensible for ES 
cell maintenance in pluripotency state, but is required for differentiation of ES cells 
(Chamberlain et al., 2008). 
One of the functions of PRC2 is to recruit PRC 1. PRC 1 core components are 
Ring 1 A, Ring 1 B and Bmi 1. Embryos mutant for the PRC 1 components also exhibit 
early embryonic lethality and gastrulation defects (Pasini et al., 2008a). ES cells that 
are null for both RinglA and RinglB loose the typical morphology of ES cells, and 
have an impaired proliferation (Endoh et al., 2008). ChIP-on-chip against specific 
PRC components PhcI and Rnf2 (PRC1) as well as Suzl2 and Eed (PRC2) 
identified 512 targets bound by the complete set of these proteins and exhibited the 
repressive mark H3K27me3 (Ku et al., 2008). The dataset was enriched in 
developmental regulators including the Hox, Dlx, Irx, Lhx, Pou, Pax and Six gene 
families. These genes were all upregulated in PRC knock downs suggesting a direct 
role for PcG proteins to silence these targets in ES cells. Similarly, during ES cell 
differentiation these genes loose H3K27me3 (Ku et al., 2008; Lee et al., 2007a). Lee 
et a! (2006) reported similar findings using the PRC2 component SUZ12 in human 
ES cells (Lee Ct al., 2006). 
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These finding support a role of PRC proteins in suppressing the expression of key 
lineage determinants in ES cells, but this does not fit with either their embryonic or 
ES cell phenotypes, which suggests that these proteins play a more fundamental role 
in differentiation. 
1.3.5. Cross-talk between epigenetic and the core factors of pluripotency 
A number of candidate Oct4, Sox2 and Nanog targets are chromatin modifiers. For 
example Oct4 represses genes such as Set7, the methyltransferase catalyzing mono-
methylation of histone H4 lysine 20 (H4K20) and Hdac6 (Babaie et al., 2007). Oct4 
also regulates Jmjdla and Jmjd2c, genes encoding the H3K9me2 demethylases 
(Figurel.4) (Loh et al., 2007). Oct4 also interacts with Stat3 to upregulate the 
expression of the PRC2 core protein Eed (Ura et al., 2008). Moreover, Oct4 down-
regulation leads to inactivation of other PRC proteins such as Suzl2 and Phd 
(Endoh et al., 2008). Oct4, Nanog and Sox2 target a number of other chromatin 
factors including Eset, Myst3 and Smarcadi (Boyer et al., 2005). As a result, Oct4 
indirectly regulates histone modification and the epigenetic status of an array of non-
target genes through such chromatin modifiers. Moreover, pluripotency factors have 
also been shown to interact directly with chromatin modifiers. As discussed above, 
Oct4, Nanog and Sox2 co-occupy many of the targets of PRC2 to mediate gene 
silencing (Lee et al., 2007a). Furthermore, Ringib, a PRC1 component, has also been 
shown to be recruited to its targets in an Oct4-dependent manner to repress gene 
expression (Endoh et al., 2008). Nanog and Oct4 also interact with the histone 
deacetylase complex NuRD (P66b and HDAC2), polycomb group (YY1, Rn12, 
Rybp) and SW1/SNF chromatin remodelling complex (Wang et al., 2006). 
Some of the pluripotency factors are themselves also regulated by epigenetic factors. 
The Oct4 locus is progressively repressed during ES cell neural differentiation. This 
repression is accompanied by the loss of active epigenetic marks and their 
replacement with repressive marks (Aoto et al., 2006). Additionally, germ cell 
nuclear factor (GCNF) interacts with Dmnt3 and recruits methyl-binding domain 
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proteins (MBDs) to the Oct4 locus to mediate its silencing by DNA methylation 
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Figure 1.4- Genetic and epigenetic mechanisms of pluripotency 
The pluripotent state is maintained by a crosstalk between 1) factors of transcriptional 
network, 2) external pathways, and 3) epigenetic determinants. The pluripotency is 
induced by the transduced transcription factors (OSKM) during the process of 
reprogramming. OSKM maintain a transcriptional network akin to the core ES cell 
transcriptional network (OSN). OSN cooperate with DNA and chromatin modifying 
enzymes as well as miRNAs to maintain pluripotency in vitro (ES cells) and in vivo 
(1CM). 
The abbreviations are as follows: JHDM, histone demethylases of the JrnjC family; K, 
K1f4; M, c-Myc: miRNA, microRNA; N, Nanog; 0, Oct4; PcG, polycomb group; S, 
Sox2; TFs, transcription factors; Xist, X inactivation specific transcript. '?' not yet 
illustrated. 
Adopted from (Do and Scholer, 2009). 
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Dnmt3a and Dnmt3b are not only bound to the Oct4 locus but have been recently 
shown to mediate also Nanog silencing after ES cell differentiation (Figure 1.5) (Li et 
al., 2007). Loh Ct al (2007) further showed that Oct4-mediated activation of Jmd1a 
and Jmjd2 positively regulate pluripotency-associated genes. While Jmijdla 
demethylates H3K9me2 at the promoters of Tcll, TcfcJ2ll, and Zfp57; Jmjd2c 
demethylates H3K9Me3 at the Nanog promoter leading to its activation (Loh et al., 
2007). 
1.4. Detail analysis of Oct4 
1.4.1. Embryonic expression of Oct4 
Pou5fl is a maternally expressed gene and the Oct4 protein is present at low levels in 
the oocyte until fertilisation (Palmieri et al., 1994). The expression becomes weak 
but detectable up until the 8 cell stage where the levels of Oct4 transcript and protein 
increase to the point that all cells in the morula stage are Oct4-positive (Palmieri et 
al., 1994). Zygotic expression of Oct4 begins at the four- to eight-cell stage. At these 
early stages, uniform expression of Oct4 is observed in all blastomeres. During 
compaction, the outermost cells down-regulate Oct4 expression and differentiate 
towards the TE lineage. This is mediated by a negative feedback loop between Oct4 
and Cdx2 (Niwa et al., 2005). The expression of Oct4 is restricted to the inner cell 
mass from the compacted morula stage onward. The primitive endoderm cells that 
start to differentiate and migrate alongside the inner surface of the TE transiently 
express higher levels of Oct4 protein than in the 1CM, something that was not 
detected by RNA localization studies (Palmieri et al., 1994; Pan et al., 2002). Post-
implantation, Oct4 expression is further restricted to the epiblast, and at gastrulation 
this expression becomes further restricted in a posterior-proximal direction where 
Oct4 remains expressed in the primitive streak region until the end of gastrulation 
(Boiani and Scholer, 2005). Following gastrulation Oct4 becomes restricted to the 
primordial germ cells (Boiani and Scholer, 2005). The expression of Oct4 strongly 
correlates with cells that maintain the widest range of potency at each stage of the 
embryo development. Moreover, most multi-lineage potent stem cell lines (ES, EG, 
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EpiS and iPS) express Oct4 (Do and Scholer, 2009). Upon the differentiation of all 
these types of embryonic pluripotent cells, Oct4 decreases confirming that Oct4 is 
marker of pluripotency. Several studies have reported that Oct4 is expressed in 
somatic stem cells. However, it has been recently shown that results can be explained 
by an expression of a pseudogene (Lengner et al., 2008). 
1.4.2. Regulation of 004 expression 
Based on experiments in transgenic lines with reporter genes, 18 Kbps of the 
promoter that recapitulates accurately the endogenous expression of Oct4 was 
characterised (Yeom et al., 1996). The TATA-less promoter of Oct4 has been shown 
to contain three regions essential for its restricted expression before and after 
implantation. The proximal promoter (PP, see Figure5a) is within the first 250 bp of 
the transcriptional start site, it contains three overlapping half-sites of hormone 
response element (HRE), which is known as canonical retinoic response elements 
(RARE) (Schoorlemmer et al., 1994; Sylvester and Scholer, 1994). The proximal 
promoter of 0cM also contains an overlapping GC box (5'-
(G/T)GGGCGG(G/A)(G/A)(C/T)-3') that is bound by the zinc finger transcription 
factor Spl (Minucci et al., 1996). However, Spi null mice have normal expression of 
Oct4, suggesting that other related zinc fmger proteins compensate for its function in 
development such as the Kruppel-like factor (KLF) protein. K112, 4 and 5 are 
essential for the maintenance of ES cells and good candidate regulators for this 
region (Jiang et al., 2008). 
Adjacent to the proximal promoter are the proximal and distal enhancers (PE and 
DE, respectively see Figuresa), both of which are essential for stage and cell type-
specific expression. DE drives expression in the 1CM and ES cells, while the PE 
regulates Oct4 expression in the ectodermal lineage as well as P19 EC cells 
(Okazawa et al., 1991; Yeom et al., 1996). Using in vitro DNA footprinting, the 
precise binding sites of protein complexes on PE and DE were identified. Two GC-
box rich sites 1A and 2A were found in PE and DE respectively, both are crucial for 
driving expression from the two enhancers but showed no ES specific expression 
(Minucci et al., 1996; Pesce and Scholer, 2001). 
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However the factors involved in regulating Oct4 promoter activity are not well 
undersood. Heterodimers of nuclear hormone receptors RAR and RXR were shown 
to positively regulate Oct4 expression in undifferentiated P19 cells, through binding 
to RARE sequence in the PP. However, during RA induced differentiation of ES 
cells, this activation can be blocked by the binding of the orphan nuclear receptors 
COUP-TF 1, COUP-TF 11 (ARP 1) and EAR2 to the RARE sequence as inactive 
homo- or hetero-dimers with RXR (Ben-Shushan et al., 1995; Sylvester and Scholer, 
1994). Unlike the orphan nuclear receptors stated above, Liver Receptor Homologue-
1 (LRH- 1) is required for the maintenance of Oct4 expression at the epiblast stage 
(Gu et al., 2005). Moreover, LRH-1 was shown to bind to PE and DE and activates 
Oct4 expression in undifferentiated ES cell (Gu et al., 2005). The other known 
positive regulators of Oct4 expression include steroid factor 1(SF1) (Barnea and 
Bergman, 2000), GA repeat binding protein a (GABP-u) (Kinoshita et al., 2007), 
and the orphan nuclear receptor Tr2, which also acts as a repressor upon 
SUMOylation (Park et al., 2007). Furthermore, 0c4 positively regulates its own 
expression through cooperative binding with Sox2 to DE (Chew et al., 2005; 
Okumura-Nakanishi et al., 2005). Essentially, Sox2 and Oct4 co-occupy a new site 
2B, located 30bps downstream from site 2A within DE, in both ES cells and embryos 
(see Figure 5a). This new site was necessary and sufficient in combination with site 
2A to drive DE expression in reporter assays (Chew et al., 2005; Okumura-Nakanishi 
et al., 2005). 
Oct4 is repressed in differentiation and is silenced in somatic tissues. This silencing 
has been shown to be mediated through the recruitment of DNA methyltransferases 
and chromatin modifying enzymes to the promoter and enhancers of Oct4 (Ben-
Shushan et al., 1993). The orphan receptor, GCNF, has been shown to interact with 
PP and to recruit Dnmt3, suggesting its involvement in the epigenetic silencing of 
Oct4 during gastrulation (Fuhrmann et al., 2001; Sato et al., 2006). G9a, a SET-
containing H3K9me histone methyltransferase, was also shown to mediate Oct4 
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Figure 1.5- The structure of the Oct4 gene and protein 
The structure of the upstream regulatory elements of the Oct4 gene. There are 4 
regions that are highly conserved among human, bovine and mouse Oct4 
promoter/enhancer elements (boxes 1 through 4). Conserved region 1 (CR1) is 
downstream of PE and immediately upstream of exon 1. Each enhancer contains 
multiple potential binding sites for transcription factors that can either induce 
activation (red) or repression (black) of Oct4 expression. Methylation in CRs represses 
Oct4 expression in differentiated and somatic cells. Abbreviation: DE, distal enhancer, 
and PR, proximal enahncer 
Schematic illustration of Oct4 domains. POUs and POUh are important for DNA 
binding, while the C and N termini are involved in binding to co-activators/co-
repressors. Abbreviations: N-: -amino, C-: Carboxyl-, POUs: POU-specific domain, 
POUh: POU-homeo domain. 




Transcription factors were also shown to be involved in the negative regulation of 
Oct4. Tcf3 has been recently shown to repress Oct4 expression in embryogenesis. It 
binds within the PP of Oct4 and represses gene expression through the recruitment of 
co-repressors C-terminal binding protein (CtBP), Split2 and Groucho (Tam et al., 
2008). Similar to Tcf3, the homeodomain transcription factor Cdx2 was also reported 
to repress Oct4 gene expression. Niwa et al (2005) proposed that reciprocal 
inhibition of Oct4 and Cdx2 controls the first lineage decision in mammalian 
development, the formation of the extra-embryonic trophectoderm (TE) from the 
1CM (Niwa et al., 2005). 
1.4.3. Structure of Oct4 
Pou517 is a highly conserved gene in vertebrates including fish and amphibians that 
is expressed only in early development within the pluripotent cells. In mouse, the 
gene comprises of five exons located on chromosome 17 within the t-region. Genes 
within the t-region are associated with lethality. The protein encoded by Pou5fl 
gene, Oct4, also known as Oct3/4, is 352 amino acid and belongs to the POU domain 
family of transcription factors. 
The POU domain family of transcription factors was defined following the 
observation that the mammalian proteins Pit-i, Oct-i, and Oct2 and the 
Caenorhabditis elegans protein unc-86 shared a region of homology, known as the 
POU domain (Clerc et al., 1988; Finney et al., 1988; Herr et al., 1988; Robertson, 
1988; Sturm et al., 1988; Sturm and Herr, 1988). The POU domain is a unique DNA 
binding domain that is composed of two highly conserved regions, the POU-specific 
and the POU-homeodomain, joined by a variable linker (Figure 1 .5b) (Botfie!d et al., 
1992; Verrijzer et al., 1992). POU proteins have been identified from various 
species, and are grouped into seven classes based on the amino acid sequence of their 
POU domains and their linker region (HinkJey et al., 1992; Spaniol et al., 1996; 
Wegner et al., 1993). 
Most POU proteins bind to an eight base pair regulatory DNA element known as the 
octamer motif ATGCAAAT (Scholer, 1991). Despite the fact that the POU-specific 
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and POU-homeo domains are both independently able to bind to DNA in sequence 
specific manner (Aurora and Herr, 1992; Klemm and Pabo, 1996), POU proteins 
require both domains for high affinity binding to their DNA targets (Aurora and 
Herr, 1992). This suggests that the linker region acts to increase the local 
concentration of DNA binding domains and therefore increasing the site-specific 
DNA binding (Ryan and Rosenfeld, 1997). 
The crystal structure of the Octi and Piti POU domains bound to their DNA 
recognition sites as a monomer and homodimer, respectively, revealed the three 
dimensional structure of the two sub-domains as well as the adaptability of POU 
proteins (Jacobson et al., 1997; Klemm et al., 1994). The POU-specific domain 
consists of four a helices grouped around a hydrophobic core. The helices form a 
helix-turn helix (HTH) motif (Klemm et al., 1994). The POU-homeodomain also 
forms a HTH motif as it consists of 3 a helices, of which the first two are relatively 
variable between different POU proteins, however the third is highly conserved 
(Jacobson et al., 1997; Klemm et al., 1994). 
Oct-i and Pit-i crystal structures also revealed the disordered structure of the linker 
region, which suggests that its main function is simply to connect the POU-specific 
and POU homeodomains, and reinforce its role in increasing DNA binding 
specificity (Ryan and Rosenfeld, 1997). In addition to this role, the linker region 
might contribute to the flexibility of POU domain in recognizing various DNA 
elements by enabling the POU-specific domain to take various orientations relative 
to the POU-homeodomain (Ryan and Rosenfeld, 1997). POU proteins were also 
shown to have different types of trans-activation domains located outside of the POU 
domain, depending on amino acid composition or acidity (Mitchell and Tjian, 1989). 
The structure of Oct4 protein and the role of its sub-domains and their relevance to 
ES cell self-renewal will be discussed in details in the last result chapter of this 
thesis. 
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1.4.4. Oct4 homologues 
The expression of Oct4 in gastrulation suggests that it has a fundamental role in the 
lineage specification that should be conserved in evolution. This notion was 
supported by the identification of Oct4 homologues in Xenopus laevis that are able to 
support murine ES cells in the absence of Oct4 (Morrison and Brickman, 2006). 
Knocking down of Oct4 homologues in Xenopus leads to precocious differentiation 
in multiple lineages indicating that Oct4 may have a conserved role in blocking 
differentiation in vertebrates. Interestingly, murine Oct4 can rescue aspects of the 
Xenopus knock down phenotype (Morrison and Brickman, 2006). 
Xenopus laevis and Xenopus tropicalis both contain three Oct4 homologues: 
Xlpou60, Xlpou25 and Xlpou9l organised in tandem within a region of the genome 
that is analogous to the mouse Oct4 t-locus (Morrison and Brickman, 2006). Their 
expression recapitulates the expression of Oct4 in mouse pre-implantation 
development. Xlpou6O is maternally expressed and decreases by the late blastula 
stage, while Xlpou9l and Xlpou25 are zygotically expressed and continue to be 
expressed alongside Xlpou61 during gastrulation in cells that did not undergo 
involution (Morrison and Brickman, 2006). 
The expression patterns and roles of the Xenopus homologues suggest that these 
members of the PouV protein family have roles in both neural development and 
isthamic specification (Snir et al., 2006). The evolutionary conserved role of PouV 
homologues was also highlighted by the characterisation of a Zebrafish PouV 
protein, Pou2/Spg (Takeda et al., 1994). Spg is a mutation in Pou2 that affects mid 
hind brain specification and isthamic development (Takeda et al., 1994). Pou2 is 
located in a chromosomal region syntenic to the Xenopus region (Belting et al., 
2001; Hauptmann et al., 2002; Lunde et al., 2004). Pre-gastrulation expression of 
Pou2 recapitulates the expression of mouse Oct4 both in the oocyte and zygote 
(Foygel et al., 2008; Howley and Ho, 2000) and its loss in the early stages of 
development leads to comparable phenotypes (Foygel et al., 2008; Lunde et al., 
2004; Reim et al., 2004). Furthermore, the proximal promoter of Pou2 harbours 
octamer binding sequences that regulate Pou2 expression in a similar fashion to Oct4 
auto-regulatory loop (Parvin et al., 2008). However, there is some controversy about 
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whether Pou2 is a true orthologue as the role of Pou2 in the isthmus appears 
conserved with Xenopus but not with mouse (Takeda et al., 1994). Moreover, Pou2 
also has a role in endoderm induction in cooperation with a Sox protein known as 
Cassanova that does not have a mammalian homologue (Foygel et al., 2008; Lunde 
et al., 2004; Reim et al., 2004). As Pou2 is also not an effective substitute for Oct4 
in ES cells, it is possible that teleosts have diverged significantly in their use of the 
Oct4 network (Morrison and Brickman, 2006). 
Other studies have uncovered conserved Oct4-related genes in different mammalian 
species including Rhesus monkeys, cows and pigs. These genes show similar pre-
implantation expression pattern to Oct4 (Kirchhof et al., 2000). Furthermore, Niwa 
and colleagues reported the conservation of Oct4 in the platypus that faithfully 
recapitulates Oct4 expression in embryogenesis (Niwa et al., 2008). Although it was 
reported that chicken genome does not contain an Oct4 homologue (Soodeen-
Karamath and Gibbins, 2001). Lavial et al (2007) have identified a chicken Oct4 
(cOct4) using subtractive hybridization of cDNAs from chicken ES cells and EBs 
(Lavial et al., 2007). cOct4 and chicken Nanog homologue cooperate to maintain 
chicken ES cells in an undifferentiated state, showing the conservation of Oct4 
mediated mechanisms underlying pluripotency. Like the Xenopus protein, Xlpou9l, 
cOct4 is able to rescue self-renewal in Oct4 null mouse ES cells (Lavial Ct al., 2007). 
1.4.5. Activation and repression functions of Oct4 
Oct4 protein is a transcription factor that was reported to bind regulatory regions of 
many genes including the Rex-i gene (Ben-Shushan et al., 1998) Rosfijord and 
Rizzino 1994), the Fgf4 gene (Schoorlemmer and Kruijer 1991; (Yuan et al., 1995), 
and the human platelet-derived growth subunits of human chorionic gonadotrophin 
gene (hCG) (Liu et al., 1997; Liu and Roberts, 1996). 
In vivo, Oct4 can act as a repressor or an activator of target genes (Ben-Shushan et 
al., 1998). It can directly activate or repress transcription of target genes when the 
cis-binding site is positioned proximal to the promoter (Scholer et al., 1991). One 
example of Oct4 direct activation is the PDGFU receptor (PDGFaR) gene. Oct4 was 
shown to bind to one of two alternative promoters of the PDGFa receptor (PDGFaR) 
gene to activate transcription. In fact, it was reported that mutating the octamer motif 
present in this promoter decreased its activity, whereas overexpressing Oct4 in 
differentiated Tera2 cells specifically enhances it (Harry J. Kraft, 1996). 
In contrast, Oct4 can also act as a direct repressor. For instance, its binding to the 
enhancer of the immunoglobulin heavy chain gene was reported to repress 
transcription in F9 EC cells. Lenardo and colleagues reported that a 300-base pair 
fragment of the heavy chain enhancer was inactive in F9 EC cells and that mutating 
the octamer motif present within the enhancer increased its activity in F9 EC cells, 
suggesting that Oct4 is directly repressing the immunoglobulin heavy chain gene in 
pluripotent cells (Lenardo et al., 1989). Another example of direct gene repression by 
Oct4 is the repression of hCG genes, which are required for implantation and the 
maintenance of pregnancy (Liu et aL, 1997; Liu and Roberts, 1996). It was reported 
that Oct4 binding sites were found within the proximal promoters of these genes, and 
that mutating the octamer binding site in the hCG-J3 gene promoter abolished its 
Oct4-mediated repression. Moreover, mouse Oct4 binding to these regulatory 
elements in co-transfection assays was shown to repress transcription from both 
human hCG a and /3 gene promoters in JAr choriocarcinoma cells (Liu et al., 1997; 
Liu and Roberts, 1996). 
Oct4 also acts indirectly by binding to other cofactors. Oct4 can indirectly repress 
FoxAl and FoxA2, members of the Forkhead Box (Fox) family, without binding to 
their promoters. Guo and colleagues reported that in transient cotransfection assays 
Oct4 inhibited FoxD3 activation of the FoxAl and FoxA2 promoters. As Guo et al 
showed that Oct4 interact with FoxD3 protein both in vitro and after cotransfection 
in 293 cells, they proposed that this repression is mediated by Oct4 interaction with 
the DNA binding domain of FoxD3 (Guo et al., 2002). Similarly, Oct4 can also 
mediate the silencing of tau interferon genes (IFNr) by binding to their activator 
(Ets-2) DNA binding domain, and quenching its transactivation function (Ezashi et 
al., 2001). Ezashi and colleagues reported that the upregulation of the IFNt resulting 
from the overexpression of Ets-2 in human JAr choriocarcinoma cells is inhibited by 
coexpression of Oct4. Moreover, the fact that expression from luciferase reporters 
driven by mutant IFNr promoters lacking potential octamer sites was still silenced by 
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Oct4 suggested that Oct4 mediates the repression via protein-protein interaction, 
especially that Oct4 and Ets-2 were coimmunoprecipitated after being expressed 
together in Jar cells. This was further endorsed by the ability of Oct4 and Ets-2 to 
form a complex in vitro in the absence of DNA through binding of the POU domain 
of Oct4 to DNA binding domain of Ets-2. 
When acting over a long distance to activate target genes, in a similar fashion to 
repression, Oct4 requires cofactors that can serve as a bridging factor between Oct4 
and the basal transcription machinery (Scholer et al., 1991). The adenovirus (Ad) 
E1A oncoprotein was reported to mimic the function of such cofactors in pluripotent 
cells. Another oncoprotein, HPV-E7, was also reported to have a similar role in 
Oct4-mediated gene activation (Brehm et al., 1999; Brehm et al., 1998; Yeom Ct al., 
1996). 
Oct4 can also synergize with other transcription factors bound to a close cis-acting 
element of target genes. It binds cooperatively with the high mobility group (HMG) 
transcription factor Sox2 within the 3'-untranslated region (UTR) of the Fgf4 gene to 
activate transcription in a stem cell specific manner (Yuan et al., 1995). Another 
example of this Oct4/Sox2 synergistic activity is the activation of the stem cell 
specific gene Utfi (Nishimoto et al., 1999). 
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Figure 1.6- Activation and repression by Oct4 on different target genes 
Oct4 represses FoxAl and FoxA2 gene expression indirectly by interacting 
with the DNA binding domain of their activator FoxD3 and neutralizing its 
function. 
Oct4 represses the human chorionic gonadotropin (hCG) genes directly by 
binding to their promoters. 
Oct4 can synergize with other factors like Sox2 to activate transcription from 
the Fgf4 gene. 
When octamer site is located further away from the target gene promoter, 
Oct4 requires adaptor proteins to bridge it to the basic transcription machinery 
for transcriptional activation. 
Oct4 can activate directly the PDGF a receptor (PDGFuR) gene by binding to 
octamer sites. 
Adopted from (Pan et al., 2002). 
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Aims 
In chapter 3 we test whether lineage repression is an essential component of the 
ability of Oct4 to regulate differentiation in embryonic populations. 




Materials & Methods 
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2. Materials and Methods 
Unless otherwise stated, chemicals were ordered from Thenno-Fisher, 
oligonucleotides were obtained from Sigma-Genosys. The water used of MilliQ 
(l8.2m) quality. 
2.1. Mammalian cell culture 
2.1.1. Non-ES cell lines 
The human embryonic kidney cell line HEK293 and the human choriocarcinoma cell 
line JAR were cultured in Dulbecco's Modified Eagle Medium (DMEM, Invitrogen) 
supplemented with 10% Foetal calf serum (Invitrogen) and penicillin-streptomycin 
(Roche). The cells were passaged every 2 to 3 days. Penicillin-streptomycin was not 
added to the medium during DNA transfections as the antibiotics interfere with 
lipofectamine and hinder cell growth post-transfection. 
2.1.2. ES Cell lines 
E14Tg2a and ZHBTc4 ES cell lines were grown in ES medium (see below) on 
gelatin-coated (0.1%) plates or flasks (Iwaki) at 37 0c in a 7% CO 2 incubator. 
2.1.2.1. ES medium 
500m1 	Glasgow Minimum Essential Medium (GMEM) (Sigma-Aldrich) 
1 lml Sodium pyruvate/L-Glutamine (5.5 ml of 100mM sodium pyruvate + 
5.5 ml 200mM L-Glutamine) 
51m1 Foetal calf serum (FCS) (Invitrogen) 
5.5ml lOOx non-essential amino acids (Invitrogen) 
555 j.il 0. 1M 2-mercaptoethanol. 
555 p1 LIF (prepared by ISCR tissue culture staff) 
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2.1.3.2. Trypsinisation of ES cells 
ES cells were washed with PBS after the medium was aspirated. 0.025% trypsin/PBS 
(v/v) was added to the cells, followed by incubation for few minutes at 3 7 °c. The 
cells are collected and washed with PBS by centrifugation at 250g for 3 mins. 
2.1.3.3. Passage of cells 
After trypsinisation, cells were resuspended in fresh pre-warmed ES medium. 1:5 of 
the cells were plated onto gelatinised flasks that were kept at 37 0C for few minutes. 
The cell lines were passaged every 3 to 4 days with media changes every 48hours. 
2.1.2.4. Freezing ES cells 
Around 1x106 cells were collected and washed once in the freezing mix (10% 
DMSO in ES cell medium). The pellet was resuspended in lml freezing mix and 
transferred to a cryotube vial (Nunc) to be placed in the -80 0C freezer. The next day 
the cryo-preserved cells were transferred to the liquid N 2 storage tank (-170 °C). 
2.1.3.5. Thawing mouse ES cells 
The vial was removed from liquid N2 and thawed immediately in a 37 0C water bath. 
The thawed cells were transferred to a universal tube containing 9ml pre-warmed ES 
cell medium. The cells were pelleted by centrifugation at 200g followed by a PBS 
wash. 
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2.2. Transfection of DNA into cells 
2.2.1. Transient transfection of ES, HEK293 and JAR cells 
2.2.1.1. Luciferase reporter assays 
The transfection of cells was performed using Lipofactamine 2000 (Invitrogen) as 
per manufacturer's instructions. Twenty-four to forty-eight hours post transfection, 
the cells were collected, lysed and monitored for both firefly and renilla luciferase 
activity using the dual luciferase reporter assay system (Promega) according to 
manufacturer's instructions. 
2.2.1.1.1. Testing the transcriptional activity of activator and repressor forms of 
Oct4 and Xlpou91 
ZHBTc4 ES cells (1x105) were plated on a 24-well plate with 2ig/ml tetracycline 
(Tc). Twenty-four hours later, 75 ng of reporter plasmids and 150 ng of the test 
plasmid were transfected according to (Brickman et al., 2001). An internal reference 
plasmid consisting of the SV40 promoter driving Renilla luciferase was used with all 
transfections (Promega). 
2.2.1.1.1a. Reporter plasmids 
Reporter plasmids are a kind gift from Prof. Hitoshi Niwa (Riken Institute, Japan) 
and were constructed by introduction of the regulatory elements listed below into the 
pGL3-Basic vector (Promega) (Niwa et al., 2002). 
6x Octamer-binding motif luciferase reporter: 6W enhancer containing 6 
copies of oligonucleotides with octamer-binding motif from the mouse 
immunoglobulin heavy chain gene enhancer upstream of the tic promoter. 
Fg[4-enhancer luciferase reporter: 460-bp PCR-amplified genomic DNA 
carrying the Fgf4 enhancer placed upstream of the tk-luc cassette in plasmid 
ptk-luc. 
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pTK luciferase reporter: 168-bp BamHhXlioI fragment derived from 
pBLCAT2 containing herpes simplex virus thymidine kinase (tk) promoter. 
2.2.1.1.1b. Test constructs 
The expression vector used was the pCAG-IP plasmid, a kind gift from Prof Hitoshi 
Niwa (RIKEN institute, Japan). pCAG-IP plasmid was constructed as fellows: "the 
pacbGHpA cassette from pPGKpurobGHpA was amplified by PCR with 
oligonucleotide primers 5'-AAGCTTATCATGACCGAGTACAAGC-3' and 5"-
GAGCCCCTGCAGGTTCTTTCCGCC-3" using Pfu. polymerase (Promega.). The 
product was digested with BspHI and PstI and ligated to the PstI-NotI backbone and 
the NotI-NcoI internal ribosome entry site (IRES) fragments of pCAG-IZ to give 
pCAG-IP. cDNAs listed below were introduced between the X72oI and NotI sites of 
pCAG-IP" (Niwa et al., 2002). 
• Empty vector (pCAG-IP with no insert) 
• Xlpou9l 
• Oct4 
• X1pou91XVP2 (Brickman laboratory reagent) 
• Oct4XVP2 (Brickman laboratory reagent) 
• Xlpou91XEnR (Brickman laboratory reagent) 
• Oct4XEnR (Brickman laboratory reagent) 
• DNA binding-mutant Oct4 
• DNA binding-mutant Oct4WP2 
• DNA binding-mutant Oct4?EnR 
Primers to generate the cDNAs are listed in the "Cloning primers" section. 
2.2.1.1.2. Testing the transcriptional of Oct4 activator form on the n-subunit of 
human chorionic gonadotropm (hCG-fl) promoter 
JAR cells were transfected at 60% confluency on a 6-well plate. 2p.g of luciferase 
reporter constructs with 2tg of test constructs using Lipofectamine 2000 (Invitrogen) 
as per tmanufacturer's protocol. pRL-SV40 (Promega) was used as internal control. 
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2.2.1.1.2a. Reporter construct 
hCG-0 luciferase reporter: -325 hCG-f-luc construct was a kind gift from Prof. 
Michael Roberts (University of Missouri, USA) (Liu and Roberts, 1996). 
2.2.1.1.2b. Test construct 
cDNAs listed below were introduced between the AlioI and NotI sites of pCAG-IP 
(Niwa et al., 2002). 
• Empty vector (pCAG-IP with no insert) 
• Oct4 
• Oct4XVP2 
2.2.1.2. Transient transfection of activator and repressor forms of Oct4 for 
protein analysis 
HEK293 cells plated onto 6 well plates were tranfected with 2g of vector DNA 
using lipofectamine 2000 (Invitrogen) following the manufacturer's protocol. Twenty 
four hours post transfection, cells were lysed to be used for western blotting analysis. 
2.2.2. Transfection of ES cells for stable integration 
On the day of transfection 2x10 7 ZHBTc4 cells were collected and washed twice in 
PBS and resuspended in 800 p1 of PBS. 100tg of linearized DNA was added to the 
cells and the mixture was transferred to an electroporation cuvette (BioRad) and left 
at RT for 3mins. Electroporation was carried out with a BioRad GenePulser using the 
following settings: capacitance, 3tF; Voltage, 800V; and time, 0.1 secs (constant). 
After electroporation, the cells were transferred into pre-warmed ES cell media 
containing 2tg/ml of tetracycline (Tc) before plating at a density of 2x10 6 cells per 
pre-gelatinised 10cm dish. 
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2.2.2.1. Vectors used for stable transfections 
The vectors used to derive cell lines from the ZHBTc4 parental cell line, were 




• DNA binding-mutant Oct4 
• DNA binding-mutant Oct4XVP2 











• 3x Flag Oct4 
• 3xFlagXlpou91 
• 3x Flag Xlpou25 














See "Cloning primers" section for the primers used to generate the cDNAs. 
2.2.2.2. Puromycin selection 
48 hours post transfection, medium was replaced with one containing 2jg/ml of 
puromycin (Sigma) to start selection for stable transfectants. The medium was 
changed every two days and the selection was kept for 9 days. 
2.2.2.3. Picking ES cell colonies 
After 9 days of antibiotic selection, the medium was removed and cells were washed 
twice with pre-warmed PBS. 5p.l trypsin was aspirated in a yellow tip and expelled 
over a colony. Using the tip, the colony was scraped and pulled up and transferred 
onto a gelatinised well of a 96 well plate. 1 8Oil of ES cell medium with 2p.g/ml 
puromycin was added following by pipetting up and down to break up the colony. 
The colony was expanded to be used in downstream experiments. Each expanded 
colony was frozen. 






• 3x Flag Xlpou9l 




• 3x Flag N25P25C91 
• 3xF1agN91P91C25 
• 3x Flag N25P91C25 
• 3xF1agN91P25C91 
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2.3. Cellular analysis 
2.3.1. Staining of ES cells 
2.3.1.1. Alkaline phosphatase staining 
The cells were washed once with pre-warmed PBS and fixed for 45 seconds. The 
cells were washed once with dH 20. Four mis of stain solution was added to 10 cm2 
plate and incubated at RT for 25mns in the dark. The stain was removed and washed 
once with dH20. The plates were air dried before examination under the microscope. 
2.3.1.1a. Fixative Solution 
The fixative solution was stored at 40C and prepared as follows: 
25m1s citrate solution (18mM citric acid, 9mM sodium citrate, 12mM NaCl) 
8ml Formaldehyde 
65m1 acetone 
2.3.1.1b. Stain solution 
An alkaline phosphatase staining kit (sigma) was used according to the 
manufacturer's protocol. Briefly, 400 jil FRV alkaline solution was mixed with 400pJ 
sodium nitrate solution and incubated for 2mins at RT. The alkaline/nitrite mixture 
was added to 1 8mls of dH20. Finally, 400 j.tl Napthol was added to the mix. 
2.3.2. MTS proliferation assay 
To determine the proliferative potential of different ES cell clones, the CeilTiter 96 
Non-Radioactive Cell Proliferation Assay (Promega) was used. The assay is a 
colorimetric alternative to [3H]thymidine incorporation assays designed to determine 
cell proliferation and cytotoxicity that uses the tetrazolium reagent MTS (3-(4,5-
dimethylthiazol-2-yl)-5(3-carboxymethonyphenol)-2-(4-sulfophenyl)-2H 
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tetrazolium). The Promega assay was carried according to the manufacturer's 
protocol. Briefly, ES cells were plated into the wells of a 96 well plate. Following 
this, an MTS assay was performed by adding 20 p.! of CeilTiter 96 AQ ueous One 
Solution Reagent to each well. The plate was then incubated for 1 h at 37 0C followed 
by absorbency reading at 490 nm. 
2.3.3. Differentiation of ES cells 
2.3.3.1. LIF withdrawal 
For differentiation experiments, cells were seeded in monolayers on gelatin-coated 
dishes in GMEM medium with 10% FCS and 2p.g/ml of tetracycline (Tc) and 
puromycin but without LIF. The day of seeding was defined as day 0 of 
differentiation. Medium was replaced every two days and cells were harvested at the 
indicated time points for downstream experiments. As a control, all cell lines used 
were also grown in the presence of LIF. 
2.3.3.2. Oct4 overexpression 
Cells were seeded in monolayers on gelatin-coated dishes in GMEM ndium with 
1 0%FCS, 2p.g of puromycin, and the presence of LIF. Oct4 overexpression condition 
is achieved by removal of tetracycline (Te) from the medium. The day of seeding 
was defined as day 0 of differentiation. Medium was replaced every two days and 
cells were harvested at the indicated time points for downstream experiments. As a 
control, all cell lines used were also grown in the presence of Tc. 
2.3.3.3. Neural differentiation 
Cells were plated on gelatinised plates at density of 104  cells/cm2 in N2B27 medium 
(Stem cell sciences mc) for 7 days. Medium was changed every day. As negative 
control, cells were plated on gelatinised plates in ES cell medium at the same 
density. Cells were collected at day 7 or 8 for downstream experiments. 
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2.3.4. FACS analysis 
Fluorescence-activated cell sorting (FACS) was used to analyse the percentage of ES 
cell clones expressing the cell surface markers SSEA1, E-Cadherin and PECAM1 
(for the antibodies see table 2.1.). Cells were collected into the cell dissociation 
buffer (Invitrogen) and incubated at 37 0C for 10 minutes. Single cell suspension was 
achieved by pipetting throtugh a syringe needle. Following PBS washes, cells were 
resuspended in 500 .il FACS buffer (1xPBS and 10% FCS) at a concentration of 106 
cells/ml. To mark apoptotic cells, 5jul10 6 cells of 7AAD solution (BD Pharmingen) 
was added to cells. Primary antibodies raised against cell surface markers were 
added to the resuspended cells at a dilution of 1:1000 and incubated on ice for 
1 Omins followed by three washes in FACS buffer. Cells were resuspended in FACS 
buffer with the secondary antibody diluted at 1:1000 and washed as before. Finally, 
the cells were resuspended in 500 jul FACS buffer and analysed in a FACS calibur 
flow cytometer (BD Biosciences). Data were analysed using the Cell Quest software 
(BD Biosciences). 
2.3.5. Immunofluorescence 
Cells grown in 12 well plates were washed twice in PBS followed by fixation in 4% 
paraformaldehyde. Cells were permeabilised in PBST (1xPBS, 0.1% Triton X100). 
Blocking was performed by adding 1% bovine serum albumin (BSA) to PBST to the 
cells and left for 30 mins at RT. Primary antibodies (See Table 2.1 for details) 
incubated overnight at 4 0C followed by three washes in PBST for 10 minutes each. 
Alexa Fluor-conjugated secondary antibodies (See Table 2.1 for details) were diluted 
in block solution and added to the cells. The cells were incubated at RT for 1 hour 
with the DAPI solution (1:1000). Finally, cells were washed 3 times in PBST, and 
either analysed under the microscope directly or stored in PBS. 
TABLE 2.1 Antibodies used for Western blotting 
Protocol / Dilution 
WB IF FACS Supplier/Reference 
Oct3\4 1 in 1000 1 in 1000 Santa Cruz (sc-9081) 
Nanog I in 1000 Chambers etal2003 
Sox2 1 in 1000 Boyer et al 2005 
Flag 1 in 1000 Sigma-Aldrich (F3165) 
VPI6 1 in 1000 Sigma-Aldrich (V4388) 
Engrailed I in 1000 AbCam (ab12454) 
f3-Actin 1 in 10000 SigmaAldrich (A3853) 
-tubulin 1 in 1000 Santa Cruz Biotechnolgy 
(sc-5 8667) 
E-cadherin 1 in 1000 Santa Cruz Biotechnolgy 
(sc-52328) 
PECAM1 1 in 1000 Santa Cruz Biotechnolgy 
(sc-28 188) 
SSEA1 1 in 1000 Santa Cruz Biotechnolgy 
(sc-2 1702) 
Anti-Rabbit-HRP (2d) 1 in 5000 GE Healthcare (NA931) 
Anti-Mouse-HRP (2m1) 1 in 5000 GE Healthcare (MA934) 
Anti-Rabbit- Alexa 
Fluor (2fld) 
1 in 1000 Invitrogen 
 (Alexa fluor-488) 
Anti-Mouse- Alexa 
Fluor (2fld) 
1 in 1000 Invitrogen 
 (Alexa fluor-546) 
2.3.6. Xenopus experiments 
2.3.6.1. RNA used for embryo injection 
To generate RNA for injections, pCS2+ plasmids harbouring the target cDNAs 
Oct4AVP2, X7pou91AVP2, Oct4AEnR, Xlpou9l)LEnR, Oct4, Xlpou9l, DNA binding 
mutant-Oct4 and Bmp4 were linearised with BssHII and used as a template for RNA 
synthesis using SP6 polymerase (Promega). 
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2.3.6.2. RNA injection in Xenopus embryos 
Xenopus laevis embryos were obtained by in vitro fertilisation cultured as described 
before (Slack et al., 1984). Embryos were injected at the two cell stage into both 
blastomeres with RNA to a fmal concentration of 500pg per embryo or morpholino 
oligonucleotides. Embryos were staged according to (Nieuwkoop, 1997) and 
collected at stages 9 and 10 for RNA extraction and at stage 10 for in situ 
hybridisation. 
2.3.6.3 In situ hybridisations 
For in situ hybridisations analysis, embryos were treated following the protocol of 
(Gammill and Sive, 2001). Eomes, Xvent2, Bmp4, FgJ8b and Gsc antisense 
riboprobes were synthesised from linearised plasmids using T7 polymerase 
(Promega) following standard protocol using digoxigenin labelled nucleotide 
(Roche). 
2.3.6.4. Morpholinos 
Antisense morpholino oligonucleotides (Genetools) specific for X7pou25, 60 and 91 
were previously described (Cao et al., 2006; Morrison and Brickman, 2006) and 
injected to a final concentration of 40ng per embryo (80ng for X7pou9l). Control 
morpholinos were injected to a final concentration of 1 6Ong per embryo. 
2.3.6.5. RNA Isolation and real-time RT-PCR 
Total RNA was prepared from 5 embryos using RNeasy mini kit (Qiagen) as per the 
manufacturer's protocol for animal cells with DNasel treatment. RNA (SOOng) was 
used as a template for cDNA synthesis using Superscript III (Qiagen). Real time 
PCR was carried out using a Lightcycler 480 (Roche) with LightCycler FastStart 
DNA Master PLus SYBR Green 1 (Roche). Primers for PCR were designed either 
using Primer 3 (Rozen and Skaletsky 2000) as described previously (Cao et al 2006; 
Morrison and Brickman, 2006) (See Table 2.2 for primer sequences and details). 
Standard curves were generated from plasmids produced by TOPO-TA cloning. 
Samples were normalised to ornithine decarboxylase (Odc). 
2.4. DNA analysis 
2.4.1. DNA quantification 
The concentrations of DNA preparations were determined by measuring the optical 
density of the samples at 260nm (OD260) using Nanodrop (ThermoScientific). DNA 
concentratioii was calculated using the relationship: 1 OD unit at 260nm = 50jig/ml 
DNA. 
2.4.2. DNA agarose gel electrophoresis 
DNA fragments were loaded with 6xDNA loading buffer (0.25% (w/v) bromophenol 
blue, 0.25% (w/v) xylene cyanol, 30% (vlv) glycerol) and separated by electrophoresis 
on 1% (wlv) agarose gels, prepared in lx TAE (40mM Tris-acetate and 2mM EDTA) 
and 1 j.tg/ml ethidium bromide.DNA fragments were run at a constant voltage of 80V for 
lh in lx TAE. Samples were loaded alongside double stranded DNA molecular weight 
markers (Promega). DNA fragments were visualized on a dual intensity ultraviolet 
transilluminator (UVP). 
2.4.3. Extraction of DNA from agarose gels 
DNA restriction fragments separated on agarose gels were purified using the QlAquick 
Gel Extraction Kit (Qiagen), according to the manufacturer's instructions. After agarose 
separation, DNA was viewed with a long wavelength ultraviolet emission (UV) 
transilluminator and the required band was cut out using a scalpel and transferred to an 
Eppendorf tube. The gel slice was dissolved by adding 3 volumes (per weight of gel 
slice) of QG buffer (QlAquick spin kit, Qiagen) and incubated at 50°C for 10 mm. The 
sample was transferred to a QlAquick spin column and centrifuged for 1 min after which 
the DNA in the column was washed with 0.75ml of PE buffer (QlAquick spin kit). 
Traces of wash buffer were removed by centrifugation for 1 mm. Finally, the DNA was 
eluted by adding 30jtl of ddH20 and centrifugation for 1 min at full speed in a 
microcentrifuge. The DNA was collected in a 1 .5m1 microfuge tube. 
2.4.4. Bacterial strains 
In most cases, the XL1-Blue Sub-cloning-Grade competent E. coli cells (Stratagene) 
were used for plasmid preparation. This strain has tetracycline resistance and its 
genotype is: recAl endAl gyrA96 thi-] hsdRl 7supE44relAl lacz. The XL 1-Gold Ultra 
competent cells (Stratagene) were used for manipulation of plasmid DNA. XL 10-Gold 
strain genotype is : Tetr A(mcrA)183 A(mcrCBhsdSMR-mrr)173 endAl supE44 thi-] 
recAl gyrA96 relAl lac Hte [F' proABlacIqZAMl5 TWO (Tetr) Amy Camr]a .The XL1-
Blue supercompetent cells (Stratagene) were used for preparation of plasmids 
manipulated for mutagenesis (as advised by the manufacturer). The XL 1-Blue 
supercompetent strain genotype is: A(mcrA) 183 A(mcrCB-hsdSMR-mrr) 1 73end 
AlsupE44thi-1 recAl gyrA96 relAl lac. 
2.4.5. Media and maintenance 
Competent cells were grown in either Luria-Bertani (LB) broth or LB agar. LB broth 
was made up by mixing 20g/l of LB broth powder (Sigma-Aldrich) with ddH20 and 
autoclaved for 20 min at 120°C. LB agar was made by mixing 37g/l of LB agar pellets 
with ddH20 following by 20 mins autoclaving. Where necessary, ampicillin (Sigma-
Aldrich) was added to 100 j.tg/ml final concentration. 
2.4.6. Bacterial transformations 
A single 50tI aliquot of frozen competent bacteria was thawed on ice. One il of plasmid 
DNA (0.5-1jtgIjil) was mixed with the thawed cells and left on ice for 30 mm. Cells 
were subjected to heat shock by immersing them in a 42°C water bath for 45s and 
subsequently kept on ice for a further 2 mm. One ml of LB medium (without ampicillin) 
was added and the transformed bacteria were incubated at 37°C in a bacterial shaker for 
lh. Transformed bacteria were plated onto agar plates containing ampicillin and 
incubated overnight at 37 °C. 
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2.4.7. Cloning 
2.4.7.1. Restriction endonuclease digestion 
Restriction digestions of DNA plasmids were performed using restriction enzymes from 
Roche. The lOx buffer provided for each enzyme was diluted to lx in the final reaction 
mixture. Incubation time and temperature were adjusted according to the conditions 
specified by the manufacturer. 
2.4.7.2. Ligation 
For this, the digested DNA was first extracted from the gel, purified and eluted in lOjtl 
of ddH20. Ligation reactions were subsequently set up using 1 1 T4-Ligase (New 
England Biolabs), in 1 xT4 Ligation buffer in a total volume of 15g1 and suspended in 
water at 4°C overnight. Samples were left at RT for at least 2 h prior to transforming 
with competent E.coli cells. To scan for correct ligation products quick protocols such as 
restriction digestion followed by sequencing. 
2.4.7.3. Polymerase chain reaction 
PCR reactions were carried out using the Qiagen Taq DNA polymerase kit (Qiagen). 
PCR reactions were set up in a total volumes of either 50tl or 20p1 consisting of lx PCR 
buffer (Qiagen), lx Q solution (Qiagen), 0.2nM dNTP (Qiagen), 0.6j.tM of each forward 
and reverse primers, 0.5jtI of Taq polymerase (Qiagen) and water. The PCR was carried 
out using a Gene Amp® PCR system 9700 (Applied Biosystems) using the following 
program: 
94°C for 5 mm, 5 cycles of denaturing at 94°C (30 s), annealing at 58 °C (30 s, the 
temperature was changed for each primer) and extending at 72 °C (3 mm) followed by 
2 1-25 cycles of the same but annealing temperature of 55 °C (30 s) and finally a further 
extension of 72°C for 7 mm. 
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2.4.7.4. TOPO cloning of PCR products 
To clone PCR fragments, the TOPO-TA cloning kit (Invitrogen) was used as per the 
manufacturer's instructions. 
2.4.7.5. Site directed mutagenesis 
Mutagenesis of Oct4 to generate Oct4 DNA-binding mutant was carried out using the 
QuikChange® Site-Directed Mutagenesis Kit (Stratagene. The primers used for creating 
point mutations are: 
Forward: 5'-TGGGCTAGAGAAGGATGTGCCCCGGGTATGGTTCTGTAACCGGC-3' 
Reverse: 5'-GCCGGTTACAGAACCATACCCGGGGCACATCCTTCTCTAGCCCA-3' 
Briefly, sample reactions were prepared in a total volume of 50il consisting of ddH20, 
5tl of 10 x Reaction Buffer (Stratagene), 50ng of double stranded plasmid DNA, 125ng 
of each forward and reverse primers, 1 j.tl of 25mM dNTP (Stratagene) and 1 p.1 of 
PfuTurbo DNA polymerase (2.5U/p.l). Mutagenesis was performed using a temperature 
cycler to first denature the plasmid and to anneal the oligonucleotide primers containing 
the desired mutation. The Thermo-cycler programme was adjusted as below: 95°C for 30 
s, 12 (for point mutations) or 18 cycles (for deletions) of denaturing at 95°C (30 s), 
annealing at 55°C (1 mm) and 68 °C (6 mm). Following temperature cycling, the 
reaction tubes were left on ice for 2 min to cool the reaction to below 37°C. XL 1-Blue 
(Stratagene) supercompetent cells were transformed as previously described. DNA was 
extracted from transformed bacteria using the QlAprep Spin Miniprep kit (Qiagen) and 
was sent for sequencing to ensure that the desired mutation has been achieved prior to 
large scale amplification of the mutated plasmids. 
2.4.7.6. DNA sequencing 
Each sequencing reaction was prepared using 3 .2pmol of either the forward primer or 
reverse primer targeted to the plasmid backbone (Sequencing services at Edinburgh 
University), 1 jig DNA in a total volume of 1 Ojil made up with ddH20. Prepared samples 
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were sent to the sequencing service at Edinburgh University (Ashworth building). 
Sequence analysis was performed using DNA STAR Lasergene® v7.0 software 
(DNASTAR). 
2.4.7.7. Cloning primers 
DEF-mutant Oct4 
• Forward: 5'-CTGTATCCGCAGCAGCACCCCCAGGTCCCCACrVFGGCA-3' 
• Reverse: 5-TGCCAAAGTGGGGACCTGGGGGTGCTGCTGCGGATACAG-3' 
DEF-mutant Xlpou91 
o Forward: 5'-CAAGGTCCTGCAGCAGCACCCCAAGTGATGCCCTC-3' 
o Reverse: 5'-GAGGGCATCACTTGGGGTGCTGCTGCAGGACCTTG-3 
Generation of Flag-tagged constructs 
• 3x Flag Forward: 5'-CCGGTCGACATGGACTACAAAGAC-3' 
• 3x Flag Reverse with A: 5 1-CCGCTCGAGACUGTCATCGTCATC-3 
o 3x Flag Reverse: 5'-CCGCTCGAGCTTGTCATCGTCATC-3' 
Generation of N-terminus-deleted Oct4 
o i\NOct4 Forward: 5'-CCGCTCGAGCCGCCATGAAGGAGCTAGAACAG-3' 
o Oct4 Reverse: 5'-ATAGTTTAGCGGCCGCTCAGTTTGAATGCATGGGAGA-3' 
Generation of N-terminus-deleted Xlpou91 
• ANXlpou9l Forward: 5-CCGCTCGAGCCGCCATGGGGGAGATGGAGC-3' 
• Xlpou9 1 Reverse: 5'-ATAGTTTAGCGGCCGCTCAGTTGCCTTGTTTACCCA-3' 
Generation of C-terminus-deleted Oct4 
0 Oct4 Forward: 5'-CCGCTCGAGATGGCTGGAC-3' 
o iCOct4 Reverse: 5'-ATAGTTTAGCGGCCGCTCACTCAATACTTGATCT-3' 
Generation of C-terminus-deleted Xlpou91 
• XIpou9 1 Forward: 5-CCGCTCGAGCCGCCATGTATAACCAACAGACCTACC-3' 
• ACXlpou9l Reverse: 5-ATAGTFTAGCGGCCGCTCAGGGGTACACCTGGCGC-3 
Generation of chimeric proteins between Xlpou91 and Xlpou25 
0 Xlpou9 1 Forward: 5-CCGCTCGAGCCGCCATGTATAACCAAçAGACCTACC-3' 
o XIpou9 1 Reverse: 5'-ATAGTTTAGCGGCCGCTCAGTTGCCTTGTTTACCCA-3' 
0 XIpou25 Forward: 5'-CCGCTCGAGCCGCCATGTACAGCCAACAGCCCTFCC-3' 
o Xlpou25 Reverse: 5'-ATAGTTITAGCGGCCGCTCAGCCAATGTGGCCCCCCA-3' 
o 91/25 3endNbrl: 
5'-GCAAACTGCTCCArVFCTGAAGAATrAGGGGCTFCCTCCTC-3' 
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o 91/25 5'endNbr2: 
5'-GAGGAGGAAGCCCCTAATFCTTCAGAAATGGAGCAGrI1TGC-3' 
o 25/9 1 3'end Nbr3: 
5'-GCAAACTGCTCCATCTCCCATFCGCTGGGAACCTCCTCCTC-3 
o 25/91 5'endNbr4: 
5'-GAGGAGGAGGTFCCCAGCGAAGGGGAGATGGAGCAGrVFGC-3' 
o N-terminus + homeo 91 Nbrl: 
5'-GCCGTCATFCTCCTCAACGGTGGGGTACACCTGGCGCTTGCC-3' 
o C-terminus 91 Nbr2: 
5'-GGCAAGCGTCAGGGAATGCCCTATATTAGGGAGAATGGCGGG-3' 
o N-terminus + homeo 25 Nbr3: 
5'-CCCGCCATFCTCCCTAATATAGGGCATFCCCTGACGCrFGCC-3' 
o C-terminus 25 Nbr4: 
5'-GGCAAGCGCCAGGTGTACCCCACCGTTGAGGAGAATGACGGC-3' 
9. Generation of chimeric proteins between Xlpou9l and Pou2 
• XIpou9 1 Forward: 5'-CCGCTCGAGCCGCCATGTATAACCAACAGACCTACC-3' 
• XIpou9l Reverse: 5'-ATAG1TTAGCGGCCGCTCAGTTGCCTFGTFFACCCA-3' 
• Pou2 Forward: 5'-CCGCTCGAGATGACGGAGAGAG-3' 
• Pou2 Reverse: 5-ATAGTTTAGCGGCCGCTTAGCT-3' 
• Reverse primer A: 5-GCTCCAAATCTTCAGAATTAGGGG-3' 
• Sense primer B: 5'-GCCCCTAATTCTGAAGATTTGGAG-3 
• Sense primer C: 5-ACTCTGACTACTGGGGAGATGGAG-3' 
• Reverse primer D: 5'-CTCCATCTCCCCAGTAGTCAGAGT-3' 
• Sense primer E: 5'-CTAGCTTTGCCCTATATTAGGGAG-3' 
• Reverse primer F: 5-CTCCCTAATATAGGGCAAAGCTAG-3' 
• Sense primer G: 5'-CAGGTGTACCCCTYFGATGACGAG-3' 
• Reverse primer H: 5'-CTCGTCATCAAAGGGGTACACCTG-3 
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2.4.8. Transformation of plasmids in E. coli 
2.4.8.1. Plasmid DNA preparation 
Plasmid preparations were carried out using QIAGEN kits and following the 
manufacturer's instructions. 
2.4.8.1a. Small scale preparation 
For small-scale preparation or 'mini preps' the QlAprep Spin Miniprep kit (Qiagen) was 
used. Bacteria were picked from single colonies and grown in 2m1 of LB broth 
containing ampicillin (or other antibiotics) overnight at 37°C in a bacterial shaker. 1 .5m1 
of culture was transferred to an eppendorf tube and centrifuged at 5000 rpm for 5 min in 
bench top microfuge. The pellet was re-suspended in 250ji1 of buffer P1 (50mM Tris-
HC1 pH 8.0, 10mM EDTA, 100gIml RNAse A). 250111 of solution P2 (200mM NaOH, 
1% SDS) was added and the tube was inverted several times to mix. To the same tube, 
350pi of solution N3 (3.0M sodium acetate, pH 5.5) was added and immediately mixed 
by inverting the tubes 4-6 times. The mixture was centrifuged in a bench top microfuge 
for 10 min at 13,000rpm and the supernatant transferred to a QlAprep column. The 
column was centrifuged for 30 s at 13,000rpm in microfuge and the flow-through 
discarded. The columns were washed with 0.75m1 of PE buffer (QlAprep Spin Miniprep 
kit, Qiagen) and the DNA was eluted with 50pi of ddH20. 
2.4.8.1b. Large scale preparation 
For large-scale plasmid preparations or 'maxi-preps' the QIAGEN Plasmid Maxi kit was 
used. Briefly, 250m1 of LB containing lOOjig/ml ampicillin was inoculated with lml of 
an overday culture of bacteria. The inoculated cultures were left to grow overnight at 
37°C with vigorous shaking. Bacteria were harvested at 13,000g for 5 min at 4°C and the 
pellet was re-suspended in lOml of re-suspension buffer P1 (50mM Tris-HC1 pH 8.0, 
10mM EDTA, 100 j.tg/ml RNAse A). Ten ml of lysis buffer P2(200mM NaOH, 1% SDS) 
were added. After 5 min incubation at RT, 10 ml of ice cold neutralization buffer P3 
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(3mM potassium acetate pH 5.5) were added and the mixture was further incubated on 
ice for 20 min with occasional inversion. The cell debris was pelleted by centrifugation 
at 15000rpm in a Beckman JA-17 rotor for 30mm. The supernatant was added to pre-
equilibrate QIAGEN-tip 500 columns and allowed to enter the resin by gravity. The 
column was washed twice with 30 ml of wash buffer QC (1M NaCl, 50mM MOPS pH 
7.0, 15% ethanol). The DNA was eluted with 15m1 of elution buffer QF (1.25M NaCl, 
50mM Tris-HCI pH 8.5, 15% Ethanol) and precipitated in 10.5m1 of isopropanol at RT. 
Centrifugation was performed for 30 min at 15000rpm at 4°C in the same rotor 
previously used and the DNA pellet was washed with 70% ethanol. The pellet was air 
dried for 5 min and re-suspended in ddH20 or Tris-EDTA buffer (10mM Tris-HC1, 1mM 
EDTA, pH 8). 
2.4.8.2. Ethanol precipitation of DNA 
Three volumes of 100% Ethanol and 1/10 volumes of 3M sodium acetate (pH 5.2) were 
added to the DNA samples. After mixing, the mixtures was kept on dry ice for 10 
minutes. The sample was spun in a microfuge (top speed) at 4 0C for 30 mins. After 
decanting the supernatant, the pellet was dried by leaving the tube open for 15mins. To 
resuspend DNA, ddH20 or TE was added followed by vortex. 
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2.5. RNA manipulation 
2.5.1. Total RNA extraction 
Total RNA was isolated from cells using the Trizol reagent (Invitrogen) as per the 
exact instructions of the manufacturer. Total RNAs were precipitated with 
isopropanol, washed with 70% ethanol, and dissolved in DEPC-treated H20. 
2.5.2. RNA quantification 
The concentrations of RNA preparations were determined by measuring the optical 
density of the samples at 260nm (0D260) using NanoDrop (ThermoScientific). RINA 
concentration was calculated using the relationship: 1 OD unit at 260nm = 40 tg/ml 
RNA. 
2.5.3. Reverse transcriptase PCR 
2.5.3.1. First strand synthesis 
Total RNA was quantified and 0.2-0.5 jtg of RNA from each sample was used for 
the reverse transcription (RT) reaction. RNA was mixed with 5 pM random 
hexamers and the mix was heated to 70°C for 10 min after which 1 x  first strand 
buffer, 10 mM dithiothreitol (DTT), 0.5 mM dNTPs and 0.75 U RNAaseOUT were 
added. After incubation at 20-22°C for 10 min and at 42°C for 2 mm, 20 units of 
SuperScript® III Reverse Transcriptase (Invitrogen) were added and the reaction was 
incubated at 42°C for 50 min followed by 70°C incubation for 15 mm. 
2.5.3.2. Real-time quantitative PCR (RT-qPCR) 
Real time PCR was performed with Lightcycler 480 (Roche) with LightCycler 
FastStart DNA MasterPLUS  SYBR Green 1 (Roche). Gene-specific primer pairs were 
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designed and their specificity checked using the Universal ProbeLibrary Assay 
Design Center (Roche Applied Science at https://www.roche-applied-
science.com/sis/rtper/upllindex.j  sp?idUPO3 0000). Primers spanning intron/exon 
boundary were selected whenever possible to avoid amplification of contaminating 
genomic DNA. Tbp the TATA binding protein gene, was used as an internal control 
to normalize input RNA. All measurements were performed in triplicate. The 
transcript levels were quantified using the standard curve method. See Table 2.2 for 
sequences of primers used in RT-qPCR. 
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TABLE 2.2. Primer sequences 





Gsc X.Iaevis GATGCCGCCAGTGCCTC TGCAGCTCAGTTCGTGACAAA SYBR 55°C 
Eomes X.laevis ACCGGCACCAGACTGAGAT TGAGGAAAGGQAACATCCTC SYBR 550C 
Fgftb X.!aevis GCAGAGCCTGGTGACCGA TCTTGTTCGCCAGGATI'TGC SYBR 550C 
Bmp4 X.laevis AGCCCACTAAGGATGTGGTG GCTGCTGAGGTTGAACACAA SYBR 55°C 
Vent2 X.laevis CCTCTGTTGAATGGCTTGCTT GAGACTTGGGCACTGTCTG SYBR 550C 
M,xer X.laevis CACCAGCCCAGCACUAACC CAATGTCACATCAAFGAAG SYBR 55°C 
Xbra X.!aevis TTCTGAAGGTGAGCATGTCG GTTTGACTTFGCTAAAAGAGACAGG SYBR 550C 
Ode X.Iaevis GCCATTGTGAAGACCTCTCTCCATTC TTCGGGTGATFCCTTGCCAC SYBR 55°C 
Pou5fl M. musculus GGCGTTCTCTTFGGAAAGGTGTTC CTCGAACCACATCCTTCTCT SYBR 58°C 
Nanog M. musculus ATGAAGTGCAAGCGGTGGCAGAAA CCTGGTGGAGTCACAGAGTAGTTC SYBR 58°C 
K1f4 M. musculus CGGGAAGGGAGAAGACACT GAGTTCCTCACGCCAACG SYBR 580C 
Sox2 M. musculus GGCGGCAACCAGAAGAACAG GCUGGCCTCGTCGATGAAC SYBR 58°C 
Rexi M. musculus ACGAGTGGCAGTTTCTTCTTGGGA TATGACTCACTTCCAGGGGGCACT SYBR 580C 
Fgf4 M. muscu/us CCGGTTCTTCGTGGCTATGA CTTACTGAGGGCCATGAACATACC SYBR 580C 
E-Cad M. musculus AGACTTFGGTGTGGGTCAGG CATGCTCAGCGTCTTCTCTG SYBR 580C 
Nodal M. musculus GGCGTACATGTTGAGCCTCT GCCTGGTGGAAAATGTCAAT SYBR 600C 
Bmp4 M. musculus CAACCCAATTATGGGCTGGC CCACAATCCAATCATTCCAGC SYBR 580C 
TBra M. musculus GTGACTGCCTACCAGAATGA ATTGTCCGCATAGGTTGGAG SYBR 600C 
Wnt3 M. muscu/us CGCTCAGCTATGAACAAGCA GGTGTTTCTCCACCACCATC SYBR 600C 
Tbx4 M. musculus ACACCTTCCCAACTCAGAGG CTTGCAGGGCAAGTCCAG SYBR 580C 
Sprouiy2 M. musculus GAGAGGGGTTGGTGCAAAG CTCCATCAGGTCTTGGCAGT UPL (3) 58°C 
Gata4 M. musculus GCCTGCGGCCTCTACATGAA CAGGACCTGCTGGCGTCTTA SYBR 60 0C 
Gata6 M. musculus GGTCTCTACAGCAAGATGAATGG TGGCACAGGACAGTCCAAG UPL(40) 580C 
Mlxii M. musculus AGTTGCTGGAGCTCGTCTTC AGGGCAATGGAGGAAAACTC SYBR 600C 
Foxa2 M. musculus CATCCGACTGGAGCAGCTA GCGCCCACATAGGATGAC SYBR 580C 
Cdx2 M. musculus GGAAGCCAAGTGAAAACCAG CTTGGCTCTGCGGTTCTG SYBR 580C 
Tbp M. musculus GGGGAGCTGTGATGTGAAGT CCAGGAAATAATTCTGGCTCA SYBR 580C 
SdJ2 M. musculus TTCTCACGACGTGCGCTAT TCATCCACAGAGGTCACACC SYBR 580C 
Msx2 M. musculus AGGAGCCCGGCAGATACT GTTTCCTCAGGGTGCAGGT UPL (70) 580C 
Fgfri M. musculus CGAATTGGAGGCTACAAGGT GAAGGCACCACAGAATCCAT UPL(l) 580C 
Otx2 M. musculus GACTGCAGGGCAGAGACG GGTAGATTTGGAGTGACGGAAC SYBR 58°C 
Dkki M. musculus CCGGGAACTACTGCAAAAAT GGTTTTCAATGATGCTTTCCTC UPL (76) 580C 
Fgfr2 M. musculus CCTGCGGAGACAGGTAACA CGGGGTGTTGGAGTTCAT SYBR 580C 
UhrJ2 M. musculus AAGGGGCAGTCAAAGAAGC GGAGTCACCTGGACACTCATC SYBR 580C 
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26. Protein analysis 
2.6.1. Lysis and preparation of total protein extracts 
Cells were washed twice with ice cold 1xPBS (Phosphate Buffered Saline (without 
CaC12 or MgC12), scraped into lml of ice cold Ix PBS and subsequently transferred to an 
eppendorf tube. The cells were centrifuged at 800 g at 4°C for 5 min and the pellets were 
immediately frozen at -70 °C until lysis was performed. Frozen pellets were lysed in 2 
volumes of NP40 lysis buffer (1% (v/v) NonidetP-40, 100mM NaC12, 20mM Tris-HC1 
(pH 7.4), 10mM NaF, 1mM sodium orthovanadate, 30mM -glycerophosphate and 
protease inhibitors ('Complete'protease inhibitor mixture, as instructed by the 
manufacturer (Roche). Cellular debris was spun down at 13,000 rpm (microfuge) for 10 
min at 4°C. The lysate was transferred to a fresh tube to assay for protein concentration. 
2.6.2. Determination of protein concentration 
Protein concentrations were determined using the Bio-Rad Dc protein assay (Bio-Rad 
Laboratories), a protein assay based on the Lowry method (Lowry et al.,1951). Working 
reagent A was made by adding 20pi of reagent S to each one ml of reagent A as 
instructed by the manufacturer. A standard curve was established by assaying 5 dilutions 
of a protein standard (e.g. BSA) within the range of 0.2mg/ml to 1.5mg/ml protein. 
1 O0jil of reagent A' was added to 2il of each dilution and subsequently mixed with 
800pi of reagent B. Absorbance was read at 750nm after 15 min and a standard curve 
was established. Absorbance at 750nm was measured for each of the experimental 
samples and their concentrations were determined by multiplying the absorbance of the 
sample by the standard curve's regression coefficient. 
2.6.3. Sodium dodecyl suiphate-polyacrylamide gel electrophoresis (SDS-PAGE) 
Gels for resolution of proteins were made by using a 30% (w/v) acrylamide/bis stock 
solution (containing a ratio of 29 acrylamide: 1 NN'-methylenebisacrylamide; Bio-Rad). 
As a polymerisation catalyst, 25% (w/v) ammonium persulphate (APS) and TEMED 
were used. For all percentages of resolving gels, a 4.5% (w/v) stacking gel was used. 
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SDS-PAGE gels were topped with 2cm of stacking gel (see Table 2.3). For separation of 
the proteins, 25g of each cell lysate was mixed with 1 volume of 2x SDS loading buffer 
(4% (w/v) SDS, 62.5mM Tris-HC1 (pH 6.8), 1% (v/v) glycerol, 0.01% (w/v) 
bromophenol blue, 10% (v/v) 13-mercaptoethanol) and heated at 90°C for 5 mm. Samples 
were loaded into the stacking gel and fractionated by electrophoresis on SDS-PAGE gels 
(7%, 10% or 12.5%) at a constant voltage of 100V during the day in running buffer 
(25mM Tris-base, 190mM Glycine, 0.1% (w/v) SDS). Proteins were separated alongside 
broad-range pre-stained Rainbow SDS-PAGE standards (GE Healthcare) 
TABLE 2.3 Proportions of the constituents of SDS-PAGE resolving and stacking 
gels. 
Gel type Resolving   Stacking 
Percentage 5.00% 10.00% 12.50% 4.50% 
30% Acrylamide (ml) 5 10 12.5 1.5 
1M Tris (ml) 11.2 (pH 8.8) 11.2 (pH 8.8) 11.2 (pH 8.8) 1.25 (pH 6.8) 
10% SDS (ml) 0.3 0.3 0.3 0.1 
25% APS (p.!) 50 50 50 25 
r
DH2MOED (p.!) 40 40 40 20 
 (ml) 13.5 8.5 6.5 7.3 
2.6.4. Western blotting of SD S-PAGE 
Following separation via SDS-PAGE, proteins were transferred to a Protran 
nitrocelluose membrane (Whatman) by electrophoretic transfer in a wet tank blotting 
system (Bio-Rad Laborartories Trans-Blot cell). The transfer was carried out in transfer 
buffer (25mM Tris, 190mM glycine and 20% (v/v) methanol) for 1 h at a constant 
voltage of 100V at 4°C. The nitrocellulose membrane was blocked at RT by 1 h 
incubation in 5% (w/v) skimmed milk powder (Marvel) dissolved in Tris Buffered 
Saline/Tween (TBST) (20mM Tris-base, 136mM NaCl, adjusted to pH 7.6 
supplemented with 0.05% Tween). The membrane was incubated for 2 h at RT (or 
overnight at 4°C) with the primary antibody (1:1000 dilution) of choice (see Table 2.1) 
diluted in 5% (w/v) Marvel/TBS-T at dilutions recommended by the supplier. The 
membrane was washed five times (10 min each at RT) in TBS-T prior to incubation with 
horseradish peroxidase (HRP) conjugated secondary anti-mouse, anti-rabbit or anti-goat 
conjugates as appropriate (GE Healthcare). The membrane was exposed to an auto-
radiographic film for times varying from 10 s to lh and visualized using the ECL-plus 
detection system (GE Healthcare). 
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2.7. Microarray analysis 
RNA was prepared from different ES cell lines as discussed above. The RNA was 
sent to collaborators, Minoru Ko and Alexei Sharov at the NIH in Baltimore for 
further analysis. Biological and technical replicates for each sample were hybridised 
to NIA Mouse 44K Microarray v2. 1 according to the published protocols (Carter et 
al., 2005, Sharov et al., 2008)). Briefly, "2.5 g of total RNA was labeled with Cy3-
CTP using a Low RNA Input Fluorescent Linear Amplification Kit (Agilent,). A 
reference target (Cy5-CTP-labeled) was prepared from the Universal Mouse 
Reference (UMR) RNA (Stratagene). Labeled samples were purified using an 
RNeasy Mini Kit (Qiagen, USA) according to the Agilent's protocol, quantified by a 
NanoDrop scanning spectrophotometer (ThennoScientific), and "hybridized to the 
NIA Mouse 44 K Microarray v2. 1 (whole genome 60-mer oligo; manufactured by 
Agilent Technologies, #012799) according to the Agilent protocol (G4140-90030; 
Agilent 60-mer oligo microarray processing protocol - SSC Wash, vl.0)" (from 
Sharov et al., 2008). All hybridizations were carried out in the two color protocol by 
combining one Cy3-CTP-labeled experimental target and Cy5-CTP-labeled 
reference target. Microarrays were scanned on an Agilent DNA Microarray Scanner, 
using standard settings. Further discussions of the protocols are detailed in Chapter 3. 
2.7.1. Statistical analysis of microarrays 
Statistical analysis was done using the NIA Array Analysis software (Sharov et al., 
2005). A. Sharov using standard statistical conditions (FDR<0.05, 2-fold expression 
levels change) to unveil genes with changes in expression levels between the samples 
and controls. 
Gene ontology (GO) analysis was done using the NIA Mouse Gene Index software, 
which evaluates statistical significance using the hypergeometric probability 




Oct4 activation function is sufficient to block 




In vertebrate development, lineage commitment occurs throughout gastrulation, a 
complex and co-coordinated series of cellular movements that progress in an anterior 
to posterior direction. 
Although the precise choreography of morphogenic movements and rearrangements 
varies between species, germ layer specification occurs throughout gastrulation in all 
species and requires a pooi of multipotent uncommitted progenitor cells to complete 
this process. The need to maintain this multipotent uncommitted population is 
common to all species in which development and differentiation occur over time. In 
mammals, the molecular mechanism(s) that regulate this process have been exploited 
to maintain progenitor populations over longer window of time in order to generate 
the additional extra-embryonic lineages. In addition to its role in early mammalian 
development, the network maintaining progenitor cells also supports ES cell self-
renewal and pluripotency. 
One of the core components of the network responsible for regulating both ES cell 
pluripotency and progenitor maintenance in embryos is the Class V POU domain 
transcription factor Oct4. 
In embryonic development, the conserved role of Oct4 related proteins is to regulate 
differentiation in a number of different progenitor populations. In mouse, Oct4 is 
expressed from the beginning of development in the unfertilised egg and the early 
blastocyst before becoming confined to the 1CM (Pesce and Scholer, 2001). Oct4 
mRNA persists in the pluripotent epiblast of the pre- and post-implementation 
embryo, and becomes progressively restricted to a posterior region in which cells are 
still undergoing mesodermlendoderm induction and ingressing through the streak 
and the node. It is then downregulated, except in the primordial germ cells during 
their migration, and the formation of the genital ridges in both sexes (Palmieri et al., 
1994). Oct4 null embryos die at pen-implantation stages due to the absence of Inner 
Cell Mass (1CM) and an expansion of trophectoderm (Nichols et al., 1998). Oct4 is 
also essential for ES cell self-renewal as its knockdown results in differentiation 
towards both primitive endoderm and trophoblast (Hay et al., 2004). 
The relationship between the activity of Oct4 in ES cells and its putative role in 
gastrulation is apparent, as PouV proteins from vertebrate species lacking extra-
embryonic development are able to maintain murine ES cells in the absence of the 
endogenous Oct4 (Morrison and Brickman, 2006). In fact, one of the Xenopus PouV 
proteins, Xlpou9 1, can do so as efficiently as the mouse protein. In Xenopus, 
knockdown of the PouV proteins results in precocious gastrulation stage 
differentiation, which can be rescued by expression of Oct4. Interestingly, while 
Oct4 activity is conserved in some vertebrates, it is not universally well conserved. 
For example, Zebrafish DrPou2 has little ability to rescue either PouV depleted 
Xenopus embryos or substitute for Oct4 in murine ES cells (Morrison and Brickman, 
2006). 
Understanding the mechanism by which PouV proteins block differentiation in the 
majority of vertebrates is vital. In Xenopus, PouV proteins appear able to maintain 
multipotent populations by suppressing differentiation during germ layer 
specification at least partly through inhibition of the Nodal related TGF-B signaling 
(Morrison and Brickman, 2006). These findings led to the suggestion that Oct4 might 
regulate differentiation by directly suppressing Nodal and Wnt responsive targets. 
In fact, it was proposed that a simple mode by which Oct4 could suppress 
differentiation in general would be the direct repression of lineage specific 
promoters. In mouse and human ES cells the inspection of genome wide Oct4 target 
screens suggested that this form of "lineage repression," was an important 
component of Oct4 activity (Boyer et al., 2005); (Loh et al., 2006). These studies 
proposed that Oct4 and its partners both activate genes encoding components of key 
signalling pathways, and repress differentiation specific genes in undifferentiated 
cells to maintain their self-renewal (Boyer et al., 2005); (Loh et al., 2006). This 
model was also based on earlier findings proposing that Oct4 is able to act as a 
repressor oras an activator of target genes (Pesce and Scholer, 2001). 
In this chapter, we test whether direct lineage repression is an essential component of 
the ability of Oct4 to regulate differentiation in embryonic populations and maintain 
their self-renewal. 
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Here we generate Oct4 and Xlpou9 1 fusion proteins that function exclusively as 
activators or repressors and ask whether these proteins can block differentiation in 
embryonic cell populations and maintain their self-renewal. 
We found that fusion proteins behaving as activators can block differentiation of 
both murine ES cells and embryonic progenitor cells in Xenopus. However, 
repressor proteins appear to induce differentiation in both models. Interestingly, we 
can derive cell lines in which Oct4 activator form expression replaces that of Oct4. 
These cell lines express high levels of pluripotency genes and no longer differentiate 
in the presence of high levels of Oct4 expression or in LIF withdrawal conditions. 
Moreover, analysis of these cell lines by microarray suggests that predicted Oct4 
repressed targets remain repressed, and that upregulated and downregulated gene-
sets in these cell lines correlate very closely with the global sets of genes up and 
down regulated by Oct4. Finally, we were also able to titrate down the levels of 
activated Oct4XVP2 in these cell lines, causing them to regain their ability to 
differentiate in the absence of LIF. Based on a preliminary analysis of our complete 
set of lines, it would appear that the major player causing the change of this 
differentiaton phenotype is levels of Nanog. 
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3.2. Results 
3.2.1. Converting Oct4 and Xlpou91 to either activators or repressors 
To test the importance of transcriptional activation and repression by PouV proteins 
in maintaining uncommitted cells during gastrulation and ES cell self-renewal, we 
constructed a series of global activator and repressor fusion proteins. We employed 
reiterated modular domain that have the capacity to generate an enhancer or a 
silencer bound to a single DNA site (Figure 3.1) These reiterated modules were 
originally tested in the context of Ga14 fusion proteins (Carey et al., 1990). 
These modular units employ either the minimal activation domain of herpes simplex 
activator VP 16 or the defined repression domain of the drosophila engrailed protein. 
Each domain is fused to the flexible hinge region of lambda Cl to create a protein 
sequence with multiple regulatory domains and the flexibility normally imparted 
from multiple DNA sites (Croston et al., 1992; Emami and Carey, 1992; Ohashi et 
al., 1994). The same strategy was used for both Oct4 and Xlpou91 (Figure 3.1). This 
approach has been effective for the generation of similar functional fusions with the 
homeodomain proteins Hex and Hesxl (Brickman et al., 2000). 
VP16 (65-KD) is a herpes simplex virus type 1 (HSV-1) protein, it induces the 
transcription of the immediate early (IE) genes during the lytic infection by the virus 
(Campbell et al., 1984). Its transcriptional activation domain is a highly acidic stretch 
in the carboxyl-terminal 78 amino acid of the protein (Triezenberg et al., 1988a; 
Triezenberg et al., 1988b), and was reported to be a very potent activator of 
transcription in mammalian cells when fused to the yeast activator GAL4 DNA 
binding domain (Sadowski et al., 1988). This VP16 activation domain is composed 
of two transactivation regions; region 1 (amino acids 411 to 456) and region 2 
(amino acids 456 to 490) (Triezenberg et al., 1988a; Triezenberg et al., 1988b). 
While both regions have transactivation ability when fused to Ga14, region 1 was 
shown to be the most critical for the transactivation by full length VP 16 (Sadowski et 
al., 1988) (Carey et al., 1990) (Croston et al., 1992; Emami and Carey, 1992; Ohashi 
et al., 1994). In fact, multimerization of VP 16 region 1 was an effective approach to 
generating synergistic increases in activator potency, and the inclusion of a flexible 
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linker sequence that allows lambda Cl to bind to non-adjacent sites enhances this 
synergy without directly contributing to the activation potential of these molecules 
(Croston Ct al., 1992; Emami and Carey, 1992; Ohashi et al., 1994) (Figure 3.1a2, 
andb2). 
Based on the ability to use domain synergy for activation, we took similar approach 
to generate the repressor constructs. The repression domains employed were derived 
from the Drosophila homoedomain protein Engrailed (EnR). EnR has the capacity to 
repress both basal and activator enhanced transcription trough binding to its specific 
targets (Han and Manley, 1993a; Han Ct al., 1991; Jaynes and O'Farrell, 1991). 
Repression of these targets is dependent on an amino terminal repression domain that 
can function when fused to a heterologous DNA binding domain (Jaynes and 
O'Farrell, 1991). This repression domain appears to contain two essential motifs. 
The first one is an alanine rich domain from residues 228 to 282. It is essential for 
EnR repression in vitro and can function as portable repressor domain when fused to 
a heterologous DNA binding domain (Han and Manley, 1993a; Tolkunova et al., 
1998). The second domain ehi (amino acids 172 to 186) represents a conserved 
motif present in a number of homeodomain proteins (Smith and Jaynes, 1996), and 
its function is more relevant to EnR mediated repression in vivo through recruitment 
of the Groucho co-repressor (Han and Manley, 1993b; Tolkunova et al., 1998). Our 
EnR sequence employed the combination of these two motifs (amino acids 168-28 1). 
Oct4 and Xlpou9 1 activation and repression domain fusions are depicted in Figure 
3.1al andbl. 
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Figure 3.1-Schematic representation of the activator and the repressor forms 
of Oct4 and Xlpou9I 
Diagram illustrating the construction of the activator form of Oct4 and 
Xlpou9 1 proteins. 
Sketch illustrating the principle behind the design of Oct4/X1pou91XVP2 
fusions. 
Diagram illustrating the construction of the repressor form of Oct4 and 
Xlpou9 1 proteins. 
Sketch illustrating the principle behind the design of Oct4IXlpou9 1 ?.EnR 
fusions 
To confirm that these fusion proteins behaved as only activators or repressors in ES 
cells, they were transiently cotransfected alongside luciferase reporter genes into the 
Tc suppressible ZHBTc4 ES cells in the presence of tetracycline (such that there was 
no endogenous Oct4 expression) (Niwa et al., 2002). The reporter genes assayed all 
employed a minimal thymidine kinase (tk) promoter driving luciferase downstream 
of Oct4 dependent sequences either from the Fgf4 enhancer or 6 reiterated copies of 
the octamer-binding motif (Niwa et al., 2002). The basal level transcription from the 
rk promoters can either be activated or repressed (Figure 3 .2a). 
Moreover, the specificity of these fusion proteins was tested using a luciferase 
reporter lacking any octamer-binding sites (Figure 3.3a). 
Figure 3.2b shows that both Oct4?VP2 and Xlpou91?VP2 function as potent 
activators of gene transcription from both the Fgf4 enhancer and the octamer-binding 
reporters. On the other hand, Oct4?EnR and Xlpou9lXEnR repressed reporter gene 
transcription (Figure 3 .2c). 
The specificity of the transcriptional activity of these fusion proteins was confirmed 
as no induction of transcription was observed from the tk promoter luciferase 
reporter lacking any PouV protein responsive elements (Figure 3.3b and c). 
Oct4 has been shown to repress transcription of p-Subunit of Human Chorionic 
Gonadotropin (hCG-13) promoter in human choriocarcinoma Jar cells (Liu et al., 
1997). To confirm that Oct4XVP2 was unable to repress transcription in these cell 
lines, Oct4)VP2 was co-transfected alongside an hCG-13 promoter into Jar cells and 
levels of relative transcription determined. Figure 3.4 demonstrates that Oct4XVP2 
was unable to repress hCG-f3 transcription, and therefore is unable to recapitulate the 
inhibition of hCG-f3-promoter by wild type Oct4. 
This data indicates that Oct4AVP2 appears to be an activator in all tested ES cell 
contexts, and to have no residual repression activity. 
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Figure 3.2-Transcriptional activity of the activator and the repressor form of 
Oct4 and Xlpou9l 
Schematic representation of the luciferase reporters used to test transcriptional 
activity of the activator and repressor forms of Oct4 and Xlpou9l: The Fgf4 
enhancer and the octamer binding motif luciferase reporters. 
Oct4 and Xlpou91 activator forms are able to activate transcription from two 
different luciferase reporters 
Oct4 and XIpou9 1 repressor forms are able to repress transcription from two 
different luciferase reporters 
DNA binding mutant activator form of Oct4 still has some residual activity 
DNA binding mutant repressor form of Oct4 retains some residual activity. 
The indicated cDNAs were cotransfected with the Fgf4 enhancer or the octamer 
binding motif luciferase reporters. Fold induction represents the increase in 
transcription compared with the vector only control. Data represent the mean value 
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Figure 3.3-Transcriptional activity of the activator and the repressor form of 
Oct4 and Xlpou9l is specific 
Schematic representation of the luciferase reporter used to test the specificity 
of Oct4 and Xlpou91 activator and repressor forms transcriptional activity: The 
thymidine kinase (TK) promoter luciferase reporters. 
Oct4 and Xlpou9 1 activator forms show background transcriptional activity 
similar to the vector only activity. 
Oct4 and Xlpou9 1 repressor forms show background transcriptional activity 
similar to the vector only activity. 
DNA binding mutant activator form of Oct4 show background transcriptional 
activity similar to the vector only activity. 
DNA binding mutant repressor form of Oct4 show background transcriptional 
activity similar to the vector only activity. 
The indicated cDNAs were cotransfected with the pTK promoter luciferase 
reporters. Fold induction represents the increase in transcription compared with the 
vector only control. Data represent the mean value of two independent 
experiments. 
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Figure 3.4-Oct4 activator form is unable to repress transcription from the - 
Subunit of Human Chorionic Gonadotropin (hCG-) promoter 
The hCG--Luciferase construct (2ug) was cotransfected into Jar cells with 2ug of 
either pCAGIP (vector only as a negative control), CAG-Oct4, CAG -Oct4XVP2. 
Oct4XVP2 is unable to recapitulate the inhibition of hCG--Luciferase by Wild 
type Oct4. 
Fold induction represents the increase or decrease in transcription compared with 
the vector only control. 
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3.2.2. Activation by Oct4 is sufficient to repress lineage specific 
differentiation in Xenopus embryos 
As it has been suggested that Oct4 and its homologues directly suppress gastrulation 
stage targets of the Nodal and Wnt pathway such as Goosecoid as a mean to regulate 
differentiation, we asked whether PouV fusion proteins (Oct4?VP2 or 
Xlpou9 1 A.VP2) acting as activators only could suppress differentiation in Xenopus 
embryos. 
Figure 3.5a1 and a2 show the overexpression phenotype of the activator and 
repressor forms of Oct4 and Xlpou91 compared to the phenotype of embryos 
depleted of all three Xenopus PouV proteins. Injection of RNA encoding Oct4 or 
Xlpou9l produces complex axis truncations, however embryos still appear to exhibit 
an overt anterior-posterior axis polarity. In the case of Xlpou9l, we also observe a 
failure in neural tube closure and exaggerated pigmentation (Figure 3.5a2). 
However, deletion of the three PouV proteins by Morpholino Oligos (MO) produces 
defects in both the head and the tail alongside an axis truncation. Interestingly, 
phenotypes obtained from injection of RNA encoding Oct4AVP2 and XZpou9JAVP2 
appear to induce phenotypes that superficially resemble the overexpression 
phenotype of the wild type proteins Oct4 and Xlpou9 1 rather than the PouV protein 
MO knockdown phenotype. In fact, while all activators overexpression phenotypes 
show no reduction in the anterior character, overexpression of the EnR fusions 
exhibit profound anterior and posterior truncations and appears to better recapitulate 
the knockdown phenotype at least on a superficial phenotype level. 
Unexpectedly, there is one aspect of wild type PouV overexpression phenotypes that 
appears linked to repression. In the Xlpou9lAEnR injected embryos there appears 
some upregulation of pigmentation, while not as significant as that observed with 
X7pou9l the significance of this remains unclear. These crude phenotypes are 
suggestive of a positive role for PouV proteins in regulating gene expression, 
however to confirm these observations we needed to look at specific markers 
regulated by PouV proteins in gastrulation. Figure 3.5b1 and b2 show the expression 
of a number of gastrulation stage markers as determined by both in situ hybridisation 
and quantitative RT-PCR on RNA from stage 10 whole embryos. 
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Figure 3.5-Activation by Oct4 is sufficient to repress lineage specific 
differentiation in Xenopus embryos 
Overexpression phenotypes of activator and repressor forms of Oct4 and Xlpou9 1. 
Overexpression phenotype of activator and repressor forms of Oct4 and 
Xlpou9l in stage 12.5 Xenopus embryo. Embryos were injected at two-cell stage 
in both blastomeres with 250 pg of mRNA 
Ovexpression phenotype of activator and repressor forms of Oct4 and 
Xlpou9 1 in Xenopus embryo at stage 39. Embryos were injected (same as a. 1). 
(b.I) Effect of overexpressing Oct4 activator and repressor forms on lineage 
specific gene expression. In situs were performed on stage 10.25 embryos 
following injection of mRNA (same as a.l). Pictures are taken of the vegetal pole 
except BMP4, which is an animal view. 
(b.2) qRT-PCR analysis of total RNA collected from stage 10.25 embryos 
following injections of mRNA (same as a.l). The relative change in gene 
expression is shown as a percentage of that from the control embryos. These 
values are the average of three independent experiments. 
Unpaired two tailed equal variance student t-test was used to compare gene 
expression levels between the control embryos and embryos overexpressing either 
Oct4 activator or repressor form (p values in black). 
It was also used to determine the statistical significance of the gene expression 
differences between embryos overexpressing Oct4 activator form, and embryos 
expressing its repressor form (p values in red). 
These Xenopus experiments were done in collaboration with Dr Gillian 
Morrison, and Dr Allessandra Livigni. 
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Interestingly, organizer markers such as Goosecoid, and Mixer are suppressed by 
Oct4XVP2 and induced by Oct4XEnR indicating an indirect mechanism of lineage 
repression. However, marginal zone markers previously shown to be PouV 
dependent such as Bmp4, the Bmp target Xvent2 or Eomes are suppressed by 
Oct4XEnR. Taken together, this data indicates that the induction of endoderm and 
organizer specification is suppressed by a network downstream of the PouV proteins 
rather than a direct repression by PouV proteins. 
An interesting candidate member of this network that appears highly responsive to 
expression of Oct4?.VP2, Oct4XEnR or morpholinos mediated depletion of PouV 
proteins is Brnp4 (Morrison and Brickman, 2006). Bmp4 has been associated with 
maintaining non-committed cells in both ES cells and in Xenopus embryos as 
expression of its constitutively active receptor blocks the onset of germ layer 
specification (Constance Lane et al., 2004: Ying et al.. 2003). As these observations 
suggest that the loss of Bmp4 expression could explain a number of the phenotypes 
observed in the PouV depleted embryos, we investigated this possibility by testing 
the capacity of Bmp4 expression to rescue the PouV depletion phenotype. While not 
tested extensively, injection of Bmp4 RNA alongside morpholinos to the PouV 
proteins appears to rescue the expression of both Xvent2 and Gsc (Figure 3.6). 
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Figure 3.6-BMP4 mRNA rescues gene expression of Xl pouV target genes 
following XIpouV deplitions in Xenopus embryos 
In situ hybridisation analysis of stage 10.25 embryos following injection of control 
morpholino, PouV Morpholino, or coinjection of BMP4 mRNA with each 
morpholino treatment. 
This experiment was done in collaboration with Dr Allssandra Livigni, and Lucy 
Jones. 
3.2.3. Activator function of 004 is sufficient to rescue ES cell self-
renewal 
As activation by PouV proteins was found to be sufficient to repress lineage specific 
differentiation in embryonic progenitors in Xenopus embryos, we wished to 
determine whether it was also sufficient to support ES cell self-renewal. We tested 
the ability of the activator and repressor forms of Oct4 and Xlpou9 1 proteins to 
rescue ES cell self-renewal using the complementation assay designed by Niwa and 
colleagues (Niwa et aL, 2002) (Figure 3.7). 
This assay uses the ZHBTc4 cell line whereby both alleles of endogenous Oct4 were 
disrupted by homologous recombination. The cells are maintained by a randomly 
integrated tetracycline-regulated Oct4 transgene that can be repressed by the addition 
of tetracycline (Tc) to the medium. The system is based on the fact that in the 
absence of Oct4 (presence of Tc) ZHBTc4 cells differentiate, and that this phenotype 
can be rescued by introduction of a second Oct4 transgene via random integration. 
Therefore, the relative ability of different PouV proteins to substitute for Oct4 can be 
evaluated based on their capacity to rescue ES cell growth when introduced into 
ZHBTc4 cells in the absence of Oct4 (presence of Tc). 
The assay was performed by electroporating 2x I 07  ZHBTc4 ES cells with 1 00.ig of 
linearised vector DNAs. To control for transfection efficiency, each transfection is 
divided in half and only one half is treated with Tc. Two days after the transfection, 
puromycin selection was applied for 9 days, and the cells were then stained with 
alkaline phosphatase (AP). The relative ability of a PouV protein to rescue ES cell 
self-renewal can be quantified by calculating a rescue index, that is the number of 
rescued alkaline phosphatase (AP) positive ES cell colonies obtained in the presence 
of Tc normalized to the number obtained in its absence for a given transfection. The 
values were then all normalized to that obtained with Oct4. 
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Figure 3.7- ZHBTc4 cell s complementation assay 
ZHBTc4 cells have both alleles of endogenous Pou5fI disrupted by homologous 
recombination. The cells are maintained by a randomly integrated tetracycline 
regulatable Oct4 transgene that can be repressed by the addition of tetracycline 
(Tc) to the medium. 
The system is based on the fact that in the absence of Oct4 (presence of Tc) 
ZHBTc4 cells differentiate to TE lineage. If Oct4 is supplied via introduction of a 
second transgene, this phenotype can be rescued and normal alkaline phosphatase 
positive ES cells can grow. Thus, the relative ability of different PouV proteins to 
substitute for Oct4 can be evaluated based on their capacity to rescue ES cell 
growth when introduced into ZHBTc4 cells in the absence of Oct4 (presence of 
Ic). 
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Figure 3.8 shows that the activator fusion proteins have the capacity to support 
undifferentiated ES cell growth in the absence of endogenous Oct4, whereas the 
repressor forms of the proteins do not. The rescue index obtained from transfection 
of activator fusions ranged from 20-70% of that obtained with the mouse Oct4, 
whereas PouVXEnR fusions produced no colonies in the absence of Oct4 and 
induced differentation in its presence (Fig 3.8a, and b3). As reported previously and 
demonstrated elsewhere in this thesis, Xlpou9l and Oct4 have similar activity in this 
assay. 
The morphologies of representative colonies rescued by various control PouV 
proteins in the presence and absence of Tc regulatable Oct4 gene expression are 
shown in Figure 3.8 bi. Colonies rescued with Xlpou91 protein are AP positive, with 
undifferentiated ES cell morphology similar to those rescued with Oct4. These 
colonies generally exhibit undifferentiated AP growth in the centre with 
differentiated cells around the periphery. In the absence of Tc, the colonies generated 
by Oct4 and Xlpou9 I appear more differentiated as a result of the overexpression of 
PouV protein (protein from both the Tc regulatable Oct4 transgene and the 
transfected PouV cDNA) (Figure 3.8b1). 
Colonies rescued by either Oct4XVP2 or Xlpou9lXVP2 exhibit a perfect 
undifferentiated ES cell morphology, and are positive for Alkaline phosphatase (AP) 
staining throughout (Figure 3.8b2). Moreover, the morphologies of colonies 
generated by these activator forms in the presence of Tc regulatable Oct4 transgene 
expression contrast greatly to those generated in the same conditions by wild type 
Oct4 and Xlpou9 1. This observation suggests that they are resistant to the Oct4 dose 
dependent differentiation response observed normally (Niwa et al., 2002). 
While no colonies were obtained when the ).EnR fusions were used to rescue Oct4 
null cells, extremely low number of differentiated colonies was obtained when these 
fusions were expressed in the presence of the Tc regulatable Oct4 transgene 
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Figure 3.8-Activator function of Oct4 is sufficient to rescue ES cell self-
renewal 
2x1 07 ZHBTc4 ES cells were transfected with lOOug of linearized vector DNAs 
by electroporation, after 9 days of selection with puromycin in the presence or 
absence of Tetracycline, the cells were stained with alkaline phosphates (AP) and 
the number of AP positive stem cell colonies were scored, and the rescue index 
calculated. 
(a) Rescue index for PouV activator and repressor forms. The Rescue index is 
calculated by dividing the number of ES cell colonies in the absence of Oct4 
(presence of Tc) by the number of AP positive ES cell colonies present in the 
presence of Oct4 (absence of Tc). Rescue index values were normalised to Oct4 
value. Data represents the mean values obtained from three independent 
experiments. 
Control panel: morphology of colonies rescued with wild type PouV 
proteins. 
Morphology of colonies transfected with Oct4 and Xlpou9 1 activator forms. 
Morphology of colonies transfected with repressor forms of Oct4 and 
Xlpou9l. 
104 
In order to exclude the possibility that the phenotypes generated by these fusion 
proteins were caused by non-specific activity of the reiterated regulatory domains 
employed, these domains were tested in the context of an Oct4 lacking the DNA 
binding ability. This lack of DNA binding ability is caused by a single amino acid 
change in the POU domain (from a Valine to Proline at position 267) (Niwa et al., 
2002). 
The absence of DNA binding activity in these new fusion proteins was confirmed in 
transient transfections with a set of Oct4 dependent reporter genes (Figure 3.2d and 
e). While these proteins are impaired in their capacity to activate or repress 
transcription from these reporters, they exhibited a very low level of residual activity. 
This activity is also observed when the DNA binding mutant Oct4 is tested on these 
reporters. Therefore, we conclude that this residual activity represents the 
recruitment of these proteins to DNA by other factors normally associated with Oct4, 
and is independent of the reiterated transcriptional regulatory units. 
Moreover, to confirm that the reduced activity of these DNA binding mutants was 
not caused by a defective expression from the constructs, we examined the protein 
levels produced by these vectors when expressed transiently in HEK 293 cells 
(Figure 3.9). A western blot with an antibody to VP16 indicates that similar levels of 
proteins are expressed form both the DNA binding mutant, and the non-mutant 
activators. 
The ability of these mutant proteins to rescue ES cells self-renewal was tested in the 
ZHBTc4 complementation assay. Both DNA binding mutant Oct4XVP2 and mutant 
Oct4)EnR generated AP negative differentiated colonies similar to those produced 
by the DNA binding mutant wild type Oct4 (Figure 3.8b1, b2, and b3), indicating 
that the rescue by the activator fusions required an intact Oct4 DNA binding domain, 
and was not a result of some unspecific effects contributed by the VP 16 domain. 
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Figure 3.9-Western analysis of activator and repressor forms of Oct4 and their 
corresponding DNA binding mutants 
Equal quantities (4ug) of CAG-Oct4VP2, CAG-Oct4?.EnR, or control constructs 
(CAG-DNA binding mutant Oct4XVP2, CAG-DNA binding mutant Oct4XEnR, and 
DNA binding mutant Oct4. CAG-3xFlag Oct4XVP2, CAG-3xFlag Oct4XEnR 
3xFlag Oct4, CAG-3xFlag XVP2, CAG-3xFlag XEriR) were transiently transfected 
into HEK293 cells. 
24 hours after transfection, lysates were analysed by western blotting with anti VP 16 
and Oct4 antibodies. 
Non-transfected cells were included as a negative control. 
1) Anti VP 16 antibody at high exposure 
(a.2) Anti VP16 antibody at low exposure 
1) Anti Oct4 antibody at high exposure 
(b.2) Anti Oct4 antibody at low exposure 
(c) 13-actin antibody 
The predicted sizes for the proteins areas follow: 
Oct4XVP2: 62.047 KDa 
Oct4XEnR: 59.05 KDa 
DNA binding mutant Oct4A.VP2: 62.047 KDa 
DNA binding mutant Oct4EnR: 59.05 KDa 
DNA binding mutant Oct4: 41.01 KDa 
3xFlag Oct4?VP2: 64.89 KDa 
3xFlag Oct4XEnR: 61.89 KDa 
3xFlag Oct4: 43.85 KDa. 
3xFlag )cVP2: 23.88 KDa 
3xFlag .EnR : 20.88 KDa 
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Interestingly, unlike the DNA binding mutant Oct4, no colonies were obtained when 
the DNA binding mutant activator or repressor domain fusions were introduced into 
cells already expressing Oct4 (absence of Tc) (Figure 3.8b1, b2, and b3). As the 
differentiation induced by Oct4 over-expression has been shown to be independent 
of DNA binding (Niwa et al., 2002), it has been suggested that high levels of Oct4 in 
a cell might "squelch" Oct4 mediated transcription by sequestration of Oct4 specific 
co-factors away from productive DNA bound complexes. A similar mechanism 
might be at work here and the reiteration of activation and repression domain 
modules could increase the affinity of non-DNA bound Oct4 for crucial co-factors 
required for ES cell growth. 
3.2.4. Clonal cell lines can be derived from colonies rescued with PouV 
activator proteins and maintained in culture 
As colonies rescued with Oct4?.VP2 and XIpou91XVP2 proteins exhibited an 
enhanced undifferentiated ES cell morphology, we wished to explore the basis for 
this phenotype by establishing cell lines in which these activators supported self-
renewal in the absence of the Tc regulatable Oct4 transgene expression. 
Following the electroporation of vectors driving the expression of Oc14, OcI4AVP2 
and X1pou91AVP2 upstream of an IRES puromycin cassette in the ZHBTc4 cells in 
the presence of Tc, individual Puro resistant colonies were expanded in ES cell self-
renewing conditions (under selection and in the presence of Tc). The same approach 
was used previously to derive cell lines expressing different PouV proteins in place 
of Oct4, and in no case was Oct4 expression detected in the expanded cell lines 
(Morrison and Brickman, 2006). 
Figure 3.10 shows the morphology of clonal cell lines derived from colonies 
produced by Oct4?.VP2 and Xlpou9 1 XVP2 in absence or presence of tetracycline at 
passage 5. Oct4XVP2 and Xlpou9lXVP2-supported cultures consist of highly 
compact undifferentiated cells with less spontaneous differentiation in the culture in 
comparison to the parental ZHBTc4 cell line, even when the Tc regulatable Oct4 
transgene is on. 
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Figure 3.10-Derivation of clonal cell lines rescued with Oct4 and Xlpou9I 
activator forms 
Morphology of Oct4?.VP2 and Xlpou9 I XVP2 cell lines at p5 in the absence and 
the presence of Oct4 transgene expression. 
Following the electroporation of Oct4XVP2 and Xlpou9 1 A.VP2 constructs in the 
ZHBTc4 cells, puromycin selection was applied for 9days in the presence (-Oct4) 
or absence (+Oct4) of Tetracycline. The rescued colonies were then picked and 
propagated. 
3.2.5. Characterization of Oct4?.VP2 cell line 
3.2.5.1. Oct4A.VP2 cell line supports normal self-renewal rate 
To assess the relative efficiency of self-renewal of the activator rescued cell lines, we 
tested the capacity of single cells to self-renew and generate normal ES cell colonies 
when grown in the presence of serum and LIF. 
As both X1pou91XVP2, and Oct4XVP2 expressing cell lines showed similar 
phenotypes and behaviour, we chose to focus our analysis on Oct4XVP2 cell line. It 
offers the advantage of studying Oct4 activator function in its relevant physiological 
environment. 
Cells were plated at clonal density and cultured for 6 days, and the resulting colonies 
stained for alkaline phosphatase (AP) activity. Colonies were scored as AP positive 
undifferentiated colonies, AP negative differentiated colonies or mixed colonies 
containing both undifferentiated and differentiated cells. Examples of these 
morphologies are shown in Fig 3.11 a. 
Based on this assessment of colony morphology, the activator expressing cell lines 
have a marginally increased rate of self-renewal over either those cells rescued by 
Oct4 or the parental ZHBTc4 cells (Figure 3.11b). These values represent average 
values from two experiments, each with two independent clones from the indicated 
cell line. 
Interestingly, colonies formed by Oct4?.VP2 expressing cell lines also exhibited 
distinct morphologies; they were smaller and less differentiated than normal Oct4-
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Figure 3.1 1-Self-renewal assay of Oct4 and Oct4AVP2 cell lines 
The indicated cell lines were plated at clonal density (60 cells/cm2), and cultured 
for 6 days in self-renewing condition then stained for alkaline phosphatase (AP) 
activity (red) 
Examples of colony morphology present in each cell line. Colonies were 
classified into three categories: Uniformly AP positive undifferentiated colonies, 
mixed colonies containing AP positive and negative cells, and AP negative 
differentiated colonies. 
Percentage of previous colony categories in each cell line. Data represents 
average values from two experiments in which tow independent clones from each 
cell line were used. 
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3.2.5.2. Proliferation rate of the activator rescued cell lines 
The observation that Oct4 activator supported cell lines formed smaller colonies than 
those of wild type Oct4 supported cells suggested that either growth or proliferation 
might be reduced in response to expression of Oct4?.VP2. To investigate this 
possibility the proliferation rate of Oct4).VP2 supported cell lines was compared to 
the proliferation rate of Oct4 maintained cells, parental ZHBTc4 cells and wild type 
E14Tg2a ES cells. Proliferation was measured by quantif'ing the increases in viable 
cells over time via an MTS assay. At least two clones for each genotype were used to 
compile the data shown in Figure 3.12. The data indicates that there is little 
difference in the proliferation rates of the different cell lines. As a result, the 
difference in the colony size is not due to a slower growth rate, but rather some 
aspect of cell size or adhesion. 
3.2.5.3. Molecular phenotype of activator (Oct4?.VP2) rescued ES cells 
As the colony size and morphologies observed in the activator supported cell lines 
were not a result of relative differences in proliferation, we examined expression of 
key pluripotency genes. Staining for Nanog, Sox2 and Oct4 revealed some 
interesting differences. An apparent subtle increase in Sox2 was observed in 
Oct4XVP2 supported cell lines alongside a slight reduction in overall levels Oct4 
transgene levels (Figure 3.13). However, the most striking observation was the 
relative increase in Nanog expression specific to the Oct4XVP2 cells. This was later 
confirmed by RT-PCR (Figure 3.23 a). At least three clones from each cell line were 
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Figure 3.12-Oct4).VP2 rescued cell lines proliferate at a similar rate to wild 
type ES cells in Self-renewing condition 
Cell growth was measured by the MTT assay and is plotted on the y-axis against 
time (days) on the x-axis. Data represents one of two experiments in which each 
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Figure 3.13-Immunocytochemistry of Oct4XVP2 cell line under self-renewing 
conditions 
Three clones from each cell line (except ZI-IBTc4 and E14Tg2a one clone each) 
cultured under self-renewing conditions were fixed and immunostained for Oct4, 
Nanog and Sox2 proteins. 
Green and Bright field images are shown for each cell line and each antibody. 
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We also examined cellular phenotypic variations present in typical ES cell cultures 
grown in LIF and serum. Flow cytometry was used to assess cell-based expression 
of a number of cell surface markers, known to characterize undifferentiated 
populations, in Oct4?.VP2-supported ES cells. Cells were stained with antibodies 
specific to stage specific embryonic antigen-1 (SSEA-l), epithelial-calcium 
dependent adhesion molecules (E-cadherin), and platelet endothelial cell adhesion 
molecule-i (PECAM-1 also known as CD3I) (Boiani and Scholer, 2005; Cui et al., 
2004). 
While expression of both E-cadherin (Figure 3.1 4a) and PECAM- 1 (Figure 3.1 4b) is 
in nearly all the cells of the Oct4?.VP2 cell line, and is essentially indistinguishable 
in all clones, the expression of SSEA-i does show some variation (Figure 3.14a). All 
three clones of Oct42cVP2 expressing cells have some reduction in the extent to 
which the population is SSEA-1 positive. Although this reduction is minimal in two 
clones, the third clone shows a significant reduction in about half the population. 
Interestingly, SSEA-1 heterogeneity in ES cells was reported previously (Cui et al, 
2004), and while the extent of SSEA-1 expression can vary in different cell lines, 
there is little correlation between SSEA1 expression and the ability of ES cells to 
contribute to blastocysts. 
3.2.5.4. Differentiation potential of the Oct4A.VP2 cell line 
The highly undifferentiated morphology and high levels of Nanog expression in 
Oct4XVP2 supported cell lines, in addition to the undifferentiated morphology of 
colonies generated by the PouV activator fonns in the presence of Tc regulatable 
Oct4 transgene expression suggest that these cells are resistant to differentiation 
induced by 0c14 overexpression (Morrison and Brickman, 2006; Niwa et al., 2002). 
All these observations prompted us to examine the response of these cell lines to 
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Figure 3.14-Oct4.VP2 cell line expresses ES cell associated cell surface 
markers under self-renewing conditions 
Three clones at least from Oct4XVP2 and Oct4 cell lines growing in self-renewing 
conditions were used for FACs analysis (only one clone shown for Oct4 cell line). 
ZHBTc4 and E14tg2a cell lines were used as positive controls. 
FACs analysis for SSEA- I and Ecadhenn double staining is shown for each 
cell line. 
FACs analysis for CD3 I staining for each cell lines. 
Numbers are the percentages of cells in each of the indicated gates 
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We tested the consequences of re-expression of Ic regulatable 0c14 transgene, as 
well as LIF withdrawal on the phenotype of activator supported cell lines. 
Figure 3.15a1 shows that unlike Oct4, and ZHBTc4 cell lines, Oct4XVP2 cells 
remain undifferentiated and positive for AP staining when Oct4 transgene is 
reactivated. Although. Oct4 levels increased upon reactivation of the Tc regulatable 
Oct4 transgene in both Oct4 and Oct4?cVP2-supported cell lines (Figure 3.15 a2), the 
total Oct4 levels in Oct4XVP2 cell line after the reactivation of Oct4 transgene are 
comparable to that of Oct4 cell line growing in self-renewal conditions. Suggesting 
that the total Oct4 levels in Oct4?.VP2 cell line after the reactivation of Tc 
regulatable Oct4 transgene might have not reached the threshold level required to 
induce ES cell differentiation. 
While the response of activator supported cell lines to Oct4 overexpression might not 
be that surprising, Figure 3.15a also shows that these lines are resistant to 
differentiation induced by LIF withdrawal. Normally ES cell cultures require LIF to 
maintain the pluripotent state, and in its absence, ES cells normally differentiate 
(Niwa et al., 2000; Smith et al., 1988; Williams et al., 1988). 
As predicted, when cultured for five days in the absence of LIF, both the ZHBTc4 
cells and Oct4 rescued cell lines adopt a differentiated morphology and loose the AP 
expression (Figure 3.15 al). However, Oct4XVP2 supported ES cells appear not to 
differentiate, instead they retain their AP positive undifferentiated morphology, and 
expand at reduced rates. Similar results were obtained when self-renewal in the 
absence of LIF was assayed at a clonal level. Oct4A.VP2-expressing cell lines 
generated tiny AP positive colonies when plated at clonal density in the absence of 
LIF (Figure 3.15b1). When these colonies were allowed to grow for another ten 
days, a significant proportion of them formed normal size undifferentiated colonies 
(30%) (Figure 3.15b2, and b3). Moreover, the colonies scored as mixed in the 
activator supported cell lines, were scored based on colony size rather than 
phenotype. These results suggest that Oct4XVP2 cell line does not differentiate upon 
LIF withdrawal, instead, they self-renew at a slower rate showing signs of LIF-
independent self-renewal. 
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Figure 3.15-Oct4XVP2 cell line does not differentiate upon LIF withdrawal or 
in Oct4 overexpression conditions 
Monolayer differentiation of Oct4XVP2 cell line: cells were plated in the 
absence of LIF, or Oct4 overexpression conditions for 5 days. As well as in self-
renewing conditions as a control. 
Oct4 overexpression condition is achieved by removal of tetracycline from the 
medium leading to the re-expression of the Ic regulatable Oct4 transgene. 
Three clones for each cell line except ZHBTc4 were used and stained for AP 
activity (red). Photos of representative clones are shown. 
-Oct4/+LIF represents self-renewing condition. 
-Oct4/-LIF represents LIF withdrawal condition. 
+Oct4/+LIF represents mOct4 overexpression condition. 
qRT-PCR analysis of Oct4 mRNA levels. RNA was collected at day 5 of the 
differentiation experiments. Levels of Oct4 expression are relative to TBP (Tata 
binding protein) level. 
Clonal density differentiation of Oct4?.VP2 cell line: cells were plated at 
clonal density in the absence of LIF or Oct4 overexpression condition for 5 days as 
well as self-renewing conditions as a control. 
The same three clones for each cell line were used and stained for AP activity 
(red). Photos of representative clones are shown. 
Morphology of Oct4).VP2 cells growing in the absence of LIF for 15 days 
cells from clonal density differentiation were allowed to grow in culture in the 
absence of LIF, and then stained for AP activity. 
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3.2.6. Investigating the response of Oct4VP2 cell line to LIF withdrawal 
To understand the molecular basis for the response of Oct4 activator-supported ES 
cells to LIP withdrawal, and investigate its capacity for LIP independent self-
renewal, we carried out microarray gene expression analysis on RNA derived from a 
set of PouV rescued cell lines including Oct4XVP2, Oct4 and the parental ZHBTc4 
cells in response to LIF withdrawal. An outline of the experimental plan is given in 
Figure 3.16. The experiment was designed to compare gene expression under 
standard self-renewing conditions and then to follow those gene expression changes 
into differentiation. Cells were plated at low density under self-renewing conditions 
for 24 hours, at this point RNA time point was taken from each cell line. The culture 
medium was changed to an identical one without LIP and two additional time points 
were taken at 48 and 120 hours after LIP withdrawal. 
Two independent clones from each cell line were used as both biological and 
technical replicates. Samples were hybridised to the NIA Mouse 44K Microarray 
v2. 1 (Carter et al., 2005), and gene expression analysed in collaboration with Minoru 
Ko and Alexei Sharov at the NIH. 
ANOVA analysis was performed by A. Sharov using standard statistical conditions 
(PDR<0.05, 2-fold expression levels change) to unveil genes with changes in 
expression levels between the samples and controls. 
Statistical analysis was done using the NIA Array Analysis software (Sharov et al., 
2005). 
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+ Lif No Lif No Lif 
24 h 2 days 5 days 
Oct4i.VP2 cell line 	 Collection Collection Collection 
Collection Collection Collection 
ZHBTc4 cell line 	 Collection Collection Collection 
Figure 3.16-Schematic representation of the micro-array experiment design 
Cells were plated at low density (3000 cells/cm2 ) under self renewing conditions 
for 24 hours; at that point RNA from all the cell lines was collected. The culture 
medium was then changed to medium without LIF. After 48 hours of LIF 
withdrawal, RNA was collected from all cell lines for the second point. At this 
stage, the cells were fed again with medium without LIF and left in culture for 
another 3 days before RNA was collected for the final point. 
Two clones from each cell lines were used as biological replicate in the whole 
experiment. 
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3.2.6.1. Genes responded to LIF withdrawal differently in Oct4?.VP2 cell line 
and Oct4/ZHBTc4 cell lines 
Gene expression analysis was performed to unveil genes that respond to LIF 
withdrawal in Oct4-supported and ZFIBTc4 cell lines and study their behaviour in 
Oct4?.VP2-supported cell line after LIF withdrawal. 
Figure 3.17a shows that the majority of genes upregulated or downregulated by more 
than two fold upon LIF withdrawal in either Oct4 rescued or parental ZHBTc4 cell 
lines did not change upon LIF withdrawal in Oct4?.VP2-supported cell lines. 
Moreover, the genes that did change in the activator support lines could not be 
associated with a particular trend in either control cell lines (Figure 3.17b). This 
difference in the gene expression response of the Oct4)VP2 cell lines correlates with 
the distinct undifferentiated, but slow growing phenotype observed in these cells 
when cultured in the absence of LIF, and suggests that this cell line is distinct at the 
molecular level from the two other cell line. 
3.2.6.2. The majority of genes regulated by Oct4 are regulated in the same 
direction by Oct4?VP2 
Previous work in the laboratory of our collaborator Minoru Ko has used the ZHBTc4 
cells to define a set of Oct4 responsive genes and targets (Matoba et al., 2006; 
Sharov et al., 2008). We have used these data sets to address the question of how the 
genes up or down regulated by Oc4XVP2 compared to the genes defined as 
responding to Oct4 withdrawal in the ZHBTc4 cells. Figure 3.18 shows a plot of the 
total set of genes responding to Oct4 depletion in the ZHBTc4 cells compared to the 
enhanced effect of Oct4).VP2 on gene expression. A positive value in Figure 3.18 
means that the gene is activated, and a negative value means the gene is suppressed. 
Not surprisingly, inspection of Figure 3.18 indicates that the majority of genes 
positively regulated by Oct4 are also positively regulated by Oct4)\.VP2. However, 
the plot also suggests that the majority of Oct4 negatively regulated genes are also 
negatively regulated by Oct4XVP2. This is particularly striking, as it would imply 
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Figure 3.17-Genes responded to LIF withdrawal differently in Oct4XVP2 cell line and Oct4/ZHBTc4 cell lines 
Genes upregulated or downregulated upon LIF withdrawal in Oct4 and ZIIRTc4 cell lines respond differently to LIF 
withdrawal in Oct4XVP2 cell line. 
Genes upregulated or downregulated upon LIF withdrawal in Oct4?VP2 cell line respond differently to LIF 
withdrawal in Oct4 and ZHBTc4 cell lines. 
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Effect of Oct4 
Figure 3.18-Most of the genes regulated by wild type Oct4 are regulated by 
its activator form (Oct4XVP2) in the same manner 
The plot shows Oct4XVP2 effect versus mOct4 effect on gene expression. 
Positive value means that the gene is activated and, negative value means the 
gene is suppressed. 
Most genes that are activated by Oct4 are also activated by Oct4)cVP2, and most 
genes that are suppressed by Oct4 are suppressed by Oct4XVP2. 
It seems that both activation and suppression are in average stronger for 
Oct4XVP2 than for Oct4. However there are genes that are affected in opposite 
way by Oct4 and Oct4XVP2 (some of them are named on the figure). 
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To further investigate whether we could detect any evidence for the existence of true 
Oct4 repressed targets we examined the complete set of genes inferred by Sharov 
and colleagues as "directly suppressed" by Oct4 individually (Sharov et al., 2008). 
We reasoned that if Oct4 activity is involved in direct lineage specific repression, 
then the binding of Oct4XVP2 to these promoters would be expected to at least de-
repress their transcription and we should observe some evidence of this in our 
microarray data. Table 3.1 lists the complete set of 52 genes inferred as directly 
repressed Oct4 targets as defined by Sharov et al 2008. Inspection of the behavior of 
these genes in our microarray indicates that 83% (43 genes) of them are repressed by 
Oct4?VP2, which supports the notion that the majority of these targets are not 
genuine direct Oct4 targets, and are instead indirectly repressed targets that are 
regulated by other aspects of the network downstream of Oct4. 
As the activity of certain Oct4 repressed promoters such as Cdx2 are vital for the 
maintenance of ES cell phenotypes, we further validated the conclusion from our 
microarray data by RT-qPCR on RNA obtained from two different clones from each 
cell line (Figure 3.19). All eight targets examined behaved as in the microarray 
analysis with the expression of some actually being lower in the Oct4XVP2 
supported cell lines than in Oct4 rescued or the parental ZHBTc4 cells. Taken 
together our data supports the notion that Oct4 is a positive regulator of a network 
that silences gene expression associated with embryonic differentiation. 
3.2.6.3. Difference in gene expression between 0ct4?..VP2 and to Oct4 and 
ZHBTc4 cell lines 
To identify differentially regulated genes that might be associated with the properties 
of Oct4AVP2-supported cells, we compared gene expression in this cell line to those 
supported by wild type Oct4 (Oct4 rescued, and ZHBTc4). 
Gene ontology (GO) annotations of upregulated and downregulated genes in 
Oct4XVP2 cell line with more than 2 fold change are listed in Table 3.2 and 3.3 and 
attached as appendices. 
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Table 3.1- List of Oct4 repressed targets 
List of Oct4 repressed targets concluded from study by Sharov et al 2008. The 
microarray analysis of Oct4XVP2 cell line showed that most of the genes 
inferred to be repressed by Oct4 are still repressed in the mOct4XVP2 cell line 
except from genes in red colour. 
Geweina:m:e 
Sdf2 stromal cell derived factor 2 
Msx2 homeobox, msh-like 2 
Fgfrl fibroblast growth factor receptor 1 
Cdx2 caudal type homeo box 2 
Otx2 orthodenticle homolog 2 (Drosophila) 
Dkkl dickkopf homolog 1 (Xenopus laevis) 
Tec tec protein tyrosine kinase 
Akap2 A kinase (PRKA) anchor protein 2 
Rbl retinoblastoma 1 
Chesi checkpoint suppressor 1 
Ak3 adenylate kinase 3 
SptIc2 serine palmitoyltransferase, long chain base subunit 2 
Arrbl arrestin, beta 1 
Fgf5 fibroblast growth factor 5 
Eomes eomesodermin homolog (Xenopus laevis) 
EgIn3 EGL nine homolog 3 (C. elegans) 
Smarca2 
SWI/SNF related, matrix associated, actin dependent 
regulator of chromatin, subfamily a, member 2 
1700034H14RikRIKEN cDNA 1700034H14 gene 
Hsp90aal heat shock protein 90, alpha (cytosolic), class A member 1 
Ddit4 DNA-damage-inducible transcript 4 
261004211.0411tik RIKEN cDNA 2610042L04 gene 
9O30025P2ORik RIKEN cDNA 9030025P20 gene 
Ss18 synovial sarcoma translocation, Chromosome 18 
Higd2a HIG1 domain family, member 2A 
Dnajbl4 Dna) (Hsp40) homolog, subfamily B, member 14 
A1450540 expressed sequence A1450540 
L0C236749 similar to Testin (TESS 
Cfdpl craniofacial development protein 1 
Ube2f ubiquitin-conjugating enzyme E2F (putative) 
Phactri )hosphatase and actin regulator 1 
KctdlO )otassium channel tetramerisation domain containing 10 
Dmrtl doublesex and mab-3 related transcription factor 1 
Rpusd4 RNA pseudouridylate synthase domain containing 4 
Tbx15 r-box 15 
Fnbpl formin binding protein 1 
Son Son DNA binding protein 
2810003C17Rik RIKEN cDNA 2810003C17 gene 
Ccdc68 coiled-coil domain containing 68 
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Gpc4 glypican 4 
Sema6a 
sema domain, transmembrane domain (TM), and 
cytoplasmic_domain,_(semaphorin)_6A 
Fati FAT tumor suppressor homolog 1 (Drosophila) 
Qk quaking 
4933403G14RikRIKEN cDNA 4933403G14 gene 
Fgfr2 fubroblast growth factor receptor 2 
Uhrf2 ubiquitin-like, containing PHD and RING finger domains 2 
Epb4.9 erythrocyte protein band 4.9 
Lgmn legumain 
Prtg protogenin homolog (Gallus gallus) 
Utrn utrophin 
Cidea 
cell death-inducing DNA fragmentation factor, alpha 
subunit-like_effector_A 
Scap SREBF chaperone 
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Figure 3.19-Most genes inferred to be repressed by Oct4 are still repressed 
in the Oct4A.VP2 cell line 
Microarray validation by qRT-PCR of few genes from the list of Oct4 repressed 
targets (Sharov et al 2008). 
Total RNA was collected during the LIF withdrawal time course as explained 
previously in the microarray experiment design. Expression levels of all analysed 
genes were normalised to TBP levels for each sample. 
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While the upregulated genes in Oct4?VP2 cells are enriched for functions related to 
plasma membrane, cell adhesion, extracellular matrix, and immune response, the 
downregulated genes are enriched for transcription factor activity, nervous system 
development. neuroenesis. erowth (actor activity, and cvtokine activity. 
[he mapping of these gene expression changes onto the genorne reveals striking 
clustering. In particular, genes upregulated in the activator supported cell lines 
appear to cluster in strong clusters on chromosomes 3, 5, 6, 7, 8, 11 and 14 (Figure 
.20a and b). A complete list of the 15 strongest clusters of upregulated genes in 
()ct42.VP2-supported cells is attached in the appendix (Table .4). 
Interestingly, Oct4VP2 cell line overexpresses many germ line and oocyte-specific 
genes. For example, Oas (cluster 3), and Omt2b (cluster 8) are known oocyte 
markers and Dppa3 also known as Stella (cluster 5), and Gsg] (cluster 6) are 
associated with germ cell specification. 
Surprisingly, this analysis also revealed that Oct4XVP2 cell line expressed high 
levels of the following neural genes: Pax6, En], NtrKI, Ntnl, Notch4, Nrxn3, En2, 
G1i2. and Hhip. These genes are all upregulated in cells grown in LIF and serum and 
their expression is maintained during LIF withdrawal (Figure 3.21a). These 
observations were particularly intriguing as PouV proteins in lower vertebrates are 
expressed in the early neural plate and later in the isthmus region (Belting et al., 
2001). As it had been previously shown that ectopic 0c14 expression in the ZHBTc6 
cells enhances neural gene expression (Niwa et al., 2002; Niwa et al., 2000), we 
tested whether activator supported lines undergo neural differentiation. In our hands, 
neither the ZHBTc4 cells them-selves nor any of our Oct4XVP2 or Oct4 supported 
lines underwent robust differentiation to morphologically normal Tuji positive 
neurons (Figure 3.21 b). We believe this is likely due to the inability of these cell 
lines to downregulate Oct4 and undergo terminal differentiation. However, when our 
lines were compared to each other, the Oct4XVP2-supported cells consistently 
expressed higher levels of both Nestin and Tuji, although morphologically they do 
not appear as neurons. 
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Figure 3.20-Genome location of genes affected by Oct4A.VP2 
Genome location of clusters of upregulated genes in Oct4?.VP2 cell line in 
comparison to Oct4 and ZHBTc4 cell lines. 
Genome location of genes downregulated in Oct4XVP2 cell line in comparison 
to Oct4 and ZHBTc4 cell lines. 
The graphs were generated using NIA Mouse Gene Index (Sharov AA, et al 2005). 
The height of bars shows the number of genes per 1Mb of sequence. 
Magenta colour means that the number of upregulated or down regulated genes in 
the Oct4XVP2 cell line is significantly over-represented in this 1Mb chromosome 
region (FDR<0.l). 
Blue colour means that the number of genes is not significantly over-represented. 
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Figure 3.21-Oct4XVP2 cell line express high levels of neural genes 
Neural genes microarray plots: the plots are comparing log intensity values 
for each gene probe among the three cell lines at the three time points of the LIF 
withdrawal experiment. The error bars represents standard deviation between two 
biological replicates (two independent clones). 
in Vitro neural monolayer differentiation: three clones from each cell line 
(except ZHBTc4 and E14Tg2a one clone each) cultured under neural 
differentiation conditions for 6 days were fixed and immunostained for Nestin 
and Tuji proteins. 
Nuclear staining (Dapi) and Bright field images are shown for each cell line. 
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While the neural signature comes clearly out of this dataset, only Nanog among 
known key pluripotency genes is overexpressed in the Oc4XVP2 cell line (Figure 
3.22). However, other ES cell associated transcripts (ECATs) (Takahashi and 
Yamanaka, 2006): GdJ3, Dppa2, Fbxol5, Dppa3. ERas, and Sox15 are also 
upregulated in the Oct4?.VP2 cell line. It will be interesting to analyse the role of 
these genes in maintaining pluripotency, and their upstream regulators (Oct4 only 
targets, Nanog only targets, or target of both Oct4, and Nanog). 
Upregulation of Nanog in the Oct4XVP2 cell line suggests it might play an important 
role in its response to LIF withdrawal, especially that Nanog overexpression is 
known to generate LIF-independent self-renewal (Chambers et al., 2003). 
3.2.6.4. Gene expression analysis of Oct4A.VP2 cells during LIF withdrawal 
time course 
While Nanog was the only known key pluripotency gene upregulated in the 
undifferentiated activator supported cell lines, expression of other pluripotency genes 
was maintained during the LIF withdrawal time course (Figure 3.22). To explore 
these changes in gene expression more carefully, we validated these findings using 
real time qRT-PCR analysis of gene expression levels of the pluripotency genes 
Oct4, Nanog, K1f4, Sox2, Rex] and Fgf4 during LIF withdrawal time course. While 
Nanog is noticeably upregulated in the undifferentiated Oct4).VP2 supported cell 
lines, the other pluripotency markers are all expressed at the same levels as in the 
control cell lines (Oct4 supported and ZHBTc4 parental cell lines). However, during 
LIF withdrawal, expression levels of all these pluripotency genes, except Fgf4, are 
maintained in Oct4XVP2 supported cells (Figure 3.23a). 
Interestingly, while most differentiation specific genes behaved in a similar manner 
during the LIF withdrawal time course in both Oct4XVP2 supported cells and control 
cell lines, Gata4 and specially Gata6 gene expression levels are significantly 
downregulated in the undifferentiated Oct4XVP2 cells and fail to increase upon LIF 
withdrawal. This suggests that the activator supported cell lines fail to from primitive 
endoderm upon LIF withdrawal and this would be consistent with the high levels of 
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Figure 3.22-Gene expression analysis of ES Cells Associated Transcripts 
(ECAT) in Oct4VP2 cell line during LIF withdrawal time course 
Microarray plots: the plots are comparing log intensity values for each gene 
probe among the three cell lines at the three time points of the LIF withdrawal 
experiment. The error bars represents standard deviation between two biological 
replicates (two independent clones). 
Total RNA was collected during the LIF withdrawal time course as explained 
previously in the microarray experiment design. 
Upregulated in Oct4A.VP2 cell line and are maintained after LIF withdrawal. 
Upregulated in Oct4XVP2 cell line and are downregulated after LIF 
withdrawal. 
Expressed at similar level in Oct4XVP2 cell line and are maintained after LIF 
withdrawal. 
Expressed at similar level in Oct4XVP2 cell line and are upregulated after 
LIF withdrawal. 
Expressed at similar level in Oct4XVP2 cell line and are downegulated after 
LIF withdrawal. 
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Figure 3.23-Gene expression analysis of Oct4X.VP2 cell line during LIF 
withdrawal time course 
Total RNA was collected during the LIF withdrawal time course as explained 
previously in the microarray experiment design. 
qRT-PCR analysis of plunpotency genes expression levels in Oct4XVP2 cell 
line during LIF withdrawal time course: Oct4, Nanog, KLF4, Sox2, Rexi and 
Fgf4 expression levels remain high even after LIF withdrawal. 
and (c) qRT-PCR analysis of expression levels of mesoderm and endoderm 
markers in Oct4XVP2 cell line during LIF withdrawal time course: GATA4 and 
GATA 6 are significantly downregulated. 
Expression levels of all analysed genes were normalised to TBP levels for each 
sample. 
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3.2.6.5. Correlation between Nanog levels and the ability of activator supported 
cell line to differentiate upon LIF withdrawal 
The expression of Nanog in Oct4?.VP2-supported cell line suggests that Oct4A.VP2 
regulates Nanog levels. We therefore asked what would be the consequences of 
reducing Oct4AVP2 levels on Nanog expression and on the response of Oct4XVP2-
supported cell line to LIF withdrawal. As Oct4AVP2 expression is selectable based 
on an IRES puromycin cassette downstream of the Oct4AVP2 coding sequence, one 
way to reduce its expression level was to modify the concentration of puromycin 
used for selection. Thus, we generated a new set of cell lines by selecting for 
transgene expression at lower puromycin concentrations. The resulting cell lines 
(Oct4?.VP2*) express lower levels of Oct4AYP2 (Figure 3.24, first panel) than the 
previously derived cell lines, and, also express correspondingly lower levels of 
Nanog (Figure 3.24). This reduction of both OcI4AVP2. and Nanog levels in 
Oct4A.VP2* cell lines was confirmed at the protein level using immunostaining 
(Figure 3.25). While there seems to be modest effects on other pluripotency factors 
at an RNA level, only Nanog shows a consistent greater than two fold change in two 
independent clonal lines. 
When the newly derived Oct4XVP2*supported  cell lines were plated at clonal 
density and allowed to expand. The formed colonies exhibited an intermediate 
phenotype between the small, highly undifferentiated phenotype of the original 
Oct4XVP2-supported lines and the typical ES cell colonies formed by any of the 
control cell lines. Colonies derived from Oct4)VP2*  cells were slightly bigger than 
those derived from the original Oct4?.VP2 cell line, with more differentiated cells in 
their periphery (Figure 3.26a). Moreover, self-renewal rate of Oct4?VP2*  cells was 
comparable to that of Oct4?.VP2, Oct4 or ZHBTc4 cell lines (Figure 3.26b). The 
Oct4A.VP2* cell line also expressed key pluripotency associated genes such as K1f4, 
Sox2, Rex], and Fg[4 at similar levels to Oct4XVP2. Oct4, and ZHBTc4 cell lines 
(Figure 3.24). Taken together, our findings suggest that the Oct4XVP2*  cells have an 
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Figure 3.24Oct4VP2*  cell line express Oct4XVP2 and Nanog at lower 
levels than Oct4A.VP2 cell line under self-renewing conditions 
Total RNA collected from the indicated cell lines was used for qRT-PCR 
analysis of expression levels of pluripotency markers and trophoblast 
differentiation marker Cdx2. 
Expression levels of all analysed genes were normalised to TBP levels for each 
sample. 
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Figure 3.25-Immunocytochemistry of Oct4VP2*  cell line under self-
renewing conditions 
Three clones from each cell line (except ZHBTc4) cultured under self-renewing 
conditions were fixed and immunostained for Oct4, Nanog and Sox2 proteins. 
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Figure 3.26-Self-renewal assay of newly derived Oct4XVP2*  cell line 
The indicated cell lines were plated at clonal density (60 cellslcm2), and cultured 
for 6 days in self-renewing condition then stained for alkaline phosphatase (AP) 
activity (red). 
Examples of colony morphology present in each cell line. Colonies were 
classified into three categories: Uniformly AP positive undifferentiated colonies, 
mixed colonies containing AP positive and negative cells, and AP negative 
differentiated colonies. 
Percentage of previous colony categories in each cell line. Data represents 
average values from two independent clones from each cell line. 	 148 
To determine whether these activator supported cell lines with reduced Nanog were 
now able to differentiate, we plated them clonally and asked whether they 
maintained undifferentiated morphology when challenged by either Oct4 
overexpression or LIF withdrawal. Figure 3.27 shows that Oct4XVP2*  cells, unlike 
Oct4XVP2 cells, differentiated in the absence of LIF. Interestingly, these cell lines 
remained at least partially resistant to the effect of Oct4 overexpression. 
Taken together these observations suggest that the capacity of Oct4 activator 
supported cells to differentiate is directly proportional to the level of the activator 
transgene. and based on our limited analysis, the single clearest response in 
undifferentiated ES cells to this transgene appears to be Nanog expression. However 
while Oct4XVP2*  cells express similar levels of Nanog as the wild type control cell 
lines (Figure 3.24), they are still relatively immune to Oct4 overexpression, 
suggesting that either Oct4 overexpression induced differentiation is very sensitive to 
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Figure 3.27Oct4XVP2*  cell line is able to differentiate upon LIF withdrawal 
or Oct4 overexpression 
Clonal density differentiation of Oct4XVP2 and Oct4XVP2*  cell lines: cells were 
plated at clonal density in the absence of LIF or Oct4 overexpression condition for 
5 days as well as self-renewing conditions as a control. Three clones for each cell 
line except ZHBTc4 were used and stained for AP activity (red). Photos of 
representative colonies are shown. 
Oct4 overexpression condition is achieved by removal of tetracycline from the 
medium leading to the re-expression of the Tc responsive Oct4 transgene. 
-Oct4/+LLF represents self-renewing condition. 
-Oct4/-LIF represents LIF withdrawal condition. 
+Oct4/+LIF represents Oct4 overexpression condition. 
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3.2.7. Identification of potential novel pluripotency genes 
We cannot be certain that only Nanog upregulation is responsible for the highly 
undifferentiated phenotype of Oct4XVP2 cell line as we also see similar expression 
dynamics in other ECAT genes such as Gdf3 gene. GdJ3 is linked to pluripotency 
and co-regulated within the Nanog locus by Oct4 (Levasseur et al., 2008). Other key 
unkown pluripotency genes that are also upregulated and affected by Oct4AVP2 
levels could be contributing to the phenotype of the cells. To limit our analysis to 
those genes directly downstream of Oct4, we overlapped our dataset with the 
available ChIP on chip data for Oct4 (Kim et al., 2008: Loh et al., 2006; Sharov et 
al., 2008) (Figure 3.28). 
Of the 980 genes upregulated in Oct4XVP2 supported cells, 147 of them had been 
identified as potential targets based on ChIP-Seq and ChIP on chip data. 
The lists of these 147 genes and their gene ontology analysis are attached as 
appendices (Table 3.5. and 6). These genes were mainly involved in cell fate 
commitment, growth, proliferation, differentiation, kinase activities, and 
developmental processes. 
Six of these 147 genes; acid phosphatase6 (Acpó), F-box protein 15 (Fbxol5), Nanog 
homeobox (Nanog), patched homologi (Ptchl), transcription factor CP2-like 1 
(Tcfcp211), and ubiquitin-like, containing PHD and RING finger domains 2 (UhrJ2) 
were common to all the previous studies (Table 3.5). 
More analysis is currently underway to further refine this list of genes, and 
investigate their functional relevance. 
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SharovO8 (73) 
6 common to all lists 
9 common to 3 lists 
30 common to 2 lists 
Figure 3.28-Venn diagram showing that 147 genes upregulated in Oct4XVP2 
cell line were identified as possible Oct4 targets 
List of 980 upregulated genes in Oct4XVP2 cell line under self-renewing 
Londitions was compared to four published lists of predicted Oct4 target genes. 
The published lists are from studies by Matoba et al 2006, Loh et al 2006. Kim et 
al 2008. Sharov et al 2008. 
Pink colour represents genes tat are common to all the lists 
Purple colour represents genes that are common to three lists 
Green colour represents genes that are common to two lists. 
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3.2.8. Genes upregulated in Oct4VP2 include genes that are either 
targets for Oct4 only, Nanog only or both 
Comparison of the list of 980 upregulated genes in Oct4?.VP2 supported cell lines to 
published lists of predicted Oct4 or Nanog targets from ChIP/chip studies and 
functional studies allows us to further categorize the upregulated genes into Oct4 
only targets, Nanog only targets, and targets of both (Kim et al., 2008; Loh et al., 
2006; Matoba et al., 2006; Sharov et al., 2008). We can also superimpose functional 
constraints on these categories based on the response of these genes to Oct4 or 
Nanog knockdown. When this analysis was performed, we found that a significant 
number of genes that are upregulated in the Oct4?VP2 supported cell lines are 
Nanog repressed targets (Table 3.7 appendix). This is particularly interesting as 
these cells express high levels of Nanog. Moreover, a number of these genes are 
developmental genes and targets of both Oct4 and Nanog. The repressed 
developmental genes are believed to be regulated by a constellation of factors that 
include Oct4, Nanog, and Sox2 (Chen et al., 2008b; Kim et al., 2008). The fact that a 
significant number of these supposedly repressed genes are upregulated in Oct4?VP2 
cells supports the notion that Oct4?VP2 acts as an activator despite its presence in 
this allegedly repressive complex and can override Nanog mediated repression. 
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3.3. Discussion 
In this chapter, I have shown that the major mechanism by which PouV proteins 
block differentiation is by positively maintaining a network that regulates 
pluripotency. Aspects of this network appear conserved and able to regulate 
gastrulation stage lineage specification and ES cell self-renewal. While PouV 
proteins acting as repressors induce differentiation, the activator forms are able to 
maintain cells in uncommifted state and block differentiation in both murine ES cells 
and embryonic progenitor cells in Xenopus. This block of differentiation by PouV 
activator fusions is regulated indirectly through the upregulation of key factors 
including Nanog. 
The notion that direct gene repression by PouV proteins is essential for ES cell self-
renewal is at odds with our findings. However, we considered the possibility that the 
fusion of PouV proteins to either VP 16 or EnR domains did not effectively transform 
them exclusively to activators or repressors, respectively. The use of this approach 
was pioneered in lower vertebrates. A number of studies have deleted endogenous 
regulatory (activation or repression) domains from the protein and replaced them 
with peptide motifs that have the opposite function (Croston et al., 1992; Jaynes and 
O'Farrell, 1991). However, these studies were limited because the removal of the 
endogenous domains may have affected the cooperative binding of co-factors and 
neutralised the regulatory function of the proteins, resulting in alteration of their 
DNA binding specificity. However, in this study we have not removed any 
endogenous PouV protein sequence, and therefore a loss in DNA binding specificity 
is unlikely. We have used this approach previously and it appears to be the most 
effective way to preserve DNA binding specificity and convert regulatory function 
(Brickman et al., 2001; Brickman et al., 2000). The use of these fusions with Hex led 
to the identification of a short list of targets in ES cells and these were later validated 
in development, indicating that there was no alterations in specificity (Zamparini, 
Watts et al. 2006). Furthermore, there are several technical reasons pointing towards 
the fact that VP 16 and EnR domains will promote strong trans-activation or trans-
repression without affecting DNA binding specificity of the fused transcription 
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factor. The inclusion of the flexible X linker between the VP 16 or EnR domain and 
the wild type protein allows it to fold correctly and minimise changes to its tertiary 
structure and therefore reduces the likelihood of the activator or repressor domain to 
interfere with its binding to DNA. Although it is possible that the addition of VP16 
or EnR heterologous domains to the PouV proteins have a gain of function effect on 
DNA binding, fusing either of these domains to a DNA binding deficient Oct4, 
generated by a single amino acid change in the POU DNA binding domain, produced 
proteins that were unable to activate or repress transcription from reporters genes 
harbouring PouV responsive elements. Suggesting that the only DNA binding ability 
of these fusion proteins is restricted to Oct4 POU domain, and therefore it is unlikely 
that VP16 or EnR domains affect Oct4 DNA binding specificity. However, to fully 
exclude the possibility of gain or loss of DNA binding caused by fusing VP16 or 
EnR domains to the wild type protein, a genome wide ChIP analysis (ChIP/Chip or 
ChIP-seq) of the wild type and the fusion proteins is necessary. 
Oct4XVP2/Oct4?EnR ChIP/Chip will determine whether they bind the same sites as 
wild type Oct4. Moreover, combining this data with expression profiles will 
delineate whether they regulate the same genes as Oct4, and therefore allow 
investigation of their ability to bind co-factors associated with wild type Oct4. 
While we are reasonably confident that the use of our modular domain system with 
the built-in flexibility of the 1 linker will convert full length transcription factors from 
activators to repressors and vice versa, we extensively tested the PouV fusion 
proteins used in this study. We concluded that the activator fusion proteins had no 
residual repression activity at three levels; 1. Reporter assays harbouring Oct4 
responsive elements. None of our activator fusions was able to repress the basal level 
transcription from the tk promoter, whereas engrailed fusions did. 2. The Oct4XVP2 
fusion protein was unable to recapitulate the direct inhibition of the 13-Subunit of 
Human Chorionic Gonadotropin (hCG-13) promoter by wild type Oct4 in Jar human 
choriocarcinoma cells. 3. In ES cells stably expressing Oct4XVP2, promoters 
normally co-occupied by Oct4 and Nanog and repressed by Nanog are still 
upregulated. Therefore, even in the context of the global repression complex 
proposed by Liang et al (2008), Oct4XVP2 acts as an activator and overrides Nanog 
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repression despite the latter being expressed at high levels in this cell line (Liang et 
al., 2008). 
While we can never be sure that we have effectively converted Oct4 from a repressor 
to an activator at every promoter it normally regulates, we conclude that Oct4?VP2 
is an effective activator of gene transcription. In fact, the ability of Oct4A.VP2 to 
recapitulate the function of wild type Oct4 and to regulate most of the genes in the 
same manner support the idea of Oct4 being mainly an activator and rarely a 
repressor of gene expression. Therefore, Oct4 suppresses lineage commitment 
indirectly. This is in agreement with what has been reported by Sharov et a! (2008). 
The majority of Oct4 tentative target genes identified in the study are potent 
repressors of transcription that were downregulated after Oct4 suppression (Sharov, 
Masui et al. 2008). 
The idea that direct repression of genes important for lineage commitment by Oct4 is 
essential for maintaining undifferentiated ES cells is based on the following 
observations: 1) the upregulation of differentiation specific genes following Oct4 
knockdown (Hay et al., 2004); 2) these genes that are upregulated following Oct4 
knockdown possess octamer binding sites in their regulatory regions or can ChIP 
Oct4 (Chen, Xu et al. 2008; Kim, Chu et al. 2008). 
The fact that Oct4 acts mainly as an activator and suppresses lineage commitment 
indirectly questions the functional significance of Oct4 repressed targets in 
undifferentiated cells. These repressed or silent targets could be non-functional false 
positive targets that were a result of random binding of Oct4 to Octamer motifs 
present in most class II promoters. Alternatively, they could be genuine Oct4 targets, 
whose repression is not necessary for maintaining uncommitted cells and blocking 
differentiation. These targets may not be active in ES cells, but could be potential 
targets of Oct4 later in differentiation. The abundance of neural genes in all the Oct4 
target data sets supports the notion that the set of functional Oct4 targets may change 
as development progresses. 
Strikingly when we assess the complete set of genes that respond negatively to Oct4 
in ES cells, the majority of them are downregulated by expression of Oct4A.VP2, 
indicating that some aspect of the Oct4 dependent network keeps these genes off. 
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Many observations support the possibility of Bmp4 being the effector downstream of 
PouV proteins to block differentiation. Bmp4 expression is dependent on PouV 
expression in Xenopus and is marginally upregulated in response to Oct4XVP2 in ES 
cells. Moreover, its overexpression in PouV depleted Xenopus embryos restored the 
normal gene expression pattern of Xvent2 and Goosecoid. Another circumstantial 
observation implicating Bmp4 comes from the fact that its downstream target Xvent2 
(also known as Xom), an immediate early target of Bmp signalling, is also 
predictably PouV dependent as it has been shown to be a target of Xlpou25 (Cao, 
Knochel et al. 2004). Although this data indicates that Bmp4 might be the effector of 
PouV proteins to suppress differentiation, more analysis is required to confirm this. 
In addition to its role in Xenopus development, Bmp4 is also associated with 
maintaining pluripotency and suppressing differentiation in mouse ES cells. It was 
identified as the component of serum required to maintain ES cells in the presence of 
LIF and absence of feeders (Ying, Nichols et al. 2003). 
The fact that Nanog was the only gene amongst the core pluripotency genes that was 
highly upregulated in Oct4XVP2 cell line could be explained by a random ability of 
the cells to tolerate only high levels of Nanog. However, this seems an unlikely 
explanation mainly because expression levels of Oct4?VP2 are positively correlated 
only with Nanog levels amongst all the key pluripotency factors. This correlation 
suggests the existence of an Oct4-Nanog pathway, and indicates that in mouse ES 
cells Oct4 might be exerting its function mainly through Nanog and factors 
downstream. 
As Nanog may be acting as a master transcriptional organizer during reprogramming 
to instill pluripotency (Silva, Chambers et al. 2006; Silva, Barrandon et al. 2008; 
Silva, Nichols et al. 2009), its ectopic expression in response to Oct4XVP2 maybe 
locking cells in a pluripotent cycle. 
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CHAPTER 4 
Mapping functional domains of Oct4 
homologues responsible for ES self-renewal 
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4.1. Introduction 
Oct4 is a transcription factor that plays a major role in regulating pluripotency and 
self-renewal in both embryos and embryonic stem cells. It is also one of the four 
factors able to induce the reprogramming of somatic cells to pluripotency and 
appears to be the only one indispensable in most reprogramming experiments (Do 
and Scholer, 2009). 
Oct4 belongs to the POU family of transcription factors. This protein family can be 
broadly broken down into seven classes based on sequence homology of their POU 
domains and their linker region (Wegner, Drolet et al. 1993; Spaniol, Bornmann et 
al. 1996). (For more details, please refer to the section of Oct4 structure in the 
general introduction). 
Interestingly, within the PouV sub-class, proteins differ in their ability to substitute 
for Oct4 function in the maintenance of ES cell self-renewal. While these proteins 
differ in their ability to support self-renewal, they appear to have equivalent activity 
in transient reporters assays (Morrison and Brickman, 2006). These findings suggest 
that the capacity of these proteins to recognize DNA and activate transcription is the 
same, and the difference in their activities might depend on the presence or the 
absence of specific protein-protein interaction motifs required for Oct4 to recognize 
complex promoters in vivo. 
Oct4 has been structurally divided into three regions; a bipartite DNA-binding 
domain consisting of the POU-specific and the POU-homeo domains joined by a 17 
amino acid linker, and both an amino-terminal (N-TD) and a carboxyl-terminal (C-
TD) transactivation domains (Pan et al., 2002). The N-TD is classified as proline rich 
whereas C-TD is a serine/threonine rich with high proline content (Okamoto, 
Okazawa et al. 1990; Rosner, Vigano et al. 1990; Scholer 1991). Several studies 
revealed functional difference between the amino and carboxyl terminal 
transactivation domains. Some reported detection of transactivation ability only in 
the N-terminus (Imagawa et al., 1991), whereas others reported that both N-TD and 
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C-TD are active (Vigano and Staudt 1996; Brehm, Ohbo et al. 1997). Furthermore, 
the activity of these transactivation domains is affected differently by protein-protein 
interaction (Ambrosetti, Scholer et al. 2000), and is regulated in a cell type 
dependent manner (Brehm, Ohbo et al. 1997). The most relevant study addressing 
the identification of Oct4 specific domains responsible for ES cell self-renewal was 
done by Niwa and his colleagues (2002). They found that both the N-TD and the C-
TD share redundant functions in ES self-renewal, and concluded that the POU 
domain of Oct4 is uniquely required to maintain the undifferentiated phenotype of 
ES cells (Niwa et al., 2002). 
The relevance of these different domains to the specific ability of certain PouV 
proteins to rescue Oct4 null ES cells is not clear. Therefore, we exploited the 
findings of a previous study in the lab assessing the ability of different classV POU 
proteins from different species to substitute for Oct4 function in mouse ES cells 
(Morrison and Brickman, 2006) in order to confirm and further refine the domains 
that are necessary for ES cell self-renewal. In this chapter, I show that PouV 
proteins able to rescue ES cell self-renewal appear to have two separable activities, a 
quantitative capacity to support clonal growth that is regulated through the C-TD and 
the support of ES cell morphology through the POU domain. 
160 
4.2. Results 
4.2.1. PouV protein sequence analysis and the construction of chimeric 
proteins 
As previously stated, recent studies in the lab, revealed that PouV proteins vary 
greatly in their ability to maintain ES cell self-renewal in spite of their sequence 
similarity. While the three Xenopus PouV proteins (Xlpou9 1, Xlpou60, and 
Xlpou25) are highly related to each other (based on the percentage of sequence 
identity of their various domains), they differ in their capacity to substitute for mouse 
Oct4 activity in the support of murine ES cells (Morrison and Brickman, 2006). 
Moreover, the study also showed that the zebrafish PouV protein, DrPou2 has no 
activity at all in this assay. 
An experimental strategy to identify functional domains responsible for maintaining 
the undifferentiated phenotype of ES cells was designed exploiting the sequence 
similarity and the functional differences of PouV proteins. Based on homology in the 
POU domain (both POU specific and POU homeodomain) (Figure 4.1a), we have 
constructed a series of chimeric proteins by replacing domains from the two proteins 
that have only low levels of Oct4-like activity, Xlpou25 and DrPou2, with those 
from the Xlpou91 protein with the Oct4-like activity (Figure 4.1b). 
While the original DrPou2 had no ability to rescue Oct4 deficient ES cells, a second 
zebrafish DrPou2 EST sequence was identified during the course of this study. This 
variant behaved in a similar maimer to Xlpou25 and possessed a low, but detectable 
ability to rescue ES cell self-renewal. 
The difference between the two variants of DrPou2 (DrPou2(T) and DrPou2(A)) is 
the substitution of one amino acid residue in the POU domain. This will be discussed 
in more details in later sections of the results. 
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The swaps (based on Figure 4.1 b) essentially divided the proteins into three regions, 
the amino (N-TD), carboxyl (C-TD) and POU DNA binding domain (POU). The 
chimeric proteins generated by N-TD, C-TD, or POU domain swapping between 
Xlpou9l and Xlpou25 or Xlpou91 and DrPou2 are schematically represented in a 
Figure 4.2, and 4.4. The nomenclature used to refer to these chimeric proteins is 
based on identifying the origin of each domain in the protein, e.g. N2P91C91, has the 
N-TD from DrPou2 fused to the POU domain and C-TD from Xlpou9 1, and 
N91P25C91 has the N-TD from Xlpou9l, the POU domain from Xlpou25, and the 
C-TD from Xlpou9 1. The designation for each chimera is listed in the figure next to 
the schematics (Figures 4.2a, and 4.4a). 
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DNA binding domain 
N-ID 	POUs H POUh C-TO 	Oct4 
I 	 N-ID 	I POUs H POUh C-TO j XIpou91 
I 	 N-TO 	I POUs f-vt POUh I C. 	XIpou25 
N-TD 	 I POUs 	POUh C-TO 	DrPou2 
Figure 4.1-PouV proteins: sequence alignments and schematic representation 
Alignment of human (hOCT4), mouse (mOct4), Xenopus (Xlpou9l, Xlpou25, 
Xlpou60), axoloti (AmOct4) and zebrafish (DrPou2) PouV proteins. (Alignment 
from Morrison and Brickman., 2006). POU specific (POUs) and POU homeodomain 
(POUh) domains are boxed in red and blue respectively. Pink indicates identical 
residues, light blue indicates similar residues, and dark blue indicates conservation 
within a subset of residues. 
Schematic representations of PouV proteins, and POU domain boundaries. 
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4.2.2. Measuring the extent of ES cells self-renewal rescue by chimeric 
PonY proteins 
The activity of PouV chimeric proteins was tested at two levels. Firstly, their ability 
to recognize and activate transcription from Oct4 responsive reporter genes in 
transient transfection was tested in order to reveal any generic changes in DNA 
binding and transcriptional activation. Secondly, they were tested in an ES cell 
complementation assay in order to assess their ability to substitute for Oct4 function 
in ES cells (Niwa et al., 2002). As outlined in the previous chapter, the 
complementation assay involves the introduction of PouV transgenes into the 
ZHBTc4 cell line, an Oct4 null ES cell line that is supported by a randomly 
integrated tetracycline regulatable Oct4 transgene that can be repressed by the 
addition of tetracycline (Tc) to the media. This system is based on the fact that 
undifferentiated colonies can form in the presence of Tc only when the exogenous 
PouV transcription can substitute for Oct4 activity. 
The ES cell self-renewal rescue ability of the various chimeric proteins is measured 
in two ways; short-term and long-term. The short-term self-renewal rescue ability of 
the chimeric proteins is determined by the number of rescued ES-like alkaline 
phosphatase (AP) positive colonies generated in the presence of Tetracycline. 
Whereas, the long-term self-renewal rescue ability is evaluated through the 
generation of self-renewing, undifferentiated clonal cell lines from the rescued ES-
like colonies. 
4.2.3. Transcriptional activity of Xlpou91 and Xlpou25fDrPou2 chimeric 
proteins 
The difference in the ability of PouV protein to support self-renewal is not caused by 
a difference in their ability to activate transcription (Morrison and Brickman, 2006). 
Therefore, to ensure that differences seen in the ability of the different PouV 
chimeric protein to rescue ES cell self-renewal is not due to a defect in their 
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transcriptional regulatory activity, we tested their ability to stimulate transcription 
from reporter genes harbouring PouV responsive elements. 
All the chimeric protein constructs were transiently cotransfected with different 
reporter genes into ZHBTc4 cells in the presence of Tc (absence of Oct4 transgene 
expression). All the reporter genes assayed employed a minimal tk promoter driving 
luciferase downstream of Oct4 responsive elements either from the Fgf4 enhancer, 6 
reiterated copies of the octamer binding motif (Niwa etal., 2002). 
Figure 4.2b1 shows that all Xlpou9l-Xlpou25 chimeric proteins activate 
transcription from the luciferase reporter containing six copies of the octamer 
binding motif in varying degrees. However, all are at least as active as Oct4 and 
none appeared to be more active than Xlpou91, which indicates that all these PouV 
chimeras have transactivation abilities that lie within a transcriptional spectrum that 
allow the support of ES cell self-renewal. 
Moreover, all Xlpou9 1 -Xlpou25 chimeric proteins stimulate similar levels of 
transcription from the luciferase reporter harbouring elements from the Fgf4 
enhancer (Figure 4.2b2), which further indicates that any differences in the 
phenotype of rescued colonies by these chimeric proteins is not due to their overall 
activity levels. 
The specificity of the transcriptional activity of these chimeric proteins was 
confirmed as none of them activated the reporter gene activity in the absence of an 
Oct4 response element (Figure 4.2b3). 
In the same way, Xlpou9l-DrPou2(T) chimeric proteins (Figure 4.3) were also tested 
for their ability to activate transcription. While, these proteins are able to activate 
transcription at similar levels to Oct4 and Xlpou9 1 from the luciferase reporter 
containing six copies of the octamer binding motif (Figure 4.3b1), they were slightly 
less active on the Fgf4 enhancer (Figure 4.3b2). However, this slight difference does 
not appear to correlate with rescue ability of the proteins (see below). 
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Figure 4.2-Cloning and transcriptional activity of Xlpou9l-Xlpou25 Chimeric 
proteins 
Schematic representation of Xlpou9 1 -Xlpou25 chimenc proteins: chimeric 
proteins were generated by swapping either the amino acid terminal (N-TD), the 
carboxyl terminal (C-TD) or the POU domain of Xlpou9 1 with Xlpou25 domains. 
XIpou9l-Xlpou25 chimeric proteins are able to activate transcription in a 
specific manner from two luciferase reporters: one containing multiple copies of the 
octamer binding motif (b.1) and the other one containing the Fgf4 enhancer (b.2). A 
luciferase reporter containing the thymidine kinase (TK) promoter was used to test 
the specificity of the chimeric proteins transcriptional activity (b.3). 
The indicated cDNAs were cotransfected with luciferase reporters. Fold induction 
represents the increase in transcription compared with the empty vector control. Data 
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Figure 4.3-Cloning and transcriptional activity of Xlpou9l-DrPou2(T) 
Chimeric proteins 
Schematic representation of Xlpou9 1 -DrPou2(T) chimeric proteins: chimeric 
proteins were generated by swapping either the amino acid terminal (N-ID), the 
carboxyl terminal (C-TD) or the POU domain of Xlpou9 I with DrPou2(T) domains. 
Xlpou9 1 -DrPou2(T) chimei-ic proteins activate transcription in a specific manner 
from two luciferase reporters: one containing multiple copies of the octamer binding 
motif (b.1) and the other one containing the Fgf4 enhancer (b.2). A luciferase 
reporter containing the thymidine kinase (1K) promoter was used to test the 
specificity of the chimeric proteins transcriptional activity (b3). 
The indicated cDNAs were cotransfected with luciferase reporters. Fold induction 
represents the increase in transcription compared with the empty vector control. Data 
represent the mean value of two independent experiments. 
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4.2.4. Measuring the ability of the different chimeric proteins to rescue 
short-term self-renewal: the generation of ES cell-like alkaline 
phosphatase positive colonies 
As explained previously, the ability of the different chimeric proteins to rescue ES 
cell self-renewal was tested using the complementation assay designed by Niwa and 
colleagues (Niwa et al., 2002). The different chimeric proteins were introduced in the 
ZHBTc4 ES cells by random integration. To control for transfection efficiency, each 
transfection was divided in half with one half grown in the absence of Tc and the 
other half grown in presence of Tc. Following transfection, puromycin selection was 
applied for 9 days, and the resulting colonies were stained for alkaline phosphatase 
(AP) activity. The rescue index of each chimeric protein was then calculated by 
dividing the number of AP positive colonies in the presence of Tc by the number of 
AP positive colonies in the absence of Tc. The values of these rescue indices are 
normalised to that obtained from Oct4, and are shown in Figure 4.4 and 4.5.Figure 
4.4b1 and 4.5b1 shows morphology of representative colonies rescued by various 
PouV proteins in the presence and absence of Oct4 regulatable transgene expression. 
As reported in Morrison and Brickman, 2006, colonies rescued with Xlpou91 protein 
exhibit similar morphology to those rescued with Oct4, whereas Xlpou25 rescued 
colonies are both small and differentiated. In the following sections, the phenotypes 
of colonies generated by each of the different chimeric proteins will be discussed. 
Sunmiary of the ability of the different Xlpou9l/Xlpou25, and Xlpou9l/ DrPou2 (T) 
chimaeric proteins to activate transcriptions and to rescue ES cell self-renewal is 
listed in table 4.1 and able 4.2 respectively. 
4.2.4.1. N-terminal domain of X1pou91 has an inhibitory effect on the rate of ES 
cell self-renewal 
Figure 4.4b2 shows the morphology of colonies rescued by the chimeric proteins 
N25P91C91 and N91P25C25. Colonies rescued with N91P25C25 protein have 
similar morphology to colonies rescued by Xlpou25 protein, while morphology of 
N25P91C91 rescued colonies is closer to those rescued with Xlpou91 with a slight 
increase in differentiated cells around the periphery. 
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Table 4.1- Summary of the ability of the different Xlpou9l and Xlpou25 
chimaeric proteins to activate transcriptions and to rescue ES cell self-
renewal. 
The transcriptional activity of the different Xlpou9l-Xlpou25 chimaeric proteins is assessed 
based on their ability to activate transcription from luc4ferase reporters harbouring Oct4 
dependent sequences either from the Fgf4 enhancer or 6 reiterated copies of the Octamer 
binding motif. The ability of the different Xlpou9l-Xlpou25 chimaeric proteins to rescue ES 
cell self—renewal is measured based on the morphology of the rescued colonies and the 
number of the rescued colonies represented as the rescue index. N: N-terminus, C:C-terminus, 
P.POU domain, 91: X1pou91, 25: Xlpou25. Rescue index value is the mean from three 
independent experiments. 
Transcriptional 
activity Morphology of 
Chimeric rescued colonies Rescue 6W 
proteins Octamer Fgf4 index 
binding enhancer 
motif  
Oct4 + + + + + 
Typical undifferentiated 
1 ES cell colonies  
Xlpou91 + + + + + + + 
Typical undifferentiated 1.01 ES cell colonies  
Xlpou25 + + + + + + 
Veri small and 047 differentiated colonies _ 
Small and differentiated 
N91P25C25 + + + + + + 
colonies, similar to 
0.53 Xlpou25 rescued 
colonies  • __________ __________ 
Undifferentiated colonies 
similar to Xlpou91 
N25P91C91 + + + + + + 




N25P25C91 colonies that are bigger 1.10 than Xlpou25 rescued 
colonies 
Undifferentiated ES cell 
N91P91C25 + + + + + + + colonies that are slightly 0.38 smaller than Xlpou91 
rescued_colonies  
Undifferentiated colonies 
slightly smaller than 
N25P91C25 + + + + + + 
Xlpou91 rescued 
0.67 colonies, with slight - .-,• 	.. 	- 
increase in differentiated 
cells around the 
Mostly differentiated 
N91P25C91 + + + + + + colonies that are slightly 0.91 bigger than Xlpou25 
rescued colonies 
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Table 42- Summary of the ability of the dfferent X1pou91 and DrPou2(T) 
chimaeric proteins to activate transcriptions and to rescue ES cell self-
renewal. 
The transcriptional activity of the different Xlpou9l-DrPou2(T) chimaeric proteins is assessed 
based on their ability to activate transcription from luciferase reporters harbouring Oct4 
dependent sequences either from the Fgf4 enhancer or 6 reiterated copies of the Octamer 
binding motif. The ability of the dWerent  Xlpou9l -DrPou2(T) chimaeric proteins to rescue ES 
cell self—renewal is measured based on the morphology of the rescued colonies and the 
number of the rescued colonies represented as the rescue index. N: N-terminus, C:C-terminus, 
P:POU domain, 91: Xlpou9l, 2: DrPou2(T). Rescue index value is the mean from two 
independent experiments. 
Transcriptional 
activity Morphology of 
Chimeric rescued colonies Rescue 6W 
proterns Octamer Fgf4 index 
binding enhancer 
motif  
Oct4 + + + + + 
Typical undifferentiated 
1 ES_cell_colonies  
Xlpou91 + + + + + + + Typical undifferentiated 1.02 ES cell colonies  
Small colonies with 
DrPou2(T) + + + + + undifferentiated centre 0.33 and differentiated cells 
around_the_periphery  
Small colonies similar to 
N91P2C2 + + + + + DrPou2(T) rescued 0.07 
colonies  
Undifferentiated colonies 
similar to Xlpou91 
N2P91C91 +++ ++ rescued colonies, with 1.85 slight increase in 
differentiated cells 
around_the_periphery  
Colonies that are similar 
N2P2C91 +++ ++ to DrPou2(T) rescued 0.49 colonies, however they 
are_bigger.  
Undifferentiated ES cell 
N91P91C2 +++ ++ colonies that are slightly 0.52 smaller than Xlpou91 
rescued colonies 
Undifferentiated colonies 
similar to Xlpou91 
N2P91C2 + + + + + 
rescued colonies, with 
0.95 
- 	. slight increase in 
differentiated cells 
around the periphery  
Colonies that are similar 
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Figure 4.4-Xlpou9I-XIpou25 chimeric proteins differ in their ability to rescue 
ES cells self-renewal 
2x 107  ZHBTc4 ES cells were transfected with 1 OOug of linearized vector DNAs by 
electroporation, after 9 days of selection with puromycin in the presence or absence 
of tetracycline, the cells were stained with alkaline phosphatase (AP) and the 
number of AP positive stem cell colonies were scored, and the rescue index 
calculated. 
(a) Rescue index of Xlpou9 1 -Xlpou25 chimenc proteins. The Rescue index is 
calculated by dividing the number of ES cell colonies in the absence of Oct4 
(presence of Tc) by the number of AP positive ES cell colonies prensent in the 
presence of Oct4 (absence of Tc). Rescue index values were normalised to Oct4 
value. Data represents the mean values obtained from three independent 
experiments. (b) Morphology of colonies rescued by the Xlpou9l-Xlpou25 chimeric 
proteins: morphology of representative colonies rescued by wild type PouV proteins 
(b.1), chimenc protein generated by N terminal swap (b.2), C terminal swap (b.3), 
and POU domain swap (b.4). 171 
The lack of a transferable activity in the Xlpou91 amino terminus was also 
confirmed quantitatively as the N9 I P25C25 protein showed no increase in the rescue 
index when compared to full-length Xlpou25 (Figure 4.4a). Surprisingly, 
N25P91C91 protein showed a higher rescue index (around 2 folds) than that of either 
wild type Oct4 or Xlpou9 1. Together, the data suggest that the N-TD of Xlpou9 I has 
little effect on the ES cell morphology, but appears to have a repressive effect on 
efficiency of self-renewal. These findings were confirmed by the results of the 
corresponding set of swaps between Xlpou9 1 and DrPou2(T) (Figure 4.5a and b2). 
In fact. N2P91C91 chimeric protein generated colonies that are morphologically 
similar to those rescued with Xlpou91, however, its rescue index was significantly 
greater than either Xlpou91 or Oct4. 
Interestingly, N2P91C91 produced extremely differentiated colonies in the presence 
of the Tc regulatable Oct4 transgene expression, a phenotype that might be caused by 
some unknown protein interactions with DrPou2 amino terminal. 
4.2.4.2. C-terminal domain of Xlpou9l increases the efficiency of ES cell self-
renewal 
In order to test whether the C-TD of Xlpou91 protein has the ability to improve the 
performance of both Xlpou25 and DrPou2(T) proteins, we generated the chimeric 
protein N25P25C91 and N2P2C91 by swapping the carboxyl terminal of Xlpou25 
and DrPou2 proteins respectively with the C terminal domain of Xlpou9 1 protein, 
and tested their ability to rescue ES cell self-renewal. As controls, N91P91C25, and 
N91P91C2 chimeric proteins were made by substituting the C terminal domain of 
Xlpou9 I protein with the C terminal from Xlpou25 or DrPou2 respectively. 
Figure 4.4b3 shows the morphologies of rescued colonies by N25P25C91 and 
N9 1 P91 C25 chimeric proteins. Although, N25P25C9 1 protein produces 
differentiated colonies that are bigger than the ones produced by Xlpou25, it has an 
Oct4-like rescue index (Figure 4.4a). A reciprocal result was obtained with 
N91P91C25, this protein was able to produce colonies with a normal ES-like 
morphology, but had a reduced Xlpou25-like rescue index (Figure 4.4a and b3). 
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Figure 4.5-Xlpou9l-DrPou2(T) and Xlpou9l-Xlpou25 chimeric proteins show 
similar ability to rescue ES cells self-renewal 
(a) Rescue index for Xlpou9 I -DrPou2(T) chimeric proteins. Rescue index values 
were normalised to Oct4 value. Data represents the mean values obtained from two 
independent experiments. (b) Morphology of colonies rescued by the Xlpou9 1-
DrPou2(T) chimeric proteins: morphology of representative colonies rescued by 
wild type PouV proteins (b.1), chimeric proteins generated by N terminal swap 
(b.2), C terminal swap (b.3), and POU domain swap (b.4). 
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Figure 4.5b3 shows that N2P2C91 generated colonies that are bigger than those 
rescued with DrPou2 protein but more differentiated than typical ES cell colonies 
and had a greater rescue index than that achieved by DrPou2. Moreover, N91P91C2 
protein also recapitulates the effect of N9 1 P91 C25 protein as it produces colonies 
that are morphologically very similar to those rescued with Xlpou91 albeit slightly 
smaller and had a lower rescue index than Xlpou91 or Oct4 (Figure 4.5a and b3). 
Therefore, these data suggest that Xlpou91 C terminal influences positively both the 
size and the number of rescued colonies. 
4.2.4.3. POU DNA binding domain from XIpou91 protein is associated with the 
undifferentiated phenotype of ES cells 
Chimeric proteins generated by substituting the POU DNA binding domain of 
Xlpou25 and DrPou2 with that of Xlpou9 1 protein and vice-versa, were used to 
examine the role of the POU DNA binding domain in the rescue of ES cell self-
renewal. 
While not always achieving quantitative rescue as determined by the rescue index, 
the POU domain appears to rescue ES cell morphologies most explicitly. Colonies 
rescued with N25P91C25 (Figure 4.04) or N2P91C2 proteins (Figure 4.5b4) exhibit 
very similar morphology to those rescued with Xlpou9l, but show a slight increase 
in the number of differentiated cells surrounding the colonies. On the other hand, 
N9 1 P25 C9 1, and N9 1 P2C9 1 chimeric proteins produced colonies that are slightly 
bigger than those obtained with Xlpou25 and DrPou2 respectively, but still show 
differentiated morphologies (Figure 4.04) and (Figure 4.5b4). 
These results indicate that the POU DNA binding domain of Xlpou9 1 influences 
hugely the morphology of the cells, and determines the undifferentiated phenotype of 
ES cells. In addition to this effect on morphology, Xlpou91 POU DNA binding 
domain seems to have a positive effect on the number of rescued colonies as Figures 
4.4a and Figure 4.5a demonstrate that both rescue indices of N25P91C25 and 
N2P91C2 proteins are higher than those from Xlpou25 and DrPou2 respectively. 
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4.2.5. Long-term self-renewal: the generation of clonal cell lines from the 
rescued colonies 
In order to confirm the findings regarding the ability of the various chimeric proteins 
to support ES cell self-renewal, colonies rescued by each chimeric protein were 
examined for their ability to generate cell lines that are able to propagate in self-
renewing conditions. Flag tagged chimeric proteins were used to generate these cell 
lines. Three copies of the Flag tag (3xFlag) were fused to the 5' amino terminal of 
each chimeric protein (Figure 4.6a). The triple Flag tag was used for two main 
reasons, the lack of antibodies against any of the PouV proteins and the generation of 
reagents that will be useful for downstream biochemical analysis. 
4.2.5.1. The addition of the Flag tag to the chimeric proteins does not alter their 
function 
In order to establish whether or not fusing the Flag tag to the amino terminal of the 
chimeric proteins will affect their function, both the abilities of these Flag tagged 
chimeric proteins to activate transcription and sustain ES cell self-renewal were 
examined. Figure 4.6 shows that no differences were observed in the ability of 
chimeric proteins with or without the Flag tag to activate transcription from the 
octamer-binding motif luciferase reporter (Figure 4.6b 1), or the Fgf4 enhancer 
luciferase reporter (Figure 4.6b2) and that none of these proteins had any activity on 
a reporter lacking octamer binding sites (Figure 4.03). Moreover, their ability to 
rescue ES cell self-renewal was almost identical to that obtained by the untagged 
proteins when assayed for either ES cell morphology or rescue index (Figure 4.7). 
These observations both support my conclusions with respect to the different domain 
swaps and indicate that cell lines derived from these tagged proteins will be 
important tools for the analysis of domain specific activities of these PouV proteins. 
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Figure 4.6—Cloning and transcriptional activity of Flag tagged Xlpou91-
Xlpou25 Chimeric proteins 
(a) Schematic representation of 3xFlagXlpou9 I -Xlpou25 chimeric proteins: 
chimenc proteins were generated by swapping either the amino acid terminal (N-
TD), the carboxyl terminal (C-TD) or the POU domain of Xlpou91 with XIpou25 
domains. Three copies of the flag tag were fused to the amino terminal of the 
chimeric proteins. (b) Xlpou9 1 -Xlpou25 chimeric proteins with or without the Flag 
tag activate transcription at similar levels in a specific manner from two luciferase 
reporters: one containing multiple copies of the octamer binding motif (b.1) and the 
other one containing the Fgf4 enhancer (b.2). A luciferase reporter containing the 
thymidine kinase (TK) promoter was used to test the specificity of the chimeric 
proteins transcriptional activity (b.3). 
The indicated cDNAs were cotransfected with luciferase reporters. Fold induction 
represents the increase in transcription compared with the empty vector control. Data 
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Figure 4.7-The addition of the Flag tag to the Xlpou9I-Xlpou25 chimenc 
proteins does not affect their ability to rescue ES cell self-renewal 
(a) Xlpou9 1 -Xlpou25 chimeric proteins with or without Flag tag have similar rescue 
indices. Rescue index values of chimeric proteins with or without Flag tag were 
normalised to 3xFlagOct4 and Oct4 values respectively. Rescue index of Flag 
tagged proteins is from one experiment. (b) Colonies rescued by Xlpou9 I -Xlpou25 
chimeric proteins with or without Flag tag have similar morphologies. Morphology 
of representative colonies rescued by wild type PouV proteins (b.1), chimeric 
proteins generated by N terminal swap (b.2), C terminal swap (b.3), and POU 
domain swap (b.4). 
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4.2.5.2. Derivation of clonal cell lines from the Flag tagged Xlpou9l-Xlpou25 
chimeric proteins 
Clonal cell lines were derived by expanding puromycin resistant colonies generated 
from electroporation of the ZHBTc4 ES cells with Flag tagged XIpou9l-Xlpou25 
chimeric cDNAs in the presence of Tc (absence of Tc regulatable 0ct4 transgene 
expression). The rescued colonies were propagated for many passages under self-
renewing conditions, and stained for Alkaline phosphatase (AP) activity. Figure 4.8 
shows alkaline phosphatase staining for each cell line with images of the morphology 
at both high (xlO) and low magnifications (x4). 
Three clonal cell lines for each chimeric protein were examined for their 
morphology. Numbers on the top of each photograph represent the name of the 
clone used for the derivation of the cell line. 
The morphology of cell lines derived from colonies rescued with Flag tagged Oct4 or 
Xlpou9 1 proteins resembles the morphology of the parental ZHBTc4 and El 4Tg2a 
cell lines, they are homogenous undifferentiated cells that are positive for Alkaline 
phosphatase staining (Figure 4.8a1). This contrasts the morphology of cell lines 
rescued with the Flag tagged Xlpou25 protein. The phenotype shown in Figure 4.8a1 
recapitulates that described by Morrison and Brickman 2006 and features a layer of 
differentiated cells with AP positive clumps of cells that appear to grow as colonies. 
As with the original Xlpou25 supported cell lines (Morrison and Brickman, 2006), 
these are very slow growing. Cell lines stably expressing chimeric proteins that have 
only the C-TD or N-TD of Xlpou9l (N91P25C25, or N25P25C91) exhibit some 
rescue, but they are mainly differentiated cells that grow slowly (they take longer to 
reach confluence than Xlpou91 or Oct4 cell line when plated at the same density) 
(Figure 4.8a2, and a3). However, chimeric proteins thatpossess the Xlpou91 POU 
domain (N25P91C91 or N25P91C25) are predominantly undifferentiated. 
Furthermore, the importance of Xlpou91 POU domain in maintaining the 
undifferentiated phenotype of cells is confirmed by the phenotypes of cells 
maintained by the chimeric protein N91P25C91, it only supports the differentiated 
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Figure 4.8-Derivation of clonal cell lines rescued with 3xFlagXlpou9I-
Xlpou25 chimeric proteins 
Following the electroporation of construct encoding the Flag tagged Xlpou9 1-
Xlpou25 chimenc proteins in the ZHBTc4 cells, puromycin selection was applied 
for 9days in the presence of tetracycline. The rescued colonies were propagated for 
many passages under self-renewing conditions in the presence of Tc, and stained 
for Alkaline phosphatase (AP) activity. 
Morphology of cell lines derived from wild type PouV proteins (a.1) chimeric 
proteins generated by N terminal swap (a.2), C terminal swap (a.3), and POU 
domain swap (a.4) is shown at both high (xl 0) and low magnification (x4). 
Three clonal cell lines for each chimenc protein were examined for their 
morphology. Numbers represent the names of the cell lines. 
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Although, the morphologies of these derived cell lines is in accordance with the 
different self-renewal rescue abilities of the various chimeric proteins, more 
extensive characterization of these cell lines is needed. However, as a first step we 
wanted to ensure that the derived cell lines express similar levels of the chimeric 
proteins. To this end, western blot analysis with anti-Flag antibody was carried out 
on lysates of cell lines that had been growing in culture under self-renewing 
conditions and puromycin selection (Figure 4.9). Lysates from the ZHBTc4 and 
E14Tg2a cell lines were used as negative controls. The cell lysates from the other 
cell lines showed specific bands that correspond to the predicted size of each 
chimeric protein. 3xOct4 cell line produced a 41.23 KDa, 3xXlpou9 1: 52.32 KDa, 
3xXlpou25: 52.87 KDa , 3xN91P25C25: 51.51 KDa, 3xN25P91C91: 53.68 KDa, 
3xN25P25C91: 53.6 KDa, 3xN9IP91C25: 51.58 KDa, 3xN25P91C25: 52.94 KDa, 
3xN91P25C91: 52.25 KDa. 
Equal amount of protein was used for each sample as confirmed with 13-actin levels. 
Numbers represents the names of the cell lines used in the analysis. 
In general, the levels of protein were similar, and where their levels varied, there was 
no correlation between the amount of the protein produced in the cell lines and the 
rescue ability of the proteins. 
As there appears no significant difference in expression level or transcriptional 
activity of these chimeric proteins in transient transfection, I was interested in 
investigating the contribution of the C-TD and POU domain to self-renewal and 
explore potential mechanism(s). While detailed mechanistic studies are beyond the 
scope of this thesis, we begin by considering each domain in detail. 
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Figure 4.9-Western blot analysis of 3xFlag-Xlpou9I-Xlpou25 chimeric 
proteins expression levels in the rescued cell lines 
Cell lines derived from rescued colonies by the 3xFIag Xlpou91-Xlpou25 chimeric 
proteins were cultured under self-renewing conditions, then lysed for western blot 
analysis with anti Flag , and anti -actin antibodies. 
Equal amount of protein was used for each sample. 
Numbers represents the names of the cell lines 
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4.2.6. Investigating the importance of Xlpou91 C-terminal domain 
4.2.6.1. Deletion of the N- and C-terminal domains from Xlpou9l and Oct4 
proteins reveals the important role of the C-TD in increasing the efficiency of 
ES cell self-renewal rescue 
The data presented above (Figure 4.4 and 4.5), indicated a role for the C-TD of 
Xlpou9 1 in augmenting self-renewal efficiency. We wanted to directly test the 
significance of this domain and investigate its role in both Xlpou9 1 and Oct4 
proteins. To achieve this, we made a series of deletion mutants for both Oct4 and 
Xlpou91 proteins lacking either the N terminal domain or the C terminal domain 
(Figure 4.1 Oa), and tested their ability to activate transcription and rescue ES cell 
self-renewal. Table 4.3 summarises the ability of the different deletion mutants for 
both Oct4 and Xlpou9 1 proteins to activate transcriptions and to rescue ES cell self-
renewal. 
Figure 4.1Obl shows that Oct4 and Xlpou91 proteins lacking either the N-TD or the 
C-TD are all impaired with respect to the activation of the luciferase reporter 
containing six copies of the octamer-binding motif. Interestingly, this defect in 
transcription activity appears most pronounced in proteins lacking the N-TD. On the 
other hand, all these mutant proteins appear equal to the full-length proteins in their 
ability to activate transcription from the Fgf4 enhancer reporter (Figure 4.10b2). As 
Fgf4 enhancer also binds Sox2, we presume that the activation function of Sox2 
maybe masking any defects in the transactivation ability of its PouV protein partner. 
The specificity of the transcriptional activity of the deletion mutant proteins was 
confirmed as they were unable to stimulate transcription from the tk promoter 
luciferase reporter (Figure 4.10b3). Moreover, all Flag and non Flag tagged proteins 
had identical activity confirming that the Flag tag does not alter the activity of the 
proteins. 
Figure 4.11 b2 shows that both AN or AC Oct4 mutant proteins produced 
morphologically normal undifferentiated cells, but showed lower rescue indices in 
comparison to the full-length Oct4 protein (Figure 4.1 Ia). This reduction in the 
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Figure 4.10 -Cloning and transcriptional activity of Flag tagged truncated Oct4 
and Xlpou91 proteins 
Schematic representation of 3xFlag tagged truncated Oct4 and Xlpou9 1 proteins: 
either the N terminal or the C terminal of the proteins was deleted. 
Truncated Oct4 and Xlpou91 proteins with or without the Flag tag activate 
transcription at similar levels in a specific manner from two luciferase reporters: 
one contains multiple copies of the octamer binding motif (b.1) and the other 
contains the Fgf4 enhancer (b.2). A luciferase reporter containing the thymidine 
kinase (1K) promoter was used to test the specificity of the proteins transcriptional 
activity (b.3). 
The indicated cDNAs were cotransfected with luciferase reporters. Fold induction 
represents the increase in transcription compared with the empty vector control. Data 
represent the mean value of two independent experiments. 
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Table 43- Investigating the importance of X1pou91 C-terminal domain. 
The transcriptional activity of the different deletion and DEF site mutant Oc14 and X1pou9I 
constructs is assessed based on their ability to activate transcription from luciferase reporters 
harbouring Oct4 dependent sequences either from the Fgf4 enhancer or 6 reiterated copies of 
the Octamer binding motf. The ability of the different mutant Oct4 and X1pou9I constructs to 
rescue ES cell self—renewal is measured based on the morphology of the rescued colonies and 
the number of the rescued colonies represented as the rescue index. 3x designated 3 copies of 
the flag tag. N: N-terminus, C:C-terminus, P.POU domain, 91: X1pou9l, 25: Xlpou25, 4: 




proteins Octamer 	Fgf4 
binding enhancer 
motif 
Morphology of 	 I 
rescued colonies I Rescue 
I index 
I 	pical undttterentiated 
\ Oct4 + + + + + I ES cell colonies 
IITh 	V 
LH + + + + + + + 
Typical undifferentiated 0.65 
JT ES cell colonies  
3x X1pou25 + + + + + + Very small and 0.45 differentiated colonies  
Undifferentiated 
colonies similar to Oct4 
3. AN ()t4 + + + + rescued colonies, with 0.31 slight increase in 
differentiated cells 
around the periphery  
Undifferentiated 
colonies similar to 
Xlpou91 rescued 
+ + + + colonies, with slight 0.33 
increase in differentiated 
cells around the 
periphery  
Undifferentiated 
Slightly colonies similar to Oct4 
3x A( 	()ct4 more than + + + 
rescued colonies, with 
0.23 slight increase in 
+ differentiated cells 
around_the_periphery  
Slightly 
more than + + + Highly differentiated 0 colonies 
+ 
3x Mutant Undifferentiated ES cell 
+ + + + + + colonies, identical to 0.88 
()ct4 Oct4 rescued colonies 
Undifferentiated ES cell 
++++ +++ 0.46  identical to Xlpou91 
rescued_colonies  
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The previous results contrast to those observed with Xlpou9 1, where deletion of the 
C-TD completely abrogated the ability of Xlpou9 1 to rescue ES cell self-renewal. In 
fact, only AN Xlpou9 1 protein was able to produce undifferentiated ES cell colonies 
(Figure 4.11 b2 and b3). Although, deletion of the amino terminus of Xlpou9 1 did not 
have much impact on the morphology of the rescued colonies, it resulted in a 
reduction of the rescue index (Figure 4.1 la), which suggests that the N-TD is 
required to achieve optimal rescue. 
These results indicate that in combination with the POU domain both the N-TD and 
the C-TD of Oct4 protein possess the ability to maintain ES cell self-renewal, 
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Figure 4.11-Xlpou9I protein missing the C terminal is unable to rescue ES cells 
self-renewal 
(a) Rescue index of flag tagged truncated Oct4 and Xlpou9 I proteins. The rescue 
index values were normalised to 3xFlagOct4 value. Data represents the mean values 
obtained from two independent experiments. (b) Morphology of colonies rescued by 
the Flag tagged truncated Oct4 and Xlpou9 1 proteins. Morphology of representative 
colonies rescued by full length PouV proteins (b.1), proteins without N terminal 
(b.2), or proteins without the C terminal (b.3). 
4.2.6.2. Protein alignment of PouV proteins reveals a possible functional DEF 
(!ocking site for ERK, F, ..X..F,j -P) site in the C terminal domain 
As the Xlpou91 C-TD appears to convey an advantage to the other PouV proteins in 
their ability to rescue 0c14 null phenotype, we looked for sequences in Oct4 and 
Xlpou9 I C-TDs that may be responsible for conferring the high self-renewal rescue 
ability. We hypothesized that these elements exist only in the C-TD of proteins with 
high rescue ability, and not the other PouV proteins with diminished ability to rescue 
ES cells self-renewal. We therefore, aligned the amino acid sequences of the C-TD 
from different PouV proteins using Clustal W multiple sequence alignment software 
(Figure 4.12a). 
The alignment uncovered a motif for a potential tyrosine kinase—Ras—mitogen-
activated protein kinase (MAPK) docking site that was present only in mouse Oct4 
(mOct4), human OCT4 (hOCT4), and Xenopus Xlpou91 proteins (Figure 4.12a). 
This motif is very similar to a DEF (docking site for ERK, F,  -X-'IY -P) site 
sequence. Figure 4.1 2b shows examples of MAP kinase docking sites including the 
DEF site from human and yeast MAPK interacting proteins. 
Figure 4.1 2c illustrates how a MAP kinase interacts with a docking site of one of its 
substrates. The MAPK docking sites are usually found near the target 
phosphorylation site on the substrate proteins, and a single docking site can enhance 
the phosphorylation of multiple target sites (Bardwell and Shah, 2006). As MAP 
kinases are proline directed kinases that phosphorylate the serine or the threonine in 
the dipeptide motif SIT-P (Bardwell and Shah, 2006), we looked for potential 
phosphorylation sites specific for MAP kinase that are present near the potential DEF 
site motif in the C-TD of Oct4, hOCT4, and Xlpou9 1. The existence of a potential 
MAP kinase phosphoiylation site near the conserved motif present in the C-TD of 
Oct4, hOCT4, and Xlpou91 proteins, support the functionality of this motif as a DEF 
docking site for MAP kinases. 
am 
(a) 
nOCT4 SSDYAQREDEAAGSPFS-'iS - -FPLAPGPHFGTPGYGS- PHE'TALYSSVPPEGEA 56 
rnOCT4 SIEYSQREEYEATGTPE'-GGAVS--FPLPPGPH-GTPGYGS-?HE'TTLYS-VPE'PEGEA 54 
X1Pou91 VYPYIRENGGEPYDTPQTLTPPSQGPFPLPQVMPSQVFPTVPLGANPTIYA-PTYHKNDM 59 
Xl Pou6O - FRMSKGHEEVGGASPGS-IQSEHI SFTPI PANSDYGIAS-LHPNRAPFYP-PPFPRNEL 56 
Xl Pou25 GMPTVEENDGEGYDVAQTMGSPPVGHYALQQVVTPQGY ----- MAAPQIYA-SAEHKNDL 54 
DrPou2 ALPFDDECVEAQYYEQSPPPPPHMGGTVLPGGQGYPGPAH--PGGAPALYM-PSLHRPDV 57 
AmOct4 -ICREEYDGFQQY PGMQP-GPPALSHLP--TSYIAQGYNG-A.AAAE'AAVYM-QPFHDSEM 
* 
54 
nOCT4 FPPVSVTTLGSPMHSN 72 
mOCT4 FPSVPVTALGSPMHSN 70 
X1Pou91 FPQNIHHGIGMGNQGN 75 
X1Pou60 FPHMAP-GISMGVLTG 71 
XlPou25 FPQTVPHGMPMGGHIG 70 
DrPou2 EKNGLHPGL-VGHLTS 72 
ArnOct4 YSQTVSRI-iLHSN---- 	66 
(b) 
MAPX DOCK1G SflES 
D.iite c 
...+ 	hXh 
14EK1 	14P wprp- -10!. NPAPDG 
MEK2 MLA WPVLPM.TI NPTIAE 
MKX3 	CES ERXID -- - LKL SCMSKP 
MKK6 SKG XRNPG--LKI PKEAFE 
MKK4 	MQG UZA- --- LEt. NFANPP 
MKK7-D1 REA RP.RID --- LNL DISPQR 
MKX7-D2 SPQ RPRPT- -- LOt. PLAN)G 
MKI(7-03 PPA RPRI4N --- LGL ?STLFT 
yStel 	TLQ RRN1XG- - LNL NL}1PDV 
yoigi KSL KRGRVPAPLNL SDSNTN 
yDig2 	HSL XRXRVPPALNF SDIQAS 
yparl PINS ERGNIPKPLNL SKPISP 
JIP1 	DTY *PXRPTr-LNL FPQVPR 
JIP3 GRS lERPIS-U4V FPLADG 
c-Jun 	SNP £ILIQSHTLNL ADPVGS 
ATF2 AVH EHIHE --- irri. KFGPAR 
ELK1 	QPQ KGUPRD-LEL PL.SPSL 
MKP1 	nv RIkAEXA-IEL EHIVPN 
MEP2 TXV RRIAXGS-VSZ. EQILPA 
MKP3 	IML ULQKGN-Z.PV RALFTR 
PTP-SL LOS RRGSNVS-L.TL DMCTPG 
HePTP 	LQE I1GSNVA-LML DVRSLG 
MA?KAPK clw: 
L *.-. .. 
MNK1 	KSR £.A*1*AL- - P.0k 
NNK2 QSK LAOP.RQI- - ASL 
RSK1 	SSI LAQERV1X- LPS 
RSK2 RST LAQUGIEZ ITS 
yRck2 	STI LQRRXZV- - QEN 
DEF-te d 
FXFP 
Elki 	AXLS ?Q?P SSGS 
C-foa YTSS YV?T YPEA 
Pral 	FTPS PT!P Sfl'E 
Fra2 SNLV FTYP SVI.E 
c-Pfyc 	psvv rt'rp t.sws 
Vinexin RRSA PPPP IThQ 
XSR 	RDSR TN?P Ak?? 
MEP1 rrrv iN?? vstp 
yDigi 	HIFA FE?? LSSS 
( 	
reses c) on substrate 
Docking site 	Substrate 
on substrate'-... 
Cognate 
d MAPK ocking site 
onMAPK 
Kioase active site 
Figure 4.12- Carboxyl terminal alignment of PouV proteins reveals a potential 
DEF site in Xlpou91 , mouse and human 004 
Amino acid sequence alignments of the carboxyl terminal (C-TD) of PouV 
proteins uncover a potential sequence for the DEF site (MAP kinase docking site). 
The DEF site is coloured in blue. CLUSTAL W (1.83) multiple sequence alignment 
software was used for the alignment. 
MAPK doking sites from human and yeast MAPK-interacting proteins: D site, 
MAPKAPK, and DEF site class. (Bardwell and Shah., 2006) 
A schematic representing docking interaction between MAP kinase and one of its 
substrate. (Bardwell and Shah., 2006) 
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To check for the existence of any putative MAP kinase phosphorylation sites, the C-
terminal domains of mouse Oct4, human OCT4, Xenopus Xlpou9l, Xlpou25, and 
Zebrafish DrPou2 proteins were analysed for potential phosphorylation site using 
NetPhos.2.0 server. This software is based on neural network method, it predicts 
phosphorylation sites at serine (S), threonine (T) or tyrosine (Y) residues in 
eukaryotic proteins (Blom et al., 1999). The output of this analysis is shown for each 
C-TD individually in the following figures: mouse Oct4 C-TD (Figure 4.13a), human 
OCT4 C-TD (Figure.4.13b), Xenopus Xlpou9l C-TD (Figure 4.13c), Xlpou25 C-TD 
(Figure 4.1 3d), and Zebrafish DrPou2 (Figure 4.1 3e). 
Taking into account the fact that MAP kinases phosphorylate the serine or the 
threonine in the dipeptide motif SIT-P, we identified MAP Kinase specific sites 
amongst all predicted phosphorylation sites. 
This analysis shows that there are two putative MAPK phosphorylation sites in the 
C-TD of mouse Oct4 (T at position 15, and S at position 38), two sites in human 
OCT4 C-TD (S at position 15, and S at position 39), and one site in Xlpou9l C-TD 
(T at position 15), whereas, there was no MAP kinase specific site in C-TD of 
Xlpou25 or DrPou2. Figure 4.14 shows the positions of the potential MAP Kinase 





.S .... Y.. . .T .................... Y.S .... T ........................... 
Phoaphorylation sites predicted: 	Ser: 2 Thr: 2 Tyr: 2 
Serine predictions 
Name Poe Context Score 	Pred 
V_________________ 
mOCT4 1 ----SIEYS 0.004 
CT4 5 SIEYSQREE 0.955 	*S* 
mOCT4 23 GGAVSFPLP 0.015 
mOCT4 38 PGYGSPHFT 0.974 	S.  
iCT4 46 TLYSVPPP 0.073 
iCT4 57 EAFPSVPVT 0.042 
tCT4 65 TALGSP?'ffiS 0.024 
uCT4 69 SPMHSN--- 0.062 
Threonine predictions 
Name Poe Context Score 	Pred 
V_________________ 
mOCT4 13 EYEATGTPF 0.401 
mOCr4 15 EATGTPFPG 0.940 	T 
nCT4 33 GPHGTPGYG 0.496 
tCT4 42 SPHFTTLYS 0.032 
TCT4 43 PHFITLYSV 0.758 	T 
tCT4 61 SVPVTALGS 0.020 
Tyros me predict ions 
Name Poe Context Score Pred 
V_________________ 
mOCT4 4 -SIEYSQRE 0.215 
tCT4 10 QREEYEATG 0.944 Y 
TCT4 36 GTPGYGSPH 0.745 * 
tcr4 45 £TTLYSVPP 0.160 
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Y.T. .T. .. .5 .......................... '1. . .Y.................... 
Phoaphorylation Bites predicted: 	Ser: 1 Thr: 2 Tyr: 3 
Serine predictions 
Name Poe Context Score Pred 
V_______________ 
XlPou9l 23 LTPPSQGPF 0.890 *S* 
XlPou9l 35 QVMPSQVPP 0.223 
Threonine predictions 
Name Poe Context Score Pred 
V________________ 
XlPou9l 15 EPYDTPQTL 0.666 T 
XlPou9l 18 DTPQTLTPP 0.829 T 
XlPou9l 20 PQTLTPPSQ 0.310 
XlPou9l 40 QVFPTVPLG 0.010 
XlPou9l 48 GANPTIYAP 0.112 
XlPou9l 53 IYAPTYHKN 0.094 
Tyrosine predictions 
Name Poe Context Score Pred 
V________________ 
XlPou91 2 ---VYPYIR 0.086 
XlPou9l 4 -VYPYIREN 0.097 
XlPou9l 13 GGEPYDTPQ 0.723 •y 
XlPou9l 50 NPTXYAPTY 0.564 *'f* 





Phosphorylation Bites predicted: 	Ser: 0 Thr: 1 Tyr: 1 
Serine predictions 
Name Pos Context Score Pred 
V________________ 
XlPou25 21 QTMGSPPVG 0.234 
XlPou25 47 QIYASAFRK 0.005 
Threonine predict ions 
Name Pos Context Score Pred 
V________________ 
XlPou25 4 -GMPTVEEN 0.516 T 
XlPou25 18 DVAQTMGSP 0.461 
XlPou25 34 QQVVTPQGY 0.087 
XlPou25 58 LFPQTVPHG 0.078 
Tyrosine predictions 
Name Poe Context Score Pred 
V________________ 
XlPou25 13 DGEGYDVAQ 0.860 *Ô 
XlPou25 27 PVGHYPLQQ 0.043 
XlPou25 38 TPQGYMAAP 0.325 







Phoaphorylation sites predicted: 	Ser: 0 Thr: 0 Tyr: 1 
Name 
Sarine predictions 
Pos 	Context 	Score 
V________________ 
Pred 
DrPou2 17 YYEQSPPPP 0.019 
DrPou2 51 LYMPSLHRP 0.031 
DrPou2 72 GHLTS---- 0.006 
Threonine predictions 
Name Poa Context Score Pred 
V________________ 
DrPou2 27 HMGGTVLPG 0.248 
DrPou2 71 VGHLTS-- - 0.302 
Tyrosine predictions 
Name Pos Context Score Pred 
V________________ 
DrPou2 13 VEAQYYEQS 0.174 
DrPou2 14 EAQYYEQSP 0.928 è 
DrPou2 35 GGQGYPGPA 0.111 
DrPou2 48 APALYMPSL 0.045 
Figure 4.13- Identification of potential phosphorylation sites in the C-TD of 
PouV proteins 
C-TDs of (a) mouse Oct4, (b) human Oct4, (c) Xlpou91 (d) Xlpou25, and (e) 
DrPou2 proteins were analysed for potential phosphorylation site using NetPhos.2.0 
server. 
The software produces predictions for serine, threonine and tyrosine 
phosphorylation sites in eukaryotic proteins. 
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hOCT4 SSDYAQREDFEAAGSPFS-GGPVS--FPLPGPHFGTPGYGS-E'HFTALYSSVPFPEGEA 56 
mOCT4 SIEYSQREEYEATGTPFP-GGAVS--FPLPPGPH-GTPGYGS-PH'TTLYS-VPFPEGEA 54 
X1Pou91 VYPYIRENGGEPYDPQTLTPPSQGPFPLPQVMPSQVFPTVPLGANPTIYA-PTYHKNDM 59 
XlPou25 GMPTVEENDGEGYDVAQTMGSPPVGHYALQQVVTE'QGY ----- MAAPQIYA-SAFHKNDL 54 
DrPou2 ALPFDDECVEAQYYEQSPPPPE'HMGGTVLPGGQGYPGPAH--PGGAPALYM-PSLHRPDV * 57 
hOCT4 FPPVSVTTLGSPMHSN 72 
rnOCT4 FPSVPVTALGSPMHSN 70 
X1Pou91 FPQAMHHGIGMGNQGN 75 
XlPou25 FPQTVPHGMAMGGHIG 70 
DrPou2 FKNGLHPGL-VGHLTS 72 
Figure 4.14-Positions of potential MAPK phosphorylation sites in the C-TD of 
PouV proteins 
This analysis shows that there are two putative MAPK phosphorylation sites in the 
C-TD of mouse Oct4 (1 at position 15, and S at position 38), two sites in human 
Oct4 C-TD (S at position 15, and S at position 39), and one site in Xlpou91 C-ID (I 
at position 15), whereas, there was no MAP kinase specific site in C-TD of Xlpou25 
or DrPou2 proteins. 
Amino acid sequence alignments of the carboxyl terminal (C-ID) of PouV proteins 
uncover a potential sequence for the DEF site (MAP kinase docking site). The DEF 
site is coloured in blue. CLUSTAL W (1.83) multiple sequence alignment software 
was used for the alignment. 
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As these sites are predicted MAP kinase phosphorylation targets, we tested their 
relevance to PouV activity by mutating the putative MAP kinase docking site in both 
Xlpou91 and mouse Oct4. The critical conserved residues of the DEF docking site 
were mutated from FPLP to AAAP (Figure 4.15a1). The resulting mutant proteins 
were tested for their transcriptional activity and their ability to rescue Oct4 null ES 
cell phenotypes. Table 4.3 summarises the ability of these mutants proteins to 
activate transcriptions and to rescue ES cell self-renewal. 
Both mutant Oct4 and Xlpou9l proteins appear to have identical activity to wild type 
proteins when tested for their ability to activate transcription from both the octamer 
binding motif luciferase reporter (Figure 4.1 5b 1), and the Fgf4 enhancer luciferase 
reporter (Figure 4.1 5b2), and (Figure 4.1 5b3). Similarly, when tested for their ability 
to rescue ES cell self-renewal, the mutant proteins appear able to support the growth 
of normal undifferentiated ES cell colonies (Figure 4.1 6b 1 and b2). However, when 
the quantitative ability of these mutant proteins to rescue self-renewal is measured, 
some reduction in their rescue indices is observed (Figure 4.1 6a). Suggesting that 
while the MAPK docking domain appeared non-essential for the support of ES cell 
self-renewal, it is a likely contributing factor to the ability of the C-TD to increase 
the efficiency of quantitative rescue when transferred from Xlpou91 to either 
Xlpou25 or DrPou2. 
4.2.7. Investigating the importance of Xlpou91 POU domain 
4.2.7.1. Alignment of DNA binding POU domains of PouV proteins reveals 
possible conserved residues responsible for maintaining the undifferentiated 
phenotype of ES cells 
Xlpou91 POU domain appears essential for maintaining the undifferentiated 
phenotype of ES cells. This is in accordance with previous findings showing that the 
POU domain of Oct4 is responsible for conferring its unique function in ES cells 
(Niwa, Masui et al. 2002; Nishimoto, Miyagi et al. 2005). 
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Figure 4.15-Cloning and transcriptional activity of Oct4 and Xlpou9I proteins 
with mutated DEF site 
(al) Mutating the DEF site sequence from FPLP to AAAP sequence. (a.2) 
Schematic representation of Flag tagged wild type and mutated Oct4 and Xlpou91 
proteins. 
(b) 3xFlag- mutated Oct4 and Xlpou91 proteins activate transcription in a specific 
manner from two luciferase reporters: one contains multiple copies of the octamer 
binding motif (b.1) and the other contains the Fgf4 enhancer (b.2). A luciferase 
reporter containing the thymidine kinase (TK) promoter was used to test the 
specificity of the proteins transcriptional activity (b.3). 
The indicated cDNAs were cotransfected with luciferase reporters. Fold induction 
represents the increase in transcription compared with the empty vector control. Data 
represent the mean value of two independent experiments. 
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Figure 4.16-Mutating the DEF site has little effect on ES cells self-renewal 
rescue ability of Oct4 and Xlpou91 proteins 
(a) Rescue index for 3x Flag Oct4 and Xlpou9 I proteins with mutated DEF site. 
The rescue index values were normalised to 3xFlag Oct4 value. Data represents the 
mean values obtained from two independent experiments. (b) Morphology of 
colonies rescued by the mutated proteins. Morphology of representative colonies 
rescued by wild type PouV proteins (b.1), and proteins with mutated DEF site (b.2) 
is shown. 
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These studies showed that a chimeric protein consisting of the activation domain of 
Oct6 and the POU domain of Oct4 could rescue the self-renewal of Oct4 null ES 
cells. They reported that the threonine residue at position 22 in the al-helix of the 
POU specific domain and the linker region of Oct4 are the critical elements 
responsible for the function of the POU domain in ES cells (Nishimoto, Miyagi et al. 
2005). However, they did not address the consequence of mutating these elements in 
the context of Oct4. 
In order to verify the importance of the elements identified in the study by Nishimoto 
and colleagues, and further uncover other elements in the linker region that are 
critical for ES cell self-renewal, we aligned the amino acid sequences of POU 
domains from various PouV proteins differing in their ability to maintain ES cell 
self-renewal. We aimed to identify residues that conserved only in PouV proteins 
with the ability to maintain the undifferentiated phenotype of ES cells. During the 
course of this study, Niwa and colleagues published an analysis of Oct4 evolution 
(Niwa et al., 2008), which included an investigation of functional differences 
between Oct4 and more primitive PouV proteins, and focused on key conserved 
positions that vary in PouV protein evolution. Their analysis, represented in Figure 
4.1 7a, and b highlights the differences in amino acid sequences of POU domains of 
Zebrafish pou2, Opossum pou2, Axolot Oct4, Xenopus Xlpou25, Xlpou60, Xlpou91, 
Platypus Oct4, mouse Oct4 and Oct6 proteins. Using this alignment, Niwa et a! 2008 
predicted the following amino acids T22, Y25, T33, F38, V41, and T88 as potential 
mediators of Oct4 specificity in ES cells. The importance of these residues for Oct4 
function was evaluated by mutating them one amino acid at the time in Oct4 to 
match their corresponding residues found in Pou2 homologues, and testing the 
abilities of the resulting Oct4 variants to rescue ES cell self-renewal in the 
complementation assay (Niwa et al., 2008). Interestingly, none of these variants had 
a significant reduction in their ability to rescue ES cell self-renewal in comparison to 
wild type Oct4. As a result, Niwa et al concluded that individual amino acid changes 
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(b) 
zebrafish pou2 T 
;S3IE . ; 
FAYMNESPYRVGVTE 
opossum pou2 S FAYMQETPCQATRPQ 
axoloti pou2 P FAYMVDNLCNQNLHE 
xenopus oct25 S YAYMVENLIQANMAE 
xenopus oct60 A YAYMGENLIQETMAE 
xenopus oct91 P YAFTHENLIIQPNMAE 
mouse Pou5fl T YTFVEDNLCTQNLLQ 
mouse Pou3fl K FAYVEDSSLAGVLAE 
fl.sc. 







(Niwa et aL, 2008) 
Figure 4.17-Alignment of the amino acid sequences of the POU domains of 
the vertebrate PouV proteins 
(a) and (b) are figures from the paper published by Niwa et a! 2008. 
Figure (a) represents alignment of the amino acid sequences of POU domains of 
vertebrate PouV proteins. As determined by the authors of the paper the upper red 
lines define the a-helix structures of the POUs and POUh domains, and the green 
line shows the linker domain. The lower yellow horizontal arrows and vertical 
lines show the lenght and boundaries of each exon. 
The blue vertical lines indicate amino acid residues different between Pou2 and 
Pou5fl orthologues, and the red vertical lines show deletions in either some or all 
Pou5fl orthologues. 
Figure (b) shows residues that are different between POU domains of Pou2 
homologues and PouSfl orthologues and the rescue ability of each protein. The 
numbers on the top indicate the position of each residue in the alignment shown in 
figure (a). Green letters show residues identical to those of the Zebrafish pou2 
protein, and red letters show residues identical to those of mouse Pou5ul protein. 
Blue letters indicate the threonine residue which was identified by Nishimoto as 
important for Pou3fl function (Niwa et a!, 2008). 
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While a single amino acid might not be able to eliminate Oct4 function in ES cells 
we have identified a single amino acid change in some DrPou2 sequences that 
eradicates completely the ability of this protein to rescue 0cM null ES cell self-
renewal. As stated in the beginning of this chapter, we have identified two EST 
sequences for the DrPou2 gene. The original DrPou2 sequence used by our group 
has an alanine (DrPou2(A)) in place of a threonine (DrPou2(T)) in the POU domain 
at position 348 in the protein (Figure 4.18), which corresponds to position 228 in the 
Oct4 sequence. In fact this T to A substitution in the DrPou(A) sequence may 
represent a polymorphism of DrPou gene that is present in some populations of the 
Zebrafish specie or could be simply a result of a cloning artefact. Further 
investigation is required to determine the nature of this amino acid substitution in the 
protein. 
In the proceeding sections 1 have presented data based on the DrPou2(T), that has a 
self-renewal rescue ability similar to that of Xlpou25 protein. However, in this 
section I compare these results to those obtained with DrPou2(A) that has no 
capacity to rescue Oct4 activity in ES cells. 
The ability of DrPou2(T) to substitute for Oct4 activity in ES cells, albeit at a very 
reduced level, suggests that this threonine residue at position 348 is critical, and 
mutating it is sufficient to abolish the function of DrPou2 protein in ES cells. To 
investigate this possibility, and to ask whether Xlpou91 C-TD would have any 
positive effect on the rescue ability of DrPou2(A) protein, we generated a series of 
chimeric proteins between DrPou2(A) and Xlpou91 by swapping the domains of the 
two proteins as explained in previous sections (Figure 4.1 9a). Table 4.4 summarises 
the ability of these chimeric proteins to activate transcription and rescue ES cell self-
renewal. 
These Xlpou9l-DrPou2(A) chimeric proteins were tested for their abilities to 
activate transcription from luciferase reporters harbouring the Fgf4 enhancer or six 
copies of the octamer-binding motif, and were all found to specifically activate 
transcription from both reporters in an identical fashion to their Xlpou9 I -DrPou2(T) 
counterparts (Figure 4. 19b1, b2 and b3). 
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Figure 4.18 - The difference between DrPou2 (T) and DrPou2(A) proteins 
The zebra fish DrPou2(A) protein has an Alanine instead of the Threonine at position 348 of the amino acid sequence of the protein. 
This threonine residue is conserved in human. mouse, Xenopus and axoloti PouV proteins. 
PouV proteins alignment as published in Morrison and Brickman., 2006. Alignment of human (hOCT4), mouse (mOct4). Xenopus 
(Xlpou9l, Xlpou25, Xlpou60), axoloti (AmOct4) and zebrafish (DrPou2) PouV proteins. (Alignment from Morrison and Brickrnan., 
residues, light blue indicates similar residues, and dark blue indicates conservation within a subset of residues. 
(a) 
XIpou9l *tP II4 Pous H PO4Th 1:4 
Dr pou2(A) 	I N-TO I POUs H POUh I C-TO 
N2P91C91 	L POUh C-ID - - ] POLl.  H - 
N-ID swap 
N91P2(A)C2 	I N-TD POUs H PO4Th  I c-m 
N2P2(A)C91 POUh N-TO POUs H - C-ID swap 
N91P91C2 	I N-ID I POUS H POUh C-ID 
N2P91C2 POUh I C-TO N-ID IPoutH 
POU-D swap 
N91P2(A)C91 - N.TD POLls H POUh 
(b.1) (b.2) 
6 x Octsm.r binding motif -* Fgf4 enhanc.r 1* 
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Figure 4.1 9—Cloning and transcriptional activity of Xlpou9l -DrPou2(A) 
Chimeric proteins 
Schematic representation of Xlpou9 1 -DrPou2(A) chimenc proteins: chimeric 
proteins were generated by swapping either the amino acid terminal (N-TD), the 
carboxyl terminal (C-ID) or the POU domain of Xlpou9 1 with DrPou2(A) domains. 
Xlpou9l-DrPou2(A) chimenc proteins are able to activate transcription in a 
specific manner from two luciferase reporters: one containing multiple copies of the 
octamer binding motif (b.1) and the other one containing the Fgf4 enhancer (b.2). A 
luciferase reporter containing the thymidine kinase (1K) promoter was used to test 
the specificity of the chimeric proteins transcriptional activity (b.3). 
The indicated cDNAs were cotransfected with luciferase reporters. Fold induction 
represents the increase in transcription compared with the empty vector control. Data 
represent the mean value of two independent experiments. 
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When these Xlpou9l-DrPou2(A) chimeric proteins were tested for their ability to 
rescue ES cell self-renewal, all proteins harbouring the POU domain from the 
DrPou2(A) protein (DrPou2(A), N91P2(A)C2, N2P2(A)C91, N91P2(A)C91) were 
unable to support undifferentiated ES cell growth, and therefore showed no rescue 
ability (Figure 4.20a, bi, b2, b3, and b4). 
These results reaffirm that this threonine in the POU specific domain of DrPou2 
protein is essential for any ES cell activity, and that without a POU domain, the C-
TD is not able to confer any advantageous effect on the rescue ability of the protein. 
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Table 4.4- Summary of the ability of the different Xlpou9l and DrPou2(A) 
chi,naeric proteins to activate transcription and to rescue ES cell self-
renewal. 
The transcriptional activity of the different Xlpou9I-DrPou2(A) chimaeric proteins is assessed 
based on their ability to activate transcription fron luciferase reporters harbouring Oct4 
dependent sequences either from the Fgf4 enhancer or 6 reiterated copies of the Octatner 
binding notif. The ability of the different X1pou9I-DrPou2(A) chimaeric proteins to rescue ES 
cell self—renewal is measured based on the norphology of the rescued colonies and the 
nunber of the rescued colonies represented as the rescue index. N: N-terminus, C:C-ter,ninus, 
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WO Typical undifferentiated 1 + + + + + + + 
ES cell colonies  1.02 
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++ 
colonies similar to 
007 DrPou2(A) expressing 
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N Undifferentiated colonies 
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(b.4) POU domain swap 
CL 0)ZIIlI 
Figure 4.20- The inability of Zebrafish DrPou2(A) protein to rescue ES cells 
self-renewal reveals the crucial role of POU domain of the PouV proteins in the 
process 
(a) Rescue index for Xlpou9 I -DrPou2(A) chimeric proteins. Rescue index values 
were normalised to Oct4 value. Data represents the mean values obtained from two 
independent experiments. (b) Morphology of colonies rescued by the Xlpou9l-
DrPou2(A) chimeric proteins: morphology of representative colonies rescued by 
wild type PouV proteins (b.1), chimeric proteins generated by N terminal swap 
(b.2), C terminal swap (b.3), and POU domain swap (b.4). 
211 
4.3. Discussion 
The mechanism by which pluripotency is established and maintained is still not fully 
understood. Oct4 was identified as a crucial factor governing pluripotency and self-
renewal in both early development and ES cells. Although Oct4 function has been 
studied extensively, the mechanism by which it controls pluripotency and self-
renewal is not clear yet. My studies have shown that the remarkable ability of 
Xlpou91 to rescue ES cell self-renewal is encoded by two functions. An activation 
domain in the C-TD that is required for the efficiency of ES cell self-renewal 
(although this activity has become somewhat redundant in Oct4), and crucial 
sequences within the POU domain that are essential for the maintenance of the 
undifferentiated phenotype of ES cells. 
In fact, previous studies tried to investigate the functional importance of each domain 
of the Oct4 protein. The activation domains of Oct4 have been characterized via 
fusion to heterologous DNA binding domains. Imagawa et al 1991 fused the N-TD 
or C-TD Oct4 to the DNA binding domain of c-Jun and tested their abilities to 
activate transcription from reporter genes containing reiterated c-Jun binding sites in 
P19 EC cells. Based on this analysis, only the N-TD was believed to have activation 
function (Imagawa et al., 1991). However, when the activation function of Oct4 was 
assayed in a native context from reiterated octamer sites, Vigano et al 1996 reported 
that both the N and C terminal domains are able to activate transcription in Hela 
cells. They also reported that the C-TD was the stronger activation domain (Vigano 
and Staudt 1996). 
Brehem et al 1997 confirmed the trans-activation ability of both the N and C-TD and 
reported that the activity of the C domain is cell type specific and is mediated by the 
POU domain. In fact, when they compared the activity of these domains when fused 
to either Ga14 or Piti DNA binding domains, they found that Ga14-C-TD fusions 
activated transcription from a reporter containing 6 copies of the octamer binding 
motif in Hela cells, but failed to activate transcription in 923 or NIH3T3 cell lines. 
However, a Pitl-C-TD fusion had the capacity to activate transcription of this 
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reporter regardless of the cell lines used (Brehm, Ohbo et al. 1997). These findings 
are consistent with the requirement for Sox2 at the Fgf4 promoter to enable the C-TD 
to activated transcription (Ambrosetti et al., 2000). 
Interestingly, while this work is all specific to transcriptional activation in reporter 
assays, it does point to a specific role for the C-TD in the regulation of transcription 
by POU proteins, which in fact is in accordance with my observations about its 
contribution to the Oct4-like function in ES cells. 
Although these studies provided valuable insight into the function of the different 
domains of Oct4 proteins, they provide no insight into the physiological roles of 
these domains in establishing and maintaining pluripotency and self-renewal. 
In 2002, Niwa and colleagues addressed this question and tried to map the functional 
domains of Oct4 that are necessary for maintaining pluripotency and self-renewal in 
ES cells. They found that Oct4 proteins lacking either the N or C-TD were able to 
rescue ES cell self-renewal in their complementation assay. They also show that 
fusing the POU domain of Oct4 to a heterologous trans-activation domain is 
sufficient for maintaining ES cell self-renewal, and therefore concluded that the POU 
domain of Oct4 is uniquely required and coupled with a generic proline rich trans-
activation domain is sufficient to maintain the undifferentiated stem cell phenotype 
(Niwa et al., 2002). However, this argument for generic activity is difficult to 
reconcile with their fmdings that the activity of N and C trans-activation domains of 
Oct4 regulate different sets of genes. 
My data clearly shows that the C-ID is not required in Oct4, but is absolutely 
required for Xlpou9 1, suggesting that Oct4 might have redundant functions that 
mask the specific role for the C-TD. Moreover, the original studies by Niwa et a! 
2002 implied that there was a more important role for the C-ID than the N-TD in ES 
cell self-renewal. They reported that transfecting Oct4 null ES cells with an Oct4 
protein lacking the C-ID produced only the third of ES cell colony number obtained 
with an Oct4 protein missing the N-ID only (Niwa et al., 2002), indicating that even 
in the context of Oct4, this domain is important. 
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The possibility that the C-TD is a stronger activation domain than the N-TD has been 
reported previously (Vigano and Staudt, 1996) and could explain why the C-TD 
appears to have a more specific role. However, I have never observed a significant 
correlation between transcriptional activation and rescue of Oct4 null ES cell 
phenotype. Instead, I favor a role for MAP kinase in the regulation of Oct4 activity 
as it has already been implicated in ES cell self-renewal (Nichols et al., 2009). While 
the phenotypes I observed were not strong, I have not yet shown that I have 
effectively neutralized the MAPK phosphorylation of the C-TD in the docking site 
mutants. In addition to that, MAPK phosphorylation in unlikely to be the only factor 
regulating C-TD activity as Xlpou25 and DrPou2(T) have some residual activity in 
their C-TD despite the absence of the consensus MAPK docking site in their C-TD 
sequences. 
In addition to the role of the C-TD, we also showed that there is a potential negative 
role for the Xlpou91 N-TD in regulating Oct4-like activity. It appeared that chimeras 
without the Xlpou9 1 N-TD showed higher rescue indices than the full length 
Xlpou9 1. Interestingly, colonies rescued by these chimeric proteins had a slightly 
higher level of background differentiation. Niwa et al 2002 reported that the N 
terminal domain of Oct4 protein is able to direct the expression of Ebaf/Leftyl gene 
and that the C terminal domain is specifically lacks this ability (Niwa et al., 2002). 
As Lefty is a negative regulator of Nodal signalling, one possible mechanism by 
which the N-terminus could be dampening the rate of self-renewal as reflected in the 
rescue index might be through Lefty mediated Nodal antagonism. 
Although the effect of Xlpou91 N-TD on the rate of ES cell self-renewal is very 
interesting, it was only detected in swap experiments and straight deletion of the N- 
TD resulted in a reduction of self-renewal efficiency in both Xlpou9 1 and Oct4 itself. 
The major determinant of PouV proteins ability to support ES cell morphology and 
undifferentiated phenotype appears to be the POU domain. Studies focusing on the 
difference between Class III and Class V POU proteins indicated that the crucial 
region of PouV protein responsible for supporting ES cell growth is the first a-helix 
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of the POU specific domain and the linker region joining the POU specific and the 
POU homeodomain. They identified the threonine residue at position 22 in the a 1-
helix of POU domain as the critical element responsible for ES cell self-renewal in 
this region. Although they did not show that any specific residue was essential for 
Oct4 activity (Nishimoto et al., 2005; Niwa et al., 2002). 
In our laboratory, we took a slightly different approach to address this question. We 
based our investigation on previous findings from our group. These findings indicate 
that Oct4 function in maintaining pluripotency and self-renewal in mammals is 
derived from a conserved role of PouV proteins to prevent premature commitment of 
cells in the developing embryo, and that only some of these PouV proteins are able to 
support ES cell self-renewal in the absence of Oct4 (Morrison and Brickman, 2006). 
In This study, we exploited the sequence similarity and the functional differences 
between the very closely related Xenopus proteins Xlpou91 and Xlpou25 to identify 
functional domains responsible for maintaining the undifferentiated phenotype of ES 
cells. The comparison of very closely related proteins rather than proteins from 
different subclasses facilitates the identification of the functional domains because 
their sequences are more conserved. 
Our study showed that even within the class V family of POU protein, the POU 
domain is the major determinant required for the support of ES cell undifferentiated 
morphology. Moreover, this study also shows that, despite their functional 
differences in ES cells, these PouV proteins all appear to activate transcription from 
reporters bearing Oct4 responsive elements to the same degree. Which in fact 
suggest that functional differences between these PouV proteins in ES cells are more 
likely to be caused by their different abilities to form promoter specific multimeric 
protein-protein complexes, rather than their ability to recognize target DNA 
sequences. In fact, the POU domain was shown to affect Oct4 function in many 
aspects. In addition to DNA binding it has been shown to be involved in protein-
protein interactions, dimerization ability, and stability. The POU domain consists of 
two DNA binding domains connected with a flexible linker. This structure allows the 
protein to form heterodimers with other transcription factors and homodimers in 
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different conformations (PORE or MORE confirmation) depending on the 
configuration of the target octamer binding site, and therefore enable it to interact 
with a variety of target sequences (Botquin, Hess et al. 1998; Remenyi, Lins et al. 
2003). The POU domain of Oct4 protein is also involved in protein-protein 
interactions and the selective recruitments of co-factors. It mediates the interaction 
with Ets2, adenovirus E1A, and Sox2 proteins (Ezashi et al., 2001; Scholer et al., 
1991; Yuan et al., 1995), and was shown to be vital for the synergistic activation of 
Fgf4 enhancer by the Sox2-Oct4 complex (Ambrosetti et al., 2000). Furthermore, 
different dimmer conformations lead to different recruitment of transcriptional co-
activators. It was shown that OBF- 1 binds to the PORE configuration of the Octl 
dimer and synergises with it in transcriptional activation, but fails to bind Octi in the 
MORE conformation (Tomilin, Remenyi et al. 2000). 
In addition to protein-protein interactions, the presence of specific sequences within 
the POU domain might effect the post-translational modification of the protein. 
Recent studies reported that Oct4 function could be regulated by post-translational 
modifications either within or mediated by the POU domain of the protein. Zhang et 
al 2007 showed that Oct4 interacts with Ubc9 and E2 conjugation enzymes to 
mediate sumoylation of lysine 118 through its POU domain, and that this 
modification is required for optimal levels of self-renewal in ES cells (Zhang et al., 
2007). Moreover, Saxe and colleagues (2009) reported that phosphorylation of Oct4 
at serine 229, which is adjacent to the POU homeodomain, partially controls its 
transactivation activity (Saxe et al., 2009). Interestingly, phosphorylation of Ser229 
prevents DNA binding of Oct4 on PORE sequences, but does not alter its binding 
ability to other octamer motif configurations (Saxe et al., 2009). 
Because the function of Oct4 is affected by its POU domain in many ways, further 
investigations of the different POU domain sequences described here will be 
necessary to determine the molecular mechanism by which they regulate PouV 
protein specificity in ES cells. 
During the course of our study, Niwa and colleagues published their study utilizing a 
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similar strategy to ours (see result section for more details). They compared amino 
acid sequence of POU domains from Oct4 homologues. They reported that mutating 
single amino acids did not have a significant effect on Oct4 ability to rescue Oct4 
null ES cells self-renewal. Therefore, they concluded that changing individual amino 
acid residues is not sufficient to abolish the ability of Oct4 to maintain ES cell self-
renewal, and suggested that the combination of all these amino acids is required for 
its function (Niwa et al., 2008). However, we found that changing the Threonine 
residue at position 348 in DrPou2 protein with an Alanine resulted in eliminating the 
ability of the protein to rescue ES cell self-renewal entirely. 
Investigating this finding might provide a better understanding of Oct4 regulated 
molecular mechanism underlying the maintenance of ES cells, especially that this 
one amino acid change did not cause a loss of general DNA binding ability of the 
protein. However, before embarking on examining the effect of this change on the 
specific proteinlprotein, protein/DNA interaction, dimerization or other possible 
post-translational modifications of the protein, it is necessary to confirm the effect of 






5. General Discussion 
5.1. Oct4 maintains self-renewal through its activator function 
One of the major findings of this study is that the activator form of Oct4, but not the 
repressor form, is able to maintain ES cells in an undifferentiated state. This finding 
is in disagreement with earlier models in which Oct4 maintains pluripotency by 
acting mainly as a direct blocker of differentiation (Pan et al., 2002). Our findings do 
not refute the key importance of inhibiting differentiation by Oct4, but point to a 
direct and primary role for Oct4 in activating pluripotency genes. 
In this study, we engineered Oct4 proteins that acts as activators (Oct4WP2) or 
repressors only (Oct4EnR), and tested their abilities to maintain uncommitted cells 
both in vivo and in vitro. The repressor form of Oct4 was not able to maintain ES 
self-renewal, and induced differentiation in both wild type ES cells and Xenopus 
embryos. In fact, the expression of the repressor form of Oct4 in Xenopus embryos 
induced the expression of differentiation-associated genes Gsc and Mixer, and 
repressed gene expression associated with uncommitted cells (e.g. Bmp4). However, 
the activator-only Oct4 (Oct4XVP2) both maintained self-renewal in ES cells, and 
inhibited differentiation genes in Xenopus embryos (e.g. Gsc and Mixer). This data 
pointed to the importance of the activator function of Oct4 in maintaining 
uncommitted cell populations both in vivo and in vitro. 
While it is still possible that Oct4XVP2 can repress certain genes in ES cells, we 
tested its function on a number of reporter genes and found that under no conditions 
did it function as a repressor. Moreover, our microarray data revealed that in 
Oct4XVP2 cell line, a proportion of genes that are normally believed to be repressed 
by the Nanog and Oct4 complex in ES cells (Loh et al., 2006) are in fact upregulated, 
indicating that Oct4XVP2 is a potent activator and overrides Nanog repression of 
these genes despite the later high expression levels in this cell line. 
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In the light of this finding, a closer analysis of earlier studies shows that gene 
activation of pluripotency genes is the primary mechanism for maintaining ES cell 
self-renewal. Activated Oct4 targets play an integral part in the core transcriptional 
circuitry of pluripotency (Zhou et al., 2007) and our data suggests that the activity of 
this network is dominant over the inadvertent expression of lineage markers. 
In this study we provide the first evidence, to our knowledge, that activation by Oct4 
is necessary and sufficient for maintaining self-renewal. A rigorous demonstration 
that this was sufficient for pluripotency would require the generation of a cell line in 
which the endogenous Oct4 had been replaced by Oct42 VP2 and the demonstration 
that these demonstrate germ line transmission. 
5.2. Oct4 maintains pluripotency by upregulating pluripotency genes 
directly and inhibiting differentiation genes indirectly 
In Xenopus embryo, Bmp4 seems to be a potential mediator of PouV protein function 
to suppress differentiation. Bmp4 expression seems dependent on PouV expression, 
injection of Oct42 VP2 mRNA elevated Bmp4 levels, whereas, Oct4XEnR 
overexpression decreased its expression levels. Moreover, injection of Bmp4 mRNA 
was able to rescue PouV knockdown phenotype. 
Similarly, we found that in ES cells Oct4?VP2 levels correlated with Nanog 
expression levels. Nanog was the only core pluripotency gene that appeared to 
respond to Oct4?VP2 levels. Interestingly, while no Nanog homologue has been 
identified in Xenopus, its closest relative would probably be the Nkx family member 
Xventl, a BMP target that depends on PouV proteins for its expression (Cao et al., 
2004). 
Oct4 has been recently shown to regulate an extended Nanog locus (Levasseur et al., 
2008), in which reside Dppa3 and GdJ3. While we have not shown direct binding of 
Oct42 XVP2 to this region, we did find that the over-expressed genes in Oct4 XVP2 
expressing cells map to specific genomic sites and that this locus represents one of 
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these clusters. In fact, these clusters of upregulated genes may represent key 
regulatory nodes in the pluripotency network. 
Our results also show that Oct4?VP2 represses key developmental genes such as 
Cdx2 and other putative Oct4 repressed targets (Loh et al., 2006). This supports the 
notion that the upregulation of these genes in response to Oct4 knockdown is 
probably an indirect consequence of differentiation. While it would seem unlikely 
that Cdx2 is directly repressed by Oct4XVP2, it is directly repressed by Nanog (Chen 
et al., 2009). Nanog has also been shown to repress other differentiation genes such 
as Eomes, 01x2 and Msx2 in genome-wide ChIP analysis (Chen et al., 2009; Kim et 
al., 2008). It is therefore likely that Nanog directly represses the lineage-specific 
genes downstream of Oct4XVP2. 
In summary, we think that Oct4XVP2 activate pluripotency regulators such as Nanog, 
which in turn will lead to the repression of differentiation specific genes. We can test 
this possibility by investigating whether Oct4XVP2 is able to repress differentiation 
specific gene expression in Nanog null cells. 
5.3. "Super-pluripotency" and the Oct4-Nanog linear pathway 
The Oct4XVP2 expressing cells possess characteristics of pluripotent cells. However, 
they are refractory to differentiation cues that I tested, and exhibit signs of LIF-
independent self-renewal. This makes the Oct4 activator-only cell line a "super-
pluripotent" cell line that is resistant to differentiation. This phenotype is reminiscent 
of Nanog overexpressing cells (Cavaleri and Scholer 2003; Yates and Chambers 
2005). In our cell line, Nanog is highly upregulated and its expression correlates with 
Oct4?.VP2 levels, strongly confirming that Oct4 directly regulates Nanog expression 
(Rodda et al., 2005). Strikingly, when these cells are grown in the presence of LIF, 
Nanog is the only key pluripotency gene that is upregulated by greater than 2-fold in 
comparison to wild type ES cells. Together these observations suggest that the key 
focal point in regulating the balance between self-renewal and differentiation is 
Nanog acting downstream of Oct4. To test this, careful kinetic studies on the 
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response of Nanog to Oct4 are necessary. 
The notion that Nanog is the main effector of Oct4 and other pluripotency factors is 
supported by recent findings. Nanog was shown to be essential for the maintenance 
of pluripotency in the 1CM downstream of Oct4 and other core factors and and that it 
is required downstream of the key factors responsible for induced pluripotency (Silva 
et al., 2009). Figure 5.1 illustrates the effect of Oct4XVP2 on the core pluripotency 
network in mouse embryonic stem cells. 
5.4. C-TD of PouV proteins and importance of ERK inhibition 
We found that the C-terminus of Xlpou9 1 is essential for self-renewal. Our 
bioinformatics analysis has revealed that within both the C-terminus of Oct4 and 
Xlpou91 lies a potential DEF site and ERK phosphorylation sites. Future work will 
concentrate on analysing whether Oct4 is phosphorylated by ERK and whether the 
DEF site, as well as the adjacent potential phosphorylation sites is involved in such 
regulation. A role for ERK in the regulation of Oct4 activity would be exciting, as it 
has been shown to be essential to maintain ES cells in the absence of serum or 
cytokines (Ying, Wray et al. 2008; Nichols, Silva et al. 2009). ERK inhibition also 
promotes the derivation of ES cells from recalcitrant mouse strains (Batlle-Morera et 
al., 2008) as well as rats (Buehr et al., 2008; Li et al., 2008) and increases the 
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Figure 5.1-Effect of Oct4XVP2 on the core pluripotency network in mouse 
embryonic stem cells 
In mouse ES cells, the three core pluripotency factors (Oct4. Nanog and Sox2) 
interact with each other creating a feed forward regulatory network as well as a 
feedback autoregulation loop. These core factors maintain ES cells in an 
undifferentiated state mainly by activating regulators involved in self-renewal. 
This allows the cells to self-renew while retaining their ability to respond to 
differentiation cues. 
Replacing Oct4 with its activator form (Oct4XVP2) in ES cells, leads to Nanog 
upregulation. These high levels of Nanog seem to lock the cells in a pluripotency 




Table 3.2- Gene ontology of upregulated genes in 0ct4AVP2 cell line. 
Gene ontology (GO annotations of upregulated genes in Oct4XVP2 cell line with more than 2 fold change performed by A.Sharov (NIH). 
AiTiiiU'ti:on en:eisymbls ______ 
Vnn 1,Otor,Hhip,Timp4,PrIpc2,Ambp,Grin 1,Cdh 17,Cstg,Ly6c,CbIn 1,Sez6,Tfpi,Fmol,Empl,Serpinel,Adipo 
q,Wifl,Pzp,Fxyd4,Ffar2,Wnt3a,Ptges,Crispld2,Rspo2,Gjb4,Tiel,cd2,KIkl 1,Cspg5,Sparcl 1,Gprc5b,LoxI4,Ef 
nbl,Sppl,Ptgsl,Meplb,Abpl,Pcolce2,Lgals3bp,Kdr,Apom,Frzb,ces2,crtacl,prss3s,ocgo,cyp2c2g,clqtnf 
1,Cyp2blg,Ceacam 1O,Fcgrt,Nt5e,K1k1b26,IIdrl,Edn2,Csf3r,1118r1,Mesdc,Cck,Thbd,Dct,Ang2,Angpt2,Gpr 
3711,Ifna2,Ang 1, B3gnt3,Htra 1, Plxncl,Lynxl,Lrig 1, Nid 1,1l17b,Jam4,Tex264,pdzkli pl,G ip,T1r3,Tpsg 1,Ddr 
extracellula r space 1.654 0 0 2,Cd63,Cfcl,Wnt8b,Zp3,Agrp,Proz,Unc5cl,Tgfbl,Il6ra,Ncam 1 ,Folrl,Rhbg,Msln,Vit,B3galntl,Gabrrl,Tnfrsf 
la,Mfge8,LrplO,Mmpl9,Lipc,Gjb5,Klklbl,Cdh2,Tnfrsf8,Rorl,Igfbp2,chga,zbtb7b,Acp6,omg,Igfbpl,spar 
c,Chrnb2,Mstl,Mfrp,Lefty2,Nmu,ScgS,Frk,Casr,Gd13,Sfrp5,Ces5,ftlna,Adam 19,Dpepl,Smoc2,Aoc3,Cpvl, 
Mcam,Sema3b,KitI,PIa2g 10,Galns,CIgn,KIklO,Vwf,Sst,Ephb4,Tspan 1,Col5a3,Gfra 1,Adora2b,Gpnmb,Kcnd 
1,Fnl,Crhr2,Ptpre,Sqle,Tmem8,Defcrrsl,Fblnl,Cst3,Smpdl3b,Eng,Igfbp5,sfrpl,Entpd2,col5a 1,Tff2,Ang4 
,Clr,Mrl,Mpo,Wnt6,Stc2,Vprebl,Pcskln,Spon2,Trh,Ptprj,vegfc,Ephxl,pga5, 
Vnn 1,Otor,Hhip,Timp4,Sgcz,Prlpc2,Ambp,Grin 1,Cdh 17,Cst9,Ly6c,Cblnl,Sez6,Tfpi,Fmol,Empl,Serpinel, 
Adipoq,Wifl,Pzp,Fxyd4,Ffar2,Wnt3a,Ptgeg,Crispld2,Rspo2,Gjb4,Tiel,cd2,Kjkl 1,Cspgs,Sparcl 1,Gprc5b,II 
7,LoxI4,Efnbl,Sppl,Ptgsl,Meplb,Abpl,pcolce2,LgaIs3bp,Kdr,Apom,Frzb,ceg2,crtacl,prss3s,ocgo,cyp2c 
29,Clqtnfl,Cyp2bl9,Ceacam 10,Fcgrt,Nt5e,K1k1b26,Saa2,IIdrl,Edn2,Csf3r,1118r1,Mesdc2,cck,Thbd,Dct, 
Ang2,Angpt2,Gpr371 1,Ifna2,Nov,Ang 1,B3gnt3,Htra 1,Plxncl,Lynx 1,Lrig 1,Nid 1,11 17b,Jam4,Tex264,Pdzkli 
extracellular re ion g 1 564 0 0 pl,Gip,T1r3,Tpsg 1,Ddr2,Cd63,Cfcl,Wnt8b,Zp3,Adamts4,Agrp,Proz,Unc5cI,Tgfbl,II6ra,Ncam 1,Folrl,Rhbg, 
Msln,Vit,B3gaIntl,Gabrrl,Tnfrsfla,Mfges,Lrplo,Mmplg,Lipc,Gjb5,KIklbl,cdh2,Tnfrsf8,Rorl,Igfbp2,chga 
,Zbtb7b,Acp6,Omg,Igfbpl,Sparc,Chrnb2,Fbln2,Mstl,rvlfrp,Lefty2,Nmu,scg5,Frk,casr,cdf3,sfrp5,ces5,Itl 
na,Chia,Adam 19,Dpepl,Smoc2,Aoc3,Cpvl,II 1f8,Mcam,Sema3b,KitI,Pla2g 10,Galns,CIgn,KlklO,Vwf,Sst,Ep 




3.178 0 0 Serpinblb,A2m,Timp4,Ambp,Serpinb6c,C5t9,Tfpi,serpinel,pzp,pbp2,cstl3,serpinb6b,serpinbgb,serpjnb activity . la,Plxncl,Papin,Serpinblc,Wfikkn2,vwf,Serpinb9,Lxn,cst3,pcskln, 





calcium ion binding 1.909 0 0 0c90,Gm467,Tesc,S bOa 13,Thbd,Cdh26,Nid1,Mylpf,Cabp4,Cspg2,Padi4,Proz,Pcdh8,Odz2,Megf6,Plscr2,P 
Iek,Trpa 1,Itsn 1,Cdh2,PIscrl,PcIo,Chga,Sparc,FbIn2,Mstl,Pkhd 1,Frem3,Smoc2,Scube3,PIa2g 10,CIgn,Lcpl 
.S1c25a23,FbInl,Utrn,Crb2,Tgm2,Clr,Cabp5,Anxa9,Pcdhl9,Mpo,Dhx32,Heg 1,Def6, 
serine-type endopeptidase 
3.351 0 0 
Serpinblb,Ambp,Serpinb6c,Tfpi,Serpinel,Pzp,Pbp2,Serpinb6b,Serpinb9b,Serpinbla,PIxncl,Papin,Serpin 
inhibitor activity blc,Wfikkn2,Vwf,Serpinb9,Pcskln, 
enzyme inhibitor activity 2.558 0 0 Serpinblb,A2m,Timp4,Ambp,Serpinb6c,Ppplrl4d,Cst9,Tfpi,Serpinel,Pzp,Pbp2,Cstl3,Serpinb6b,Serpinb 
9b,Serpinbla,PIxncl,Papin,Serpinblc,Wfikkn2,Vwf,Serpinb9,Lxn,Cst3,Ppplrlb,Pcskln, 
Grid2,Aqpg,Pkd2)1,Grin 1,PkdlI2,Fxyd4,Gjb4,Aqp3,Gjb3,Cacna lg,Kcna5,Kcnc4,Scn3a,CIic3,CIca 1,Grin2d, 
alpha-type channel activity 2.067 0 0 Scnn lb,Kcnn3,Ryr3,Itpr3,Kctd8,Aqp7,Gabrrl,GjbS,Trpa 1 ,Gjcl,Chrnb2,Clcnka,P2rx5,Kctd 1,Gja7,Accn3,T 
rpm6,Kcns3,Kctdl5,Kcndl,Kcnjl2,Cnga3,Kcnul, 
Grid2,Abcbl 1,Aqpg,Pkd2I 1,Ambp,Grin 1,Cdhl7,Abca4,S1c6a7,Fmol ,Pkd 112,S1c16a9,Fxyd4,SIc4al,Gjb4,A 
qp3,S1c16a5,Gjb3,SIco2bl,Rbpl,Abpl,Atpl2a,Cacna lg,Apom,Notch4,Fabp3,Atp6vOa4,Kcna5,Saa2,Abcc 
3,Nrxn3,SIcl 5a 1,Atp6vlc2,SIc5a1,Sfxn3,S1c30a2,Kcnc4,S1c4a2,SIc6a 13,Scn3a,Cygb,Robo4,Lynx1,S1c28 
transporter activity 1.536 0 0 a 1,CIic3,SIcSa4a,Cd63,S1c25a1,CIcal,Grin2d,Scnn lb,Kcnn3,Ryr3,Atp8a2,S1c7a9,Itpr3,S1c6a4,Nxf2,Folrl, 
Rhbg,Kctd8,Aqp7,S1c23a 1,S1c23a2,S1c13a5,Gabrrl,Lipc,Gjb5,Trpa 1,Gjcl,Crabp2,S1c25a20,Chrnb2,Ap3m 
2,Fabpl,Clcnka,P2rx5,RIbpl,Kctd 1,Gja7,Snxl,Slc39a4,Accn3,Abccl 1,Slco2a 1,Trpm6,Sv2c,Kcns3,Kctd 15, 
Kcnd 1,Ucp3,S1c12a7,S1c25a23,S1c5a2,S1c16a4,Kcnj 12,Slc5a4b,Cnga3,S1c36a3,Kcnu 1 ,SIc4al 1 ,Pgml,Uqc 
rcl,Atplb3, 
prostag Ia ndin metabolism 9.238 0 0 Ptges,Ptgsl,Hpgd,Tnfrsfla, 
intracellular ligand-gated 
9.238 0 0 ion_channel_activity  CIca1,Ryr3,Itpr3,Cnga3, 
prostanoid metabolism 9.238 0 0 Ptges,Ptgsl,Hpgd,Tnfrsfla, 
Abcbl 1,Aqpg,Hhip,Sgcz,Drp2,Cdhl7,Ly6c,Abca4,S1c6a7,Ly6a,Entpd3,Lim2,Kit,Edg2,SIc4a 1 ,Gjb4,Cd2,Sst 
r2,BInk,Aqp3,Thyl,Efnbl,Gjb3,Cd37,Cacna lg,Cnnm 1,Ptprb,Ggtla 1 ,Crtacl,Kcna5,Fcgrt,Fcgr2b,Ptch 1,Abc 
c3,Odz1,Slc5a1,I1 18r1,Kcnc4,S1c4a2,Thbd,Slc6a 13,Robo4,Cd3d,Cryab,Lynx1,Cd82,Icam2,)am4,Prkcq,It 
plasma membrane 1.516 0 0 gb3,S1c25a 1,CIca 1,Ap3b2,II6ra,S1c6a4,Pcdh8,Aplg2,Ncam 1,Odz2,Rhbg,Zap7O,Kctd8,Aqp7,S1c23a 1,SIcl 
3a5,Gabrrl,Tnfrsfla,Mfge8,LrplO,Gjb5,Gjcl,Cdh2,Rorl,Ptprcap,P2rx5,Cd300d,Kctd 1,Gja7,S1c39a4,Mca 
m,Accn3,Kitl,Nf2,SIco2a 1,Nfam 1,Kcns3,Kctd 15,Lcpl,Gpnmb,Kcndl,S1c12a7,Il lOrb,Ptpre,Tmem8,Rapsn, 
Utrn,Kcnj 12,Entpd2,Mrl,TIn 1,Kcnul,Vprebl,Ptprj, 
regulation of body fluids 3.943 0 0 Nfe2,Tfpi,Thbd,Proz,Mstl,Rab27a,Clcnka,Vwf,II lOrb,Entpd2, 
channel or pore class Grid2,Aqpg,Pkd2ll,Grinl,Pkdll2,Fxyd4,Gjb4,Aqp3,Gjb3,Cacnalg,Kcna5,Kcnc4,Scn3a,Clic3,Clcal,Grin2d, 
transporter activity 
1.995 0 0 Scnnlb,Kcnn3,Ryr3,Itpr3,Kctd8,Aqp7,Gabrrl,Gjb5,Trpa 1,Gjcl,Chrnb2,Clcnka,P2rx5,Kctdl,Gja7,Accn3,T 
 rpm6,Kcns3,Kctdl5,Kcndl,Kcnjl2,Cnga3,Kcnul, 
ang iogenesis 1 	3.403 0 1 	0.001 Serpinel,Tiel,Kdr,Angpt2,Robo4,Ang 1,Mmpl9,Edgl,Crhr2,Eng,Epasl,Vegfc, 
226 
Wt'tI:on IEFihThët' en:eis.yinI5Ths 
I-p 
blood vessel 
3.233 0 0.001 Serpinel,Tiel,Kdr,Angpt2,Robo4,Ang 1,Mmpl9,Edg 1,Crhr2,Eng,Epasl,Ptprj,Vegfc, 
morphogenesis  
protein polymerization 4.715 0 0.001 Tubb3,Tubb2a,Gas7,Tuba3,TubaI3,Ttl13,Tubb2b, 
connexon complex 6.218 0 0.001 Gjb4,Gjb3,Gjb5,Gjc1,Gja7, 
connexon channel activity 6.218 0 0.001 Gjb4,Gjb3,Gjb5,Gjcl,Gja7, 
gap-junction forming 
6.218 0 0.001 
channel_activity  
Gjb4,Gjb3,Gjb5,Gjc1,Gja7, 
structural constituent of 
eye_lens  
6.218 0 0.001 Li m 2, C ryg e, C ryg f, C rya b, C ryg b, 
hemostasis 3.829 0 0.002 III  lOrb,Entpd2, 
cell growth 3.355 0.00011 0.002 Empl,Fh$ 1,Nov,Htra 1,Tgfb1,Igfbp2,Igfbp1,Lefty2,Socs7,Creg 1,Igfbp5, 
Otor,Hhip,My17,Tnnt2,Serpinel,Hesxl,Lim2,Kit,En 1,Phex,Wnt3a,Efhb,Tiel,Myom2,117,Sppl,Pax7,Kdr,Ptc 
organ development 1.627 0.0001 0.002 h 1,Mybpc3,Fhl 1,Atohl,SIc5al,Angpt2,Hoxb6,Robo4,Ang 1 ,Cryab,Crygb,Mylpf,1d3,Sfpi 1,Wnt8b,Adamts4,T 
gfbl,Hoxcl2,Zap7O,Mmpl9,Hspb2,Chat,Mitf,Edg 1,Rpgripl,Pkhdl,Cxcr4,Adam 19,Gadd45g,Hmgb3,Nfam 
1,Pax6,Sox9,Myodl,Crhr2,Utrn,Eng,Wnt6,Vprebl,Vdr,Csrp3,Epasl,Smyd 1,Ptprj,Vegfc, 
icosanoid metabolism 4.85 0.0001 0.003 Aloxl2e,Ptges,Ptgsl,GgtIal,Hpgd,Tnfrsfla, 
regulation of cell size 3.175 0.0002 1 	0.004 Empl,FhI 1,Nov,Htra 1,Tgfb1,Igfbp2,Igfbp1,Lefty2,Socs7,Creg1,Igfbp5, 
Grid2,Grinl,Cblnl,Fmol,CaIm4,Ptges,Sstr2,Ptgsl,Cacnalg,Cyp2c29,Cyp2b19,Fads2,Cd38,Cryab,Lnpep, 
cell fraction 1.94 0.0002 0.004 Lynxl,CIic3,Dad 1,A4gaIt,FoIrl,Dgat2,UIk1,Hspb2,Chrnb2,Drd la,Rac2,Dpepl,Cyp2c37,Cpne6,Utrn,H6pd, 
Ephxl,Pga5, 
regulation of lymphocyte 
3.804 0.0002 0.004 
activation  
117,Efnbl,Fcgr2b,Prkcq,Tgfbl,Zap7O,Hmgb3,Nfaml, 
regulation of cell activation 3.804 0.0002 0.004 117,Efnbl,Fcgr2b,Prkcq,Tgfbl,Zap7O,Hmgb3,Nfaml, 
response to wounding 2.209 0.0003 0.005 Tfpi,Ggtla 1,Fcgr2b,Csf3r,Thbd,Rel,Il 17b,Prkcq,T1r3,Proz,Tgfbl,Tnfrsfla,Mstl,Rab27a,Ccr4,Il 1f8,Gadd45g 
,Vwf,Lcpl,Fn 1,IIlOrb,Entpd2, 
regulation of cell migration 4.042 0.0003 0.005 Tiel,Robo4,Itgb3,Cxcr4,Sst,Pax6,Lamal, 
blood vessel development 2.765 0.0003 0.006 Serpinel,Tiel,Kdr,Angpt2,Robo4,Angl,Mmpl9,Edgl,Crhr2,Eng,Epasl,ptprj,vegfc, 
striated muscle thick 
8.084 0.0004 0.006 
filament  
Myom2,Mybpc3,Obscn, 
A band 8.084 0.0004 0.006 Myom2,Mybpc3,Obscn, 
photoreceptor cell 
development 





response to external 
1.961 0.0004 0.006 
Pdcl2,Tfpi,Kit,Ggtla 1,Fcgr2b,Csf3r,Thbd,ReI,1117b,Prkcq,Tlr3,Proz,Tgfb1,Tnfrsf1a,Mstl,Rab27a,Ccr4,Rac2 
stimulus ,Cxcr4,Cxcr3,II 1f8,Accn3,Gadd45g,Vwf,Lcpl,Fn 1,11 lOrb,Utrn,Entpd2, 
inorganic anion exchanger 
8.084 0.0004 0.006 
activity  
Slc4al,Slc4a2,Slc4all, 
regulation of B cell 
activation 
5.052 0.0004 0.006 117,Fcgr2b,Tgfbl,Hmgb3,Nfaml, 
insulin-like growth factor 
5.052 0.0004 0.005 
binding  
Nov,Htral,Igfbp2,Igfbpl,!gfbp5, 
gap junction 5.052 0.0004 0.005 Gjb4,Gjb3,Gjb5,Gjcl,Gja7, 
lymphocyte proliferation 3.902 0.00041 0.006 117,Efnbl,Fcgr2b,Prkcq,Zap7O,Cxcr4,Ccnd3, 
regulation of cell motility 3.902 0.0004 0.006 Tiel,Robo4,Itgb3,Cxcr4,Sst,Pax6,Lamal, 
vasculature development 2.694 0.0005 0.007 Serpinel,Tiel,Kdr,Angpt2,Robo4,Angl,Mmpl9,Edgl,Crhr2,Eng,Epasl,Ptprj,Vegfc, 
UDP-galactosyltransferase 
5.879 0.0005 0.007 
activity  
Abo,A4galt,B3gaIntl,Wdfy3, 
regulation of lymphocyte 
5.879 0.0005 0.006 
differentiation  
117,Zap7O,Hmgb3,Nfaml, 
membrane fraction 1.929 0.0005 0.007 Grid2,Grin 1,Cbln 1,Fmol,Ptges,Sstr2,Ptgs1,Cacna lg,Cyp2c29,Cyp2bl9,Fads2,Cd38,Lnpep,Lynx1,Clic3,D 
adl,A4galt,Folrl,Dgat2,Ulkl,Chrnb2,Drd la,Rac2,Dpepl,Cyp2c37,Cpne6,Utrn,H6pd,Ephxl, 
blood coagulation 3.495 0.0006 0.007 Tfpi,Thbd,Proz,Mstl,Rab27a,Vwf,Il lOrb,Entpd2, 
Hhip,Empl,Serpinel,En 1,Wnt3a,Tiel,Nr2e3,Efnbl,Pax7,Kdr,Ptch 1,Fhll,Atoh 1 ,Cck,Angpt2,Hoxb6,Nov,Ro 
morphogenesis 1.599 0.0006 0.007 bo4,Angl,Htral,Chll,1d3,Wnt8b,Tgfbl,Hoxcl2,Gas7,Pcdh8,Ulkl,Mmpl9,Igfbp2,Igfbpl,Edgl,Lefty2,Rpgr 
ipl,Rac2,Adam 19,Socs7,Plekhcl ,Lhxl,Pax6,Wasl,Gfra 1,Sox9,Lama1,Crhr2,Eng,Creg 1,Igfbp5,Snai 1,Wnt 
6,Vdr,Epasl,Smyd 1,Ptprj,Vegfc, 
Oasld,Ly6c,Oaslb,Cd2,Blnk,1l7,Gbp4,Efnbl,Oas2,Ggtla 1,Fcgrt,Fcgr2b,Saa2,Csf3r,Oaslc,Ifna2,Oasle,Re 
response to biotic stimulus 1.647 0.0006 0.007 1,11 17b,Prkcq,Tlr3,Sfpi 1,Tnfrsfl4,Tgfbl,Zap7O,Tnfrsfla,Oaslh,Tnfsfl8,Ccr4,Tcea3,Cxcr4,Itlna,Cxcr3,fl 1f8 
,Cfp,Gadd45g,Hmgb3,Nfam 1,Wasl,Fn 1,Ccnd3,Defcr-rsl,Ang4,Oasl2,Clr,Mrl,Vprebl,Spon2, 
wound healing 3.163 0.0008 0.009 Tfpi,Thbd,Proz,Mstl,Rab27a,Vwf,Fn 1,11 1Orb,Entpd2, 
regulation of locomotion 3.65 0.0009 0.01 Tiel,Robo4,Itgb3,Cxcr4,Sst,Pax6,Lamal, 
coagulation 3.316 0.001 0.011 Tfpi,Thbd,Proz,Mstl,Rab27a,Vwf,I110rb,Entpd2, 
positive regulation of 
lymphocyte_proliferation 
5.389 0.001 0.011 117,Efnbl,Prkcq,Zap7O, 
response to drug 5.389 0.001 t 	0.011 Phfll,Dl4Ertd668e,Abpl,Drdla, 
228 
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Oasld,Ly6c,Oaslb,Cd2,Blnk,117,Gbp4,Efnbl,Oas2,Ggtla 1,Fcgrt,Fcgr2b,Saa2,Csf3r,Oaslc,Ifna2,Oasle,Re 




6.929 0.001 0.011 Tt116,Tt113,TtI, 
regulation of angiogenesis 6.929 0.001 0.011 Serpine1,Tie1,Crhr2, 
water channel activity 6.929 0.001 0.01 Aqp9,Aqp3,Aqp7, 
Oasld,Oaslb,1l7,Gbp4,Efnbl,Oas2,Ggtla 1,Fcgrt,Fcgr2b,Saa2,Csf3r,Oaslc,Oasle,ReI,II 17b,Prkcq,T1r3,Sf 
immune response 1.699 0.0012 0.011 p1 1,Tnfrsfl4,Tgfbl,Zap7O,Tnfrsfla,Oaslh,Tnfsfl8,Ccr4,Cxcr4,II 1f8,Cfp,Gadd45g,Hmgb3,Nfam 1,Fn 1,Ccn 
d3,Ang4,OasI2,Clr,Mrl,Vprebl,Spon2, 
Grid2,Pkd2I 1,Grin 1,Abca4,S1c6a7,Pkd1I2,Fxyd4,Slc4a 1,Atpl2a,Cacna 1g,Notch4,Atp6vOa4,Kcna5,Atp6v1 
ion transporter activity 1.566 0.0013 0.012 
c2,SIc5a 1,Sfxn3,S1c30a2,Kcnc4,S1c4a2,SIc6a 13,Scn3a,S1c28a 1,C11c3,CIca 1,Grin2d,Scnn lb,Kcnn3,Ryr3,At 
p8a2,Itpr3,S1c6a4,Rhbg,Kctd8,S1c23a2,Gabrrl,Trpa 1,Chrnb2,Clcnka,P2rx5,Kctd 1,Slc39a4,Accn3,Trpm6, 
Kcns3,Kctd 15,Kcndl,S1c12a7,Kcnj 12,Cnga3,Kcnu 1,SIc4a 1 1,Ugcrcl,Atplb3, 
oxidoreductase activity, 
acting on the CH-OH group 
of donors, NAD or NADP as 
2.502 0.0013 0.012 Akrlcl8,Hsdl7b2,Hpgd,Ldhal6b,Idh2,Rnasel,Akrlcl3,Akrlb7,Me3,Tdh,Gpdl,I-I6pd,Adhl, 
acceptor  
extracellular matrix 1.959 0.0013 0.012 
Timp4,Sgcz,Wnt3a,Sparcll,0c90,Adamts6,Nidl,Papin,Zp3,Adamts4,Tgfbl,Mmpl9,Sparc,FbIn2,Adaml9, 
Smoc2,Vwf,Co15a3,Fnl,Lama 1,Fbln 1,Entpd2,Col5a 1,Spon2, 
growth factor binding 3.429 0.0015 0.014 111r12,Nov,Htral,Igfbp2,Igfbpl,1I10rb,Igfbp5, 
growth 2.382 0.0016 0.015 Empl,Ptchl,FhIl,Nov,Htral,Tgfbl,Igfbp2,Igfbpl,Lefty2,Gdf3,Socs7,Lgmn,Cregl,IgfbpS, 
enzyme linked receptor 
2.104 0.0017 0.015 
Hhip,Kit,Rspo2,CInk,Kdr,Ptprb,Smad6,Angpt2,Htra 1,Ddr2,Erbb3,Tgfb1,Ptprcap,Wfikkn2,Ephb4,Gfra1,Ptp 
protein signaling pathway  re,Eng,Ptpri, 
ligand-gated ion channel 
2.552 0.0017 0.014 
activity  
Grid2,Grin 1,CIca 1,Grin2d,Scnn 1b,Ryr3,Itpr3,Gabrrl,Chrnb2,P2rx5,Accn3,Cnga3, 
lymphocyte activation 2.552 0.0017 0.014 117,Efnbl,Fcgr2b,Prkcq,Sfpil,Tgfbl,Zap7O,Cxcr4,Gadd4sg,Hmgb3,Nfam 1,Ccnd3, 
Grid2,Pkd2Il,Grinl,C1q13,Adipoq,Pkd 112,Lim2,Fxyd4,Slc4al,Slco2bl,Atpl2a,Cacna lg,Atp6vOa4,Clqtnfl, 
ion transport 1.523 0.0017 0.014 
Kcnas,Atp6vlc2,SIc5a 1,Sfxn3,S1c30a2,Kcnc4,S1c4a2,Scn3a,Clic3,Clca 1,Grin2d,Scnnlb,Kcnn3,Ryr3,Atp8 
a2,Itpr3,Kctd8,S1c23a1,Slc23a2,S1c13a5,Gabrrl,Trpa 1,Tst,Chrnb2,Clcnka,P2rx5,Kctd 1,S1c39a4,Accn3,Tr 












ion channel activity 1.764 0.002 0.016 pr3,Kctd8,Gabrrl,Trpal,Chrnb2,Clcnka,P2rx5,Kctdl,Accn3,Trpm6,Kcns3,Kctd 15,Kcnd 1,Kcnj 12,Cnga3,Kc 
nul, 
muscle development 2.333 0.0021 0.017 Myl7,Tnnt2,Efhb,Myom2,Mybpc3,Fhl 1,Cryab,Mylpf,Tgfb1,Hspb2,Chat,Myod 1 ,Utrn,Csrp3, 
fatty acid metabolism 2.266 0.0021 0.016 AIoxl2e,Adipoq,Ptges,Scdl,Ptgsl,Acoxl,Ggtlal,Fads2,Hpgd,Tnfrsfla,Slc27a3,Fadsl,Ucp3,Prkagl,Scap, 
water transporter activity 6.063 0.0023 0.018 Aqp9,Aqp3,Aqp7, 
carbon-nitrogen ligase 
activity, with glutamine as 6.063 0.0023 0.017 Cpsl,Gdpd2,Gpnmb, 
amido-N-donor  
anion exchanger activity 6.063 0.0023 0.017 SIc4al,Slc4a2,SIc4a11, 
water transport 6.063 0.0023 0.017 Aqp9,Aqp3,Aqp7, 
anion:anion antiporter 
6.063 0.0023 0.017 
activity  
Slc4a1,S1c4a2,Slc4a1 1, 
pregnancy 6.063 0.0023 0.017 Thbd,Mstl,SuItlel, 
bicarbonate transporter 
6.063 0.0023 0.017 
activity  
SIc4al,S1c4a2,90all, 
fluid transport 6.063 0.0023 0.017 Aqp9,Aqp3,Aqp7, 
eye development (sensu 
4.042 0.0024 0.017 
Vertebrata)  
L1m2,Cryab,Crygb,Mitf,Pax6, 
regulation of lymphocyte 




4.042 0.0024 0.017 
activity  
Abo,B3gnt3,A4galt,B3galntl,Wdfy3, 
Pkd2l 1,Grin 1,Abca4,S1c6a7,Pkd 112,Atpl2a,Cacna lg,Notch4,Atp6vOa4,Kcna5,Atp6vlc2,SIc5a 1,Sfxn3,Slc3 
cation transporter activity 1.601 0.0024 0.017 0a2,Kcnc4,S1c6a13,Scn3a,S1c28a1,Scnn lb,Kcnn3,Ryr3,Atp8a2,Itpr3,S1c6a4,Rhbg,Kctd8,S1c23a2,Trpal,C 
hrnb2,P2rx5,Kctd 1,S1c39a4,Accn3,Trpm6,Kcns3,Kctd 15,Kcndl,Slc12a7,Kcnj 12,Cnga3,Kcnu 1,Uqcrcl,Atp 
1b3, 
nucleotide catabolism 4.619 0.0029 0.02 Entpd3,Nt5e,Uppl,Entpd2, 
transmembrane receptor 





cell adhesion 1.62 0.0032 0.021 cdh8,Ncaml,Mfge8,Cdh2,Omg,Edgl,Frem3,Aoc3,Prtg,Mcam,K1U,Crim2,Plekhcl,Vwf,Co15a3,Gpnmb,Fnl, 
Lama 1,Tmem8,Eng,CoI5a 1,Pcdh19,Spon2, 
cytokine binding 2.745 0.0034 0.022 111r12,II 18r1,II6ra,Tnfrsfla,Tnfrsf8,Ccr4,Cxcr4,Cxcr3,IIlOrb, 
I cell proliferation 3.849 0.0034 0.023 Efnbl,Prkcq,Zap70,Cxcr4,Ccnd3, 
interaction between 
3.849 0.0034 0.022 Edn2,Thbd,Mst1,Sult1e1,Ppp1r1b, 
organisms  
cation channel activity 1.839 0.0037 0.024 Pkd2I 1,Grin 1,Pkd 112,Cacna lg,Kcna5,Kcnc4,Scn3a,Scnn lb,Kcnn3,Ryr3,Itpr3,Kctd8,Trpa 1,Chrnb2,P2rx5, 
Kctd 1,Accn3,Trpm6,Kcns3,Kctd 1 5,Kcnd 1,Kcnj 12,Cnga3,Kcnu 1, 
oxidoreductase activity, 
acting on CH-OH group of 2.284 0.004 0.025 Akrlcl8,Hsdl7b2,Hpgd,Ldhal6b,Idh2,Rnasel,Akrlcl3,Akrlb7,Me3,Tdh,Gpdl,H6pd,Adhl, 
donors  
AIoxl2e,Adipoq,Ptges,Scd 1,Gjb3,Ptgsl,Creg2,Slc45a2,Acoxl,Ggtla 1,Fads2,Aspa,Cpsl,Dct,Nr5a2,Urocl,B 
organic acid metabolism 1.645 0.004 0.025 aat,Hpgd,FoIrl,Ktnl,Slc23a2,Tnfrsfla,Idh2,S1c27a3,Fadsl,Hal,Kitl,Tdo2,Ucp3,GIuI,Me3,Gpdl,Prkagl,sca 
p,Cdol, 
Aloxl2e,Adipoq,Ptges,Scdl,Gjb3,Ptgsl,Creg2,S1c45a2,Acoxl,Ggtla 1,Fads2,Aspa,Cpsl,Dct,Nr5a2,Urocl,B 
carboxylic acid metabolism 1.645 0.004 0.025 aat,Hpgd,Folrl,Ktn 1,S1c23a2,Tnfrsfla,Idh2,Stc27a3,Fadsl,Hal,Kitl,Tdo2,Ucp3,Glul,Me3,Gpd 1,Prkagl,Sca 
p,Cdol, 
tissue kallikrein activity 5.389 0.0045 0.027 K1k1b26,KIk1b1,K1k1b24, 
photoreceptor cell 





5.389 0.0045 0.027 Thbd,Mstl,SuItlel, 
extracellular matrix (sensu 
1.862 0.0046 0.028 Timp4,Sgcz,Wnt3a,Sparcl 1,0c90,Nid 1,Zp3,Adamts4,Tgfbl,Mmpl9,Sparc,FbIn2,Adam 19,Smoc2,Vwf,Co15 
Metazoa) a3,Fn1,Lama1,FbIn1,Entpd2,CoI5a1,Spon2, 
serine-type peptidase 
1.886 0.0048 0.029 
Tmprss7,Serpinel,Klkl 1,Tmprssl ld,Prss3S,K1k1b26,Odzl,Htra 1,Tpsg 1,Rimbp2,Proz,Klklbl ,Tmprss5,Ms 
activity tl,CpvI,K1k1b24,CIgn,KIklO,K1k13,C1 r,Prep, 
serine-type endopeptidase 
1.944 0.005 0.03 
Tmprss7,Serpinel,KIkll,Tmprsslld,Prss35,K1k1b26,Odzl,Htral,Tpsgl,Proz,KIklbl,Tmprsss,Mstl,KIklb 
activity  24,CIgn,KIk1O,K1k13,C1r,Prep, 
phospholipid binding 2.978 0.0052 0.031 Hipl,Plekha2,Sytl4,Mfge8,Pclo,Cpne6,Anxag, 
heparin binding 2.978 0.0052 0.031 Abpl,Pcolce2,Ncaml,Lipc,Gpnmb,Fnl,CoI5al, 
transmembrane receptor 
protein_kinase_activity 
2.598 0.0056 0.033 Kit,Rspo2,Kdr,Ly6g6e,Ddr2,Erbb3,Ncam 1,Ror1,Ephb4, 
231 
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cellular morphogenesis 1.788 0.0057 0.033 Empl,Wnt3a,Nr2e3,Efnb1,FhI1,Cck,Nov,Htra1,ChI1,Tgfb1,Gas7,uikl,Igfbp2,Igfbpl,Lefty2,Rpgrjp1,Rac2, 
Socs7,Plekhc1_,Pax6,Wasi,Lama 1,Creg 1,Igfbp5, 
immune cell activation 2.282 0.0057 0.033 1i7,Efnbl,Fcgr2b,Prkcq,Sfpil,Tgfbl,Zap7O,Cxcr4,Gadd45g,Hmgb3,Nfam 1,Ccnd3, 
cell activation 2.256 0.0064 0.037 117,Efnbl,Fcgr2b,Prkcq,Sfpil,Tgfbl ,Zap7O,Cxcr4,Gadd45g,Hmgb3,Nfam 1,Ccnd3, 
glutathione transferase 
activity 
4.042 0.0067 0.038 Gsta3,Gstp1,Gsta2,Gsto1, 
Aloxl2e,Abca4,St8sia6,Pla2g4e,Adipoq,Ptges,Scd 1,Akrlcl8,Hsd 17b2,Ptgsl,Acoxl,Ggtlal,Fabp3,Fads2,Nr 
cellular lipid metabolism 1.632 0.0069 0.039 5a2,Baat,Hpgd,A4gaIt,Dgat2,Tnfrsfla,S1c27a3,Fadsl,SuItlel,OsbpIlO,Akrlb7,ucp3,pla2g4d,pmvk,pjp5k 
2b,Prkag 1,Scap,Adh 1, 
trypsin activity 2.055 0.0069 0.039 
Tmprss7,Klkll,Tmprsslld,Prss3S,K1k1b26,Htral,Tpsgl,Proz,Klklbl,Tmprsss,Mstl,Kikj.b24,Klklo,Klkl3 
.Clr, 
cell-cell signaling 1.835 0.007 0.038 Grid2,Grinl,Wnt3a,Gjb4,Gjb3,Grap,Naalad2,Nrxn3,Lynxl,Wnt8b,Gabrrl,Chat,Gjb5,pcIo,Chrnb2,Drdla,G 
1a7,Sv2c, Dig 7, Rapsn,Wnt6, 
chloride transporter activity 4.85 0.0079 0.043 Sic4a1,Slc4a2,Sic4a1 1, 
sym porter activity 2.377 0.0081 0.044 S1c6a7,Slcl5a 1,SicSal,Sic6a 13,S1c28a 1,S1c6a4,S1c23a 1,S1c23a2,S1c12a7,Slc5a2, 
cell surface 2.28 0.0082 0.044 Hhip,Ly6c,Ly6a,Kit,Thyl,Fcgr2b,Robo4,Jam4,Itgb3,Mfge8,Nfaml, 
T cell activation 2.76 0.0094 0.05 117,Efnbl,Prkcq,Zap7O,Cxcr4,Gadd45g,Ccnd3, 
Aloxl2e,Abca4,St8sia6,PIa2g4e,Adipoq,Ptges,Sccj 1,Akrlcl8,Hsd 17b2,Ptgsl,Acoxi,Ggtia 1 ,Fabp3,0c90,Fa 
lipid metabolism 1.532 0.0101 0.053 ds2,AIdhla3,Cidea,Nr5a2,Baat,Hpgd,A4gaIt,Dgat2,Tnfrsfla,LrplO,L.ipc,Slc27a3,Fadsl,suftlel,osbpllo,p 
ia2g 10,Akrlb7,Ucp3,Pia2g4d,Pmvk,Pip5k2b,Prkag 1,Scap,Adh 1, 
regulation of immune 
2.425 0.0102 0.054 117,Efnbl,Fcgr2b,Rel,Prkcq,Tgfbl,Zap7O,Hmgb3,Nfaml, 
response 
metal ion transport 1.611 0.0124 0.064 Grinl,Lim2,Atpl2a,Cacnalg,Kcna5,SicSal,Sfxn3,Kcnc4,Scnnlb,Kcnn3,Itpr3,Kctcj8,sic23a1,s1c23a2,slcl 
3a5,Kctdl,Sic39a4,Accn3,Trpm6,Kcns3,Kctd 15,Kcnd 1,S1c12a7,S1c5a2,Kcnj 12,Cnga3,Kcnu 1,Vdr,Atplb3, 
positive regulation of T cell 




4.409 0.0126 0.065 
development  
Kit,S1c45a2,Dct, 
pigmentation 4.409 0.0126 0.065 Kit,S1c45a2,Dct, 
Pkd2i 1,Grinl,Pkd 112,L1m2,Atpl2a,Cacna lg,Atp6vOa4,Kcna5,Atp6vlc2,Sicsa 1,Sfxn3,Slc3Oa2,Kcnc4,Scn3 
cation transport 1.509 0.013 0.066 a,Scrinlb,Kcnn3,Ryr3,Atp8a2,Itpr3,Kctd8,slc23a 1,Slc23a2,S1c13a5,Trpa 1,Kctd 1,S1c39a4,Accn3,Trpm6,K 
cns3,Kctd 15,Kcnd 1,S1c12a7,SicSa2,Kcnj 12,Cnga3,Kcnul,Vdr,Atplb3, 




0.0132 0.067 Map3k6,Gadd45g,Nrk,Irak2, 
232 
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secretory granule 3.592 0.0132 0.066 SytI4,Scg5,Ang4,Pcsk1n, 
positive regulation of 
3.592 0.0132 0.066 
protein_kinase_activity  
Map3k6,Gadd45g,Nrk,Irak2, 
fatty acid biosynthesis 2.632 0.0134 0.066 Aloxl2e,Scdl,Ptgsl,GgtIal,Fads2,Fadsl,Prkagl, 
positive regulation of cell 
activation  
3.109 0.0142 0.069 117,Efnbl,Prkcq,Tgfbl,Zap7O, 
positive regulation of 
lymphocyte_activation 
3.109 0.0142 0.069 117,Efnbl,Prkcq,Tgfbl,Zap7O, 
oxidoreductase activity, 
acting on paired donors, 
with incorporation or 2.064 0.0153 0.074 Fmol,Scd 1,Cyp2a4,Ptgs1,Cyp2c29,Cyp2b19,Fads2,Nos1,Fads1,Cyp24a1,cyp2c37,sqIe, 
reduction of molecular 
oxygen  
polysaccharide binding 2.309 0.0153 0.074 Abpl,Pcolce2,Cspg2,Ncaml,Lipc,Chia,Gpnmb,Fnl,CoI5al, 
solute:sodium symporter 
2.771 0.0159 0.077 
activity  
S1c6a7,SIc5a 1,S1c6a13,S1c28a 1,Slc6a4,S1c23a2, 
glycosaminoglycan binding 2.395 0.0171 0.081 Abpl,Pcolce2,Cspg2,Ncaml,Lipc,Gpnmb,Fnl,CoI5al, 
neuropeptide signaling 
2.273 0.0174 0.082 
pathway  
Pamci,Pkd1I2,Gprl 16,Sstr2,Agrp,Mchrl,Nmu,Scg5,Rassf2, 
carbohydrate binding 1.685 0.0175 0.081 Pkd 112,Siglecf,Clec4a3,Abpl,Pcolce2,Ptprb,CIec4a 1,Thbd,Cd209d,Lman ll,Cspg2,Asb2,Asgr2,Ncam 1,Lipc, 
Itlna,Chia,Fbxo2,Gpnmb,Fnl,Ccnd3,Col5a 1, 
aromatic amino acid family 
metabolism  
3.403 0.0177 0.081 S1c45a2,Dct,Ktnl,Tdo2, 
organ morphogenesis 1.549 0.0193 0.087 Hhip,Serpinel,Wnt3a,Tiel,Pax7,Kdr,Ptchl,Atohl,Angpt2,H0xb6,Robo4,Angl,1d3,wnt8b,Tgfbl,Hoxc12,M 
mplg,Edg 1,Rpgripl,Adam 19,Pax6,Sox9,Crhr2,Eng,Wnt6,Vdr,Epasl,Smyd 1,Ptprj,Vegfc, 
external side of plasma 
membrane 
2.351 0.0195 0.088 Ly6c,Ly6a,Kit,Thyl,Fcgr2b,Robo4,Itgb3,Mfge8, 
pattern binding 2.238 0.0196 0.088 Abpl,Pcolce2,Cspg2,Ncaml,Lipc,Chia,Gpnmb,Fnl,CoI5al, 
regulation of growth 2.238 0.0196 0.088 Ptch 1,Nov,Htra 1,Igfbp2,Igfbp1,Socs7,Lgmn,Creg 1,Igfbp5, 
carboxylic acid biosynthesis 2.46 0.0215 0.095 Atoxl2e,Scdl,Ptgsl,GgtIal,Fads2,Fadsl,Prkagl, 
organic acid biosynthesis 2.46 0.0215 0.095 AIoxl2e,Scdl,Ptgsl,GgtIal,Fads2,Fadsl,Prkagl, 
nucleotide receptor 
2.309 0.0223 0.097 
activity, G-protein coupled  
Ffar2,Sstr2,Sstr4,Gprl5,Bdkrb2,Cxcr4,Cxcr3,Adora2b, 
233 
IE-hl  _ 
purinergic nucleotide 
receptor activity, G-protein 2.309 0.0223 0.097 Ffar2,Sstr2,Sstr4,Gprl5,Bdkrb2,Cxcr4,Cxcr3,Adora2b, 
coupled  
purinergic nucleotide 
2.309 0.0223 0.097 Ffar2,Sstr2,Sstr4,Gprl5,Bdkrb2,Cxcr4,Cxcr3,Adora2b, 
receptor_activity 
nucleotidereceptoractivity 2.309 0.0223 0.097 Ffar2,Sstr2,Sstr4,Gprl5,Bdkrb2,Cxcr4,Cxcr3,Adora2b, 
eyedevelopment 2.621 0.0226 0.098 Lim2,Cryab,Crygb,Mitf,Rpgripl,Pax6, 
lymphocytedifferentiation 2.621 0.0226 0.098 117,Sfpil,Zap7O,Gadd45g,I-Imgb3,Nfaml, 
cellmigration 1.837 0.0227 0.097 Tiel,Efnbl,Kdr,Csf3r,Cck,Robo4,1117b,ChIl,Itgb3,Cdh2,Lmxlb,Cxcr4,Sst,Pax6,Lamal, 
positive regulation of T cell 
3.233 0.0232 0.098 
activation  
117,Efnbl,Prkcq,Zap7O, 
eye development (sensu 




Table 3.3- Gene ontology of downregulated genes in Oct4?%.VP2 cell line. 
Gene ontology (GO) annotations of downregulated genes in Oct4?VP2 cell line with more than 2 fold change performed by A.Sharov 
(NIH) 
A'ottin 
transcription factor activity 2.27 0 0 




1,Dmrt2,Cebpb,Ar,Irx3,Onecutl,D1x4,Hoxa7,Mkx,Asb4,Emxl,Runxltl,Satbl,Hoxb4,Hand 1,Dmrt3,Foxq 1 
,Irx2,Spib,Gata5,Tafl3,Nr4a2,Ipfl,Lefl,Foxl2,Foxc2,Rai 14,Irf8,Dmrtbl,Irx5,Jundl,Nr2cl,Pou3f3,Hes6,B 
arxl,Trim30,En2,Invs,Gbx2,Nr2fl,Apol6,EIfl,Lhx2,Proxl,Tbx6, 
Rhoxl 1,Egrl,Cart1,Hod,Trpv6,Asb9,Foxd 1,Foxc1,Id1,Sox4,Egr2,Wtl,Stat4,Esrrg,Gata4,Meis1,Tcfec,Gat 
a6,GrhI2,Trpc3,Zfpm2,PouSfl,Gata3,Soxl7,Hmx3,Msxl,Foxgl,Jun,Ovoll,1s12,Hlf,Lyll,1d2,Mpdz,Ripk4,R 
xrg,Thrb,Hlxb9,Emx2,Tbxl5,Grm 1,Ilmxl,Trpc7,Atf5,Pou6fl,Foxa3,Vax2,Nkxô- 
transcri tion re 	ulator activit g 1 964 0 0 
3,Tbx2l,Bach2,Nabl,Foxpl,RhoxlO,BcI6b,Foxf2,Ncoa2,Tsc22d3,Nkx3- 
1,Bcl 1 la,Dmrt2,Cebpb,Ar,Irx3,Onecutl,Dlx4,Hoxa7,Mkx,Asb4,Emxl,Runxltl,Satbl,Hoxb4,Hand 1,Dmrt 
3,Foxq 1,Irx2,Spib,Gata5,Tafl3,Nr4a2,Ipfl,Lefl,FoxI2,Foxc2,Rai 14,Irf8,Dmrtbl,Irx5,Jund 1,Nr2cl,Pou3f3 
,I-les6,Barx1,Ptrf,Trim30,AscI2,Rest,En2,Invs,Gbx2,Nr2f1,Apol6,Rnf6,Elf1,Wwtrl,Lhx2,Prox1,Gtf2a llf,Tb 
x6, 
Rhoxi 1,Egrl,Cartl,Hod,Trpv6,Asb9,Foxd 1,11 1O,Foxcl,Egr4,Id 1,Ms131,Sox4,Igfbp3,Xdh,Egr2,Rnf128,Wtl 














Rhoxi 1,Egrl,Cartl,Hod,Trpv6,Asb9,Foxd 1,11 10,Foxc1,Egr4,Id 1,Ms13 1,Sox4,Egr2,Rnf128,Wtl,Stat4,Esrrg 
,Gata4,Meisl,Tcfec,Ptx3,Gata6,GrhI2,Trpc3,Zfpm2,Pou5f1,Gata3,Soxl7,Hmx3,Msxl,Foxgl,Jun,Ovol 1,L 
mo4,1s12,Hlf,LyI 1,1d2,Mpdz,Fosl1,Ripk4,Rxrg,Pogk,Cpebl,Sfrp4,Thrb,Hlxb9,Emx2,Tbx15,Grm 1,Hmx1,Trp 
c7,Atf5,Pou6f1 ,Foxa3,Vax2, Nkx6- 
re ulation of metabolism g 1 677 0 0 
3,Tbx2 1,Bach2,Nabl,Foxpl ,Rfxdcl,RhoxlO,Fhl2,Bcl6b,Foxf2,Ncoa2,Tsc22d3,Nkx3- 
1,Bcl 1 la,Dmrt2,Cebpb,Ar,1l3,Irx3,Shh,Gsn,Zf,Onecutl,II lb,D1x4,Bncl,Prdm8,Hoxa7,Mkx,Cebpd,Asb4,E 
mxl,Runxltl,Satbl,Zfp94,Egf,l-loxb4,l-land 1,Kcnh8,Dmrt3,Foxq1,Zfp422,ScmI2,Irx2,Zfp52,Spib,K1f3,Ga 
ta5,Prkca,Tafl3,Zfp64 1,Nr4a2,Ipfl,Shprh,Cebpg,Lefl,Foxl2,Foxc2,Rai 14,Prkce,Sirt4,Irf8,Klf7,Dmrtbl,Irx 
5,Jund 1,Rabl5,Nr2cl,Pou3f3,Hes6,Barxl,Ptrf,Cebpa,K1f6,Trim3O,Ascl2,Kcnh5,Rest,En2,Invs,Gbx2,Zfp54 
g Nr2fl,ApoI6,Rnf6,EIfl,Per2,Wwtrl,Lhx2,Proxl,Rem2,Phfl9,Gtf2alIf,Nsbpl,Setbpl,Marcks,Tbx6, 
Rhoxl 1,Egrl ,Cartl,Hod,Trpv6,Asb9,Foxd 1,11 1O,Foxcl,Egr4,Id 1,Ms13 1,Sox4,Egr2,Rnf128,Wtl,Stat4,Esrrg 
,Gata4,Meisl,Tcfec,Gata6,GrhI2,Trpc3,Zfpm2,Pou5fl,Gata3,Soxl7,Hmx3,Msxl,Foxgl,Jun,OvoI 1,Lmo4,Is 
12,Hlf,Lyl 1,1d2,Mpdz,Fosl 1,Ripk4,Rxrg,Pogk,Cpebl,Sfrp4,Thrb,Hlxbg,Emx2,Tbxl5,Grm 1,Hmxl,Trpc7,Atf5 
,Pou6fl,Foxa3,Vax2,Nkx6- 
regulation of cellular 
1.679 0 0 
3,Tbx2l,Bach2,Nabl,Foxpl,Rfxdcl,RhoxlO,Fh12,Bcl6b,Foxf2,Ncoa2,Tsc22d3,Nkx3- 
metabolism . 1,Bcl 1 la,Dmrt2,Cebpb,Ar,113,Irx3,Zf,Onecutl,Il lb,D1x4,Bncl,Prdm8,Hoxa7,Mkx,Cebpd,Asb4,Emxl,Runx 
ltl,Satbl,Zfp94,Egf,Hoxb4,Hand 1,Kcnh8,Dmrt3,Foxq 1,Zfp422,Scml2,Irx2,Zfp52,Spib,K1f3,Gata5,Prkca, 
abl5,Nr2cl,Pou3f3,Res6,Barxl,Ptrf,Cebpa,K1f6,Trim3O,Ascl2,Kcnh5,Rest,En2,Invs,Gbx2,Zfp54,Nr2fl,Ap 
o16,Rnf6,Elf1,Per2,Wwtrl,Lhx2,Prox1,Rem2,Phf19,Gtf2a 1lf,Nsbp1,Setbp1,Marcks,Tbx6, 
Rhoxl 1,Egrl,Cartl,Hod,Trpv6,Asb9,Foxd 1,Foxcl,Egr4,Id 1,Ms131,Sox4,Egr2,Wtl,Stat4,Esrrg,Gata4,Meis 
1,Tcfec,Gata6,Trpc3,Zfpm2,Pou5fl,Gata3,Soxl7,Hmx3,Msxl,Foxg 1,Jun,Ovol 1,Lmo4,1s12,Hlf,Lyll,Mpdz,F 
osl 1,Ripk4,Rxrg,Pogk,Sfrp4,Thrb,hlxb9,Emx2,Tbxl5,Grm 1,Hmxl,Trpc7,Atf5,Pou6fl,Foxa3,Vax2,Nkx6- 





1.719 0 0 1,Bcl 1 la,Dmrt2,Cebpb,Ar,Irx3,Zf,Onecutl,D1x4,Bncl,Prdm8,Hoxa7,Mkx,Cebpd,Asb4,Emxl,Runxltl,Sat 




Rhoxl 1,Egrl,Cartl,Hod,Trpv6,Asbg,Foxd 1,Foxcl,Egr4,Id 1,Ms13 1,Sox4,Egr2,Wtl,Stat4,Esrrg,Gata4,Meis 
1,Tcfec,Gata6,Grhl2,Trpc3,Zfpm2,Pou5fl,Gata3,Soxl7,Hmx3,Msxl ,Foxg 1,Jun,Ovol 1,Lmo4,1s12,Hlf,Lyl 1,1 
d2,Mpdz,Fosll,Ripk4,Rxrg,Pogk,Sfrp4,Thrb,Hlxb9,Emx2,Tbxl5,Grm 1,Hmxl ,Trpc7,Atf5,Pou6fl,Foxa3,Va 
x2,Nkx6-3,Tbx2l,Bach2,Nabl,Foxpl,Rfxdcl,RhoxlO,Fh12,Bcl6b,Foxf2,Ncoa2,Tsc22d3,Nkx3- 
regulation of transcription 1.7 0 0 1,Bcl 1 la,Dmrt2,Cebpb,Ar,Irx3,Zf,Onecutl,D1x4,Bncl,Prdm8,lloxa7,Mkx,Cebpd,Asb4,Emxl,Runxltl,Sat 
bl,Zfp94,Hoxb4,Hand 1,Kcnh8,Dmrt3,Foxq 1,Zfp422,Scml2,Irx2,Zfp52,Spib,K1f3,Gata5,Taf13,Zfp641,Nr4 






Tcfec,Chrdl 1,Artn,Gata6,Met,Wnt5a,Fst,Efnb2,Gata3,Hrasls,Hmx3,Msx 1,Lamb1- 
1,Acta 1,Slitrk3,iun,Ovol 1,Lmo4,Fgf5,1s12,1d2,Thbs1,Sema3c,Ank,pogk,Sfrp4,Thrb,Emx2,Lrp5,wnt2,vax2 
,Ifnz,Tbx2l,Wnt4,Jph2,Reln,Angptl,Tgfa,Chrdl2,Scn8a,Nkx3- 
development 1.732 0 0 1,Smo,Bcll la,Dmrt2,Crb3,Cebpb,Ar,Wntga,Agtrla,Shh,Onecutl,Amot,D1x4,Rhob,Hsd 1 lbl,Ifrd 1,Mdfi,Ho 
xa7,McoIn3,Epb4.115,Emx1,Tnfrsf12a,Fgf15,Runxltl,Egf,Fzd6,Hoxb4,Fzd1,Hand1,cff2,Dmrt3,Foxq1,Kra 
s,Sema3e,Lama4,Cyr61,Nog,PIxna3,Ptger4,Dkk3,wnt7a,Bmp5,Nr4a2,Ipfl,palm,cables1,Lef1,Irf8,spred 
2,Dmrtbl,Hes6,Spol 1,Cebpa,Spryd3,Ptk7,Spry1,Ascl2,Gas2,l-ltr2b,En2,Dcamkl 1,Bmprlb,Gbx2,Nr2f1,Rn 
f6,Dock2,Fgf8,Igf2,Lhx2,Prox1,Rps4x,)ph 1,Kif5c,Myl 1,Tbx6, 
Rhoxl 1,Egrl,Cartl,Hod,Trpv6,Asb9,Foxd 1,Foxcl,Egr4,Id 1,Ms131,Sox4,Egr2,Wtl,Stat4,Esrrg,Gata4,Meis 
1,Tcfec,Gata6,GrhI2,Trpc3,Zfpm2,Pou5f1,Gata3,Sox17,Hmx3,Msx1,Foxg 1,3un,0vol 1,Lmo4,1s12,Hlf,LyI 1,1 
regulation of nucleobase, 
d2,Mpdz,Fosll,Ripk4,Rxrg,Pogk,Sfrp4,Thrb,Hlxb9,Emx2,Tbxl5,Grm 1,Hmxl,Trpc7,Atf5,Pou6f1,Foxa3,Va 
x2,Nkx6-3,Tbx2l,Bach2,Nabl,Foxpl,Rfxdcl,RhoxlO,Fhl2,Bcl6b,Foxf2,Ncoa2,Tsc22d3,Nkx3- 
nucleoside, nucleotide and 1.685 0 0 1,Bcl 1 la,Dmrt2,Cebpb,Ar,Irx3,Zf,Onecutl,Dlx4,Bncl,prdm8,Hoxa7,Mkx,Cebpd,Asb4,Emxl,Runxltl,Sat 
nucleic acid metabolism bl,Zfp94,Hoxb4,Hand 1,Kcnh8,Dmrt3,Foxq 1,Zfp422,Scml2,Irx2,Zfp52,Spib,K1f3,Gata5,Taf13,Zfp641,Nr4 
a2,Ipfl,Shprh,Cebpg,Lefl,FoxI2,Foxc2,Rail4,sirt4,Irf8,Klf7,Dmrtbl,Ir -xs,Jund 1,Rabl5,Nr2cl,Pou3f3,Hes 
6,Barx1,Ptrf,Cebpa,K1f6,Trim30,A5c12,Kcnh5,Rest,En2,Invs,Gbx2,zfp54,Nr2f1,Apol6,Rnf6,Elf1,per2,wwtr 
1,Lhx2,Proxl,Rem2,Phfl9,Gtf2a llf,Nsbpl,Setbpl,Marcks,Tbx6, 
Rhoxi 1,Egrl,Cartl,Hod,Trpv6,Asb9,Foxd 1,Foxcl,Egr4,Id 1,Ms13 1,Sox4,Egr2,Wtl ,Stat4,Esrrg,Gata4,Meis 
1,Tcfec,Gata6,Trpc3,Zfpm2,PouSfl,Gata3,Soxl7,I-Imx3,MsxJ.,Foxg 1,Jun,Ovoll,Lmo4,1s12,Hlf,Lyl 1,Mpdz,F 
osl 1,Ripk4,Rxrg,Pogk,Sfrp4,Thrb,Hlxb9,Emx2,Tbxl5,Grm 1,Hmxl,Trpc7,Atf5,Pou6fl,Foxa3,Vax2,Nkx6- 
3,Tbx2 1,Bach2,Nab1,Foxpl,Rfxdcl,Rhox10,Fh12,BcI6b,Foxf2,Ncoa2,Tsc22d3,Nkx3- 
transcription, DNA-dependent 1.693 0 0 1,Bcl 1 la,Dmrt2,Cebpb,Ar,Irx3,Zf,Onecutl,D1x4,Bncl,prdm8,Hoxa7,Mkx,Cebpd,Asb4,Emxl,Runxltl,Sat 






Rhoxi 1,Egrl,Cartl,Hod,Aph la,Trpv6,Asb9,Foxd 1,11 10,Foxc1,Egr4,Id 1 ,Msl31,Sox4,Igfbp3,Pkia,Xdh,Egr2, 
Rnf128,Wtl,Lta,Stat4,Esrrg,Gata4,Meisl,Tcfec,Ptx3,Gata6,Grhl2,Fst,Trpc3,Zfpm2,pou5fl,Gata3,Soxl7,p 
















regulation of physiological 
1.535 0 0 
1,Bcll la,Dmrt2,Cebpb,Ar,1l3,Irx3,Shh,Gsn,zf,Onecutl,Amot,Gnaol,Il lb,Dap,Dlx4,Bncl,Rhob,Prdm8,Ho 






Rhoxl 1,Egrl,Cartl ,Hod,Trpv6,Asb9,Foxd 1,11 10,Foxcl,Egr4,Id 1,Msl3 1,Sox4,Igfbp3,Egr2,Rnf128,Wtl,Lta, 
Stat4,Esrrg,Gata4,Meisl,Tcfec,Ptx3,Gata6,Grhl2,Trpc3,Zfpm2,Pou5fl ,Gata3,Soxl7,Plcbl ,Hrasls,Hmx3,M 
sxl,Foxgl,Jun,Ovol 1,Lmo4,Fgf5,Isl2,Hlf,Lyl 1,1d2,Mpdz,Fosl 1,Ripk4,Rxrg,Pogk,Clqtnf2,Cpebl,Sfrp4,Thrb 
,Hlxb9,Emx2,Tbxl5,Grm 1,Hmxl,Trpc7,AtfS,Pou6fl,Foxa3,Vax2,Ifnz,Nkx6- 
3,Tbx2l,Bach2,Nabl,Foxpl,Rfxdcl,RhoxlO,Fhl2,Map3k8,Bcl6b,Foxf2,Tgfa,Ncoa2,Tsc22d3,Nkx3- 
regulation of cellular 
1.537 0 0 1,Bcll la,Dmrt2,Cebpb,Ar,1l3,Irx3,Shh,Gsn,Zf,Onecutl,Amot,Illb,Dap,Dlx4,Bncl,Rhob,prdm8,Iloxa7,vik 
physiological process x,Cebpd,Asb4,Emxl,Runxltl,Satbl,Zfp94,Egf,Hoxb4,Hand 1,Pmaipl,Kcnh8,Dmrt3,Tnfsfl3b,Bcl2l 1,Foxq 
1,Zfp422,Scm12,Irx2,Kras,Lama4,Cyr61,Kiss1r,Zfp52,Spib,Klf3,Gata5,Prkca,Rab5c,Taf13,zfp641,Nr4a2j 






Rhoxi 1,Egrl,Cartl,Hod,Trpv6,Asb9,Foxd 1,Foxcl,Egr4,Id 1,Msl31,Sox4,Egr2,Wtl,Stat4,Esrrg,Gata4,Meis 
1,Tcfec,Gata6,GrhI2,Trpc3,Zfpm2,Pou5f1,Gata3,Soxl7,Hmx3,Msxl,Foxg 1,3un,Ovol1,Lmo4,1s12,HIf,Lyl 1,1 
d2,Mpdz,FosI 1,Ripk4,Rxrg,Pogk,Sfrp4,Thrb,HIxb9,Emx2,Tbx1 5,Grm 1,Hmxl,Trpc7,Atf5,Pou6f1,Foxa3,Va 
x2,Nkx6-3,Tbx21,Bach2,Nab1,Foxp1,Rfxdc1,Rhox10,Fh12,Bcl6b,Foxf2,Ncoa2,Tsc22d3,Nkx3- 
transcription 1.641 0 0 1,13cl 1 la,Dmrt2,Cebpb,Ar,Irx3,Zf,Onecutl,Dlx4,Bncl,Prdm8,Hoxa7,Mkx,Cebpd,Asb4,Emxl,Runxltl,Sat 





cell differentiation 2.037 0 0 
Sfrp4,Emx2,Ifnz,Reln,Angptl,Chrdl2,Smo,Bcl 1 la,Crb3,Cebpb,Shh,Onecutl,Amot,Rhob,Ifrd 1,Mdfi,Mcoln3 
,Emxl,Tnfrsfl2a,Fgfl5,Runxltl,Kras,Sema3e,Nog,Bmp5,Nr4a2,Lefl,Irf8,Hes6,Cebpa,Ptk7,Spryl,Ascl2, 
En2,Dcamkl 1,Bmprlb,Gbx2,Rnf6,Dock2,Fgf8,Proxl,Kif5c,Tbx6, 
diacylglycerol metabolism 25.306 0 0 Mogatl,Cdsl,Dgkh, 
molybdenum ion binding 25.306 0 0 Aox3,Xdh,Aoxl, 
collagen binding 25.306 0 0 Matri4,Matn3,Mrc2, 
Egrl,Hod,Aphla,Fltl,Foxcl,Id 1,Wtl,Gata4,Gata6,Met,Wnt5a,Fst,Efnb2,Gata3,Hmx3,Msxl,Acta 1,1d2,Thb 
or an develo ment g 	P 1 877 0 0 
sl,Ank,Thrb,Emx2,Wnt2,Ifnz,Wnt4,Reln,Angptl,Tgfa,Scn8a,Smo,Bcl 1 la,Cebpb,Ar,Agtrla,Shh,Amot,Rho 
. b,Hsd 1 lbl,Ifrdl,Hoxa7,Emxl,Tnfrsfl2a,FgflS,Hoxb4,Hand 1,Kras,Lama4,Cyr6l,Nog,Ptger4,Wnt7a,Bmp5 
,Lefl,Irf8,Spol 1,Cebpa,Spryl,Htr2b,En2,Bmprlb,Nr2fl,Dock2,Fgf8,Igf2,Lhx2,Proxl,Jph 1,Myl 1,Tbx6, 
Rhoxi 1,Ddx3y,Sp8,Egrl,Cartl,Hod,Trpv6,Asbg,Foxd 1,Foxcl,Egr4,Sox4,Egr2,Wtl,Zicl,Stat4,Esrrg,Gata 
4,Meisl,Tcfec,Gata6,Grhl2,Trpc3,Zfpm2,Pou5fl,Gata3,Soxl7,Flmx3,Msxl,Foxgl,Jun,Hist3h2ba,Ovol 1,Isl 
2,Hlf,Lyl 1,Mpdz,Fosl 1,Ripk4,Rxrg,Sfrp4,Thrb,Hlxb9,Emx2,Tbxl 5,Grm 1,Hmxl,Prpflg,Trpc7,Atf5,Pou6fl,F 
oxa3,Vax2,Nkx6-3,Tbx2l,Bach2,Foxpl,Rfxdcl,RhoxlO,Bcl6b,Foxf2,Tsc22d3,Nkx3- 
DNA binding 1.531 0 0 1,Dmrt2,Cebpb,Ar,Irx3,Recql,Sos2,Zf,Onecutl,D1x4,Bncl,Prdm8,Zfp560,Floxa7,Mkx,Cebpd,Asb4,Emxl, 




Sp8,Hod,Ephb1,Foxd 1,Flt1,Id 1,Igfbp3,Xdh,Wt1,Gata4,Artn,Gata6,Wnt5a,Fst,Efnb2,Hrasls,Hmx3,Slitrk3,J 





system development 2.227 0 0 ,Emx2,Reln,Smo,Cebpb,Agtrla,Shh,Emxl,Tnfrsfl2a,Sema3e,Nog,Nr4a2,Cablesl,Hes6,Ptk7,Spryl,Ascl2, 
En2,Dcamkll,Gbx2,Nr2fl,Fgf8,Lhx2,Kif5c, 
neutral lipid metabolism 11.247 0 0 Apob,Mogatl,Cdsl,Dgkh, 
acylglycerol metabolism 11.247 0 0 Apob,Mogatl,Cdsl,Dgkh, 
239 
giirpititi:o:n 
Fri cn:eIsyAm1b 1s 
epithelial cell differentiation 8.435 0 0 Xdh,Wtl,)un,Crb3,Ptk7, 
sex differentiation 4.898 0 0 Wtl,Fst,Wnt4,Dmrt2,Ar,Shh,Dmrt3,Dmrtbl,Spol 1, 
behavior 2.789 0 0 
Itga8,Egr2,Zic1,Artn,Met,Cmtm8,Reln,Scn8a,Cc120,Amot,Gnao1 ,Il lb,Vdacl,Mcoln3,Cyr6l,Tshr,Prkca,Prk 
ce,Cxcll6,Astnl,Dock2, 
Irs4,Pdyn,Il 10,Areg,Irs3,Lta,Artn,Wnt5a,Nrg4,Tnfsfl4,Fgf5,Cxcl7,Uts2,Sema3c,Irsl,Wnt2,Ifnz,Pramel3, 
receptor binding 1.957 0 0 Wnt4,Cmtm8,Angptl,Tgfa,Ncoa2,1l3,Calcb,Cc120,Adm2,Dok2,Illb,Nsmaf,Fgfl5,Egf,Ctf2,Tnfsfl3b,Lama4 
.Fgf2l,Fgfl3,Wnt7a,Bmp5,Prlpm,Cxcl 16,Spred2,Spryd3,Inha,Fgf8,Igf2,Pnoc, 
Hod,Fltl,Id 1,Wt1,Gata4,Gata6,Wnt5a,Fst,Efnb2,Hmx3,1d2,Thbs1,Thrb,Wnt2,Wnt4,Angptl,Tgfa,Smo,Ceb 
organ morphogenesis 2.101 0 0 pb,Ar,Shh,Amot,Rhob,hsd 1 lbl,Hoxa7,Tnfrsfl2a,Fgfl5,Hoxb4,Handl,Cyr6l,Wnt7a,Lefl,Spol 1,Cebpa,Sp 
ryl,Htr2b,Fgf8,Igf2, 
glycerolethermetabolism 9.64 0 0 Apob,Mogatl,Cdsl,Dgkh, 
glycerolipidmetabolism 9.64 0 0 Apob,Mogatl,Cdsl,Dgkh, 
appendagemorphogenesis 5.368 0 0 Sp8,Wnt5a,Lrp5,Wnt9a,Shh,Wnt7a,Fgf8, 
limbmorphogenesis 5.368 0 0 Sp8,Wnt5a,Lrp5,Wnt9a,Shh,Wnt7a,Fgf8, 
appendagedevelopment 5.368 0 0 Sp8,Wnt5a,Lrp5,Wnt9a,Shh,Wnt7a,Fgf8, 
Mcf2,Sema6a,Ephbl,Foxdl,Egr2,Zicl,Artn,Met,Efnb2,Hmx3,Msxl,Slitrk3,Lmo4,Fgf5,Sema3c,Emx2,Reln, 
nervous system development 2.116 0 0 Smo,Cebpb,Shh,Emxl,Tnfrsfl2a,Sema3e,Nog,Nr4a2,Cablesl,Hes6,Ptk7,Ascl2,En2,Dcamkll,Gbx2,Nr2fl, 
Lhx2,Kif5c, 
central nervous system 
development 3.426 0 0 Zicl,Met,Hmx3,Msxl,Emx2,Reln,Smo,Shh,Emxl,Nog,En2,Nr2fl,Lhx2, 
establishmentofcellpolarity 12.653 0 0 Crb3,Ptk7,Dock2, 
cell mi 	ration g 2 656 0 0 
Ephbl,Foxdl,Fltl,Artn,LrpS,Reln,Shh,Amot,Illb,Tnfrsfl2a,FgflS,Lama4,Kisslr,Prkca,Srgapl,Gbx2,Nr2fl 
. ,Astnl,Dock2,Kif5c, 
insulinreceptorbinding 8.435 0 0 Irs4,Irs3,Irsl,Dok2, 
Foxdl,Foxcl,Sox4,Meisl,Tcfec,Soxl7,Hmx3,Msxl,Jun,Lmo4,Hlxb9,Hmxl,Atf5,Pou6fl,Foxa3,Foxf2,Nkx3 
transcription factor complex 1.987 0 0 
1,Irx3,Onecutl,D1x4,Hoxa7,Hoxb4,Hand 1,Foxq 1,Irx2,Taf13,Lef1,Foxc2,Pou3f3,Hes6,Barx1,Cebpa,Gbx2, 
Nr2fl,Wwtrl,Lhx2,Proxl, 
vasculaturedevelopment 3.067 0 0 Fltl,Id 1,Efnb2,Thbs1,Angpt1,Tgfa,Smo,Shh,Amot,Rhob,Tnfrsf12a,Hand 1,Lama4,Cyr61, 
locomotorybehavior 2.942 0 0 Artn,Cmtm8,Reln,Scn8a,Cc120,Amot,Gnaol,Il lb,Mcoln3,Cyr6l,Tshr,Prkca,Cxcl 16,Astn 1,Dock2, 
braindevelopment 3.501 0 0 Met,Kmx3,Msxl,Emx2,Reln,Shh,Emxl,Nog,En2,Nr2fl,Lhx2, 
embryonic development 2.477 0 0 
Sp8,Fltl,Gata4,Wnt5a,Hmx3,Lmo4,Lrp5,Cebpb,Ar,Wntga,Shh,Amot,Lama4,Cyr6l ,Wnt7a,Lefl,Cebpa,Ptk 
7,Ascl 2,Fgf8,Tbx6, 
collagencatabolism 7.498 0 0.001 Mmpl6,Mmp8,Mmpl4,Mmp2, 
BMPsignalingpathway 6.025 0 0.001 Fst,Chrdl2,Bmper,Nog,Bmprlb, 
lipoproteinbinding 10.122 0 0.001 Ponl,Lrp8,Cxcl16, 
IEflid ___________________________________ en:ezsy1nib'Ths A'iittin 
Kctd 12b,Trpv6,Kcna 1,Cacna2d 1,GIrb,Chrnb1,Trpc3,Kcnmb2,Kctd4,Trpc7,Gabra4,Kcnk1,Gabra2,Klh124,C1 I 
ion channel activity 1.974 0.0001 0.001 ic6,Scn8a,Kctd 14,Kcne3,Kcnj3,Vdacl,McoIn3,Kcnmb4,Gabra3,Kcnh8,Kcnk6,PlIp,Scnla,Cacnb2,Kcnt2,Kc 
na7,Kcnh5,Glra2,Kctdl6, 
frizzled-2 signaling pathway 5.623 	10.0001 0.001 Wnt5a,Wnt2,Wnt4,Wnt9a,Wnt7a, 
blood vessel morphogenesis 3.067 0.0001 0.001 Fltl,Id 1,Thbsl,Angptl,Tgfa,Smo,Shh,Amot,Rhob,Tnfrsfl2a,Hand 1,Cyr6 1, 
Wnt receptor signaling 
2.924 0.0001 0.001 Wnt5a,Sfrp4,LrpS,Wnt2,Wnt4,Wnt9a,Kremen2,Fzd6,Fzd 1,Dkk3,Wnt7a,Lef1,Csnkle, 
pathway  
Kctdl2b,Trpv6,Kcna 1,Cacna2d 1,Glrb,Chrnb1,Trpc3,Kcnmb2,Kctd4,Trpc7,Gabra4,Kcnk1,Gabra2,K1h124,Cl 
alpha-type channel activity 1.91 0.0001 0.002 ic6,Scn8a,Kctd 14,Kcne3,Kcnj3,Vdacl,Mcoln3,Kcnmb4,Gabra3,Kcnh8,Kcnk6,Gja3,Pllp,Scnla,Cacnb2,Kcnt 
2,Kcna7,Kcnh5,Glra2,Agp5,Kctd 16, 
blood vessel development 2.885 0.0002 0.002 Fltl,Id 1,Thbs1,Angptl,Tgfa,Smo,Shh,Amot,Rhob,Tnfrsf12a,Hand 1,Lama4,Cyr61, 
embryonic limb morphogenesis 4.601 0.0002 0.002 Sp8,Wnt5a,Lrp5,Wnt9a,Shh,Wnt7a, 
embryonic appendage 
4.601 0.0002 0.002 Sp8,Wnt5a,Lrp5,Wnt9a,Shh,Wnt7a, 
morphogenesis  
Foxd 1,Foxcl,Sox4,Meisl,Tcfec,Soxl7,Hmx3,Msxl,Jun,Lmo4,Hlxbg,Hmxl,Atf5,Pou6fl,Foxa3,Foxf2,Nkx3 
nucleoplasm 1.799 0.0002 0.003 - 
1,Irx3,Onecutl,D1x4,Hoxa7,hoxb4,Hand 1,Foxq 1,Irx2,Taf13,Lef1,Foxc2,Pou3f3,Hes6,Barxl,Cebpa,Rest,G 
bx2,Nr2fl,Rnf6,Wwtrl,Lhx2,Proxl,Nsbpl, 
dorsal/ventral pattern 
5.272 0.0002 0.003 Sp8,Smo,Shh,Bmprlb,Lhx2, 
formation  
locomotion 2.256 0.0002 0.003 
Ephbl,Foxdl,Fltl,Artn,LrpS,Reln,Shh,Amot,Il lb,Tnfrsfl2a,FgflS,Lama4,Kisslr,Tshr,Prkca,Srgapl,Gbx2, 
Nr2fl ,Astn 1 ,Dock2, Kif5c, 
fat cell differentiation 8.435 0.0002 0.003 Cebpb,Runxltl,Cebpa, 
sodium:hydrogen antiporter 
8.435 0.0002 0.002 S1c9a2,S1c9a7,S1c9a5, 
activity  
monovalent cation:proton 
8.435 0.0002 0.002 S1c9a2,S1c9a7,S1c9a5, 
antiporter_activity  
channel or pore class 
Kctd 12b,Trpv6,Kcna 1,Cacna2d 1,Glrb,Chrnbl,Trpc3,Kcnmb2,Kctd4,Trpc7,Gabra4,Kcnkl,Gabra2,K1h124,Cl 
1.845 0.0004 0.004 ic6,Scn8a,Kctd 14,Kcne3,Kcnj3,Vdacl,Mcoln3,Kcnmb4,Gabra3,Kcnh8,Kcnk6,Gja3,Pllp,Scn la,Cacnb2,Kcnt 
transporter activity 
 2,Kcna7,Kcnh5,Glra2,Agp5,Kctd 16, 
S1c39a8,Slcga2,Kctdl2b,Trpv6,Kcnal,Slc23al,Slcl la 1,Cacna2d 1,Slc4Oa 1,Trpc3,Atp2a3,Kcnmb2,S1c9a7, 
metal ion transport 1.874 0.0005 0.005 Kctd4,Trpc7,Kcnkl,Scn8a,Kctdl4,Kcne3,Kcnj3,Kcnmb4,Kcnh8,Kcnk6,Scnla,Cacnb2,S1c9a5,Kcnt2,Sfxn5, 
S1c5a5,Kcna7,Kcnh5,Kctd 16, 
tissue development 2.257 0.0005 0.005 
Foxcl,Wtl,Gata3,Ovol 1,Ank,Angptl,Smo,Shh,Onecut1,Mcoln3,Epb4. 115,Foxq 1,Ptger4,Spry1,Bmprlb,Fgf 
8,Lhx2,Proxl,Tbx6, 
cell motility 2.176 0.0007 0.006 
Ephbl,Foxd 1,Fltl,Artn,LrpS,Reln,Shh,Amot,Il lb,Tnfrsfl2a,Fgfl5,Lama4,Kisslr,Prkca,Srgapl,Gbx2,Nr2fl 
,Astn 1,Dock2,Kif5c, 
241 
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localization of cell 2.176 0.0007 0.006 
Ephbl,Foxd 1,Fltl,Artn,Lrp5,Reln,Shh,Amot,P lb,Tnfrsfl2a,Fgfl5,Lama4,Kissl r,Prkca,Srgapl,Gbx2,Nr2fl 
,Astn 1,Dock2,Kif5c, 
morphogenesis of a branching 
4.686 0.0007 0.006 Fltl,Agtrla,Shh,Egf,Cyr6l, 
structure  
regulation of angiogenesis 7.23 0.0007 0.007 Idl,Thbsl,Amot, 
enzyme linked receptor protein 
2.195 0.0008 0.007 Eph b l,Fltl,Ephal,Fst,Angptl,Chrdl2,Dok2,Bmper,GrblO,Nog,Prkca,Bmp5,Ptprk,Stxbp4,Ptprs,plat,Bmprl 
signaling pathway b,Ptprt,Ptpru, 
gonad development 4.439 0.0011 0.01 Wtl,Fst,Wnt4,Ar,Spol 1, 
development of primary sexual 
4.439 0.0011 0.01 Wtl,Fst,Wnt4,Ar,Spoll, 
characteristics  
angiogenesis 2.859 0.0012 0.011 Fltl,Id 1,Thbsl,Angptl,Tgfa,Amot,Rhob,Tnfrsfl2a,Hand 1,Cyr6l, 
transmembrane receptor 
protein tyrosine phosphatase 5.191 0.0012 0.01 Ptprk,Ptprs,Ptprt,Ptpru, 
signaling_pathway  
Spnal,Uspgy,Fstl 1,Cubn,P1a2g5,Snedl,Atp2a3,Pcdhbl7,Thbsl,Pcdhb2o,Slc25a24,Matn4,Matn2,Capn2,Ci 
calcium ion binding 1.592 0.0013 0.011 b2,Vwa2,Pcdhl7,Ncoa2,Anxa8,Pcdhb2 1,P1s3,Gsn,Calnl,F13a1,Mmp8,Efempl,Matn3,Efcab4a,Pcdhbl4,E 
ml2,Egf,Cdh22,Anxa 10,Aytl 1,Nkd 1,Cdh 10,Prkca,Lrp8,l-Ipca,FkbplO,Sytl 1,Vldlr,Efhd 1,Abtb2,Dsc2,Mmp2, 
Man lcl,Mucdh l,Myll, 
cell-cell signaling 2.017 0.0013 0.011 Pdyn,Glrb,Chrnbl,Egr2,Wnt5a,Gabra4,Wnt2,Gabra2,Wnt4,wntga,Tph2,Shh,primal,vdacl,Gabra3,Gja3, 
Wnt7a,Nr4a2,Spryl,Glra2,Fgf8,Pnoc, 
urogenital system 
3.749 0.0016 0.012 development  Aphla,Wtl,Agtrla,Shh,Nog,Spryl, 
metanephros development 4.217 0.0017 0.013 Aphla,Wtl,Agtrla,Nog,Spryl, 
non-G-protein coupled 7TM 
6.326 0.0017 0.013 Smo,Fzd6,Fzdl, receptor_activity  
vasculogenesis 6.326 0.00171 0.013 Smo,Shh,Amot, 
establishment and/or 
6.326 0.0017 0.013 Crb3,Ptk7,Dock2, maintenance_of_cell_polarity 
S1c39a8,S1c9a2,Kctd 12b,Trpv6,Kcna 1,S1c23a1,Slcl lal,Co14a6,Cacna2d 1,Glrb,Chrnbl,Slc4Oa 1,Slcl6a7,C 
ion transport 1.528 0.0018 0.013 thrcl,Trpc3,Atp2a3,C1q12,Kcnmb2,S1c9a7,Ptger3,Ank,Kctd4,Trpc7,Gabra4,Kcnkl,Gabra2,clic6,scn8a,co 
lecl2,Kctd 14,Kcne3,Kcnj3,Vdacl,Mcoln3,Kcnmb4,Gabra3,Kcnh8,Kcnk6,CoI7a 1,Immp2l,Pllp,Scn la,Cacnb 
2,Slc9a5,Svop,Kcnt2,Sfxn5,Slcola5,Slc5a5,Kcna7,Kcnh5,Atpl lb,Glra2,Sftpd,Kctd 16, 
cation channel activity 1.918 0.0019 0.014 Kctd 12b,Trpv6,Kcna 1,Cacna2d 1,Chrnbl,Trpc3,Kcnmb2,Kctd4,Trpc7,Kcnkl,Scn8a,Kctd 14,Kcne3,Kcnj3,M 
coln3,Kcnmb4,Kcnh8,Kcnk6,Scn la,Cacnb2,Kcnt2,Kcna7,Kcnh5,Kctd 16, 
potassium channel activity 2.239 0.0024 0.018 Kctd 12b,Kcna 1,Kcnmb2,Kctd4,Kcnkl,Kctd 14,Kcne3,Kcnj3,Kcnmb4,Kcnh8,Kcnk6,Kcnt2,Kcna7,Kcnh5,Kct ___ d16, 
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GABA receptor activity 3.49 0.0029 0.021 Glrb,Gabra4,Gabra2,Gabra3,Gpr156,Glra2, 
growth factor activity 2.181 0.0034 0.023 Areg,Artn,Nrg4,Fgf5,Tgfa,1l3,Illb,Fgfl5,Egf,Fgf2l,Fgfl3,Bmp5,Jnha,Fgf8,Igf2, 
calcium-activated potassium 
5.623 0.0034 0.023 Kcnmb2,Kcnmb4,Kcnt2, 
channel_activity 
protein homodimerization 
3.374 0.0038 0.025 Cebpb,Cebpd,Runxltl,Handl,Dgkh,Cebpa, activity  
negative regulation of Hod,Id 1,Pkia,Rnf128,Wtl,Fst,Zfpm2,Thrb,Atf5,Nab1,Foxp1,Bcl6b,Ncoa2,Anxa8,chrdl2,Tsc22d3,cebpb,11 
biological process 
1.614 0.0038 0.024 3,Shh,Gsn,Rhob,Bmper,Pmaipl,Tnfsfl3b,Bcl2l 1,AnxalO,Kisslr,Nog,Dkk3,Prkca,Pak7,Sirt4,Spred2,Cebpa 
,Gas2,Rest,EIf1,Prox1, 
pattern specification 2.144 0.0041 0.026 Sp8,Flt1,Fst,Emx2,Lrp5,Smo,Shh,Hoxa7,Hoxb4,Cyr6l,Nog,Bmp5,Lefl,Bmprlb,Lhx2, 
cytokine activity 1.928 0.0043 0.027 II 10,Areg,Lta,Tnfsfl4,FgfS,Cxcl7,Ifnz,Cmtm8,Angptl,1l3,Cc120,Illb,Fgfl5,ctf2jnfsfl3b,Fgf13,Bmps,cxcl 
16,Spred2,Fgf8, 
axon guidance 3.028 0.0044 0.027 Ephbl,Foxd 1 ,Artn,Shh,Tnfrsfl2a,Gbx2,Kif5c, 
transcription from RNA 
1.815 0.0044 0.026 Hod,Foxd 1,Id 1,Wtl,Gata4,Meisl,Gata6,Zfpm2,PouSfl,Jun,Lmo4,Hlxb9,Atf5,Fh12,Bcl6b,Foxf2,Ncoa2,I-Ian 
polymerase II promoter d 1,Ipfl,Lefl,Foxl2,Hes6,Wwtrl,Gtf2allf, 
fibroblast growth factor 
4.217 0.005 0.029 Fgf5,FgflS,Fgfl3,Fgf8, receptor_binding  
embryonic morphogenesis 2.617 0.0051 0.029 Sp8,Wnt5a,Hmx3,Lmo4,Lrp5,Wnt9a,Shh,Wnt7a,Ptk7, 
small GTPase mediated signal 
1.837 0.0055 0.031 
Cdc42epl,Hrasls,Arl4c,Rab27b,Reln,Sos2,Dok2,Rhob,Rnd3,Cdgap,Kras,Rabsc,Rab3l,srgapl,Rab2o,Rab 
transduction 15,Arl 1 1,Rgl3,Rhoc,Dock2,Rem2,Mfhasl, 
potassium ion transport 2.029 0.006 0.034 Kctdl2b,Kcnal,Kcnmb2,Slcga7,Kctd4,Kcnkl,Kctd 14,Kcne3,Kcnj3,Kcnmb4,Kcnh8,Kçnk6,Kcnt2,Kcna7,Kc 
nh5,Kctdl6, 
rhythmic process 3.163 0.0062 0.034 Egr2,HIf,Prokrl,Csnkle,Spol 1,Per2, 
negative regulation of signal 
3.514 0.0063 0.034 Chrdl2,Bmper,Dkk3,Prkca,Elf1, transduction  
kidney development 3.514 0.0063 0.034 Aph la,Wtl,Agtrla,Nog,Spryl, 
steroid hormone receptor 
2.88 0.0066 0.035 Esrrg,Rxrg,Thrb,Ar,Nr4a2,Nr2cl,Nr2fl, activity  
ligand-dependent nuclear 
2.88 0.0066 0.035 Esrrg,Rxrg,Thrb,Ar,Nr4a2,Nr2cl,Nr2fl, receptor_activity 
mesoderm development 3.969 0.0072 0.038 Ovoll,Epb4.115,Lhx2,Tbx6, 
embryonic development 
3.969 0.0072 0.038 Gata4,Ar,Amot,Ascl2, 
(sensu_Mammalia)  
regulation of peptidyl-tyrosine 




acetylga lactosa m i nyltra nsferas 
3.969 0.0072 0.036 Galnt7,Galntl4,B3galnt2,Galntl4, 
e_activity  
Foxdl,Foxcl,Sox4,Meisl,Tcfec,Soxl7,Hmx3,Msxl,Jun,Lmo4,HIxb9,Hmxl,Atf5,Pou6fl,Foxa3,Snrpd3,Fox 
nuclear lumen 1.53 0.0074 0.037 
f2,Nkx3- 
1,Irx3,Onecutl,Dlx4,Hoxa7,l-loxb4,Hand 1,Foxq 1,Irx2,Tafl3,Lefl,Foxc2,Pou3f3,hes6,Barxl,Cebpa,Rest,G 
bx2,Nr2fl,Rnf6,Wwtrl,Lhx2,Proxl,Nsbpl, 
sulfotransferaseactivity 3.067 0.0077 0.038 Chstl 1,Chstl,Hs3st3bl,Chst7,Hs3stl,Sultlbl, 
voltage-gated ion channel 
1.984 0.0078 0.039 
Kctdl2b,Kcna 1,Cacna2d 1,Kctd4,Kcnkl,Clic6,Scn8a,Kctd 14,Kcne3,Kcnj3,Kcnh8,Scnla,Cacnb2,Kcna7,Kcn 
activity h5,Kctdl6, 
neurotransmitter receptor 
2.2 0.0081 0.039 Glrb,Chrnbl,Oprkl,Prokrl,Htrlb,Gabra4,Gabra2,Gabra3,Sortl,Kisslr,Tacr2,Glra2, 
activity  
neurotransmitterbinding 2.2 0.0081 0.039 Glrb,Chrnb1,Oprkl,Prokrl,Htrlb,Gabra4,Gabra2,Gabra3,Sortl,Kisslr,Tacr2,Glra2, 
neurogenesis 1.924 0.0088 0.043 Mcf2,Ephbl,Foxdl,Egr2,Artn,Slitrk3,Emx2,Reln,Cebpb,Shh,Emxl,Tnfrsfl2a,Nr4a2,En2,Gbx2,Nr2fl,Kif5c, 
negative regulation of cellular 
1.58 0.009 0.044 
Hod,Id 1,Rnf128,Wtl,Fst,Zfpm2,Thrb,Atf5,Nab1,Foxp1,Bcl6b,Ncoa2,Chrdl2,Tsc22d3,Cebpb,113,Shh,Gsn,R 
process hob,Bmper,Pmaipl,Tnfsfl3b,Bc121 1,Kisslr,Nog,Dkk3,Prkca,Pak7,Sirt4,Cebpa,Gas2,Rest,Elf1,Proxl, 
regulation of transcription 
Hod,Foxdl,Idl,Wtl,Gata4,Meisl,Gata6,Zfpm2,Jun,Hlxb9,Atf5,Fhl2,Bcl6b,Ncoa2,I-landl,Ipfl,Lefl,Foxl2,H 
from RNA polymerase II 1.814 0.0097 0.047 
es6,Wwtrl, 
promoter 
immunecellchemotaxis 4.601 0.0099 0.047 Il1b,Prkca,Dock2, 
branching morphogenesis of a 
4.601 0.0099 0.047 Fltl,Agtrla,Cyr6l, 
tube  
malesexdifferentiation 4.601 0.0099 0.047 Wtl,Ar,Shh, 
uretericbuddevelopment 4.601 0.0099 0.047 Agtrla,Nog,Spryl, 
regulation of signal 
2.279 0.0116 0.054 Reln,Chrdl2,Bmper,Dkk3,Prkca,Spred2,Cnksr2,Spryl,EIf1,Dock2, 
transduction 
neurondifferentiation 1.946 0.0124 0.058 Mcf2,Ephbl,Foxdl,Egr2,Artn,Slitrk3,Emx2,Cebpb,Shh,Emxl,Tnfrsfl2a,Nr4a2,En2,Gbx2,Kif5c, 
GABA-Areceptoractivity 3.124 0.0134 0.063 Glrb,Gabra4,Gabra2,Gabra3,Glra2, 
cell-celladhesion 2.087 0.0135 0.062 Pcdhbl7,Pcdhb20,Pcdhl7,Pcdhb2l,Scarf2,Pcdhbl4,Cdh22,Arvcf,CdhlO,Dsc2,Astnl,Mucdhl, 
taxis 2.335 0.0137 0.063 Artn,Cmtm8,Cc120,Amot,Illb,Cyr6l,Prkca,Cxcll6,Dock2, 
chemotaxis 2.335 0.0137 0.063 Artn,Cmtm8,Ccl2O,Amot,Il lb,Cyr6l,Prkca,Cxcll6,Dock2, 
solute :cation antiporter 
4.217 0.0151 0.07 S1c9a2,S1c9a7,S1c9a5, 
activity  
solute:hydrogen antiporter 
4.217 0.0151 0.07 S1c9a2,S1c9a7,S1c9a5, 
activity  
neurotransmittermetabolism 1 	4.217 1 0.0151 0.069 Tph2,Primal,Nr4a2, 
adultbehavior 1 4.217 10.0151 1 	0.068 Met,Scn8a,Tshr, 
A'I1t1tifl ME ________________________________________________________________________________ n:eisrniIs 
immune cell migration 4.217 0.0151 0.068 Illb,Prkca,Dock2, 
polypeptide N- 
acetylgalactosaminyltransferas 4.217 0.0151 0.068 Galnt7,Galntl4,Galntl4, 
e_activity  
extraceUular matrix (sensu 
1.748 0.0152 0.067 
Frasl,Adamtslg,Co14a6,Cthrcl,Lambl- 
Metazoa) 1,Timp3,Matn4,Matn2,Mmpl6,Reln,Mmp8,Hc,Matn3,Col7al,Lama4,Hapin4,Mmpl4,Mmp2,GpcS,Mmp25, 
identical protein binding 2.567 0.0157 0.069 Vwa2,Cebpb,Cebpd,Runx1t1,lland1,Dgkh,Cebpa, 
anti-apoptosis 2.567 0.0157 0.068 At15,Tsc22d3,Cebpb,113,Tnfsfl3b,Bcl2l 1,Pak7, 
tube morphogenesis 3.012 0.0168 0.072 Fltl,Lmo4,Agtrla,Cyr6l,Ptk7, 
tight junction 2.663 0.0201 0.082 Cldn7,Cldnl,Cgn,Cldnl8,Mpdz,Ocln, 
morphogenesis of an 
2.663 0.0201 0.081 epithelium  Xdh,Wtl,Jun,Lmo4,Crb3,Ptk7, 
solute:solute antiporter 
3.893 0.022 0.088 S1c9a2,Slc9a7,Slc9a5, 
activity  
circadian rhythm 3.893 0.022 0.087 Prokrl,Csnkle,Per2, 
cation:cation antiporter 
3.893 0.022 0.087 S1c9a2,S1c9a7,S1c9a5, 
activity  
negative regulation of 
1.529 0.023 0.092 
Hod,Id 1,Rnf128,Wtl,Zfpm2,Thrb,Atf5,Nab1,Foxp1,Bcl6b,Ncoa2,Anxa8,Tsc22d3,Cebpb,1l3,shh,Gsn,Rhob 
physiological process ,Pmaipl,Tnfsfl3b,Bc121 1,Anxa 10,Kisslr,Prkca,Pak7,Sirt4,Cebpa,Gas2,Rest,Proxl, 
regulation of protein amino 
3.213 0.0235 0.093 113,Egf,Prkca,Prkce, acid_phosphorylation  
regulation of amino acid 
metabolism  
3.213 0.0235 0.093 113,Egf,Prkca,Prkce, 
embryonic development 
2.811 0.0251 0.1 
(sensu_Vertebrata)  Gata4,Ar,Amot,Lefl,Ascl2, 
Table 3.4- List of the strongest clusters of upregulated genes in Oct4A.VP2 cell line. 
The strongest 15 clusters of overexpressed genes in Oct4XVP2 cell line relative to Oct4 cell line (p < 1 .OE-6). The scoring of the clusters 
integrates information on average overexpression of genes and their proximity. 
Log ratio 
Chr Strand Start Symbol Gene name Score Oct4?,VP2I 
004 
[llI  
chr2 + 25002766 Nrarp Mus musculus Notch-regulated ankyrin repeat protein (Nrarp), mRNA 0.3137 0.0502 
chr2 - 25113189 Grini Mus musculus glutamate receptor, ionotropic, NMDA1 (zeta 1) (Grini), 1.0629 0.0805 
mRNA 
chr2 + 25217882 Entpd2 Mus musculus ectonucleoside triphosphate diphosphohydrolase 2 0.319 0.0791 
(Entpd2), mRNA 
chr2 + 25278846 Clic3 Mus musculus chloride intracellular channel 3 (Clic3), mRNA 0.4876 0.3902 
chr2 - 25397424 Gm996 Mus musculus gene model 996, (NCBI) (Gm996), mRNA 0.3128 1.2649 
chr2 - 26174320 Card9 PREDICTED: Mus musculus caspase recruitment domain family, member 9, 0.4041 0.4875 
transcript variant 3 (Cardg), mRNA 
Mus musculus ABO blood group (transferase A, alpha 1-3-N- 
chr2 - 26664006 Abo acetyl g a lactosa m i nyltra nsfe rase, transferase B, 0.6881 0.3059 
alpha 1-3-galactosyltransferase) (Abo), mRNA 
chr2 + 27708061 ColSal Mus musculus procollagen, type V, alpha 1 (ColSal), mRNA 0.318 0.182 
chr2 - 146868986 Nkx2-2 Mus musculus NK2 transcription factor related, locus 2 (Drosophila) (Nkx2- 0.6869 0.0422 
2), mRNA 
chr2 + 148086782 Sstr4 Mus musculus somatostatin receptor 4 (Sstr4), mRNA 0.5515 0.0417 
chr2 - 1480959061 Thbd Mus musculus thrombomodulin (Thbd), mRNA 0.5359 0.1218 
MR 
Log ratio 
Chr Strand Start Symbol Gene name Score  Oct4?XP2/ 
Oct4  
chr2 + 148511521 Cst13 Mus musculus cystatin 13 (Cst13), mRNA 0.7688 0.1356 
chr2 + 148526587 Cst9 Mus musculus cystatin 9 (Cstg), mRNA 1.0253 0.4305 
chr2 - 148563158 Cst3 Mus musculus cystatin C (Cst3), mRNA 0.3257 1.3465 
Cluster 3 
chr5 - 120990949 Oas2 Mus musculus 2'-5' oligoadenylate synthetase 2 (Oas2), mRNA 0.6548 0.0519 
chr5 - 121046842 Oasle Mus musculus 2l_5  oligoadenylate synthetase 1E (Oasle), mRNA 0.5155 0.0838 
chr5 - 121060709 Oaslc Mus musculus 2-5 oligoadenylate synthetase 1C (Oaslc), mRNA 0.536 0.178 
chr5 + 121073251 Oaslb Mus musculus 2-5 oligoadenylate synthetase lB (Oaslb), mRNA 0.8709 0.2261 
chr5 + 121122037 Oaslh Mus musculus 2-5 oligoadenylate synthetase 1H (Oaslh), mRNA 0.4109 4.5589 
chr5 + 121175152 Oasld Mus musculus 2'-5' oligoadenylate synthetase 1D (Oasld), mRNA 1.073 5.3095 
Cluster 4 
chr6 - 113331801 Tada3l Mus musculus transcriptional adaptor 3 (NGG1 homolog, yeast)-like 0.3642 0.0195 
chr6 + 113355036 Tt113 Mus musculus tubulin tyrosine ligase-like family, member 3 (Tt113), mRNA 0.3443 0.0223 
chr6 + 113437203 I117rc Mus musculus interleukin 17 receptor C (Ill7rc), mRNA 0.3196 0.0244 
chr6 - 113459415 Prrt3 Mus musculus proline-rich transmembrane protein 3 (Prrt3), mRNA 0.4042 0.0386 
chr6 + 113604243 Irak2 Mus musculus interleukin-1 receptor-associated kinase 2 (Irak2), mRNA 0.3034 1.2742 
chr6 - 115207967 Timp4 Mus musculus tissue inhibitor of metalloproteinase 4 (Timp4), mRNA 1.1752 0.2749 
chr6 - 115694749 Tmem40 Mus musculus transmembrane protein 40 (Tmem40), mRNA 0.3151 0.223 
chr6 - 117899177 Fxyd4 
Mus musculus FXYD domain-containing ion transport regulator 4 (Fxyd4), 
0.8679 0.1381 
mRNA 
chr6 + 117976427 Rasgefla PREDICTED: Mus musculus RasGEF domain family, member 1A 0.4602 0.1428 




Chr Strand Start Symbol Gene name Score  
Oct4?XP2/ 
Oct4  
chr6 - 120896968 Mical3 Mus musculus microtubule associated monoxygenase, calponin and LIM 0.4346 0.1144 domain containing 3 (Mical3), mRNA 
chr6 + 121265845 S1c6a13 Mus musculus solute carrier family 6 (neurotransmitter transporter, 0.532 0.0937 
GABA), member 13 (Slc6a13), mRNA 
chr6 + 121600994 A2m Mus musculus alpha-2-macroglobulin (A2m), mRNA 1.2839 0.1933 
chr6 - 122571018 Gdf3 Mus musculus growth differentiation factor 3 (Gdf3), mRNA 0.3699 0.1341 
chr6 + 122592028 Dppa3 Mus musculus developmental pluripotency-associated 3 (Dppa3), mRNA 0.6708 0.3883 
chr6 + 122673107 Nanog PREDICTED: Mus musculus Nanog homeobox (Nanog), mRNA 0.4882 0.4754 
chr6 + 122887466 Clec4al Mus musculus C-type lectin domain family 4, member al (Clec4al), mRNA 0.6313 0.5354 
chr6 + 122918133 Clec4a3 Mus musculus C-type lectin domain family 4, member a3 (Clec4a3), mRNA 0.7521 1.678 
chr6 + 134947410 Apoldi PREDICTED: Mus musculus apolipoprotein L domain containing 1 (Apoldi), 0.9952 0.1094 mRNA 
chr6 + 135031343 Gprc5a Mus musculus G protein-coupled receptor, family C, group 5, member A 0.5753 0.1223 
(Gprc5a), mRNA 
chr6 - 135103211 Hebpl Mus musculus heme binding protein 1 (Hebpl), mRNA 0.4482 0.1034 
chr6 - 135203021 Gsgl Mus musculus germ cell-specific gene 1 (Gsgl), mRNA 0.8275 0.1894 
chr6 - 135274821 Pbp2 Mus musculus phosphatidylethanolamine binding protein 2 (Pbp2), mRNA 0.8911 2.2829 
chr6 + 1353282371 Empi Mus musculus epithelial membrane protein 1 (Empi), mRNA 0.949 2.4865 
chr7 + 43219260 Siglecf Mus musculus sialic acid binding Ig-like lectin F (Siglecf), mRNA 0.7657 0.1029 
chr7 + 43295589 Lim2 Mus musculus lens intrinsic membrane protein 2 (Lim2), mRNA 0.8849 0.171 
chr7 + 43311991 Etfb Musmusculus electron transferring flavoprotein, beta polypeptide (Etfb), 0.4154 0.1713 mRNA 
chr7 + 43502748 Ceacam18 Mus musculus CEA-related cell adhesion molecule 1 (Ceacam18), mRNA 0.456 0.1266 
248 
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Oct4  
chr7 + 43580608 Kik13 Mus musculus kaiiikrein 13 (K1k13), mRNA 0.3513 1.5903 
chr7 + 43642658 Kikil Mus musculus kallikrein 11 (Kikil), mRNA 0.7766 1.662 
chr7 + 43649081 KlklO Mus musculus kallikrein 10 (KiklO), mRNA 0.3525 1.3954 
chr7 + 43834792 Kikibi Mus musculus kallikrein 1-related peptidase bi (Kikibi), mRNA 0.4043 1.4099 
chr7 + 43880718 Kiklb26 Mus musculus kallikrein 1-related petidase b26 (Klklb26), mRNA 0.5879 1.6478 
chr7 + 44056304 Kik1b24 Mus musculus kaiiikrein 1-related peptidase b24 (K1k1b24), mRNA 0.3569 1.1982 
chr7 - 44961034 Fcgrt Mus musculus Fc receptor, IgG, alpha chain transporter (Fcgrt), mRNA 0.6001 0.3509 
chr7 - 45101673 Cd37 Mus musculus CD37 antigen (Cd37), mRNA 0.6842 0.4157 
chr7 - 45700821 Grin2d Mus musculus glutamate receptor, ionotropic, NMDA2D (epsilon 4) 0.4554 0.295 
(Grin2d), mRNA 
chr7 + 46244485 Myodl Mus musculus myogenic differentiation 1 (Myodl), mRNA 0.3394 0.2227 
chr7 + 46619874 Saa2 Mus musculus serum amyloid A 2 (Saa2), mRNA 0.5865 0.3214 
chr7 - 46945816 Ptpn5 Mus musculus protein tyrosine phosphatase, non-receptor type 5 (Ptpn5), 0.4546 0.2733 
mRNA 
Cyba chr8 - 125310857 Mus musculus cytochrome b-245, alpha polypeptide (Cyba), mRNA 0.3059 0.1146 
chr8 - 125340293 Snai3 Mus musculus snail homolog 3 (Drosophila) (Snai3), mRNA 0.4777 0.1133 
chr8 - 125460724 Aprt Mus musculus adenine phosphoribosyl transferase (Aprt), mRNA 0.3959 0.1733 
chr8 - 125464327 GaIns Mus musculus galactosamine (N-acetyl)-6-sulfate sulfatase (Gains), mRNA 0.3551 0.1812 
chr8 - 125515261 Cbfa2t3h Mus muscuius core-binding factor, runt domain, alpha subunit 2, 0.4727 1.9641 
transiocated to, 3 homolog (human) (Cbfa2t3h), mRNA 
chr8 - 126026018 Suit5al Mus muscuius suifotransferase family 5A, member 1 (Sult5al), mRNA 0.4196 0.6186 
chr8 + 126064817 Dpepl Mus musculus dipeptidase 1 (renal) (Dpepi), mRNA 0.365 0.6649 
chr8 + 126293171 Mclr Mus musculus melanocortin 1 receptor (Mclr), mRNA 0.3715 0.4787 
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004  
chr8 + 126297513 Tubb3 Mus musculus tubulin, beta 3 (Tubb3), mRNA 0.6688 0.5874 
chr9 + 77894875 Ick Mus musculus intestinal cell kinase (Ick), mRNA 0.3084 0.0771 
chr9 + 78016339 Gstal Mus musculus glutathione S-transferase, alpha 1 (Ya) (Gstal), mRNA 0.727 0.0882 
chr9 + 78042812 Gstal Mus musculus glutathione S-transferase, alpha 1 (Ya) (Gstal), mRNA 0.727 0.0921 
chr9 + 78075611 Gsta2 Mus musculus glutathione S-transferase, alpha 2 (Yc2) (Gsta2), mRNA 0.4538 0.0992 
chr9 + 78113713 Omt2b Mus musculus oocyte maturation, beta (Omt2b), mRNA 0.3748 2.368 
chr9 - 78116701 Gsta2 Mus musculus glutathione S-transferase, alpha 2 (Yc2) (Gsta2), mRNA 0.4538 5.4531 
chrlo - 127912690 Mbc2 Mus musculus membrane bound C2 domain containing protein (Mbc2), 0.4804 0.0472 
mRNA 
chrlo - 127970471 Erbb3 Mus musculus v-erb-b2 erythroblastic leukemia viral oncogene homolog 3 0.4644 0.0661 
(avian) (Erbb3), mRNA 
chr10 + 128193858 Mmp19 Mus musculus matrix metallopeptidase 19 (Mmplg), mRNA 0.4102 0.0674 
chr10 + 128303937 Cd63 Mus musculus Cd63 antigen (Cd63), mRNA 0.476 0.2767 
chrlo - 128361199 Mettl7b Mus musculus methyltransferase like 7B (Mettl7b), mRNA 0.4484 1.0164 
chril - 94053687 Wfikkn2 Mus musculus WAP, follistatin/kazal, immunoglobulin, kunitz and netrin 0.3786 0.0243 
domain containing 2 (Wfikkn2), mRNA 
chril - 94159384 Abcc3 Mus musculus ATP-binding cassette, sub-family C (CFTR/MRP), member 3 0.5861 0.0394 (Abcc3), mRNA 
chril - 94224460 Cacnalg Mus musculus calcium channel, voltage-dependent, T type, alpha 1G 0.6518 0.0677 
subunit (Cacnalg), mRNA 
chril - 94294993 Spata20 Mus musculus spermatogenesis associated 20 (Spata20), mRNA 0.3924 0.0734 
chril + 95840634 Gip Mus musculus gastric inhibitory polypeptide (Gip), mRNA 0.4817 0.2788 
Log ratio 
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Oct4  
chril - 95915001 Ndp52 
PREDICTED: Mus musculus nuclear domain 10 protein 52, transcript 
0.4744 0.2946 
variant 4 (Ndp52), mRNA 
chril + 95950308 Tt116 Mus musculus tubulin tyrosine ligase-like family, member 6 (Ttl16), mRNA 0.4031 0.2785 
chril + 96017396 L0C432593 
PREDICTED: Mus musculus hypothetical gene supported by AK078606 
0.534 0.2654 
(L0C432593), mRNA 
chril + 96115044 Hoxb6 Mus musculus homeo box B6 (Hoxb6), mRNA 0.5302 1.7663 
chril + 97178543 Socs7 Mus musculus suppressor of cytokine signaling 7 (Socs7), mRNA 0.3578 0.364 
chril - 97531246 Pip5k2b 
Mus musculus phosphatidylinositol-4-phosphate 5-kinase, type II, beta 
0.3156 0.2708 
(Pip5k2b), mRNA 
chril + 98164479 Ppplrlb 
Mus musculus protein phosphatase 1, regulatory (inhibitor) subunit lB 
0.3208 0.1917 
(Ppplrlb), mRNA 
chrll - 98584012 Nrldl 
Mus musculus nuclear receptor subfamily 1, group D, member 1 (Nrldl), 
0.3803 0.1543 
mRNA 
chril - 98798269 Gjcl Mus musculus gap junction membrane channel protein chi 1 (Gjcl), mRNA 0.4051 0.2197 
chril - 98880560 Tns4 Mus musculus tensin 4 (Tns4), mRNA 0.5247 0.2885 
chr13 + 3837001 Calm4 Mus musculus calmodulin 4 (Calm4), mRNA 0.881 -0.0049 
chr13 + 3853513 CalmS Mus musculus calmodulin 5 (Calm5), mRNA 1.3542 -0.0066 
chr13 + 3923937 Tubal3 Mus musculus tubulin, alpha-like 3 (Tubal3), mRNA 0.3564 -0.0065 
chrl3 - 4131860 Akrlcl8 
Mus musculus aldo-keto reductase family 1, member C18 (Akrlcl8), 
0.6991 0.7956 
mRNA 
chrl3 + 4190429 Akrlcl3 Mus musculus aldo-keto reductase family 1, member C13 (Akrlcl3), 0.3627 2.0674 
mRNA 




Chr Strand Start Symbol Gene name Score Oct4?.VP2/ 
Oct4  
chr13 - 32849524 Serpinbia 
Mus musculus serine (or cysteine) peptidase inhibitor, dade B, member la 
0.5608 0.0341 
(Serpinbia), mRNA 
chr13 - 32888861 Serpinbic 
Mus musculus serine (or cysteine) peptidase inhibitor, dade B, member ic 
0.4394 0.0735 
(Serpinbic), mRNA 
chr13 + 32972673 Serpinb6b 
Mus musculus serine (or cysteine) peptidase inhibitor, dade B, member 6b 
0.6722 0.122 
(Serpinb6b), mRNA 
chr13 ± 33010714 Serpinb9 
Mus musculus serine (or cysteine) peptidase inhibitor, dade B, member 9 
0.3426 0.2485 
(Serpinbg), mRNA 
chr13 + 33034866 Serpinb9b 
Mus musculus serine (or cysteine) peptidase inhibitor, dade B, member 9b 
0.5868 2.8076 
(Serpinbgb), mRNA 
chr13 + 33086037 Serpinbib 
Mus musculus serine (or cysteine) peptidase inhibitor, dade B, member lb 
1.3932 3.4834 
(Serpinbib), mRNA 
chr14 - 49687359 Ttc5 Mus musculus tetratricopeptide repeat domain 5 (Ttc5), mRNA 0.3061 0.0997 
chr14 - 49828426 Osgep Mus musculus 0-sialoglycoprotein endopeptidase (Osgep), mRNA 0.3798 0.1017 
chr14 + 49846908 Apexi Mus musculus apurinic/apyrimidinic endonuclease 1 (Apexi), mRNA 0.435 0.1113 
chr14 + 49866252 Pnp Mus musculus purine-nucleoside phosphorylase (Pnp), mRNA 0.3587 0.1152 
chr14 + 49877928 Pnp Mus musculus purine-nucleoside phosphorylase (Pnp), mRNA 0.3587 1.9293 
chr14 + 50013027 Angi Mus musculus angiogenin, ribonuclease A family, member 1 (Angi), mRNA 0.5193 2.2226 
chr14 - 50117436 Ang2 Mus musculus angiogenin, ribonuclease A family, member 2 (Ang2), mRNA 0.5315 1.6288 
chr14 + 50283706 L00638695 Mus musculus similar to Spetex-2C protein (L00638695), mRNA 0.7666 1.2144 
chr14 + 50474740 L0C434459 Mus musculus similar to RIKEN cDNA 4930503E14 (L0C434459), mRNA 0.7675 0.9864 
chr14 - 50685828 Ang4 Mus musculus angiogenin, ribonuclease A family, member 4 (Ang4), mRNA 0.3178 0.8629 
chr14 + 50721996 AY358078 Mus musculus cDNA sequence AY358078 (AY358078), mRNA 1.0044 1.1207 
chr14 + 51032654 Rpgripl 









chrl4 - 51082364 Suptl6h 
Mus musculus suppressor of Ty 16 homolog (S. cerevisiae) (Suptl6h), 
0.3529 0.9296 
mRNA 
chr14 - 51233128 Sa112 Mus musculus sal-like 2 (Drosophila) (Sa112), mRNA 0.3047 0.863 
chr14 - 53193482 Dadi Mus musculus defender against cell death 1 (Dad 1), mRNA 0.4532 0.2021 
chr14 + 53381113 Mrp152 Mus musculus mitochondrial ribosomal protein L52 (Mrp152), mRNA 0.3618 0.1579 
chrl4 + 53417248 LrplO Mus musculus low-density lipoprotein receptor-related protein 10 (LrplO), 0.411 0.1613 
mRNA 
chr14 - 53461382 Prmt5 Mus musculus protein arginine N-methyltransferase 5 (Prmt5), mRNA 0.4443 0.1773 
chrl4 - 53568317 Psmb5 Mus musculus proteasome (prosome, macropain) subunit, beta type 5 0.3664 1.0867 
(Psmb5), mRNA 
chr14 - 54015349 Zfhx2 Mus musculus zinc finger homeobox 2 (Zfhx2), mRNA 0.3556 0.6115 
chr14 - 54052648 Ap1g2 Mus musculus adaptor protein complex AP-1, gamma 2 subunit (Aplg2), 0.4312 0.6322 
mRNA 
chr14 + 54176075 Dhrs2 Mus musculus dehydrogenase/reductase member 2 (Dhrs2), mRNA 0.3254 0.5381 
chr14 + 54464555 Cpne6 Mus musculus copine VI (Cpne6), mRNA 0.3242 0.4023 
chr14 + 54514102 Wdr23 Mus musculus WD repeat domain 23 (Wdr23), mRNA 0.3276 0.7074 
chr14 + 55319138 Atpl2a Mus musculus ATPase, H+/K+ transporting, nongastric, alpha polypeptide 0.6687 0.328 
(Atpl2a), mRNA 
chr14 + 56752289 Sap18 Mus musculus Sin3-associated polypeptide 18 (SaplS), mRNA 0.4964 0.1663 
chr14 - 56784169 Zdhhc20 Mus musculus zinc finger, DHHC domain containing 20 (Zdhhc20), mRNA 0.4585 0.1962 
chrl4 + 58155318 Rcbtbl Mus musculus regulator of chromosome condensation (RCC1) and BTB 0.798 0.151 
(POZ) domain containing protein 1 (Rcbtbl), mRNA 
chr14 - 58231021 Phfll Mus musculus PHD finger protein 11 (Phfll), mRNA 2.2317 0.3196 




Chr Strand Start Symbol Gene name Score  Oct4?VP2/ 
Oct4  
chr14 - 58356118 Setdb2 PREDICTED: Mus musculus SET domain, bifurcated 2, transcript variant 2 1.8408 0.9091 
(Setdb2), mRNA 
chr14 + 58395072 Cab391 Mus musculus calcium binding protein 39-like (Cab391), mRNA 1.5962 6.9097 
chr14 - 58513496 Cdadcl PREDICTED: Mus musculus cytidine and dCMP deaminase domain 1.3971 6.2889 
containing 1, transcript variant 15 (Cdadcl), mRNA 
chr14 + 58579390 Tmem46 Mus musculus transmembrane protein 46 (Tmem46), mRNA 1.5531 5.9003 
chr14 - 58601631 Atp8a2 Mus musculus ATPase, aminophospholipid transporter-like, class I, type 0.4476 5.5678 
8A, member 2 (Atp8a2), mRNA 
chriS - 74575097 Lynxl Mus musculus Ly6/neurotoxin 1 (Lynxl), mRNA 0.508 0.0175 
chr15 - 74624127 Ly6k Mus musculus lymphocyte antigen 6 complex, locus K (Ly6k), mRNA 0.4581 0.0243 
chriS - 74822131 Ly6a Mus musculus lymphocyte antigen 6 complex, locus A (Ly6a), mRNA 0.9588 0.0366 
chriS - 74872267 Ly6c Mus musculus lymphocyte antigen 6 complex, locus C (Ly6c), mRNA 1.0214 0.0776 
chriS - 74901895 Ly6c Mus musculus lymphocyte antigen 6 complex, locus C (Ly6c), mRNA 1.0214 2.4282 
chr15 + 75531534 Rhpni Mus musculus rhophilin, Rho GTPase binding protein 1 (Rhpnl), mRNA 0.3252 0.8342 
chriS - 76439636 51c39a4 Mus musculus solute carrier family 39 (zinc transporter), member 4 0.3617 0.4561 
(969a4), mRNA 
chr17 + 33162394 Myolf Mus musculus myosin IF (Myolf), mRNA 1.0917 0.0943 
chr17 + 33984846 Btnll Mus musculus butyrophilin-like 1 (Btnli), mRNA 0.9689 0.1227 
chr17 + 34006550 BC051142 Mus musculus cDNA sequence BC051142 (BC051142), mRNA 0.6292 0.1391 
chr17 + 34172264 Notch4 Mus musculus Notch gene homolog 4 (Drosophila) (Notch4), mRNA 0.6271 0.22 
chr17 - 34633552 Ng23 Mus musculus Ng23 protein (Ng23), mRNA 0.7847 0.5576 
chr17 + 34684986 Ly6g6e Mus musculus lymphocyte antigen 6 complex, locus G6E (Ly6g6e), mRNA 0.5831 1.0264 
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chr17 - 34737052 Apom Mus musculus apolipoprotein M (Apom), mRNA 1 	0.643 0.8945 
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Table 3.5- List of the 147 genes upregulated in Oct4A.VP2 cell line, which were identified as possible Oct4 targets. 
The published lists are from studies by Matoba et al 2006, Loh et at 2006. Kim et al 2008, and Sharov et at 2008. 
Pink colour represents genes tat are common to all the lists, Purple colour represents genes that are common to 3 lists, and the green 
colour represents genes that are common to two lists. 
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Acp6 acid phosphatase 6, lysophosphatidic target target target target target 
Fbxol5 F-box protein 15 target target target target target 
Nanog Nanog homeobox  target target target target 
Ptchl patched homolog 1  target target target target 
Tcfcp2I1 transcription factor CP2-like 1  target target target target 
Uhrf2 ubiguitin-like, containing PHD and RING finger domains 2 _______ target target target target 
Ctnnall catenin (cadherin associated protein), alpha-like 1 target target target target  
Nfatc2ip 
cytoplasm ic, calci neurin- 
target target target target 
Tdh L-threonine dehydrogenase target target target target  
Trh thyrotropin releasing hormone target target target target  
Uppi uridine phosphorylase 1 target target target target  
Gadd45g growth arrest and DNA-damage-inducible 45 gamma target target  target target 
Piscri phospholipid scramblase 1 target target  target target 
Pax6 paired box gene 6  target target target 
Sfrpl secreted frizzled-related protein 1  target target target 
Affi AF4/FMR2 family, member 1 target target target  
Ptges prostaglandin E synthase target target target I 
Rpia ribose 5-phosphate isomerase A target I 	target target  
S1c23a2 Isolute carrier family 23 (nucleobase transporters), member 2 target I target target  
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Snail snail homolog 1 (Drosophila) target target target  
SapiS Sin3-associated polypeptide 18  target target  
Smoc2 SPARC related modular calcium binding 2  target target  
Tcfeb transcription factor EB  target target  
CdyI chromodomain protein, Y chromosome-like target target  target  
Manba mannosidase, beta A, lysosomal target target  target  
Ms4alO membrane-spanning 4-domains, subfamily A, member 10 target target  target  
PdcI2 phosducin-like 2 target target  target  
Rage renal tumor antigen target target  target  
Etvl ets variant gene 1  target  target  
Ly6cl lymphocyte antigen 6 complex, locus Cl  target  target  
Prmt8 protein arginine N-methyltransferase 8 target target  target 
Lrrn2 leucine rich repeat protein 2, neuronal  target  target 
K1f2 Kruppel-like factor 2 (lung) target  target target 
Cd38 CD38 antigen  target target 
D14Ertd436e DNA segment, Chr 14, ERATO Doi 436, expressed  target target 
Dppa3 developmental pluripotency-associated 3  target target 
Grsfl G-rich RNA sequence binding factor 1  target target 
Itpka inositol 1,4,5-trisphosphate 3-kinase A  target target 
Nucksi nuclear casein kinase and cyclin-dependent kinase substrate 1  target target 
Rorl receptor tyrosine kinase-like orphan receptor 1  target target 
Tmem8 transmembrane protein 8 (five membrane-spanning domains)  target target 
Vegfc vascular endothelial growth factor C  target target 
Msc musculin  target target  
Myof myoferlin  target target  
Sppl secreted phosphoprotein 1  target target  
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Hmga2 high mobility group AT-hook 2 target target  
Vcan 
Versican 	core 	protein 	precursor 	(Large 	fibroblast 
proteoglycan) (Chondroitin sulfate proteoglycan core protein 
2) (PG-M)  
target target 
ZbtblO zinc finger and BTB domain containing 10 target  target  
Calcoco2 calcium binding and coiled-coil domain 2 target  target  
1d3 inhibitor of DNA binding3 target  target  
Micall 
microtubule 	associated 	monoxygenase, 	calponin 	and 	LIM 
domain containing 1  
target target 
Morci microrchidia 1 target  target  
Tcea3 transcription elongation factor A (SIl), 3 target  target 
Erbb3 v-erb-b2 erythroblastic leukemia viral oncogene homolog 
(avian target 
Ets2 E26 avian leukemia oncogene 2, 3' domain target  
Irgg immunity-related GTPase family, Q target  
Pricklel prickle like 1 (Drosophila) target  
Abca4 ATP-binding cassette, sub-family A (ABC1), member 4  target  
Adam19 a disintegrin and metallopeptidase domain 19 (meltrin beta)  target  
Adcy5 adenylate cyclase 5  target  
Adrb3 adrenergic receptor, beta 3  target  
Atoh8 atonal homolog 8 (Drosophila)  target  
Atp8a2 ATPase, aminophospholipid transporter-like, class I, type 8A, 
member 2  
target 
Cd63 melanoma 1 antigen  target  
CInk cytokine-dependent hematopoietic cell linker  target  
Crtacl cartilage acidic protein 1  target  
Cxcr3 chemokine (C-X-C motif) receptor 3  target  
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Ephb4 Eph receptor B4  target  
Foxn2 forkhead box N2  target  
Glis3 GLIS family zinc finger 3  target  
Hoxb6 homeo box B6 [  target  
Lbxcorl ladybird homeobox 1 homolog (Drosophila) corepressor 1  target  
Lmxlb LIM homeobox transcription factor 1 beta  target  
Lrigl leucine-rich repeats and immunoglobulin-like domains 1  target  
Ncaml neural cell adhesion molecule 1  target  
Nfix nuclear factor I/X  target  
Odz2 odd Oz/ten-m homolog 2 (Drosophila)  target  
P fia2 p 
protein tyrosine phosphatase, 	receptor type, f polypeptide 
(PTPRF), interacting protein (liprin), alpha 2 
tar et g 
Ptprj )rotein tyrosine phosphatase, receptor type, J  target  
Rhbg Rhesus blood group -associated B glycoprotein  target  
Sez6 seizure related gene 6  target  
S1c16a9 
solute carrier family 16 (monocarboxylic acid transporters), 
member 9  
target 
Tnfrsf8 tumor necrosis factor receptor superfamily, member 8  target  
Tox thymocyte selection-associated high mobility group box  target  
Tt116 tubulin tyrosine ligase-like family, member 6  target  
UncScl unc-5 homolog C (C. elegans)-like  target  
Wdfy3 WD repeat and FYVE domain containing 3  target  
Yesi Yamaguchi sarcoma viral (v-yes) oncogene homolog 1  target  
Dpysl3 dihydropyrimidinase-like 3  target  
Kiti Ikit ligand I  target  
Zc3havl Izinc finger CCCH type, antiviral 1 1  target  
259 
Symbol Gene name 
)O LIi 
'I 
Acoxi acyl -Coenzyme A oxidase - like  target  
Ak7 adenylate kinase 7  target  
BC032203 BC032203 cDNA sequence BC032203  target  
Bud3l BUD31 homolog (yeast)  target  
Cdc42ep3 CDC42 effector protein (Rho GTPase binding) 3  target  
Cidea 
cell death - inducing DNA fragmentation factor, alpha subunit -
like effector A 
arge 
Dppa2 developmental pluripotency associated 2  target  
Empi epithelial membrane protein 1  target  
Fancm Fanconi anemia, complementation group M  target  
Gjcl gap junction protein, gamma 1  target  
Gjcl gap junction protein, gamma 1  target  
Gnpnatl glucosamine - phosphate N -acetyltransferase 1  target  
Gprc5b G protein-coupled receptor, family C, group 5, member B 
[ 
 target  
Htral HtrA serine peptidase 1  target  
Igfbp2 insulin - like growth factor binding protein 2  target  
Kit kit oncogene  target  
Lgmn legumain  target  
Mesdcl mesoderm development candidate 1  target  
Mylpf myosin light chain, phosphorylatable, fast skeletal muscle  target  
Ng23 Ng23 protein  target  
Pcolce2 procollagen C-endopeptidase enhancer 2  target  
PIa2g4e phospholipase A2, group IVE  target  
Prtg protogenin homolog (Gallus gallus)  target  
Rab27a RAB27A, member RAS oncogene family  target  
Scap SREBF chaperone  target  
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Shf Src homology 2 domain containing F  target  
SIclSal solute carrier family 15 (oligopeptide transporter), member 1  target  
S1c39a4 solute carrier family 39 (zinc transporter), member 4  target  
Tfpi tissue factor pathway inhibitor  target  
Tmem20 transmembrane protein 20  target  
Tspan17 tetraspanin 17  target  
Ulki Unc-51 like kinase 1 (C. elegans)  target  
Utrn utrophin  target  
Zfp459 zinc finger protein 459  target  
Adamts4 a disintegrin-like and metallopeptidase (reprolysin type) with 
thrombospondin type 1 motif, 4 
tar et g 
Ap3b2 adaptor-related protein complex 3, beta 2 subunit  target 
Atohi atonal homolog 1 (Drosophila)  target 
Cdk5r2 cyclin-dependent kinase 5, regulatory subunit 2 (p39)  target 
Cdxl caudal type homeo box 1  target 
Cfcl cripto, FRL-1, cryptic family 1  target 
Cst3 cystatin C  target 
Edn2 endothelin 2  target 
Evxl even skipped homeotic gene 1 homolog  target 
Fam26e family with sequence similarity 26, member E  target 
Ff1 fibronectin 1  target 
Gjb3 gap junction protein, beta 3  target 
lIdri immunoglobulin-like domain containing receptor 1  target 
Lefty2 left-right determination factor 2  target 
Msln : mesothelin  target 
Nkx2-2 lNK2 transcription factor related, locus 2  target 
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Nrarp Notch-regulated ankyrin repeat protein  target 
Osr2 odd-skipped related 2 (Drosophila)  target 
Pimi proviral integration site 1  target 
Ptger2 prostaglandin E receptor 2 (subtype EP2)  target 
Rundc3a RUN domain containing 3A  target 
Shisa2 shisa homolog 2 (Xenopus laevis)  target 
S1c12a7 solute carrier family 12, member 7  target 
Sox13 SRY-box containing gene 13  target 
Spic Spi-C transcription factor (Spi-1/PU.1 related)  target 
Stc2 stanniocalcin 2  target 
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Table 3.6- Gene ontology of the 147 genes upregulated in Oct4?.VP2 cell line which were identified as possible Oct4 targets. 
The genes identified are involved in cell fate commitment, growth, proliferation, differentiation, Kinase activities, and developmental 
process. 
An:n:oi'ätin U I1 GenieIs4mi5is 
growth 0 0 Adrb3,Empl,Htral,Igfbp2,Lefty2,Lgmn,Ptchl,Tcfcp2ll, 
negative regulation of growth 0 0 Adrb3,Lgmn,Ptchl, 
growth factor activity 0.0012 0.006 Acoxl,Kitl,Lefty2,Sppl,Vegfc, 
positive regulation of cell proliferation 0.0092 0.03 Kit,Kitl,Osr2,Sppl,Vegfc, 
cell fate commitment 0.0026 0.011 Atohl,Nanog,Nkx2-2,Pax6, 
regulation of cell differentiation 0 0 Atohl,Kitl,Nanog,Nkx2-2,Pax6,Sppl,Ulkl, 
positive regulation of cell differentiation 0 0 Atohl,Kitl,Nkx2-2,Pax6, 
morphogenesis of an epithelium 0 0 Grsfl,1d3,Pax6,Ptchl,Tcfcp2ll,Vegfc, 
neuron migration 0.0004 0.003 Atohl,Lmxlb,Pax6, 
axon guidance 0.0076 0.027 Atohl,Etvl,Pax6, 
transcription factor complex 0 0 
Cdxl,Foxn2,Hoxb6,Lbxcorl,Lmxlb,Pax6,Sapl8,Soxl3,Spic, 
Tcfcp2ll,Tcfeb, 
positive regulation of transcription 0.0011 0.006 Affl,Atohl,Etvl,Glis3,K1f2,Nkx2-2,Pax6,Tcfeb, 
embryonic morphogenesis 0.0007 0.004 Atoh 1,Grsfl,Lmxlb,Osr2,Ptchl,Vegfc, 
dorsal/ventral pattern formation 0 0 Lmxlb,Pax6,Ptchl, 
pattern specification process 0 0 Cdxl,Grsfl,Hoxb6,Lmxlb,Nanog,Pax6,Ptchl,Sfrpl, 
regionalization 0.001 0.005 Grsfl,Lmxlb,Pax6,Ptchl,Sfrpl, 
heart development 0.00411 0.016 Adam 19,Gjcl,1d3,Ptprj,Vcan, 
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gland development 0.0065 0.024 Pax6,Ptch 1,Tcfcp2ll, 
chemotaxis 0.0013 0.006 Cxcr3,Kit,Sppl,Utrn, 
locomotory behavior 0.0014 0.007 Adcy5,Cxcr3,Kit,Spp1,Trh,Utrn, 
wound healing 0.0076 0.027 Fnl,Rab27a,Tfpi, 
glycosaminoglycan binding 0 0 Fnl,Ncaml,Pcolce2,Ptchl,Vcan, 
adaptive immune response based on somatic 
recombination of immune receptors built 0.0076 0.028 Gadd45g,Rab27a,Sppl, 
from_immunoglobulin_superfamily_domains  
enzyme linked receptor protein signaling 
0 0 Cidea,Clnk,Ephb4,Fnl,Htra 1,Kit,Ptprj,Ulkl,Vegfc, 
pathway  
positive regulation of protein kinase activity 0.0127 0.041 Gadd45g,Kit,Kitl, 
protein-tyrosine kinase activity 0.0015 0.007 Ephb4,Kit,Ncaml,Rorl,Yesl, 
transmembrane receptor protein tyrosine 
0.0002 0.001 Clnk,Ephb4,Fnl,Kit,Ulkl,Vegfc, kinase_signaling_pathway  
transmembrane receptor protein kinase 
0 0 Ephb4,Kit,Ncaml,Rorl, 
activity  
symporter activity 0.0002 0.001 S1c12a7,Slcl5al,S1c16a9,S1c23a1,S1c23a2, 
late endosome 0 0 Cd63,Gnpnatl,Lgmn, 
'4 
Table 3.7- List of genes upregulated in Oct4A.VP2 that are targets of either Oct4 only, Nanog only, or both. 
The table includes regulation of the genes after Nanog or Oct4 siRNA treatment: UP means genes are upregulated after the siRNA 
treatment, Down means genes are downregulated after the siRNA treatment. 
The columns labelled Nanog targets and Oct4 targets refer to Nanog and Oct4 targets identified in previous studies. Targets identified in 
each study were allocated a specific colour: Blue colour refers to targets from Loh et al 2006, purple colour refers to targets from Matoba 
et al 2006, Green colour refers to Kim et al 2008, and pink colour refers to sharov et al 2008. Targets identified in multiple studies are 
coloured in more than one colour (each colour representing the appropriate study the target was identified in). 
Symbol Gene name I 	I I 	I 
Calcoco2 calcium binding and coiled-coil domain 2 UP target  UP 
Pricklel prickle like 1 (Drosophila) UP target  UP 
1d3 inhibitor of DNA binding 3 UP  UP 
Ms4alO membrane-spanning 4-domains, subfamily A, member 10 UP  target UP 
Snail snail homolog 1 (Drosophila) UP  target UP 
Ctnnall catenin (cadherin associated protein), alpha-like 1 UP target target Down 
Bud3l BUD31 homolog (yeast) UP target  
Tmem20 transmembrane protein 20 UP target  
Adrb3 adrenergic receptor, beta 3 UP target target  
Cd38 CD38 antigen UP target target  
D14Ertd436e DNA segment, Chr 14, ERATO Dol 436, expressed UP target target  
Dppa3 developmental pluripotency-associated 3 UP target target  
Gjb3 gap junction protein, beta 3 UP target target  
Aspa I 	 aspartoacylase UP I 	target  
Glrx I glutaredoxin UP I target  
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Symbol Gene name  
) 	1) 	1 
Gsta3 glutathione S-transferase, alpha 3 UP target  
K1h113 kelch-like 13 (Drosophila) UP target  
S1c25a20 solute carrier family 25 (mitochondrial carnitine/acylcarnitine 
translocase),_member_20  up target 
SIco2al solute carrier organic anion transporter family, member 2a1 UP target  
Mylpf myosin light chain, phosphorylatable, fast skeletal muscle UP  
Prtg protogenin homolog (Gallus gallus) UP  
Scap SREBF chaperone up  
Grsfl G- rich RNA sequence binding factor 1 up  target  
Cryab crystallin, alpha B UP  
Echdc2 enoyl Coenzyme A hydratase domain containing 2 up  
Eng endoglin up  
Foirl folate receptor 1 (adult) up  
Hist2h3c2 histone cluster 2, H3c2 up  
Lxn latexin up  
Mmrn2 multimerin 2 up  
Pcdh8 protocadherin 8 up  
Prame16 preferentially expressed antigen in melanoma like 6 uP  
Prep prolyl endopeptidase up  
Stmn3 stathmin-like 3 up  
Tesk2 testis -specific kinase 2 up  
TtI tubulin tyrosine ligase up  
Micall microtubule associated monoxygenase, calponin and LIM domain 
containing_1  Down target UP 
Manba mannosidase, beta A, lysosomal Down  target up 
PdcI2 phosducin - like 2 Down  target UP 
Uppi uridine phosphorylase 1 Down  target UP 
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Symbol Gene name 
.1! 
I1 
Gjcl gap junction protein, gamma 1 Down target  
Crtacl cartilage acidic protein 1 Down target target  
Fads2 fatty acid desaturase 2 Down target  
Sin3a transcriptional regulator, SIN3A (yeast) Down target  
Tubb2b tubulin, beta 2B Down target  
BC032203 cDNA sequence BC032203 Down  
Igfbp2 insulin - like growth factor binding protein 2 Down  
Sppl secreted phosphoprotein 1 Down  
Nanog  Down  target  
Ephb4 Eph receptor B4 Down  target  
Itpka inositol 1,4,5 -trisphosphate 3 - kinase A Down  target  
Cab391 calcium binding protein 39 - like Down  
Car13 carbonic anhydrase 13 Down  
Idh2 isocitrate dehydrogenase 2 (NADP+), mitochondrial Down  
MovlO Moloney leukemia virus 10 Down  
Myolf  Down  
Osgep 0-sialoglycoprotein endopeptidase Down  
Pgml phosphoglucomutase 1 Down  
PIa2glO phospholipase A2, group X Down  
Scdl stearoyl-Coenzyme A desaturase 1 Down  
Tmem40 transmembrane protein 40 Down  
Gadd45g growth arrest and DNA-damage-inducible 45 gamma  target target UP 
ZbtblO zinc finger and BIB domain containing 10  UP 
Hmga2 high mobility group AT-hook 2  target UP 
Erbb3 v-erb-b2 erythroblastic leukemia viral oncogene homolog 3 (avian)  UP 
Ets2 E26 avian leukemia oncogene 2, 3' domain  target  UP 
CdyI chromodomain protein, Y chromosome-like  target target Down 
267 
Symbol Gene name I 
Rage renal tumor antigen  target target Down 
Affi AF4/FMR2 family, member 1  target target Down 
Ptges prostaglandin E synthase  target target Down 
Acp6 acid phosphatase 6, lysophosphatidic  target target Down 
Fbxol5 F-box protein 15  target target Down 
Piscri phospholipid scramblase 1  target target Down 
Nfatc21p nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 2 interacting 
protein  
target Down 
Tdh L-threonine dehydrogenase  target Down 
Trh thyrotropin releasing hormone  target Down 
Prmt8 protein arginine N-methyltransferase 8  target Down 
Vcan versican  target Down 
K1f2 Kruppel-like factor 2 (lung)  target Down 
Tcea3 transcription elongation factor A (SIl), 3  target Down 
Morci microrchidia 1  target Down 
Rpia ribose 5-phosphate isomerase A  target Down 
S1c23a2 solute carrier family 23 (nucleobase transporters), member 2  target Down 
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